10030778|Intravenous azithromycin-induced ototoxicity.|ototoxicity|33|44|azithromycin|12|24
10048291|Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of dihydrotachysterol by rifampicin, could have led to increased calcium-release into the circulation.|increased calcium-release|143|168|dihydrotachysterol|91|109
10048291|Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol.|hypercalcemia|21|34|dihydrotachysterol|84|102
10082597|METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.|pseudoporphyria|32|47|naproxen|58|66
10082597|METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.|pseudoporphyria|32|47|oxaprozin|71|80
10082597|Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.|erythropoietic protoporphyria|134|163|Naproxen|0|8
10082597|RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.|cutaneous fragility|163|182|naproxen|34|42
10082597|RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.|cutaneous fragility|163|182|oxaprozin|96|105
10082597|RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.|tense bullae|146|158|naproxen|34|42
10082597|RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.|tense bullae|146|158|oxaprozin|96|105
10084639|BACKGROUND: How to best treat psychotic patients who have had past clozapine-induced agranulocytosis or granulocytopenia remains a problem.|granulocytopenia|104|120|clozapine|67|76
10084639|CONCLUSION: The results suggest that olanzapine may be useful in treating patients with clozapine-induced granulocytopenia without the risk of recurrence of hematologic side effects.|granulocytopenia|106|122|clozapine|88|97
10099659|Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.|neurotoxicity|43|56|5-fluorouracil|17|31
10099659|We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.|neurologic toxicity|151|170|5-FU|32|36
10099659|We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.|prolonged myelosuppression|119|145|5-FU|32|36
10099659|We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.|severe mucositis|76|92|5-FU|32|36
10102531|This case suggests that BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible encephalopathy syndrome.|encephalopathy syndrome|135|158|BH-AC|24|29
10102531|We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.|encephalopathy syndrome|31|54|BH-AC|180|185
10102531|We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.|encephalopathy syndrome|31|54|idarubicin|239|249
10190739|In one case, the readministration of riluzole was followed by the relapse of hepatitis.|hepatitis|77|86|riluzole|37|45
10190739|We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.|hepatitis|56|65|riluzole|79|87
10203437|Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease.|Lupus-like syndrome|0|19|5-aminosalicylic acid|30|51
10225085|Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.|methemoglobinemia|270|287|lidocaine|111|120
10225085|Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.|Methemoglobinemia|0|17|bupivacaine|44|55
10225085|Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.|Methemoglobinemia|0|17|lidocaine|84|93
10225085|We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.|methemoglobinemia|111|128|bupivacaine|158|169
10225085|We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.|methemoglobinemia|111|128|lidocaine|198|207
10229976|Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient.|asthma|73|79|aspirin|57|64
10327035|An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.|encephalopathy|23|37|methotrexate|79|91
10327035|We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.|neurotoxicity|77|90|MTX|65|68
10332990|We describe a life threatening side effect of acute epoprostenol infusion (pulmonary edema) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology.|pulmonary edema|75|90|epoprostenol|52|64
10337682|A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.|pruritic bullous eruption|56|81|prednisone|91|101
10348150|Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.|acute interstitial pneumonitis|20|50|Hydroxyurea|0|11
10348150|The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.|interstitial pneumonitis|38|62|hydroxyurea|78|89
10348150|This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.|acute interstitial pneumonitis|46|76|hydroxyurea|26|37
10357715|Allergic and irritant contact dermatitis to calcipotriol.|irritant contact dermatitis|13|40|calcipotriol|44|56
10357715|Calcipotriol (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas allergic reactions are less common.|allergic reactions|110|128|Calcipotriol|0|12
10357715|Calcipotriol (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas allergic reactions are less common.|irritation of the skin|78|100|Calcipotriol|0|12
10357715|The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with calcipotriol.|irritant type of reaction|185|210|calcipotriol|232|244
10367184|Myotonia associated with sarcoidosis: marked exacerbation with pravastatin.|Myotonia|0|8|pravastatin|63|74
10367184|Pravastatin is associated with myotonia in animals.|myotonia|31|39|Pravastatin|0|11
10367184|This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans.|myotonia|171|179|pravastatin|40|51
10393393|Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction.|angioedema|80|90|aspirin|20|27
10393393|Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction.|systemic anaphylactoid reaction|97|128|aspirin|20|27
10393393|Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction.|urticaria|63|72|aspirin|20|27
10395123|CONCLUSION: Fixed drug eruption is associated with many drugs but this is the first such report with omeprazole.|eruption|23|31|omeprazole|101|111
10395123|Fixed drug eruption in hands caused by omeprazole.|eruption|11|19|omeprazole|39|49
10395123|The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment.|eruption|65|73|omeprazole|95|105
10405480|A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.|diffuse erythema|121|137|salazosulfapyridine|248|267
10405480|A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.|fever up to 39 degrees C|187|211|salazosulfapyridine|248|267
10405480|A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.|malaise|174|181|salazosulfapyridine|248|267
10405480|A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.|pustules|142|150|salazosulfapyridine|248|267
10405480|Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.|Acute generalized exanthematous pustulosis|0|42|salazosulfapyridine|54|73
10405480|We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.|acute generalized exanthematous pustulosis|20|62|salazosulfapyridine|81|100
10410183|CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU/L (normal < 230).|elevated serum CK concentration|96|127|olanzapine|72|82
10410183|DISCUSSION: Olanzapine, like other atypical antipsychotic drugs, may cause muscle injury with concomitant elevations of serum CK of muscle origin.|muscle injury with concomitant elevations of serum CK|75|128|Olanzapine|12|22
10410183|Marked elevation of serum creatine kinase associated with olanzapine therapy.|elevation of serum creatine kinase|7|41|olanzapine|58|68
10410183|OBJECTIVE: To report a case of marked elevation of serum creatine kinase (CK) associated with olanzapine therapy.|elevation of serum creatine kinase|38|72|olanzapine|94|104
10414481|Diclofenac-associated hepatitis.|hepatitis|22|31|Diclofenac|0|10
10414481|This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.|hepatitis|62|71|diclofenac|103|113
10426918|2-CdA induces lymphocytopenia, which may explain the improvement in this patient's psoriasis.|lymphocytopenia|14|29|2-CdA|0|5
10431414|One case of priapism occurred during heparin therapy for a previous surgical operation to the knee is reported.|priapism|12|20|heparin|37|44
10431414|Priapism as a complication of heparin therapy.|Priapism|0|8|heparin|30|37
10431414|The association between heparin and priapism is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect.|abnormal platelet aggregation|66|95|heparin|24|31
10431414|The association between heparin and priapism is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect.|priapism|36|44|heparin|24|31
10435399|It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.|agranulocytosis|48|63|clozapine|117|126
10435399|It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.|neutropenia|32|43|clozapine|117|126
10435399|OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).|diurnal variation of the white blood cells|121|163|clozapine|60|69
10439378|Acute neutrophilic dermatosis induced by all-trans-retinoic acid treatment for acute promyelocytic leukemia.|Acute neutrophilic dermatosis|0|29|all-trans-retinoic acid|41|64
10442258|Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.|hair loss|78|87|paroxetine|113|123
10442258|Hair loss associated with paroxetine treatment: a case report.|Hair loss|0|9|paroxetine|26|36
10442258|We report on a 37-year-old female who complained of moderate hair loss during paroxetine treatment.|hair loss|61|70|paroxetine|78|88
10452772|CONCLUSION: Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant protamine allergy.|protamine allergy|170|187|insulin|26|33
10452772|METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|angioedema|76|86|insulin|30|37
10452772|METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|angioedema|76|86|insulin|131|138
10452772|METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|severe urticaria|58|74|insulin|30|37
10452772|METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|severe urticaria|58|74|insulin|131|138
10452772|METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|wheezing|103|111|insulin|30|37
10452772|METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|wheezing|103|111|insulin|131|138
10452772|OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin.|allergic symptoms|153|170|insulin|114|121
10452772|OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin.|allergic symptoms|153|170|NPH insulin|81|92
10452772|Patients receiving neutral protamine Hagedorn (NPH) insulin are at increased risk for the development of protamine hypersensitivity.|protamine hypersensitivity|105|131|neutral protamine Hagedorn (NPH) insulin|19|59
10452772|Protamine allergy as a complication of insulin hypersensitivity: A case report.|Protamine allergy|0|17|insulin|39|46
10452772|She continued to receive regular insulin 4 times per day over the following 3 years with only occasional hives.|hives|105|110|insulin|33|40
10452772|The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin.|angioedema|44|54|insulin|151|158
10452772|The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin.|angioedema|44|54|NPH|99|102
10452772|The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin.|urticaria|30|39|insulin|151|158
10452772|The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin.|urticaria|30|39|NPH|99|102
10458196|A 5-month-old infant became lethargic and poorly responsive after receiving 1 drop of brimonidine in each eye.|lethargic|28|37|brimonidine|86|97
10458196|A 5-month-old infant became lethargic and poorly responsive after receiving 1 drop of brimonidine in each eye.|poorly responsive|42|59|brimonidine|86|97
10458196|An 11-day-old infant became lethargic and apneic after a single drop of brimonidine.|apneic|42|48|brimonidine|72|83
10458196|An 11-day-old infant became lethargic and apneic after a single drop of brimonidine.|lethargic|28|37|brimonidine|72|83
10458196|Apparent central nervous system depression in infants after the use of topical brimonidine.|central nervous system depression|9|42|brimonidine|79|90
10458196|CONCLUSIONS: Topical brimonidine may be associated with central nervous system depression in infants.|central nervous system depression|56|89|brimonidine|21|32
10458196|PURPOSE: To report two cases in which topical brimonidine resulted in apparent central nervous system depression and unresponsiveness in an infant.|central nervous system depression|79|112|brimonidine|46|57
10461415|Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato-biliary enzymes and transient biliary stasis.|elevated hepato-biliary enzymes|143|174|ceftriaxone|126|137
10461415|Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato-biliary enzymes and transient biliary stasis.|transient biliary stasis|179|203|ceftriaxone|126|137
10461415|Hepato-biliary abnormalities secondary to ceftriaxone use: a case report.|Hepato-biliary abnormalities|0|28|ceftriaxone|42|53
10465148|Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.|Anterior lumbosacral radiculopathy|0|34|methotrexate|53|65
10465148|Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.|progressive paraparesis|42|65|methotrexate|84|96
10466445|During the first days of arsenic trioxide treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes.|decrease in the D-dimers|60|84|arsenic trioxide|25|41
10466445|During the first days of arsenic trioxide treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes.|slight decrease in peripheral blood leukocytes|147|193|arsenic trioxide|25|41
10467499|A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.|chills|41|47|minocycline|165|176
10467499|A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.|fatigue|49|56|minocycline|165|176
10467499|A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.|fever|34|39|minocycline|165|176
10467499|A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.|generalized, pruritic, macular eruption|102|141|minocycline|165|176
10467499|A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.|night sweats|58|70|minocycline|165|176
10467499|With the negative viral serologies, the clinical picture was most consistent with an infectious mononucleosis-like syndrome produced by the minocycline ingestion.|mononucleosis-like syndrome|96|123| minocycline|139|151
10473079|We conclude that the presence of this metabolic defect combined with topical 5-FU (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of life-threatening toxicity after treatment with a topical drug.|life-threatening toxicity|171|196|5-FU|77|81
10473079|We now report the first known cancer patient who developed life-threatening complications after treatment with topical 5-FU and was shown subsequently to have profound DPD deficiency.|life-threatening complications|59|89|5-FU|119|123
10475726|An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms.|acute ischaemic event|3|24|venlafaxine|52|63
10475726|The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties.|ischaemic events|46|62|venlafaxine|19|30
10475726|This is the first report of a possible association between an acute cardiovascular event and venlafaxine.|acute cardiovascular event|62|88|venlafaxine|93|104
10475726|We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with venlafaxine, and developed acute myocardial ischaemia within the first week of treatment.|acute myocardial ischaemia|142|168|venlafaxine|115|126
10482872|Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?|embryopathy|36|47|cyclophosphamide|9|25
10482872|The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype.|embryopathy|144|155|CP|141|143
10482872|The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype.|multiple congenital anomalies|82|111|CP|65|67
10482872|The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|blepharophimosis|172|188|cyclosposphamide|43|59
10482872|The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|craniosynostosis|154|170|cyclosposphamide|43|59
10482872|The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|developmental delay|133|152|cyclosposphamide|43|59
10482872|The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|distal limb defects|228|247|cyclosposphamide|43|59
10482872|The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|flat nasal bridge|190|207|cyclosposphamide|43|59
10482872|The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|hypoplastic thumbs|258|276|cyclosposphamide|43|59
10482872|The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|oligodactyly|281|293|cyclosposphamide|43|59
10482872|We conclude that (a) cyclophosphamide is a human teratogen, (b) a distinct phenotype exists, and (c) the safety of CP in pregnancy is in serious question.|human teratogen|43|58|cyclophosphamide|21|37
10487084|In all cases, seizures were controlled by withdrawal of phenytoin and reduction of drug levels.|seizures|14|22|phenytoin|56|65
10487084|Paradoxical seizures in phenytoin toxicity.|seizures|12|20|phenytoin|24|33
10487084|We present three patients with paradoxical seizures; their serum phenytoin levels were 43.5 mcg/mL, 46.5 mcg/mL and 38.3 mcg/mL.|seizures|43|51|phenytoin|65|74
10492493|CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.|angioedema|68|78|losartan|37|45
10492493|Losartan-induced angioedema.|angioedema|17|27|Losartan|0|8
10492493|OBJECTIVE: To report a case of angioedema associated with losartan administration.|angioedema|31|41|losartan|58|66
10492493|The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.|angioedema|17|27|losartan|41|49
10494874|We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after danazol treatment for uterine fibromatosis.|hepatic adenomas|68|84|danazol|105|112
10510017|Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.|thrombocytopenia|16|32|Heparin|0|7
10510017|Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).|thrombocytopenia|26|42|heparin|10|17
10510017|There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.|thrombocytopenia|163|179|heparin|147|154
10510017|We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).|hemorrhagic complications|86|111|heparin|38|45
10510017|We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).|thrombocytopenia|54|70|heparin|38|45
10513720|Taxane-induced glaucoma.|glaucoma|15|23|Taxane|0|6
10513720|We report a case of glaucoma induced by doxetaxel therapy for metastatic breast cancer.|glaucoma|20|28|doxetaxel|40|49
10516999|Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure.|hyperphosphatemia|6|23|sodium phosphate|34|50
10516999|We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate (Fleet enema).|hyperphosphatemia|26|43|sodium biphosphate|103|121
10516999|We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate (Fleet enema).|hyperphosphatemia|26|43|sodium phosphate|82|98
10524732|Prolongation of the QT interval and ventricular tachyarrhymias have been described in patients on amiodarone therapy.|Prolongation of the QT interval|0|31|amiodarone|98|108
10524732|Prolongation of the QT interval and ventricular tachyarrhymias have been described in patients on amiodarone therapy.|ventricular tachyarrhymias|36|62|amiodarone|98|108
10524732|We report a case of recurrent torsades de pointes following treatment with pentavalent antimonial drugs and amiodarone.|torsades de pointes|30|49|amiodarone|108|118
10530201|Emphasis is given to the differentiation of diphenylhydantoin induced gingival hyperplasia from the angiomatous enlargement of the gingiva before any treatment is planned.|gingival hyperplasia|70|90|diphenylhydantoin|44|61
10555917|A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe.|anemia|63|69|D-Pen|115|120
10555917|A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe.|anemia|63|69|D-penicillamine|98|113
10555917|A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe.|thrombocytopenia|74|90|D-Pen|115|120
10555917|A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe.|thrombocytopenia|74|90|D-penicillamine|98|113
10555917|Cessation of D-Pen and the start of corticosteroid therapy were followed by recovery from bicytopenia.|bicytopenia|90|101|D-Pen|13|18
10555917|In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D-penicillamine.|inhibition of hematopoiesis|9|36|D-penicillamine|87|102
10555917|These findings suggest that bicytopenia in this patient was caused by D-Pen and may be due to different sensitivities in the hematopoietic lineage.|bicytopenia|28|39|D-Pen|70|75
10560960|A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.|agranulocytosis|82|97|methimazole|60|71
10566542|Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case.|hypocalcemic tetany|14|33|alendronate sodium|95|113
10566542|Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case.|hypocalcemic tetany|14|33|fleet phospho-soda|44|62
10566542|This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypocalcemic tetany|143|162|alendronate|67|78
10566542|This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypocalcemic tetany|143|162|Fleet Phospho-Soda|192|210
10566542|This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypocalcemic tetany|143|162|Fosamax|80|87
10566542|This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypophosphatemia|122|138|alendronate|67|78
10566542|This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypophosphatemia|122|138|Fleet Phospho-Soda|192|210
10566542|This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypophosphatemia|122|138|Fosamax|80|87
10575189|Described here are 2 patients who developed thrombotic microangiopathy of the kidneys after receiving high cumulative doses of the new anticancer drug gemcitabine.|thrombotic microangiopathy|44|70|gemcitabine|151|162
10575189|Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.|renal failure|32|45|gemcitabine|73|84
10575189|Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.|Thrombotic microangiopathy|0|26|gemcitabine|73|84
10579985|The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.|B-cell non-Hodgkin's lymphoma|89|118|infliximab|163|173
10579985|The relationship between infliximab treatment and lymphoma in Crohn's disease.|lymphoma|50|58|infliximab|25|35
10579985|The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.|nodular sclerosing Hodgkin's lymphoma|48|85|infliximab|128|138
10579985|We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.|lymphoma|80|88|infliximab|124|134
10586009|Codeine intoxication in the neonate.|Codeine intoxication|0|20|Codeine|0|7
10586009|We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.|codeine intoxication|20|40|codeine|20|27
10589077|Hydroxyurea (HU) and sodium phenylbutyrate (SPB) have been shown to increase fetal hemoglobin (Hb F) levels in patients with thalassemia intermedia.|increase fetal hemoglobin|68|93|Hydroxyurea|0|11
10589077|Hydroxyurea (HU) and sodium phenylbutyrate (SPB) have been shown to increase fetal hemoglobin (Hb F) levels in patients with thalassemia intermedia.|increase fetal hemoglobin|68|93|sodium phenylbutyrate|21|42
10589077|Of the four patients who responded to HU with an increase in total Hb, all reported symptomatic improvement and three have not required further transfusions.|increase in total Hb|49|69|HU|38|40
10589077|Prolonged responses were achieved with low doses of HU (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb.|hepatic toxicity|141|157|HU|52|54
10589077|Prolonged responses were achieved with low doses of HU (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb.|mild reversible hematologic|110|137|HU|52|54
10589077|Sodium phenylbutyrate was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite increasing Hb F levels.|increasing Hb F|124|139|HU|50|52
10589077|Sodium phenylbutyrate was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite increasing Hb F levels.|increasing Hb F|124|139|Sodium phenylbutyrate|0|21
10589077|We conclude that low-dose HU therapy in patients with thalassemia intermedia may increase total Hb levels sufficiently to eliminate the need for transfusions.|increase total Hb|81|98|HU|26|28
10589077|We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with SPB.|increases in total Hb|52|73|HU|165|167
10589077|We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with SPB.|increases in total Hb|52|73|SPB|197|200
10592946|A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.|delirious|146|155|oolong tea|89|99
10592946|After abstinence from oolong tea his delirium resolved.|delirium|37|45|oolong tea|22|32
10592946|Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.|caffeine intoxication|65|86|caffeine|65|73
10592946|Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.|caffeine intoxication|65|86|oolong tea|53|63
10592946|Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.|rhabdomyolysis|7|21|caffeine|65|73
10592946|Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.|rhabdomyolysis|7|21|oolong tea|53|63
10592946|The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.|delirium|137|145|caffeine|34|42
10592946|The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.|hyponatremia|163|175|caffeine|34|42
10592946|The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.|rhabdomyolysis|203|217|caffeine|34|42
10592946|The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.|rhabdomyolysis|107|121|caffeine|34|42
10592946|The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.|rhabdomyolysis|26|40|caffeine|127|135
10592946|The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.|water intoxication|80|98|caffeine|127|135
10592946|We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.|caffeine toxicity|20|37|caffeine|20|28
10592946|We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.|coexisting hyponatremia|129|152|caffeine|20|28
10592946|We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.|injured the muscle cells|38|62|caffeine|20|28
10592946|We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.|potassium depletion|94|113|caffeine|20|28
10592946|We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.|rhabdomyolysis|184|198|caffeine|20|28
10599932|After the addition of citalopram, a desmethylclomipramine plasma level increase and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed.|8-hydroacy-desmethylclomipramine plasma level decrease|87|141|citalopram|22|32
10599932|After the addition of citalopram, a desmethylclomipramine plasma level increase and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed.|desmethylclomipramine plasma level increase|36|79|citalopram|22|32
10607332|We report 3 cases of HIV-1 infected patients who experienced symptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir.|angiolipomas|73|85|indinavir|165|174
10610018|Elevated serum triglycerides with clozapine resolved with risperidone in four patients.|Elevated serum triglycerides|0|28|clozapine|34|43
10610018|In two patients clozapine was reinstated after risperidone was discontinued; serum triglyceride levels increased.|serum triglyceride levels increased|77|112|clozapine|16|25
10610018|This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.|elevated serum triglyceride levels|114|148|clozapine|152|161
10614572|Intravenous valproate associated with significant hypotension in the treatment of status epilepticus.|hypotension|50|61|valproate|12|21
10614572|To our knowledge, this is the first report of significant hypotension associated with intravenous valproate in the treatment of status epilepticus in the pediatric population.|hypotension|58|69|valproate|98|107
10614572|We report a case of severe hypotension associated with intravenous valproate used to treat status epilepticus in an 11-year-old girl.|hypotension|27|38|valproate|67|76
10619721|In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.|rippling phenomena worsened|21|48|pyridostigmine|54|68
10633877|A diagnosis of masked theophylline poisoning should be considered in similar situations involving a rapid decrease of insulin requirements.|theophylline poisoning|22|44|theophylline|22|34
10633877|Salicylate intoxication was excluded, and theophylline was finally incriminated.|intoxication|11|23|theophylline|42|54
10633877|Theophylline intoxication mimicking diabetic ketoacidosis in a child.|Theophylline intoxication|0|25|Theophylline|0|12
10633877|This compound, used by adults in the child's home, had caused accidental theophylline poisoning, mimicking diabetic ketoacidosis.|theophylline poisoning|73|95|theophylline|73|85
10646879|Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.|ifosfamide-induced encephalopathy|50|83|ifosfamide|50|60
10646879|Ten to 15% of patients treated with ifosfamide develop an encephalopathy.|encephalopathy|58|72|ifosfamide|36|46
10646879|We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.|ifosfamide-induced encephalopathy|50|83|ifosfamide|50|60
10650865|Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding--successful thrombolysis under heparin therapy.|Portal vein thrombosis|0|22|F VIII|116|122
10650865|We report on a 14-year-old boy with severe haemophilia A who developed a portal vein thrombosis during continuous infusion of F VIII.|portal vein thrombosis|73|95|F VIII|126|132
10656221|A 60-year-old woman with diabetes mellitus (type 2) developed an acute icteric hepatitis-like illness 6 weeks after the initiation of gliclazide therapy.|acute icteric hepatitis-like illness|65|101|gliclazide|134|144
10656221|Gliclazide-induced acute hepatitis.|acute hepatitis|19|34|Gliclazide|0|10
10656221|In conclusion, this case strongly suggests that gliclazide can induce acute icteric liver necro-inflammation which may be misdiagnosed clinically as acute viral hepatitis.|acute icteric liver necro-inflammation|70|108|gliclazide|48|58
10656221|We believe that this is the first description of acute hepatitis caused by an idiosyncratic adverse reaction to gliclazide or to one of its metabolites.|acute hepatitis|49|64|gliclazide|112|122
10656221|We describe the case of acute hepatitis induced by gliclazide, a second generation sulfonylurea.|acute hepatitis|24|39|gliclazide|51|61
10667036|Caution is, therefore, needed to prevent undesired accumulation of TCA that may lead to protracted Cushing's syndrome.|Cushing's syndrome|99|117|TCA|67|70
10667036|Cushing's syndrome persisted more than 6 months while TCA concentrations remained detectable for at least 80 days.|Cushing's syndrome|0|18|TCA|54|57
10667036|The presented patient was treated with 200 mg TCA and developed Cushing's syndrome 6 weeks later (cortisol and ACTH concentrations were below limits of detection, TCA concentrations were > 3 micrograms/l).|Cushing's syndrome|64|82|TCA|46|49
10679548|Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced.|abnormal computed tomographic scans|36|71|nitrofurantoin|107|121
10679548|Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced.|impaired lung function|9|31|nitrofurantoin|107|121
10679548|Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin.|Bronchiolitis obliterans organising pneumonia|0|45|nitrofurantoin|73|87
10679548|The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury.|BOOP|195|199|nitrofurantoin|103|117
10679548|The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury.|bronchiolitis obliterans organising pneumonia|148|193|nitrofurantoin|103|117
10679548|The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury.|lung disease|63|75|nitrofurantoin|103|117
10679548|The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP.|fatal outcome|64|77|nitrofurantoin|113|127
10679548|The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP.|nitrofurantoin induced BOOP|113|140|nitrofurantoin|113|127
10679548|The spectrum of nitrofurantoin lung injury continues to widen.|lung injury|31|42|nitrofurantoin|16|30
10679548|The two middle aged women presented with respiratory symptoms after prolonged treatment with nitrofurantoin.|respiratory symptoms|41|61|nitrofurantoin|93|107
10679548|We suggest that the previous classification of nitrofurantoin induced lung injury into "acute" and "chronic" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged.|nitrofurantoin induced lung injury|47|81|nitrofurantoin|47|61
10682234|Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.|akathisia|64|73|interferon-alpha|90|106
10682234|The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.|akathisia|57|66|interferon-alpha|73|89
10682234|The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.|neurotoxicity|195|208|interferon-alpha|225|241
1068531|Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma: report of two cases.|Acute erythroid leukemia|0|24|cyclophosphamide|31|47
1068531|The development of erythroid leukemia plus carcinoma in these two men suggests mutagenic change secondary to cyclophosphamide therapy.|carcinoma|43|52|cyclophosphamide|109|125
10688731|Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent.|Scleroderma-like reaction|0|25|UFT|53|56
10688731|Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent.|Scleroderma-like reaction|0|25|uracil-tegafur|37|51
10688731|This is the first report of UFT-induced scleroderma-like reaction.|UFT-induced scleroderma-like reaction|28|65|UFT|28|31
10688731|We report a case of a scleroderma-like reaction induced by long-term administration of UFT.|scleroderma-like reaction|22|47|UFT|87|90
10698143|Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.|Central nervous system manifestations|0|37|ibuprofen|44|53
10698143|Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.|dizziness|57|66|Ibuprofen|0|9
10698143|Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.|GI upset|47|55|Ibuprofen|0|9
10698143|Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.|mild sedation|72|85|Ibuprofen|0|9
10698143|Presently, treatment of acute ibuprofen intoxication with complications requires supportive therapy until the symptoms resolve over 24 to 48 hours.|ibuprofen intoxication|30|52|ibuprofen|30|39
10698143|We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.|depressed level of consciousness|59|91|ibuprofen|111|120
10707759|Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome.|acute respiratory failure|39|64|Flecainide|0|10
10707759|Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome.|pneumonitis|22|33|Flecainide|0|10
10707759|Flecainide is a rare cause of hypersensitivity pneumonitis, and few cases have been reported.|hypersensitivity pneumonitis|30|58|Flecainide|0|10
10707759|We describe a case of interstitial hypoxaemiant pneumonitis probably related to flecainide in a patient with the LEOPARD syndrome, a rare congenital disorder.|interstitial hypoxaemiant pneumonitis|22|59|flecainide|80|90
10717401|Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.|Sagittal sinus thrombosis|0|25|L-asparaginase|84|98
10717401|Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.|transient free protein S deficiency|42|77|L-asparaginase|84|98
10717401|We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.|seizure|142|149|L-asparaginase|186|200
10717401|We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.|transient ischemic attacks|101|127|L-asparaginase|186|200
10723699|We report on a young adolescent with benign intracranial hypertension which we attribute to the use of minocycline for acne.|benign intracranial hypertension|37|69|minocycline|103|114
10728450|We report 2 patients who developed polyarteritis nodosa following vaccination against hepatitis B.|polyarteritis nodosa|35|55|vaccination against hepatitis B|66|97
10732843|In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose methotrexate therapy might have promoted the development of lung cancer.|lung cancer|165|176|methotrexate|105|117
10745478|This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with cocaine-induced refractory coronary vasospasm.|refractory coronary vasospasm|194|223|cocaine|178|185
10749332|However, as illustrated by these and other cases reported to date, the onset of troglitazone-induced liver injury is insidious and temporally variable.|liver injury|101|113|troglitazone|80|92
10749332|It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug-class effect or specific to troglitazone.|hepatotoxicity|34|48|troglitazone|65|77
10749332|It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug-class effect or specific to troglitazone.|hepatotoxicity|34|48|troglitazone|116|128
10749332|Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of troglitazone without significant hepatotoxicity.|hepatotoxicity|138|152|troglitazone|105|117
10749332|The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury.|irreversible liver injury|104|129|troglitazone|42|54
10749332|Troglitazone-induced fulminant hepatic failure.|fulminant hepatic failure|21|46|Troglitazone|0|12
10752888|Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.|lung disease|23|35|Nitrofurantoin|0|14
10752888|We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.|distortion of the lung parenchyma|145|178|nitrofurantoin|24|38
10752888|We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.|fibrosis|213|221|nitrofurantoin|24|38
10752888|We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.|pulmonary toxicity|47|65|nitrofurantoin|24|38
10752888|We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.|widespread reticular pattern|101|129|nitrofurantoin|24|38
10755579|Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency.|death|19|24|Fluoxetine|0|10
10755579|The medical examiner's report indicated death caused by fluoxetine toxicity.|death|40|45|fluoxetine|56|66
10755579|The medical examiner's report indicated death caused by fluoxetine toxicity.|fluoxetine toxicity|56|75|fluoxetine|56|66
10755579|This is the first report of a fluoxetine-related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism.|death|49|54|fluoxetine|30|40
10759907|A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.|spinal cord lesion|127|145|zolmitriptan|167|179
10759907|Spinal cord infarction during use of zolmitriptan: a case report.|Spinal cord infarction|0|22|zolmitriptan|37|49
10759907|The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.|spinal cord infarction|44|66|zolmitriptan|96|108
10772434|CASE SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a hypersensitivity reaction to carboplatin after nine courses.|hypersensitivity|79|95|carboplatin|108|119
10772434|This regimen could prove useful for other patients who develop hypersensitivity reactions to carboplatin and allow therapy to continue.|hypersensitivity|63|79|carboplatin|93|104
10774758|Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use.|renal insufficiency|27|46|nimesulide|72|82
10774758|This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of nimesulide.|adverse effect of fetal renal circulation|31|72|nimesulide|98|108
10779995|Although the t-AML developed following oral etoposide therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated.|t-AML|13|18|etoposide|44|53
10779995|Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause?|Secondary leukemia|0|18|etoposide|63|72
10779995|The authors present a case of t-AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide, given for palliation purpose.|t-AML|30|35|etoposide|125|134
10803790|BACKGROUND: Cyanamide, an aversive agent widely used in Japan, is known to induce various degrees of hepatic lesion with ground-glass inclusion bodies.|hepatic lesion with ground-glass inclusion bodies|101|150|Cyanamide|12|21
10803790|Case 2: A 43-year-old male alcoholic remained completely abstinent with cyanamide treatment for 5 years and complained of general fatigue.|general fatigue|122|137|cyanamide|72|81
10803790|Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight fever after 1.5 years of abstinence with cyanamide treatment.|fatigue|61|68|cyanamide|123|132
10803790|Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight fever after 1.5 years of abstinence with cyanamide treatment.|fever|82|87|cyanamide|123|132
10803790|Case 4: A 61-year-old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight elevation of serum transaminases.|elevation of serum transaminases|120|152|cyanamide|84|93
10803790|CONCLUSION: In some abstainers who take cyanamide for several years, thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes.|ground-glass hepatocytes|140|164|cyanamide|40|49
10803790|CONCLUSION: In some abstainers who take cyanamide for several years, thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes.|septum-like liver fibrosis|74|100|cyanamide|40|49
10803790|Cyanamide-induced liver dysfunction after abstinence in alcoholics: a long-term follow-up study on four cases.|liver dysfunction|18|35|Cyanamide|0|9
10803790|When cyanamide-treated alcoholics relapse into drinking, more severe inflammation develops in the liver.|inflammation|69|81|cyanamide|5|14
10808214|A patient with an allergy to a macrolide antibiotic was given tacrolimus and developed a sudden cutaneous reaction.|sudden cutaneous reaction|89|114|tacrolimus|62|72
10812579|A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.|nonconvulsive status epilepticus|69|101|morphine|141|149
10812579|A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.|generalized tonic-clonic seizure|2|34|naloxone|101|109
10812579|Nonconvulsive status epilepticus: the role of morphine and its antagonist.|Nonconvulsive status epilepticus|0|32|morphine|46|54
1082426|Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.|bacterial peritonitis|12|33|vasopressin|59|70
10840527|Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms (EPS).|EPS|301|304|risperidone|38|49
10840527|Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms (EPS).|extrapyramidal symptoms|276|299|risperidone|38|49
10870485|Three months following splenectomy, multiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the CHOP regimen.|multiple abscesses|36|54|CHOP|150|154
1087773|After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.|anti-native DNA antibodies|183|209|ethambutol|88|98
1087773|After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.|hepatitis|153|162|ethambutol|88|98
1087773|After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.|polyarthritis|129|142|ethambutol|88|98
1087773|After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.|rash|144|148|ethambutol|88|98
1087773|Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|anti-native DNA antibodies|29|55|ethambutol|77|87
1087773|Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|anti-native DNA antibodies|29|55|rifampicin|92|102
1087773|Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|hepatitis|15|24|ethambutol|77|87
1087773|Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|hepatitis|15|24|rifampicin|92|102
1087773|Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|Polyarthritis|0|13|ethambutol|77|87
1087773|Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|Polyarthritis|0|13|rifampicin|92|102
10879669|A case of normotensive scleroderma renal crisis after high-dose methylprednisolone treatment.|normotensive scleroderma renal crisis|10|47|methylprednisolone|64|82
10885900|HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens.|HUS|0|3|mitomycin C|83|94
10885900|Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.|Severe hemolytic uremic syndrome|0|32|carboplatin|84|95
10885900|Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.|Severe hemolytic uremic syndrome|0|32|gemcitabine|100|111
10885900|We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up.|HUS|21|24|carboplatin|76|87
10885900|We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up.|HUS|21|24|gemcitabine|92|103
10891991|An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment.|menstrual cycle disturbances|168|196|valproate|117|126
10891991|BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy.|hyperandrogenism|107|123|sodium valproate|167|183
10891991|BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy.|menstrual disorders|62|81|sodium valproate|167|183
10891991|BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy.|polycystic ovaries|83|101|sodium valproate|167|183
10891991|BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy.|Reproductive endocrine disorders|12|44|sodium valproate|167|183
10891991|CONCLUSIONS: The 3 cases presented here illustrate the development of reproductive endocrine disorders after the initiation of valproate therapy in women with epilepsy.|reproductive endocrine disorders|70|102|valproate|127|136
10891991|OBJECTIVE: To describe the development of valproate-related reproductive endocrine disorders in women with epilepsy.|reproductive endocrine disorders|60|92|valproate|42|51
10891991|PATIENTS: Three patients developed a reproductive endocrine disorder during treatment with valproate.|reproductive endocrine disorder|37|68|valproate|91|100
10891991|RESULTS: Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women.|serum testosterone|72|90|valproate|19|28
10891991|The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.|amenorrhea|164|174|valproate|200|209
10891991|The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.|gained weight|136|149|valproate|200|209
10891991|The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.|polycystic changes|4|22|valproate|76|85
10897389|However, recurrent staphylococcus aureus sepsis developed during CyA therapy.|staphylococcus aureus sepsis|19|47|CyA|65|68
10897389|Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis.|lethal|26|32|cyclosporine|58|70
10897389|Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis.|septicemia|10|20|cyclosporine|58|70
10904571|A 60 year-old woman with chronic renal failure developed acute proximal muscle weakness after receiving a regular dosage of colchicine.|proximal muscle weakness|63|87|colchicine|124|134
10904571|Colchicine-induced myopathy in renal failure.|myopathy|19|27|Colchicine|0|10
10904571|Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine-induced myopathy.|myopathy|122|130|colchicine|103|113
10904571|Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine-induced myopathy.|vacuolated fibers|62|79|colchicine|103|113
10904571|Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine-induced myopathy.|variation in muscle fiber size|23|53|colchicine|103|113
10907391|A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.|disabling neurotoxicity|28|51|paclitaxel|133|143
10907391|Phantom limb pain as a manifestation of paclitaxel neurotoxicity.|neurotoxicity|51|64|paclitaxel|40|50
10907391|Phantom limb pain as a manifestation of paclitaxel neurotoxicity.|Phantom limb pain|0|17|paclitaxel|40|50
10907391|Physicians should be aware that PLP can occur after initiation of paclitaxel.|PLP|32|35|paclitaxel|66|76
10907391|We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.|phantom limb pain|61|78|paclitaxel|101|111
10907391|We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.|PLP|80|83|paclitaxel|101|111
10923593|Skin manifestations of a case of phenylbutazone-induced serum sickness-like reactions.|serum sickness-like reactions|56|85|phenylbutazone|33|47
10923593|Skin manifestations of a case of phenylbutazone-induced serum sickness-like reactions.|Skin manifestations|0|19|phenylbutazone|33|47
10928688|Our experience supports hemodialysis for ESRF patients with atenolol toxicity.|atenolol toxicity|60|77|atenolol|60|68
10963515|Allergic reaction to gemfibrozil manifesting as eosinophilic gastroenteritis.|eosinophilic gastroenteritis|48|76|gemfibrozil|21|32
10963515|We describe a case of EGE manifested as an allergy to gemfibrozil.|EGE|22|25|gemfibrozil|54|65
10970989|This is the second report of lactic acidosis in a patient on stavudine and lamivudine.|lactic acidosis|29|44|lamivudine|75|85
10970989|This is the second report of lactic acidosis in a patient on stavudine and lamivudine.|lactic acidosis|29|44|stavudine|61|70
10970989|We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.|lactic acidosis|53|68|lamivudine|86|96
10970989|We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.|lactic acidosis|53|68|stavudine|72|81
10981493|Ataxia caused by propafenone has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature.|Ataxia|0|6|propafenone|17|28
10981493|A wide variety of adverse central nervous system effects have been reported in association with propafenone; dizziness is the most common.|adverse central nervous system effects|18|56|propafenone|96|107
10981493|A wide variety of adverse central nervous system effects have been reported in association with propafenone; dizziness is the most common.|dizziness|109|118|propafenone|96|107
10981493|Propafenone-induced ataxia: report of three cases.|ataxia|20|26|Propafenone|0|11
10981493|We describe 3 elderly patients with moderate to severe ataxia that occurred while they were taking propafenone.|ataxia|55|61|propafenone|99|110
10987357|A 74-year-old man received oral administration of pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later.|loss of consciousness|195|216|pilsicainide|50|62
10987357|When pilsicainide is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid life-threatening arrhythmias due to high plasma concentrations of the drug.|life-threatening arrhythmias|133|161|pilsicainide|5|17
11001600|The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.|dystonia|151|159|risperidone|108|119
11008259|Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.|non-convulsive status epilepticus|15|48|tiagabine|52|61
11008259|The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.|non-convulsive status epilepticus|14|47|tiagabine|80|89
11008259|This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.|non-convulsive status epilepticus|28|61|tiagabine|74|83
110153|There have been many reports of probable lithium-induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range.|organic brain syndromes|57|80|lithium|41|48
110153|When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity.|intense anxiety|77|92|lithium|173|180
110153|When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity.|neurotoxicity|181|194|lithium|173|180
110153|When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity.|psychotic symptoms|54|72|lithium|173|180
11020127|Protease inhibitor-induced carbamazepine toxicity.|carbamazepine toxicity|27|49|carbamazepine|27|40
11020127|Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|carbamazepine toxicity|131|153|carbamazepine|131|144
11020127|Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|carbamazepine toxicity|131|153|ritonavir|21|30
11020127|Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|carbamazepine toxicity|131|153|saquinavir|35|45
11020127|Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|progressive ataxia|101|119|carbamazepine|131|144
11020127|Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|progressive ataxia|101|119|ritonavir|21|30
11020127|Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|progressive ataxia|101|119|saquinavir|35|45
11020127|Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity.|clinical toxicity|122|139|Ritonavir|0|9
11020127|Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity.|diminishing carbamazepine metabolism|39|75|Ritonavir|0|9
11020127|Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity.|increase in serum levels|93|117|Ritonavir|0|9
11020127|The patient was diagnosed with carbamazepine toxicity related to the introduction of ritonavir.|carbamazepine toxicity|31|53|carbamazepine|31|44
11020127|The patient was diagnosed with carbamazepine toxicity related to the introduction of ritonavir.|carbamazepine toxicity|31|53|ritonavir|85|94
11022272|Anaphylaxis to calcitonin.|Anaphylaxis|0|11|calcitonin|15|25
11022272|CONCLUSION: We have introduced a case of anaphylaxis by calcitonin that suggest an IgE mediated hypersensitivity reaction.|anaphylaxis |41|53|calcitonin|56|66
11022272|The intramuscular challenge test with 25 UI of Miacalcic was positive with an immediate anaphylactic reaction.|anaphylactic reaction|88|109|Miacalcic|47|56
11022272|We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|conjunctivitis|91|105|calcitonin|170|180
11022272|We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|conjunctivitis|91|105|Calsynar|231|239
11022272|We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|perspiration|110|122|calcitonin|170|180
11022272|We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|perspiration|110|122|Calsynar|231|239
11022272|We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|rhinitis|81|89|calcitonin|170|180
11022272|We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|rhinitis|81|89|Calsynar|231|239
11026106|Minocycline as a cause of drug-induced autoimmune hepatitis.|autoimmune hepatitis|39|59|Minocycline|0|11
11026106|Minocycline-induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis.|autoimmune hepatitis|20|40|Minocycline|0|11
11026106|We describe the clinical and liver biopsy morphologic features for 4 patients with minocycline-induced autoimmune hepatitis (group 1).|autoimmune hepatitis|103|123|minocycline|83|94
11030530|L-asparaginase-provoked seizures as singular expression of central nervous toxicity.|central nervous toxicity|59|83|L-asparaginase|0|14
11030530|L-asparaginase-provoked seizures as singular expression of central nervous toxicity.|seizures|24|32|L-asparaginase|0|14
11030530|Patients treated with L-asparaginase may present with hemorrhagic and thrombotic cerebrovascular events.|hemorrhagic|54|65|L-asparaginase|22|36
11030530|Patients treated with L-asparaginase may present with hemorrhagic and thrombotic cerebrovascular events.|thrombotic cerebrovascular events|70|103|L-asparaginase|22|36
11030530|We report a case of seizure associated with L-asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events.|seizure|20|27|L-asparaginase|44|58
11033734|Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified.|neutropenic fever|93|110|cilastatin|68|78
11033734|Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified.|neutropenic fever|93|110|imipenem|59|67
11033734|Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.|seizures|13|21|cilastatin|73|83
11033734|Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.|seizures|13|21|imipenem|64|72
11033734|Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects.|Proconvulsive|0|13|cilastatin|35|45
11033734|Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects.|Proconvulsive|0|13|imipenem|26|34
11033734|Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|convulsions|28|39|cilastatin|63|73
11033734|Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|convulsions|28|39|imipenem|54|62
11033734|Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|seizure|100|107|cilastatin|63|73
11033734|Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|seizure|100|107|imipenem|54|62
11033734|Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|seizure|172|179|cilastatin|127|137
11033734|Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|seizure|172|179|imipenem|118|126
11034877|Gabapentin-induced mood changes with hypomanic features in adults.|hypomanic|37|46|Gabapentin|0|10
11034877|Gabapentin-induced mood changes with hypomanic features in adults.|mood changes|19|31|Gabapentin|0|10
11034877|We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects.|behavioural side effects|78|102|gabapentin|34|44
11034877|We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects.|behavioural side effects|78|102|GBP|46|49
11059196|Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.|Acute pancreatitis|0|18|5-aminosalicylic acid|78|99
11059196|We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.|acute pancreatitis|68|86|5-aminosalicylic acid|121|142
11077455|CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.|visual field constriction|19|44|vigabatrin|75|85
11077455|Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.|visual field constriction|142|167|vigabatrin|120|130
11077455|PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.|visual field constriction|21|46|vigabatrin|77|87
11077455|The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.|visual field loss|129|146|vigabatrin|107|117
11077455|The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.|field defects|4|17|vigabatrin|75|85
11093071|Depressive symptoms disappeared after interferon therapy was stopped.|Depressive symptoms|0|19|interferon|38|48
11093071|Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.|psychiatric side effects|163|187|IFN-alpha|56|65
11093071|Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.|psychiatric side effects|163|187|interferon alpha|38|54
11093071|While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent changes in serotonergic or noradrenergic neurotransmission caused by IFN-alpha.|changes in serotonergic or noradrenergic neurotransmission|102|160|IFN-alpha|171|180
11096051|Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.|vancomycin toxicity|73|92|vancomycin|73|83
11096051|Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.|vancomycin toxicity|91|110|vancomycin|91|101
11099623|We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.|morbidity|68|77|hyperbaric oxygen|111|128
11105373|A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.|brown discolouration of the fingernails|34|73|0.1% tretinoin cream|142|162
11105373|A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.|brown discolouration of the fingernails|34|73|4% hydroquinone in sorbolene cream|103|137
11105373|Nail staining from hydroquinone cream.|Nail staining|0|13|hydroquinone|19|31
11109149|Gangrene of the fingertips after bleomycin and methotrexate.|Gangrene|0|8|bleomycin|33|42
11109149|Gangrene of the fingertips after bleomycin and methotrexate.|Gangrene|0|8|methotrexate|47|59
11109149|This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.|acral vascular toxicity|66|89|bleomycin|45|54
11109149|We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.|acute digital ischemia|72|94|bleomycin|152|161
11109149|We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.|acute digital ischemia|72|94|methotrexate|166|178
11109149|We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.|gangrene|99|107|bleomycin|152|161
11109149|We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.|gangrene|99|107|methotrexate|166|178
11111942|Diarrhea-associated over-anticoagulation in a patient taking warfarin: therapeutic role of cholestyramine.|Diarrhea-associated over-anticoagulation|0|40|warfarin|61|69
11111942|We present a case of significant over-anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy.|diarrhea|102|110|warfarin|127|135
11111942|We present a case of significant over-anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy.|over-anticoagulation|33|53|warfarin|127|135
11122162|MI related to the use of activated and non-activated PCCs predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate.|MI|0|2|PCCs|53|57
11122162|Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.|myocardial infarction|109|130|prothrombin complex concentrate|69|100
11122162|We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following PCC-related MI.|MI|122|124|PCC|110|113
11126885|Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.|thrombocytopenia|118|134|quinine|45|52
11126885|Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.|thrombocytopenia|118|134|quinine|166|173
11126885|Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.|thrombocytopenia|182|198|quinine|166|173
11126885|Occult quinine-induced thrombocytopenia.|thrombocytopenia|23|39|quinine|7|14
11126885|Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.|thrombocytopenia|60|76|quinine|169|176
11131346|An 8-year-old child with familial Mediterranean fever exhibited signs of colchicine intoxication while receiving prophylactic doses of the drug.|colchicine intoxication|73|96|colchicine|73|83
11131346|CONCLUSION: To the best of our knowledge, this is the first time colchicine intoxication in this age group has been described in the English literature.|colchicine intoxication|65|88|colchicine|65|75
11131346|Near fatal acute colchicine intoxication in a child.|colchicine intoxication|17|40|colchicine|17|27
11131346|Near fatal acute colchicine intoxication in a child.|Near fatal|0|10|colchicine|17|27
11142491|Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.|Acute myeloid leukemia|0|22|fludarabine|104|115
11142491|Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.|lung cancer|27|38|fludarabine|104|115
11142491|We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem-cell transplantation.|AML|43|46|fludarabine|147|158
11142491|We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem-cell transplantation.|lung cancer|51|62|fludarabine|147|158
11147747|In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.|incontinence|131|143|lithium carbonate|50|67
11147747|In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.|incontinence|74|86|paroxetine|144|154
11147747|In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.|incontinence|74|86|sertraline|159|169
11147747|In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.|incontinence|74|86|venlafaxine|224|235
11147747|This concerns 2 male patients who experienced incontinence while taking venlafaxine.|incontinence|46|58|venlafaxine|72|83
11155197|Case studies in heparin-induced thrombocytopenia.|thrombocytopenia|32|48|heparin|16|23
11155197|Major points illustrated are, (1) occurrence of HIT with any dose or form of heparin; (2) misperceptions on the diagnostic criteria; (3) correct (thrombin inhibitors) and incorrect (platelet transfusions and warfarin) management; (4) influence of management strategy on clinical outcomes; (5) severity of the syndrome; and (6) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time.|HIT|48|51|heparin|77|84
11155197|Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.|thrombocytopenia|24|40|heparin|8|15
11171531|After several unrevealing medical work-ups, he was found to have a high blood lead level (122 microg/dL); he has a history of scraping and sanding lead paint without adequate protective measures.|high blood lead level|67|88|lead|78|82
11171531|It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.|hypertension|139|151|lead|91|95
11171531|It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.|lead-induced hypertension|185|210|lead|185|189
11171531|Poorly controlled hypertension in a painter with chronic lead toxicity.|lead toxicity|57|70|lead|57|61
11171531|This case demonstrates an occupational activity (construction) that has now become the dominant source of lead exposure for U.S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic lead toxicity, and the importance of preventing further exposure and using proper methods to treat acute toxicity.|lead toxicity|254|267|lead|254|258
11174414|Severe rash, including the Stevens-Johnson syndrome (SJS), is the major toxicity of nevirapine and is described in the package labeling with a prominent, boxed warning.|Severe rash|0|11|nevirapine|84|94
11174414|Severe rash, including the Stevens-Johnson syndrome (SJS), is the major toxicity of nevirapine and is described in the package labeling with a prominent, boxed warning.|SJS|53|56|nevirapine|84|94
11174414|Severe rash, including the Stevens-Johnson syndrome (SJS), is the major toxicity of nevirapine and is described in the package labeling with a prominent, boxed warning.|Stevens-Johnson syndrome|27|51|nevirapine|84|94
11174414|Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine.|Stevens-Johnson syndrome|0|24|nevirapine|59|69
11174414|Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of nevirapine-associated SJS has been documented in the dermatology literature.|SJS|150|153|nevirapine|128|138
11174414|We describe 2 cases of SJS related to nevirapine use and review the literature on this newly recognized association.|SJS|23|26|nevirapine|38|48
11180704|Oral intake and acarbose were withheld and the ileus spontaneously resolved after 2 days.|ileus|47|52|acarbose|16|24
11191005|There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.|increases urate excretion|73|98|losartan|63|71
11200291|Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.|Atrial fibrillation|0|19|etanercept|50|60
11200291|Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.|Atrial fibrillation|0|19|methotrexate|66|78
11202801|A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.|hepatic angiosarcoma|55|75|cyclophosphamide|104|120
11202801|Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.|Hepatic angiosarcoma|0|20|cyclophosphamide|37|53
11202801|We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.|hepatic angiosarcoma|95|115|cyclophosphamide|16|32
11207969|ARA-C is frequently associated with dermatologic toxicity, but this is only the second case of toxic epidermal necrolysis described in connection with this drug.|dermatologic toxicity|36|57|ARA-C|0|5
11207969|ARA-C is frequently associated with dermatologic toxicity, but this is only the second case of toxic epidermal necrolysis described in connection with this drug.|toxic epidermal necrolysis|95|121|ARA-C|0|5
11207969|On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.|bullous lesions on the hands and soles that disseminated, evolving to necrosis|115|193|ARA-C|56|61
11207969|On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.|death|207|212|ARA-C|56|61
11207969|On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.|sepsis|195|201|ARA-C|56|61
11207969|Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.|Toxic epidermal necrolysis|0|26|cytosine arabinoside|54|74
11207969|We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).|TEN|54|57|ARA-C|111|116
11207969|We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).|TEN|54|57|cytosine arabinoside|89|109
11207969|We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).|toxic epidermal necrolysis|26|52|ARA-C|111|116
11207969|We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).|toxic epidermal necrolysis|26|52|cytosine arabinoside|89|109
11212595|Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.|obsessive-compulsive symptoms|15|44|Quetiapine|0|10
11212595|Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.|OCS|109|112|Quetiapine|0|10
11212595|Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.|OCS|46|49|Quetiapine|0|10
11212595|The first known report of quetiapine exacerbating OCS in a 43-year-old man with obsessive-compulsive disorder (OCD), trichotillomania, delusional disorder and bipolar II disorder is presented.|exacerbating OCS|37|53|quetiapine|26|36
11215836|He was diagnosed with possible serotonin syndrome; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later.|serotonin syndrome|31|49|clomipramine|79|91
11215836|OBJECTIVE: To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen.|serotonin syndrome|52|70|clomipramine|94|106
11215836|OBJECTIVE: To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen.|serotonin syndrome|52|70|clozapine|113|122
11215836|Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine.|serotonin syndrome|9|27|clomipramine|44|56
11215836|Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine.|serotonin syndrome|9|27|clozapine|77|86
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|agitated|175|183|clomipramine|66|78
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|agitated|175|183|clozapine|14|23
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|behaving oddly|98|112|clomipramine|66|78
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|behaving oddly|98|112|clozapine|14|23
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|confused|189|197|clomipramine|66|78
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|confused|189|197|clozapine|14|23
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|shivering|142|151|clomipramine|66|78
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|shivering|142|151|clozapine|14|23
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|sweating profusely|122|140|clomipramine|66|78
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|sweating profusely|122|140|clozapine|14|23
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|tremulous|164|173|clomipramine|66|78
11215836|The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|tremulous|164|173|clozapine|14|23
11225532|Quinine induced coagulopathy--a near fatal experience.|coagulopathy|16|28|Quinine|0|7
11225532|The cause of his bleeding was a severe thrombocytopoaenia, induced by chronic ingestion of quinine.|severe thrombocytopoaenia|32|57|quinine|91|98
11236070|Dose-dependent olanzapine-associated leukopenia: three case reports.|leukopenia|37|47|olanzapine|15|25
11236070|These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.|agranulocytosis|74|89|olanzapine|97|107
11236070|These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.|leukopenia|60|70|olanzapine|97|107
11236070|We report three cases of patients who developed leukopenia during olanzapine treatment.|leukopenia|48|58|olanzapine|66|76
11243427|CONCLUSION: This case illustrates a potential link between dermatologic and ocular 5-FU toxicities.|dermatologic and ocular 5-FU toxicities|59|98|5-FU|83|87
11243427|Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and 5-FU-induced ectropion.|ectropion|96|105|5-FU|83|87
11243427|DISCUSSION: Patients with 5-FU-induced ectropion experience tender, red, scaled lids, making contact lens wear difficult.|ectropion|39|48|5-FU|26|30
11243427|DISCUSSION: Patients with 5-FU-induced ectropion experience tender, red, scaled lids, making contact lens wear difficult.|tender, red, scaled lids|60|84|5-FU|26|30
11243427|Ectropion secondary to bolus injection of 5-fluorouracil.|Ectropion|0|9|5-fluorouracil|42|56
11243427|Exacerbation of 5-FU dermatologic toxicities in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions.|dermatologic toxicities|21|44|5-FU|16|20
1124417|Presented is a case of acute renal failure induced by acetazolamide therapy for glaucoma.|acute renal failure|23|42|acetazolamide|54|67
1124417|Renal failure associated with acetazolamide therapy for glaucoma.|Renal failure|0|13|acetazolamide|30|43
1124417|This sulfonamide like nephropathy should be differentiated from acetazolamide-related calcium phosphate nephrolithiasis.|calcium phosphate nephrolithiasis|86|119|acetazolamide|64|77
11247558|Ischaemic colitis in a patient taking meloxicam.|Ischaemic colitis|0|17|meloxicam|38|47
11247558|Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.|endoscopic lesions|13|31|meloxicam|67|76
11247558|We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.|bloody diarrhoea|41|57|meloxicam|70|79
11247558|We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.|intestinal toxic effects|37|61|meloxicam|16|25
11250985|As these cases revealed, close monitoring of blood chemistry is mandatory after starting spironolactone, and patients should be advised to stop spironolactone immediately if diarrhoea develops.|diarrhoea|174|183|spironolactone|144|158
11250985|In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia.|serious and, occasionally, fatal hyperkalaemia|99|145|spironolactone|40|54
11250985|In some cases this seems to happen because spironolactone causes diarrhoea.|diarrhoea|65|74|spironolactone|43|57
11250985|Serious adverse events experienced by patients with chronic heart failure taking spironolactone.|Serious adverse events|0|22|spironolactone|81|95
11292139|We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin and developed a peculiar dermnatitis in the irradiated field after being exposed to subsequent chemotherapy with oxaliplatin.|dermnatitis|144|155|oxaliplatin|107|118
11295724|An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.|severe enteropathy|31|49|clofazimine|78|89
11295724|Clofazimine enteropathy caused by crystal deposition can be life-threatening.|enteropathy|12|23|Clofazimine|0|11
11295724|Clofazimine enteropathy caused by crystal deposition can be life-threatening.|life-threatening|60|76|Clofazimine|0|11
11295724|Clofazimine enteropathy in a pediatric bone marrow transplant recipient.|enteropathy|12|23|Clofazimine|0|11
11302479|She developed a severe urticarial rash 3 weeks following initiation of therapy with Enoxaparin.|severe urticarial rash|16|38|Enoxaparin|84|94
11315123|We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.|blurred vision|76|90|cibenzoline|142|153
11315123|We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.|cardiac failure|111|126|cibenzoline|142|153
11315123|We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.|cibenzoline intoxication|142|166|cibenzoline|142|153
11315123|We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.|QRS broadening|92|106|cibenzoline|142|153
11319599|Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.|aspergillus arthritis|9|30|fludarabine|44|55
11319599|We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.|aspergillus arthritis of the knee joint|30|69|fludarabine|80|91
11328247|CONCLUSION: The present findings suggest that fluvoxamine can cause increased libido in some patients.|increased libido|68|84|fluvoxamine|46|57
11328247|Increased libido in a woman treated with fluvoxamine: a case report.|Increased libido|0|16|fluvoxamine|41|52
11328247|OBJECTIVE: The aim of this paper is to describe a case of increased libido during fluvoxamine therapy.|increased libido|58|74|fluvoxamine|82|93
11328247|RESULTS: The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an increased libido with the administration of fluvoxamine.|increased libido|110|126|fluvoxamine|154|165
11328247|The increased libido disappeared after fluvoxamine was discontinued.|increased libido|4|20|fluvoxamine|39|50
11332679|An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported.|pancreatitis|24|36|meglumine antimoniate|44|65
11332679|Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.|pancreatitis|109|121|meglumine antimoniate|132|153
11335880|CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.|Hashimoto's disease|69|88|IFN-alpha|95|104
11335880|Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of thyroid disorders during the IFN-alpha treatment.|autoimmune thyroiditis|158|180|IFN-alpha|249|258
11335880|Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of thyroid disorders during the IFN-alpha treatment.|thyroid disorders|220|237|IFN-alpha|249|258
11335880|Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.|Hashimoto's disease|0|19|interferon-alpha|27|43
11335880|OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.|Hashimoto's disease|44|63|IFN-alpha|89|98
11335880|OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.|Hashimoto's disease|44|63|interferon-alpha|71|87
11341670|During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.|peripheral edema|219|235|omeprazole|143|153
11341670|During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.|peripheral edema|219|235|pantoprazole|196|208
11341670|Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.|Pheripheral edema|0|17|lansoprazole|103|115
11341670|Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.|Pheripheral edema|0|17|omeprazole|91|101
11341670|Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.|Pheripheral edema|0|17|pantoprazole|120|132
11346113|Motor fluctuations appear after 2-3 years of levodopa treatment, and affect at least 50% of patients after five years.|Motor fluctuations|0|18|levodopa|45|53
11352235|CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.|weight loss|24|35|leflunomide|116|127
11352235|Leflunomide-associated weight loss in rheumatoid arthritis.|weight loss|23|34|Leflunomide|0|11
11352235|METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.|weight loss|100|111|leflunomide|170|181
11352235|OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.|weight loss|41|52|leflunomide|78|89
11352235|RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.|weight loss|79|90|leflunomide|43|54
11359026|It is increasingly recognized that dose adjustment of oral valacyclovir in renal failure is necessary to avoid neurotoxicity.|neurotoxicity|111|124|valacyclovir|59|71
11359026|Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.|Neurotoxicity|0|13|valacyclovir|17|29
11359026|She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.|neurotoxicity|14|27|valacyclovir|57|69
11373877|Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy.|Avascular necrosis of the femoral head|0|38|cyproterone acetate|85|104
11373877|We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed femoral head avascular necrosis.|femoral head avascular necrosis|291|322|cyproterone acetate|189|208
11388112|Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.|polymorphic ventricular tachycardia|21|56|Levofloxacin|0|12
11388112|We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.|polymorphic ventricular tachycardia|28|63|levofloxacin|120|132
11399735|So far, few cases of pulmonary side effects caused by ticlopidine have been reported.|pulmonary side effects|21|43|ticlopidine|54|65
11399735|Special care should be taken when pulmonary symptoms appear in association with ticlopidine treatment.|pulmonary symptoms|34|52|ticlopidine|80|91
11399735|Ticlopidine-induced interstitial pulmonary disease: a case report.|interstitial pulmonary disease|20|50|Ticlopidine|0|11
11399735|We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine.|interstitial pulmonary disease|20|50|ticlopidine|121|132
11399735|We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine.|lymphocytic colitis|79|98|ticlopidine|121|132
11406880|A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.|myoclonus|71|80|methadone|24|33
11406880|Methadone-induced myoclonus in advanced cancer.|myoclonus|18|27|Methadone|0|9
11414270|OBJECTIVE: To report a case of fatal hyperkalemia owing to succinylcholine administration in a patient with mucositis secondary to chemotherapy.|fatal hyperkalemia|31|49|succinylcholine|59|74
11414270|Succinylcholine-induced hyperkalemia in a patient with mucositis secondary to chemotherapy.|hyperkalemia|24|36|Succinylcholine|0|15
11414270|We believe that mucositis was a contributing factor to this case of fatal hyperkalemia after administration of succinylcholine, with a mechanism similar to that reported with thermal injury.|fatal hyperkalemia|68|86|succinylcholine|111|126
11424102|Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma.|Cutaneous seeding|0|17|ethanol injection|55|72
11424102|We describe a case of needle-track cutaneous seeding of hepatocellular carcinoma (HCC) after sonographically guided percutaneous ethanol injection (PEI).|cutaneous seeding|35|52|ethanol injection|129|146
11428480|Adenosine-induced ventricular fibrillation.|ventricular fibrillation|18|42|Adenosine|0|9
11428480|However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.|acceleration of the ventricular rate|113|149|adenosine|9|18
11428480|We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.|ventricular fibrillation|12|36|adenosine|154|163
11431864|After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the psychotic reaction disappeared a few hours later.|psychotic reaction|172|190|methylprednisolone|18|36
11435808|Continuous EEG monitoring is helpful in managing seizures that occur as a complication of CBZ OD, after the course of recovery or worsening, and in providing assistance with prognosis.|seizures|49|57|CBZ|90|93
11435808|Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.|cortical hyperexcitability|69|95|CBZ|8|11
11435808|Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.|cranial nerve areflexia|143|166|CBZ|8|11
11435808|Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.|profound burst-suppression EEG pattern|99|137|CBZ|8|11
11435808|Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.|reversible encephalopathy|29|54|CBZ|8|11
11443640|Massive plasmocytosis due to methimazole-induced bone marrow toxicity.|bone marrow toxicity|49|69|methimazole|29|40
11443640|Massive plasmocytosis due to methimazole-induced bone marrow toxicity.|Massive plasmocytosis|0|21|methimazole|29|40
11443640|To our knowledge this is the first report of pancytopenia due to MMI, where the usual hypoplasia found is replaced by massive plasmocytosis.|massive plasmocytosis|118|139|MMI|65|68
11443640|To our knowledge this is the first report of pancytopenia due to MMI, where the usual hypoplasia found is replaced by massive plasmocytosis.|pancytopenia|45|57|MMI|65|68
11450788|We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.|fulminant hepatic failure|20|45|didanosine|62|72
11452688|This report details a case of bilateral avascular necrosis of the femoral heads in a patient receiving 'standard' doses of dexamethasone as part of the antiemetic regimen used in cisplatin-based combination chemotherapy.|bilateral avascular necrosis of the femoral heads|30|79|dexamethasone|123|136
11468878|Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.|hemorrhage|149|159|metformin|185|194
11468878|An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.|severe inferior digestive hemorrhage|95|131|metformin|45|54
11468878|Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?|Digestive hemorrhage|0|20|metformin|60|69
11476690|Ulcer became worse after tobramycin and gentamycin treatment for 2 days.|Ulcer became worse|0|18|gentamycin|40|50
11476690|Ulcer became worse after tobramycin and gentamycin treatment for 2 days.|Ulcer became worse|0|18|tobramycin|25|35
11483161|Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac.|intracranial bleeding|36|57|amprenavir|20|30
11483161|The bleeding resolved on discontinuation of APV.|bleeding|4|12|APV|44|47
11483161|We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV).|intracranial bleeding|40|61|amprenavir|159|169
11485141|According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.|cutaneous eruption|91|109|gemcitabine|64|75
11485141|CONCLUSIONS: We report the first case of gemcitabine-induced LABD.|LABD|61|65|gemcitabine|41|52
11485141|Linear immunoglobulin A bullous dermatosis induced by gemcitabine.|Linear immunoglobulin A bullous dermatosis|0|42|gemcitabine|54|65
11485141|OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.|LABD|80|84|gemcitabine|97|108
11485141|OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.|linear immunoglobulin (Ig) A bullous dermatosis|31|78|gemcitabine|97|108
11485141|Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.|symmetric, bullous, herpetiform eruption|61|101|gemcitabine|46|57
11485141|Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.|LABD|96|100|Vancomycin|0|10
11487721|Although taxol has shown significant activity in advanced ovarian cancer, peripheral neuropathy is likely to become the major dose-limiting toxicity.|peripheral neuropathy|74|95|taxol|9|14
11487721|A rare case of advanced ovarian carcinoma who developed difficulty walking 25 days after treatment with weekly paclitaxel.|difficulty walking|56|74|paclitaxel|111|121
11487721|We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3).|difficulty walking|63|81|taxol|193|198
11487721|We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3).|loss of proprioception|134|156|taxol|193|198
11487721|We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3).|marked pain|93|104|taxol|193|198
11489400|Relief by naloxone of morphine-induced spasm of the sphincter of Oddi in a post-cholecystectomy patient.|spasm|39|44|morphine|22|30
11489400|We present the case of a patient who had undergone cholecystectomy previously, but in whom morphine given in the Emergency Department precipitated pain consistent with biliary colic; the pain resolved promptly after administration of naloxone.|biliary colic|168|181|morphine|91|99
11489400|We present the case of a patient who had undergone cholecystectomy previously, but in whom morphine given in the Emergency Department precipitated pain consistent with biliary colic; the pain resolved promptly after administration of naloxone.|pain|147|151|morphine|91|99
11506739|Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C.|Myasthenia gravis|0|17|IFN-alpha|34|43
115078|A patient with rheumatoid arthritis developed an acute intrahepatic cholestasis after 100 mg of sodium aurothiomalate.|intrahepatic cholestasis|55|79|sodium aurothiomalate|96|117
11510798|Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.|Acute lung injury|0|17|5-fluorouracil|34|48
11510798|Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.|Acute lung injury|0|17|oxaliplatinum|53|66
11510798|Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|bilateral patchy pulmonary infiltrates|34|72|5-fluorouracil|147|161
11510798|Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|bilateral patchy pulmonary infiltrates|34|72|oxaliplatinum|129|142
11510798|Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|Diarrhoea|0|9|5-fluorouracil|147|161
11510798|Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|Diarrhoea|0|9|oxaliplatinum|129|142
11510798|Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|T-CD4+ lymphopenia|11|29|5-fluorouracil|147|161
11510798|Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|T-CD4+ lymphopenia|11|29|oxaliplatinum|129|142
11510798|It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.|pulmonary adverse reaction|108|134|5-fluorouracil|197|211
11510798|It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.|pulmonary adverse reaction|108|134|oxaliplatinum|179|192
11514944|BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.|teratogenic|23|34|Accutane|12|20
11514944|RESULTS: The estimated number of Accutane prescriptions for reproductive-aged women has more than doubled in the past 10 years; it is the most widely used teratogenic drug in the United States, with approximately 2.5 per 1,000 reproductive-aged women exposed to Accutane in 1999.|teratogenic|155|166|Accutane|33|41
11518127|A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.|high fever|99|109|pranlukast|33|43
11518127|A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.|interstitial pneumonitis|67|91|pranlukast|33|43
11518127|Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.|interstitial pneumonia|6|28|ONO-1078|40|48
11518127|Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.|interstitial pneumonia|6|28|pranlukast|50|60
11545487|An asymptomatic HIV-infected woman experienced right-sided renal colicky pain during treatment with indinavir.|renal colicky pain|59|77|indinavir|100|109
11545487|Indinavir-associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient.|interstitial nephritis|49|71|Indinavir|0|9
11545487|Indinavir-associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient.|nephrolithiasis|21|36|Indinavir|0|9
11545487|Papillary necrosis associated with the HIV protease inhibitor indinavir.|Papillary necrosis|0|18|indinavir|62|71
11545487|Physicians should be aware that indinavir nephrolithiasis may cause papillary necrosis.|nephrolithiasis|42|57|indinavir|32|41
11545487|Physicians should be aware that indinavir nephrolithiasis may cause papillary necrosis.|papillary necrosis|68|86|indinavir|32|41
11545487|The HIV protease inhibitor indinavir may cause nephrolithiasis and interstitial nephritis.|interstitial nephritis|67|89|indinavir|27|36
11545487|The HIV protease inhibitor indinavir may cause nephrolithiasis and interstitial nephritis.|nephrolithiasis|47|62|indinavir|27|36
11545487|The renal consequences of indinavir-associated nephrotoxicity are uncertain.|nephrotoxicity|47|61|indinavir|26|35
11545487|We report a case of papillary necrosis in a patient treated with indinavir.|papillary necrosis|20|38|indinavir|65|74
11550988|We describe 2 male patients, a 49-year-old with psoriatic arthritis and impaired renal function and a 43-year-old renal transplant recipient, who both sustained a marked decline in glomerular filtration rate in conjunction with a selective inhibitor of cyclooxygenase-2 (COX-2), rofecoxib.|decline in glomerular filtration rate|170|207|rofecoxib|279|288
11554897|CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.|encephalopathy|64|78|LTG|13|16
11554897|Evaluation revealed elevated serum LTG levels and no other etiology for encephalopathy.|elevated serum LTG levels|20|45|LTG|35|38
11554897|METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.|stuporous|36|45|lamotrigine|66|77
11554897|METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.|stuporous|36|45|LTG|79|82
11554897|METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.|stuporous|36|45|valproic acid|88|101
11554897|METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.|stuporous|36|45|VPA|103|106
11554897|PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.|encephalopathy|73|87|lamotrigine|30|41
11554897|Stupor from lamotrigine toxicity.|Stupor|0|6|lamotrigine|12|23
11563738|The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.|acute intoxication|40|58|olanzapine|62|72
11563738|This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.|dead|59|63|olanzapine|96|106
11568758|Lichenoid drug eruption to salsalate.|Lichenoid drug eruption|0|23|salsalate|27|36
11568758|This eruption emerged after 1 month of therapy with salsalate, persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication.|eruption|5|13|salsalate|52|61
11568758|We describe a patient who experienced a lichenoid eruption after the initiation of salsalate for relief of arthritic pain.|lichenoid eruption|40|58|salsalate|83|92
11573852|Amphotericin B-induced seizures in a patient with AIDS.|seizures|23|31|Amphotericin B|0|14
11573852|CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.|grand mal seizures|71|89|amphotericin B|121|135
11573852|CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.|seizures|66|74|Amphotericin B|13|27
11573852|Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.|seizures|55|63|amphotercin B|99|112
11573852|Didanosine also has a potential for inducing seizures.|seizures|45|53|Didanosine|0|10
11573852|OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.|seizure|52|59|amphotericin B|97|111
11573852|The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.|seizures|77|85|amphotericin B|41|55
11573852|To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.|seizures|29|37|amphotericin B|54|68
11576059|Vocal cord paralysis as a consequence of peritonsillar infiltration with bupivacaine.|Vocal cord paralysis|0|20|bupivacaine|73|84
11576059|We present the case of a 5-year-old girl who developed bilateral vocal cord paralysis following preoperative peritonsillar bupivacaine infiltration.|bilateral vocal cord paralysis|55|85|bupivacaine|123|134
11590881|A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.|right bundle branch block|95|120|carbamazepine|156|169
11590881|Carbamazepine induced right bundle branch block in a Greenlandic patient.|right bundle branch block|22|47|Carbamazepine|0|13
11642488|Cicatricial entropion associated with chronic dipivefrin application.|Cicatricial entropion|0|21|dipivefrin|46|56
11642488|CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.|entropion|217|226|dipivefrin|168|178
11642488|Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.|cicatricial entropion|99|120|dipivefrin|174|184
11642488|PURPOSE: To report patients who presented to the oculoplastics department for repair of cicatrical entropion after topical use of dipivefrin.|cicatrical entropion|88|108|dipivefrin|130|140
11672959|A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.|constellation of dermatitis|31|58|sulphasalazine|144|158
11672959|A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.|fever|60|65|sulphasalazine|144|158
11672959|A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.|hepatitis|87|96|sulphasalazine|144|158
11672959|A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.|lymphadenopathy|67|82|sulphasalazine|144|158
11672959|It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|fatal|169|174|sulphasalazine|125|139
11672959|It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|fatal|169|174|sulphasalazine|203|217
11672959|It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|immunoallergic reaction|176|199|sulphasalazine|125|139
11672959|It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|immunoallergic reaction|176|199|sulphasalazine|203|217
11672959|It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|sulphasalazine syndrome|125|148|sulphasalazine|125|139
11672959|It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|sulphasalazine syndrome|125|148|sulphasalazine|203|217
11672959|The 3-week sulphasalazine syndrome strikes again.|sulphasalazine syndrome|11|34|sulphasalazine|11|25
11688826|Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.|SIADH|128|133|CDDP|192|196
11688826|Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.|SIADH|44|49|cisplatin|61|70
11688826|Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.|Syndrome of inappropriate secretion of ADH|0|42|cisplatin|61|70
11688826|We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|SIADH|130|135|CDDP|185|189
11688826|We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|SIADH|130|135|cisplatin|174|183
11688826|We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|SIADH|130|135|VDS|206|209
11688826|We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|SIADH|130|135|vindesine|195|204
11688826|We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|syndrome of inappropriate secretion of antidiuretic hormone|69|128|CDDP|185|189
11688826|We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|syndrome of inappropriate secretion of antidiuretic hormone|69|128|cisplatin|174|183
11688826|We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|syndrome of inappropriate secretion of antidiuretic hormone|69|128|VDS|206|209
11688826|We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|syndrome of inappropriate secretion of antidiuretic hormone|69|128|vindesine|195|204
11696132|After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.|anisocoria|61|71|scopolamine|103|114
11696132|Anisocoria from transdermal scopolamine.|Anisocoria|0|10|scopolamine|28|39
11700998|De novo absence status of late onset following withdrawal of lorazepam: a case report.|De novo absence status|0|22|lorazepam|61|70
11700998|The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam.|nonconvulsive generalized status epilepticus|166|210|lorazepam|241|250
11703329|Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity.|life-threatening vincristine neurotoxicity|78|120|vincristine|95|106
11703329|Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent severe neurotoxicity of polychemotherapy by avoiding vincristine.|severe neurotoxicity|88|108|vincristine|141|152
11703329|The disease predisposes to severe vincristine neurotoxicity.|vincristine neurotoxicity|34|59|vincristine|34|45
11703329|We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine.|severe motor neuropathy|102|125|vincristine|187|198
11706664|Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate.|asymptomatic hepatitis|6|28|amodiaquine|86|97
11706664|Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate.|asymptomatic hepatitis|6|28|artesunate|102|112
11706664|This report describes an unexpected drug-induced hepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and artesunate.|hepatitis|49|58|amodiaquine|117|128
11706664|This report describes an unexpected drug-induced hepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and artesunate.|hepatitis|49|58|artesunate|133|143
11712064|Systemic allergic contact dermatitis to 8-methoxypsoralen (8-MOP).|Systemic allergic contact dermatitis|0|36|8-methoxypsoralen|40|57
11712064|Systemic allergic contact dermatitis to 8-methoxypsoralen (8-MOP).|Systemic allergic contact dermatitis|0|36|8-MOP|59|64
11712064|We describe a patient who had a systemic allergic contact dermatitis to 8-MOP develop during her second course of PUVA treatment for psoriasis.|systemic allergic contact dermatitis|32|68|8-MOP|72|77
11719751|A 33-year-old man with a history of recreational benztropine abuse presented to the emergency department with confusion, abdominal pain, and distention.|abdominal pain|121|135|benztropine|49|60
11719751|A 33-year-old man with a history of recreational benztropine abuse presented to the emergency department with confusion, abdominal pain, and distention.|confusion|110|119|benztropine|49|60
11719751|A 33-year-old man with a history of recreational benztropine abuse presented to the emergency department with confusion, abdominal pain, and distention.|distention|141|151|benztropine|49|60
11722307|Agranulocytosis and granulocytopenia associated with quetiapine.|Agranulocytosis|0|15|quetiapine|53|63
11722307|Agranulocytosis and granulocytopenia associated with quetiapine.|granulocytopenia|20|36|quetiapine|53|63
11722307|CONCLUSION: Although a definite association has not been proven, clinicians should be aware of the possibility of agranulocytosis while using quetiapine.|agranulocytosis|114|129|quetiapine|142|152
11722307|METHOD: We describe three case-reports concerning haematological adverse effects of quetiapine.|haematological adverse effects|50|80|quetiapine|84|94
11722307|RESULTS: Quetiapine was associated with leucopenia in two patients and clinically apparent agranulocytosis in one patient.|agranulocytosis|91|106|Quetiapine|9|19
11722307|RESULTS: Quetiapine was associated with leucopenia in two patients and clinically apparent agranulocytosis in one patient.|leucopenia|40|50|Quetiapine|9|19
11724089|CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.|toxic epidermal necrolysis|84|110|ofloxacin|66|75
11724089|However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.|Stevens-Johnson syndrome|67|91|ofloxacin|138|147
11724089|However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.|toxic epidermal necrolysis|95|121|ofloxacin|138|147
11724089|It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.|toxic epidermal necrolysis|75|101|ofloxacin|57|66
11724089|OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.|toxic epidermal necrolysis|37|63|ofloxacin|99|108
11724089|Ofloxacin: a probable cause of toxic epidermal necrolysis.|toxic epidermal necrolysis|31|57|Ofloxacin|0|9
11724089|This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.|toxic epidermal necrolysis|38|64|ofloxacin|80|89
11724089|This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.|toxic epidermal necrolysis|153|179|ofloxacin|80|89
11737689|A boy with chronic neutropenia and recurrent inflammatory skin lesions developed multiple erythematous nodules following administration of G-CSF.|multiple erythematous nodules|81|110|G-CSF|139|144
11737689|A girl with cystic fibrosis and cyclic neutropenia developed an erythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with G-CSF.|erythematous papular eruption|64|93|G-CSF|163|168
11737689|Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy.|Neutrophilic dermatoses|0|23|G-CSF|125|130
11737689|Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy.|Neutrophilic dermatoses|0|23|granulocyte colony-stimulating factor|86|123
11737689|Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (G-CSF) for treatment of idiopathic neutropenia.|neutrophilic skin lesions|8|33|G-CSF|113|118
11737689|Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (G-CSF) for treatment of idiopathic neutropenia.|neutrophilic skin lesions|8|33|granulocyte colony-stimulating factor|74|111
11737689|Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (G-CSF) for treatment of idiopathic neutropenia.|Painful|0|7|G-CSF|113|118
11737689|Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (G-CSF) for treatment of idiopathic neutropenia.|Painful|0|7|granulocyte colony-stimulating factor|74|111
11737689|We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G-CSF therapy.|neutrophilic dermatoses|61|84|G-CSF|122|127
11737689|We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G-CSF therapy.|skin eruptions|22|36|G-CSF|122|127
1174301|There is a putative role of liothyronine administration in precipitating or activating hyperthyroidism.|hyperthyroidism|87|102|liothyronine|28|40
1174301|Triiodothyronine-induced thyrotoxicosis in ophthalmic Graves disease.|thyrotoxicosis|25|39|Triiodothyronine|0|16
11749112|This case report describes the development of asymptomatic visual field defects (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment.|VFDs|81|85|tiagabine|155|164
11749112|This case report describes the development of asymptomatic visual field defects (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment.|visual field defects|59|79|tiagabine|155|164
11757641|Pulmonary toxicity with mefloquine.|Pulmonary toxicity|0|18|mefloquine|24|34
11757641|This is the second report of acute lung injury and diffuse alveolar damage caused by mefloquine.|acute lung injury|29|46|mefloquine|85|95
11757641|This is the second report of acute lung injury and diffuse alveolar damage caused by mefloquine.|diffuse alveolar damage|51|74|mefloquine|85|95
11757641|This report presents a case of acute lung injury developing within hours after administration of mefloquine for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy.|acute lung injury|31|48|mefloquine|97|107
11762672|An adult male presented with central blindness after ingesting methanol.|central blindness|29|46|methanol|63|71
11762672|Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.|visual impairment|36|53|methanol|19|27
11788010|Extra caution should be taken in using octreotide or its long-acting analog in patients otherwise predisposed to intrahepatic bile stasis.|intrahepatic bile stasis|113|137|octreotide|39|49
11788010|Gallstones and bile sludge are common side effects of octreotide therapy but rarely become symptomatic or require treatment.|bile sludge|15|26|octreotide|54|64
11788010|Gallstones and bile sludge are common side effects of octreotide therapy but rarely become symptomatic or require treatment.|Gallstones|0|10|octreotide|54|64
11788010|Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report.|Hepatolithiasis|0|15|octreotide|44|54
11788010|In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.|alters bile acid composition|66|94|octreotide|55|65
11788010|In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.|gallbladder stasis|35|53|octreotide|55|65
11788010|In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.|hasten intrahepatic sludge|108|134|octreotide|55|65
11788010|In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.|stone formation|139|154|octreotide|55|65
11788010|This is the first reported case of hepatolithiasis during octreotide therapy.|hepatolithiasis|35|50|octreotide|58|68
11788010|We report a case of hepatolithiasis (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with octreotide.|hepatolithiasis|20|35|octreotide|150|160
11795358|However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.|endometrial carcinoma|188|209|tamoxifen|119|128
11795358|In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.|endometrial carcinoma|60|81|tamoxifen|89|98
11804071|INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.|drug eruptions|33|47|INH|0|3
11804071|Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.|anagen effluvium|36|52|Isonicotinic acid hydrazide|0|27
11804071|Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.|lichenoid eruption|68|86|Isonicotinic acid hydrazide|0|27
11804071|Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.|anagen effluvium|5|21|INH|56|59
11804071|Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.|lichenoid eruption|27|45|INH|56|59
11807466|Linear IgA bullous dermatosis occurring after carbamazepine.|Linear IgA bullous dermatosis|0|29|carbamazepine|46|59
11807466|We report a patient who experienced LABD shortly after starting carbamazepine therapy.|LABD|36|40|carbamazepine|64|77
11816261|After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|agitation|99|108|metoclopramide|23|37
11816261|After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|confusion|88|97|metoclopramide|23|37
11816261|After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|diaphoresis|117|128|metoclopramide|23|37
11816261|After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|fever|110|115|metoclopramide|23|37
11816261|After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|hypertension|158|170|metoclopramide|23|37
11816261|After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|tachycardia|141|152|metoclopramide|23|37
11816261|After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|tachypnea|130|139|metoclopramide|23|37
11816261|CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|extrapyramidal reactions|85|109|metoclopramide|163|177
11816261|CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|extrapyramidal reactions|85|109|sertraline|132|142
11816261|CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|extrapyramidal reactions|85|109|venlafaxine|146|157
11816261|CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|serotonin syndrome|53|71|metoclopramide|163|177
11816261|CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|serotonin syndrome|53|71|sertraline|132|142
11816261|CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|serotonin syndrome|53|71|venlafaxine|146|157
11816261|OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|extrapyramidal movement disorders|64|97|metoclopramide|113|127
11816261|OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|extrapyramidal movement disorders|64|97|sertraline|152|162
11816261|OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|extrapyramidal movement disorders|64|97|venlafaxine|166|177
11816261|OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|serotonin syndrome|32|50|metoclopramide|113|127
11816261|OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|serotonin syndrome|32|50|sertraline|152|162
11816261|OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|serotonin syndrome|32|50|venlafaxine|166|177
11816261|Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction.|Serotonin syndrome|0|18|metoclopramide|69|83
11816261|She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.|agitation|85|94|metoclopramide|21|35
11816261|She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.|diaphoresis|108|119|metoclopramide|21|35
11816261|She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.|dysarthria|96|106|metoclopramide|21|35
11816261|She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.|movement disorder|127|144|metoclopramide|21|35
11816261|She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness.|movement disorder|83|100|metoclopramide|57|71
11816261|She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness.|unresponsiveness|117|133|metoclopramide|57|71
11819156|A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.|malignant neuroleptic syndrome|62|92|haloperidol|143|154
11834188|BACKGROUND: reports on delated cutaneous reactions to captopril have been seldom reported.|delated cutaneous reactions|23|50|captopril|54|63
11834188|Captopril is an angiotensin-converting enzyme (ACE) inhibitor and their cutaneous side-effects are documented, but little has been published concerning the usefulness of patch test when they occur.|cutaneous side-effects|72|94|Captopril|0|9
11834188|Dermatitis to captopril.|Dermatitis|0|10|captopril|14|23
11834188|We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test.|cutaneous reaction|51|69|captopril|81|90
11837564|A 62-year-old Caucasian man with atrial fibrillation who was taking warfarin reported an episode of hematochezia; his international normalized ratio (INR) was 1.74.|hematochezia|100|112|warfarin|68|76
11837564|Warfarin-associated bleeding complication saved life.|bleeding|20|28|Warfarin|0|8
11837564|Warfarin-associated bleeding generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life.|bleeding|20|28|Warfarin|0|8
11850606|A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.|dilated cardiomyopathy|28|50|interferon alpha|67|83
11850606|A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.|polymyositis|10|22|interferon alpha|67|83
11850606|In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.|cardiomyopathy|56|70|interferon alpha|14|30
11850606|In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.|polymyositis|39|51|interferon alpha|14|30
11850606|Polymyositis is a rare complication of interferon alpha treatment as a result of immune-modulating role of the drug itself.|Polymyositis|0|12|interferon alpha|39|55
11850606|To treat hepatitis B, interferon alpha was administered until the proximal muscle weakness developed.|muscle weakness|75|90|interferon alpha|22|38
11868077|Long-term follow-up after neoplastic seeding complicating percutaneous ethanol injection for treatment of hepatocellular carcinoma.|neoplastic seeding|26|44|ethanol|71|78
11868077|We describe a case of subcutaneous metastasis along the needle track after percutaneous ethanol injection (PEI) for treatment of hepatocellular carcinoma.|subcutaneous metastasis|22|45|ethanol|88|95
11876387|Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography.|Aggressive endometrial carcinoma|0|32|tamoxifen|73|82
11876387|Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended.|endometrial disorders|35|56|tamoxifen|6|15
11876387|Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended.|endometrial disorders|35|56|tamoxifen|95|104
11876387|We described a very atypical case of a high stage, high grade endometrial cancer associated with tamoxifen in a 64-year-old woman with a past history of breast cancer.|endometrial cancer|62|80|tamoxifen|97|106
11881322|Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy.|cholangiopathy|136|150|itraconazole|57|69
11881322|Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy.|ductopenia|10|20|itraconazole|57|69
11881322|CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.|cholestatic pattern of injury|63|92|Itraconazole|13|25
11881322|CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.|damage to the interlobular bile ducts|98|135|Itraconazole|13|25
11881322|CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.|ductopenia|157|167|Itraconazole|13|25
11881322|CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.|liver injury|34|46|Itraconazole|13|25
11881322|Hepatotoxicity related to itraconazole: report of three cases.|Hepatotoxicity|0|14|itraconazole|26|38
11881322|METHODS: Three patients with apparent itraconazole-induced liver injury were studied.|liver injury|59|71|itraconazole|38|50
11881322|The occurrence of acute hepatitis is best known for ketoconazole.|hepatitis|24|33|ketoconazole|52|64
11881322|We report on three patients who developed acute liver damage during therapy with itraconazole, and in whom liver biopsy specimens were obtained.|liver damage|48|60|itraconazole|81|93
11881322|We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug-induced vanishing bile duct syndrome.|vanishing bile duct syndrome|109|137|itraconazole|16|28
11881322|With itraconazole, hepatotoxic reactions have only very rarely been reported, and histologic data are lacking.|hepatotoxic|19|30|itraconazole|5|17
11886466|Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia.|Thrombotic stroke|0|17|porcine factor VIII|45|64
11886466|We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII.|thrombotic left middle cerebral artery distribution stroke|81|139|pFVIII|165|171
11886466|We speculate that platelet activation induced by pFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre-existing cardiovascular risk factors.|thrombosis|80|90|pFVIII|49|55
11903249|Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.|Cutaneous sarcoidosis|0|21|interferon alfa|29|44
11903249|Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.|Cutaneous sarcoidosis|0|21|ribavirin|49|58
11903249|There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.|granulomatosis|83|97|interferon alfa|103|118
11903249|There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.|granulomatosis|83|97|interferon alfa|161|176
11903249|There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.|granulomatosis|83|97|ribavirin|182|191
11903249|We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.|sarcoidosis|27|38|interferon alfa|101|116
11903249|We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.|sarcoidosis|27|38|ribavirin|121|130
11918514|CONCLUSIONS: Although mirtazapine offers clinicians a combination of strong efficacy and good safety, we suggest bearing SS in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions.|SS|121|123|mirtazapine|22|33
11918514|DISCUSSION: A review of the cases of SS with implication of mirtazapine as the cause was performed.|SS|37|39|mirtazapine|60|71
11918514|OBJECTIVE: To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.|serotonin syndrome|33|51|mirtazapine|73|84
11918514|OBJECTIVE: To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.|SS|53|55|mirtazapine|73|84
11918514|Severe serotonin syndrome induced by mirtazapine monotherapy.|serotonin syndrome|7|25|mirtazapine|37|48
11943900|Pulmonary toxicity secondary to procarbazine.|Pulmonary toxicity|0|18|procarbazine|32|44
11961411|A 64-year-old man presented with proteinuria during postoperative interferon (IFN)-beta therapy against malignant melanoma.|proteinuria|33|44|interferon (IFN)-beta|66|87
11961411|Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma.|Minimal change nephrotic syndrome|0|33|interferon-beta|66|81
11961411|To our knowledge this is the first report that demonstrates histological abnormalities of the glomerulus associated with postoperative IFN-beta therapy for the malignant melanoma.|histological abnormalities of the glomerulus|60|104|IFN-beta|135|143
11972105|The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.|delayed elimination|32|51|ciprofloxacin|90|103
11972105|The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.|delayed elimination|32|51|methotrexate|55|67
11972105|The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.|toxicity|117|125|ciprofloxacin|90|103
11978156|CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.|thrombocytopenia|71|87|lansoprazole|93|105
11978156|DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole.|thrombocytopenia|58|74|lansoprazole|99|111
11978156|DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole.|thrombocytopenic|325|341|lansoprazole|354|366
11978156|He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).|platelet count decreased|82|106|lansoprazole|23|35
11978156|Lansoprazole-induced thrombocytopenia.|thrombocytopenia|21|37|Lansoprazole|0|12
11978156|OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.|thrombocytopenia|33|49|lansoprazole|88|100
11978156|To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.|thrombocytopenia|72|88|lansoprazole|105|117
11984077|Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.|anaphylactoid reaction|17|39|amifostine|43|53
11984077|The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.|allergic reactions|108|126|amifostine|45|55
11984077|The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.|hypocalcemia|91|103|amifostine|45|55
11984077|The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.|hypotension|78|89|amifostine|45|55
11984077|The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.|nausea|60|66|amifostine|45|55
11984077|The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.|vomiting|68|76|amifostine|45|55
11984077|The patient suffered a life-threatening anaphylactoid reaction to amifostine.|life-threatening anaphylactoid reaction|23|62|amifostine|66|76
11999915|Agranulocytosis during clozapine therapy.|Agranulocytosis|0|15|clozapine|23|32
11999915|Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine.|agranulocytosis|21|36|clozapine|96|105
11999915|Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine.|Granulocytopenia|0|16|clozapine|96|105
11999915|The female patient received clozapine in a daily dose of 400 mg, which induced agranulocytosis after 2 months.|agranulocytosis|79|94|clozapine|28|37
11999915|The male patient was treated with 225-mg/day clozapine and the time to the diagnosis of agranulocytosis was 6 weeks.|agranulocytosis|88|103|clozapine|45|54
12013364|A 53-year-old man developed NMS without rigidity while taking olanzapine.|NMS|28|31|olanzapine|62|72
12013364|Atypical neuroleptic malignant syndrome associated with olanzapine.|neuroleptic malignant syndrome|9|39|olanzapine|56|66
12022905|CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.|painful erection|210|226|zuclopenthixol|123|137
12022905|CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.|Priapism|13|21|zuclopenthixol|79|93
12022905|DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.|priapism|30|38|zuclopenthixol|69|83
12022905|OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.|priapism|62|70|zuclopenthixol|39|53
12022905|Priapism associated with zuclopenthixol.|Priapism|0|8|zuclopenthixol|25|39
12022905|The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.|priapism|41|49|zuclopenthixol|16|30
12042592|After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.|sepsis|142|148|metamizole|165|175
12042592|Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.|agranulocytosis|109|124|Metamizole|0|10
12053072|Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.|hemolytic-uremic syndrome|50|75|mitomycin|32|41
12053072|We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.|HUS|36|39|mitomycin C|61|72
12066972|Levofloxacin-induced toxic epidermal necrolysis in an elderly patient.|toxic epidermal necrolysis|21|47|Levofloxacin|0|12
12066972|To our knowledge, this case is the first published report of levofloxacin-induced TEN.|TEN|82|85|levofloxacin|61|73
12078977|A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.|grand mal seizures|52|70|bleomycin|134|143
12078977|A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.|grand mal seizures|52|70|cisplatin|107|116
12078977|A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.|grand mal seizures|52|70|vinblastine|118|129
12078977|Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.|Posterior leukoencephalopathy|0|29|bleomycin|51|60
12078977|Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.|Posterior leukoencephalopathy|0|29|cisplatin|40|49
12078977|Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.|Posterior leukoencephalopathy|0|29|vinblastine|65|76
12086549|After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.|hemorrhagic lesion|61|79|IL-2|31|35
12086549|After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.|pancytopenia|146|158|IL-2|31|35
12086549|After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.|toxic epidermal necrolysis|99|125|IL-2|31|35
12086549|OBJECTIVE: To report a case of cutaneous and hematologic toxicity in a patient treated with IL-2.|cutaneous and hematologic toxicity|31|65|IL-2|92|96
12086549|Subcutaneous IL-2 is safe and well tolerated, with a mortality rate <3%.|mortality rate <3|53|70|IL-2|13|17
12086549|Toxic epidermal necrolysis associated with interleukin-2.|Toxic epidermal necrolysis|0|26|interleukin-2|43|56
12092878|A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.|anaphylactoid reaction|10|32|Gelofusine|58|68
12092878|Gelofusine allergy--the need for identification jewellery.|Gelofusine allergy|0|18|Gelofusine|0|10
12095907|The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.|hyperammonemia|39|53|valproate|21|30
12095907|The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.|mental status changes|58|79|valproate|21|30
12095907|Valproate-induced hyperammonemia as a cause of altered mental status.|altered mental status|47|68|Valproate|0|9
12095907|Valproate-induced hyperammonemia as a cause of altered mental status.|hyperammonemia|18|32|Valproate|0|9
12100953|Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas.|Leiomyosarcoma|0|14|cyclophosphamide|40|56
12107858|The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.|NMS|16|19|amisulpride|77|88
12107858|The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.|NMS|16|19|clozapine|49|58
12107858|The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.|NMS|16|19|risperidone|60|71
12111771|A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL).|cough|45|50|fludarabine|95|106
12111771|A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL).|fever|35|40|fludarabine|95|106
12111771|Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.|lung disease|93|105|Fludarabine|0|11
12111771|Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.|lung disease|93|105|fludarabine|122|133
12111771|Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.|lung toxicity|20|33|Fludarabine|0|11
12111771|Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.|Multiple pulmonary nodules|0|26|fludarabine|55|66
12111771|Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.|pulmonary toxicity|67|85|fludarabine|55|66
12111771|This case extends the spectrum of fludarabine pulmonary toxicity to include pulmonary nodules.|pulmonary nodules|76|93|fludarabine|34|45
12111771|This case extends the spectrum of fludarabine pulmonary toxicity to include pulmonary nodules.|pulmonary toxicity|46|64|fludarabine|34|45
12111771|To our knowledge, four cases of interstitial pneumonitis associated with fludarabine have been reported in medical literature.|interstitial pneumonitis|32|56|fludarabine|73|84
12114387|Epoprostenol may be associated rarely with severe erythroderma.|erythroderma|50|62|Epoprostenol|0|12
12114387|Severe erythroderma as a complication of continuous epoprostenol therapy.|erythroderma|7|19|epoprostenol|52|64
12114387|We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.|fever|236|241|epoprostenol|143|155
12114387|We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.|nausea|211|217|epoprostenol|143|155
12114387|We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.|rapidly progressive erythema|172|200|epoprostenol|143|155
12114387|We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.|scaling|202|209|epoprostenol|143|155
12114387|We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.|vomiting|222|230|epoprostenol|143|155
12121061|A 50-year-old diabetic and hypertensive male patient is reported who had ticlopidine-induced marrow aplasia partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine.|marrow aplasia|93|107|ticlopidine|73|84
12121061|There is no consensus on the treatment of ticlopidine-induced marrow aplasia.|marrow aplasia|62|76|ticlopidine|42|53
12121061|Ticlopidine-induced marrow aplasia treated with cyclosporine.|marrow aplasia|20|34|Ticlopidine|0|11
12126225|A 53-year-old man developed lower leg edema 4 weeks after rosiglitazone was increased from 4 mg once/day to 4 mg twice/day.|lower leg edema|28|43|rosiglitazone|58|71
12126225|A 75-year-old man developed bilateral lower leg edema 6 months after switching from troglitazone to pioglitazone.|bilateral lower leg edema|28|53|pioglitazone|100|112
12126225|A 77-year-old man developed ankle, hand, and facial swelling 2 weeks after starting rosiglitazone.|ankle, hand, and facial swelling|28|60|rosiglitazone|84|97
12135176|Two cases of polymorphic ventricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia.|polymorphic ventricular tachycardia|13|48|verapamil|82|91
12135176|Verapamil is widely used for the termination of paroxysmal supraventricular tachycardia (PSVT) with little proarrhythmic effect.|proarrhythmic effect|107|127|Verapamil|0|9
12135176|We describe two cases of PSVT that changed to non-sustained polymorphic ventricular tachycardia after administration of verapamil.|non-sustained polymorphic ventricular tachycardia|46|95|verapamil|120|129
12141409|Epsilon-aminocaproic acid and renal complications: case report and review of the literature.|renal complications|30|49|Epsilon-aminocaproic acid|0|25
12150593|Neonatal mydriasis: intravenous lidocaine adverse reaction.|mydriasis|9|18|lidocaine|32|41
12150593|We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to lidocaine overdose.|pupillary mydriasis|67|86|lidocaine|100|109
12150593|We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with lidocaine.|dilated pupils|123|137|lidocaine|163|172
12153007|Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin.|acute myeloid leukemia|30|52|2-deoxycoformycin|99|116
12153007|Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin.|Myelodysplasia|0|14|2-deoxycoformycin|99|116
12153007|To the best of our knowledge only two previous cases of AML have been linked to treatment of HCL with purine analogs, both with 2-chlorodeoxyadenosine.|AML|56|59|2-chlorodeoxyadenosine|128|150
12163813|CONCLUSIONS: Peripheral administration of low-dose vasopressin for septic shock should be discouraged because of the risk of ischemic skin complications.|ischemic skin complications|125|152|vasopressin|51|62
12163813|OBJECTIVE: To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low-dose vasopressin in a patient with catecholamine-resistant septic shock.|skin necrosis|40|53|vasopressin|119|130
12163813|Skin necrosis after extravasation of low-dose vasopressin administered for septic shock.|Skin necrosis|0|13|vasopressin|46|57
12166705|Mitomycin-C induced hemolytic uremic syndrome: a case report.|hemolytic uremic syndrome|20|45|Mitomycin-C|0|11
12166705|Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.|hemolytic uremic syndrome|148|173|Mitomycin-C|0|11
12181031|Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.|vasculitis|9|19|cladribine|132|142
12181031|Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.|Systemic vasculitis|0|19|cladribine|69|79
12181031|We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.|systemic vasculitis|54|73|cladribine|139|149
12181031|We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.|thrombocytopenia|90|106|cladribine|139|149
12187348|Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone.|mammary hyperplasias|13|33|D-penicillamine|78|93
12187348|Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone.|mammary hyperplasias|13|33|Neothetazone|98|110
12187348|Gigantomastia induced by bucillamine.|Gigantomastia|0|13|bucillamine|25|36
12187348|Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.|giant hypertrophy|65|82|bucillamine|17|28
12187348|Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.|mammary hyperplasia|192|211|D-penicillamine|123|138
12187348|The authors report the first case of bucillamine-induced giant mammary hyperplasia.|giant mammary hyperplasia|57|82|bucillamine|37|48
12196666|The authors describe three families in whom the occurrence of FVS in all the siblings strongly suggests hereditary susceptibility to valproic acid-induced adverse outcome.|FVS|62|65|valproic acid|133|146
12196666|The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.|developmental delay|121|140|valproate|10|19
12196666|The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.|distinctive facial appearance|55|84|valproate|10|19
12196666|The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.|fetal valproate syndrome|4|28|valproate|10|19
12196666|The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.|FVS|30|33|valproate|10|19
12196666|The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.|major and minor malformations|86|115|valproate|10|19
12196666|Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility.|Valproate embryopathy|0|21|Valproate|0|9
12218252|Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.|Generalised pustular psoriasis|0|30|cyclosporin a|42|55
12218252|We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.|aggravation of the joint condition|205|239|cyclosporin A|141|154
12218252|We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.|generalised pustular exacerbation|165|198|cyclosporin A|141|154
12221670|The first case concerns a 70-year-old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily.|aplastic anemia|63|78|ticlopidine|118|129
12221670|The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia.|marrow aplasia|130|144|ticlopidine|44|55
12221670|The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia.|neutropenic|113|124|ticlopidine|44|55
12221670|Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon.|aplastic anemia|20|35|Ticlopidine|0|11
12221670|Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon.|TIAA|37|41|Ticlopidine|0|11
12221670|Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases.|aplastic anemia|20|35|Ticlopidine|0|11
12221670|When the data of the 57 patients are evaluated, a reversible direct cytotoxic effect of ticlopidine on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed.|cytotoxic effect|68|84|ticlopidine|88|99
12234159|Fixed drug eruption to rofecoxib.|Fixed drug eruption|0|19|rofecoxib|23|32
12234159|Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.|herpetiform fixed drug eruption|43|74|Rofecoxib|0|9
12234159|Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.|red-brown lesion|161|177|Rofecoxib|0|9
122410|A patient who had been treated with large doses of thyroid hormone for several years developed features of secondary hypothyroidism after thyroid hormone withdrawal.|hypothyroidism|117|131|thyroid hormone|51|66
12324937|BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.|hemolytic-uremic syndrome|85|110|gemcitabine|62|73
12324937|BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.|hemolytic-uremic syndrome|85|110|Gemcitabine|12|23
12324937|BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.|HUS|112|115|gemcitabine|62|73
12324937|BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.|HUS|112|115|Gemcitabine|12|23
12324937|BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.|renal toxicity|33|47|Gemcitabine|12|23
12324937|CONCLUSION: There are only a few confirmed cases of gemcitabine-associated HUS despite the widespread use of the drug.|HUS|75|78|gemcitabine|52|63
12324937|Gemcitabine-associated hemolytic-uremic syndrome.|hemolytic-uremic syndrome|23|48|Gemcitabine|0|11
12324937|Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.|HUS|65|68|gemcitabine|32|43
12324937|Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.|HUS|65|68|gemcitabine|119|130
12324937|METHODS: A case is presented of a 45-year-old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation.|HUS|120|123|gemcitabine|65|76
12324937|RESULTS: Including our own patient, a total of 26 cases of gemcitabine-associated HUS were identified.|HUS|82|85|gemcitabine|59|70
12365708|An amiodarone optic neuropathy has been described.|optic neuropathy|14|30|amiodarone|3|13
12365708|Biomicroscopy revealed amiodarone corneal deposits.|corneal deposits|34|50|amiodarone|23|33
12365708|CASE REPORT: Soon after initiation of amiodarone HCl (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, color vision anomalies, and gradually decreased vision.|color vision anomalies|138|160|amiodarone HCl|38|52
12365708|CASE REPORT: Soon after initiation of amiodarone HCl (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, color vision anomalies, and gradually decreased vision.|decreased vision|176|192|amiodarone HCl|38|52
12365708|CASE REPORT: Soon after initiation of amiodarone HCl (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, color vision anomalies, and gradually decreased vision.|glare|131|136|amiodarone HCl|38|52
12365708|CASE REPORT: Soon after initiation of amiodarone HCl (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, color vision anomalies, and gradually decreased vision.|visual "shining|113|128|amiodarone HCl|38|52
12365708|Visual changes secondary to initiation of amiodarone: a case report and review involving ocular management in cardiac polypharmacy.|Visual changes|0|14|amiodarone|42|52
12365708|While both amiodarone and digoxin can cause permanent visual changes, the ocular effects are often reversible.|ocular effects|74|88|amiodarone|11|21
12365708|While both amiodarone and digoxin can cause permanent visual changes, the ocular effects are often reversible.|ocular effects|74|88|digoxin|26|33
12365708|While both amiodarone and digoxin can cause permanent visual changes, the ocular effects are often reversible.|visual changes|54|68|amiodarone|11|21
12365708|While both amiodarone and digoxin can cause permanent visual changes, the ocular effects are often reversible.|visual changes|54|68|digoxin|26|33
1238016|Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.|circumoral and pharyngeal burns|30|61|benzalkonium|94|106
1238016|Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.|circumoral and pharyngeal burns|30|61|Zephiran|108|116
12390172|CONCLUSION: Long-term treatment with rifabutin may have a reversible and previously undescribed side-effect on retinal function.|side-effect on retinal function|96|127|rifabutin|37|46
12390172|PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.|decreased vision|88|104|rifabutin|139|148
12390172|PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin.|retinal damage|121|135|rifabutin|139|148
12390172|Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.|anterior segment deposits|24|49|rifabutin|76|85
12390172|Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin.|Retinal dysfunction|0|19|rifabutin|76|85
12390172|We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin.|visual disturbance|128|146|rifabutin|169|178
12397859|A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.|benzodiazepine withdrawal symptoms|49|83|nefazodone|106|116
12399645|A case of SIADH induced by mizoribin administration.|SIADH|10|15|mizoribin|27|36
12399645|ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.|ADH hypersecretion|0|18|mizoribin|68|77
12399645|ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that bredinin might adversely induce SIADH.|SIADH|138|143|bredinin|106|114
12399645|In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.|SIADH|47|52|mizoribin|89|98
12399645|In summary, we report herein the first case of SIADH believed to be an adverse effect of mizoribin, which may therefore needed to be added to the list of drugs which can induce SIADH.|SIADH|177|182|mizoribin|89|98
12399645|We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.|SIADH|136|141|mizoribin|176|185
12399645|We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 1.5 months after commencement of mizoribin prescription when his arthritis was improved.|syndrome of inappropriate secretion of antidiuretic hormone|75|134|mizoribin|176|185
12405893|The disease-modifying drugs he was taking, cyclosporin and methotrexate, were stopped, and the lymphoma resolved spontaneously without the use of chemotherapy.|lymphoma|95|103|cyclosporin|43|54
12405893|The disease-modifying drugs he was taking, cyclosporin and methotrexate, were stopped, and the lymphoma resolved spontaneously without the use of chemotherapy.|lymphoma|95|103|methotrexate|59|71
12424571|Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C.|nephrotic syndrome|15|33|interferon-alpha|41|57
12424571|We herein report this rare case of acute onset of nephrotic syndrome during interferon-alpha retreatment.|nephrotic syndrome|50|68|interferon-alpha|76|92
12432978|A 21-year-old man with Tourette's syndrome, pedophilia, Asperger's syndrome, and multiple sclerosis experienced seizures after receiving therapy with interferon beta-1a.|seizures|112|120|interferon beta-1a|150|168
12432978|Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.|extrapyramidal symptoms|13|36|clomipramine|156|168
12432978|Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.|extrapyramidal symptoms|13|36|interferon beta-1a|133|151
12432978|Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.|Seizures|0|8|clomipramine|156|168
12432978|Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine.|Seizures|0|8|interferon beta-1a|133|151
12439602|A 68-year-old female patient with advanced ovarian carcinoma collapsed whilst receiving a carboplatin and cyclophosphamide infusion.|collapsed|61|70|carboplatin|90|101
12439602|A 68-year-old female patient with advanced ovarian carcinoma collapsed whilst receiving a carboplatin and cyclophosphamide infusion.|collapsed|61|70|cyclophosphamide|106|122
12439602|Carboplatin hypersensitivity presenting as coronary vasospasm - a case report.|coronary vasospasm|43|61|Carboplatin|0|11
12439602|Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.|hyperacute changes on ECG|128|153|carboplatin|20|31
12439602|Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.|Hypersensitivity|0|16|carboplatin|20|31
1244265|A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem.|acute respiratory failure|69|94|methazolamide|151|164
1244265|A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem.|acute respiratory failure|69|94|Neptazane|166|175
1244265|A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem.|metabolic acidosis|99|117|methazolamide|151|164
1244265|A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem.|metabolic acidosis|99|117|Neptazane|166|175
12452753|Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week.|allergic reactions|38|56|Capecitabine|0|12
12452753|CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild allergic reactions to capecitabine.|allergic reactions|112|130|capecitabine|134|146
12452753|Fluorouracil for allergic reactions to capecitabine.|allergic reactions|17|35|capecitabine|39|51
12452753|It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.|allergic reaction|27|44|capecitabine|71|83
12452753|OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had allergic reactions to capecitabine.|allergic reactions|90|108|capecitabine|112|124
12452753|She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.|dizziness|63|72|capecitabine|119|131
12452753|She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.|generalized rash|16|32|capecitabine|119|131
12452753|She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.|itching|37|44|capecitabine|119|131
12452753|She developed a generalized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of capecitabine.|sore throat|46|57|capecitabine|119|131
12455453|After five and six weeks of continuous oral administration of methylprednisolone, the boys developed steroid diabetes.|steroid diabetes|101|117|methylprednisolone|62|80
12455453|Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia.|glycemia|97|105|methylprednisolone|13|31
12460237|Contrary to previous recommendations, our experience cautions against the further use of high-dose cytarabine in patients who develop PPE, and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies.|PPE|134|137|cytarabine|99|109
12460237|It has been suggested that PPE caused by cytarabine does not recur with subsequent cytarabine re-challenge.|PPE|27|30|cytarabine|41|51
12460237|Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia.|palmar-plantar erythrodysaesthesia|10|44|cytarabine|65|75
12460237|We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe bullous eruption, following successive cycles of high-dose cytarabine for the treatment of acute lymphoblastic leukaemia.|bullous eruption|108|124|cytarabine|167|177
12460237|We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe bullous eruption, following successive cycles of high-dose cytarabine for the treatment of acute lymphoblastic leukaemia.|PPE|68|71|cytarabine|167|177
12477460|Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.|malignant transformation of endometriosis|92|133|tamoxifen|74|83
12477460|BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.|Ovarian cancer|12|26|tamoxifen|94|103
12477460|CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.|malignant transformation of endometriosis|32|73|Tamoxifen|12|21
12477460|Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.|Ovarian endometrioid adenocarcinoma|0|35|tamoxifen|103|112
12488741|Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.|Clinical, spectroscopic, and imaging abnormalities|0|50|metronidazole|84|97
12488741|Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.|lactate elevation|49|66|metronidazole|74|87
12488741|Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.|Reversible MR imaging and MR spectroscopy abnormalities|0|55|metronidazole|76|89
12494253|After nine previous uncomplicated cycles she developed severe anaphylaxis to cisplatin.|anaphylaxis|62|73|cisplatin|77|86
12494253|Anaphylaxis to cisplatin following nine previous uncomplicated cycles.|Anaphylaxis|0|11|cisplatin|15|24
12494253|Anaphylaxis to cisplatin is an infrequent life-threatening complication which may occur even in patients who have received prior treatment with cisplatin.|Anaphylaxis|0|11|cisplatin|15|24
12503933|Although isradipine has been associated with hepatocellular injury, there are no reports of fulminant liver failure with this agent, and our patient had been treated for >2 years without signs of toxicity.|hepatocellular injury|45|66|isradipine|9|19
12503933|A second possibility is an interaction between clarithromycin and isradipine, potentially increasing the hepatic toxicity of isradipine.|increasing the hepatic toxicity|90|121|clarithromycin|47|61
12503933|A second possibility is an interaction between clarithromycin and isradipine, potentially increasing the hepatic toxicity of isradipine.|increasing the hepatic toxicity|90|121|isradipine|66|76
12503933|A second possibility is an interaction between clarithromycin and isradipine, potentially increasing the hepatic toxicity of isradipine.|increasing the hepatic toxicity|90|121|isradipine|125|135
12503933|CASE SUMMARY: A 58-year-old white woman developed fulminant liver failure while being treated with the macrolide antibiotic clarithromycin for pneumonia.|fulminant liver failure|50|73|clarithromycin|124|138
12503933|CONCLUSIONS: Clarithromycin may be a cause of fulminant liver failure either alone or by inhibiting the metabolism of other drugs.|fulminant liver failure|46|69|Clarithromycin|13|27
12503933|Fulminant liver failure associated with clarithromycin.|Fulminant liver failure|0|23|clarithromycin|40|54
12503933|OBJECTIVE: To report a patient developing fulminant liver failure while being treated with clarithromycin for pneumonia.|fulminant liver failure|42|65|clarithromycin|91|105
12503933|The most likely cause of liver failure in this patient was, therefore, clarithromycin, which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure.|fulminant hepatic failure|153|178|clarithromycin|71|85
12503933|The most likely cause of liver failure in this patient was, therefore, clarithromycin, which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure.|liver failure|25|38|clarithromycin|71|85
12504711|A paradoxical ocular effect of brimonidine.|paradoxical ocular effect|2|27|brimonidine|31|42
12504711|CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.|paradoxical raised IOP|70|92|brimonidine|48|59
12504711|PURPOSE: We report an unusual paradoxical effect of brimonidine.|paradoxical effect|30|48|brimonidine|52|63
12504711|RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.|IOP elevation|43|56|Brimonidine|9|20
12507063|Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.|anxiety|84|91|gabapentin|9|19
12507063|Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.|diaphoresis|93|104|gabapentin|9|19
12507063|Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.|generalized seizures|164|184|gabapentin|9|19
12507063|Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.|generalized seizures|164|184|gabapentin|221|231
12507063|Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.|palpitations|110|122|gabapentin|9|19
12507063|Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.|status epilepticus|189|207|gabapentin|9|19
12507063|Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.|status epilepticus|189|207|gabapentin|221|231
12507063|Gabapentin withdrawal presenting as status epilepticus.|status epilepticus|36|54|Gabapentin|0|10
12523465|Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.|altered mental status|167|188|zonisamide|195|205
12523465|Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.|visual hallucinations|141|162|zonisamide|195|205
12523465|Visual hallucinations associated with zonisamide.|Visual hallucinations|0|21|zonisamide|38|48
12540009|Doxycycline-induced hypoglycemia in a nondiabetic young man.|hypoglycemia|20|32|Doxycycline|0|11
12540009|We report the first case of doxycycline-induced hypoglycemia in a young nondiabetic man.|hypoglycemia|48|60|doxycycline|28|39
12546343|For patients who suffer from osteogenic sarcoma and have anaphylactic reactions to MTX, this desensitization protocol will allow these patients to continue with needed therapeutic or palliative chemotherapy.|anaphylactic reactions|57|79|MTX|83|86
12546343|He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.|chest tightness|140|155|MTX|75|78
12546343|He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.|cough|129|134|MTX|75|78
12546343|He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.|diffuse urticaria|93|110|MTX|75|78
12546343|He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.|facial swelling|112|127|MTX|75|78
12546343|He had an immediate hypersensitivity reaction during the initiation of the MTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness.|hypersensitivity reaction|20|45|MTX|75|78
12546343|He was later skin tested to confirm allergy to MTX.|allergy|36|43|MTX|47|50
12546343|Successful desensitization to high-dose methotrexate after systemic anaphylaxis.|systemic anaphylaxis|59|79|methotrexate|40|52
12546343|The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases.|anaphylactic reactions|101|123|MTX|127|130
12552054|The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine.|Balint syndrome|29|44|cytarabine|139|149
12552054|The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine.|Balint syndrome|29|44|methotrexate|122|134
12552054|The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine.|posterior leukoencephalopathy|63|92|cytarabine|139|149
12552054|The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine.|posterior leukoencephalopathy|63|92|methotrexate|122|134
12561997|We present a unique case of GTBM in a patient with myeloma following treatment with Melphalan.|GTBM|28|32|Melphalan|84|93
12567347|Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.|cortical venous thrombosis|125|151|L-asparaginase|60|74
12567347|Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.|dural puncture headache|196|219|L-asparaginase|60|74
12581772|Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation.|Interstitial pneumonitis|0|24|sirolimus|41|50
12581772|Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.|pneumonitis|28|39|Rapamycin|0|9
12581772|Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.|pneumonitis|28|39|sirolimus|10|19
12581772|Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.|pulmonary infiltrate|185|205|Rapamycin|0|9
12581772|Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.|pulmonary infiltrate|185|205|sirolimus|10|19
12581772|Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.|pulmonary infiltrate|185|205|SR|234|236
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|hyperlipidemia|166|180|Rapammune|38|47
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|hyperlipidemia|166|180|Rapamycin|0|9
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|hyperlipidemia|166|180|sirolimus|10|19
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|hyperlipidemia|166|180|SR|21|23
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|hypertension|152|164|Rapammune|38|47
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|hypertension|152|164|Rapamycin|0|9
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|hypertension|152|164|sirolimus|10|19
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|hypertension|152|164|SR|21|23
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|infection|186|195|Rapammune|38|47
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|infection|186|195|Rapamycin|0|9
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|infection|186|195|sirolimus|10|19
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|infection|186|195|SR|21|23
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|myelosuppression|134|150|Rapammune|38|47
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|myelosuppression|134|150|Rapamycin|0|9
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|myelosuppression|134|150|sirolimus|10|19
12581772|Rapamycin/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and infection.|myelosuppression|134|150|SR|21|23
12587815|A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium.|fever|28|33|lithium|177|184
12587815|A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium.|fever|28|33|olanzapine|162|172
12587815|A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium.|generalized rigidity|35|55|lithium|177|184
12587815|A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium.|generalized rigidity|35|55|olanzapine|162|172
12587815|A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium.|increased serum transaminase and creatine kinase|75|123|lithium|177|184
12587815|A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium.|increased serum transaminase and creatine kinase|75|123|olanzapine|162|172
12587815|A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium.|leukocytosis|57|69|lithium|177|184
12587815|A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium.|leukocytosis|57|69|olanzapine|162|172
12587815|Concomitant administration of lithium with olanzapine may place patients at risk for NMS.|NMS|85|88|lithium|30|37
12587815|Concomitant administration of lithium with olanzapine may place patients at risk for NMS.|NMS|85|88|olanzapine|43|53
12587815|Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.|Neuroleptic malignant syndrome|0|30|lithium|69|76
12587815|Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.|Neuroleptic malignant syndrome|0|30|olanzapine|58|68
12590235|Both 6-MP and AZA are widely used and are known to cause hepatotoxicity in a proportion of patients.|hepatotoxicity|57|71|6-MP|5|9
12590235|Both 6-MP and AZA are widely used and are known to cause hepatotoxicity in a proportion of patients.|hepatotoxicity|57|71|AZA|14|17
12590235|Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease.|Hepatotoxicity|0|14|6-thioguanine|31|44
12590235|This case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of thiopurine-induced hepatic injury.|hepatic injury|180|194|thiopurine|161|171
12590235|We believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of 6-TG as a cause of liver enzyme abnormalities.|abnormal liver enzymes|43|65|6-TG|153|157
12590235|We believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of 6-TG as a cause of liver enzyme abnormalities.|liver enzyme abnormalities|172|198|6-TG|153|157
12590235|We describe a case of significant elevation of serum transaminases in a patient treated with 6-TG for a flare of Crohn's disease.|elevation of serum transaminases|34|66|6-TG|93|97
12598508|Early peritoneal dialysis has not previously been reported for lisinopril induced multiorgan failure.|multiorgan failure|82|100|lisinopril|63|73
12605322|We observed transient panhypogammaglobulinaemia in a patient with neuropsychiatric SLE after treatment with prednisolone and cyclophosphamide.|panhypogammaglobulinaemia|22|47|cyclophosphamide|125|141
12605322|We observed transient panhypogammaglobulinaemia in a patient with neuropsychiatric SLE after treatment with prednisolone and cyclophosphamide.|panhypogammaglobulinaemia|22|47|prednisolone|108|120
1261772|Fulminant hepatic failure developed in a 24-year-old black woman who had been treated with propylthiouracil and propranolol for hyperthyroidism.|Fulminant hepatic failure|0|25|propranolol|112|123
1261772|Fulminant hepatic failure developed in a 24-year-old black woman who had been treated with propylthiouracil and propranolol for hyperthyroidism.|Fulminant hepatic failure|0|25|propylthiouracil|91|107
1261772|Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil.|Fulminant hepatitis|0|19|propylthiouracil|56|72
1261772|These observations indicate that submassive hepatic necrosis may result from treatment with propylthiouracil and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug.|hepatic injury|201|215|propylthiouracil|92|108
1261772|These observations indicate that submassive hepatic necrosis may result from treatment with propylthiouracil and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug.|submassive hepatic necrosis|33|60|propylthiouracil|92|108
12621956|The diagnosis of hypothermia was delayed until it was apparent for several days but resolved with the discontinuation of risperidone and continuation of clozapine.|hypothermia|17|28|risperidone|121|132
12621956|This is a case report of subtle, mild hypothermia in a 54-year old female patient receiving risperidone for schizophrenia.|hypothermia|38|49|risperidone|92|103
12625995|Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly clozapine, and is easily misdiagnosed in children.|Akathisia|0|9|clozapine|102|111
12625995|Clozapine-induced akathisia in children with schizophrenia.|akathisia|18|27|Clozapine|0|9
12625995|Two cases of childhood-onset schizophrenia associated with clozapine-induced akathisia responsive to beta-blocker treatment are described.|akathisia|77|86|clozapine|59|68
12630660|After reviewing the literature we suggest the CPM was a complication of lithium toxicity which affected the lateral geniculate nucleus which produced blindness.|blindness|150|159|lithium|72|79
12630660|After reviewing the literature we suggest the CPM was a complication of lithium toxicity which affected the lateral geniculate nucleus which produced blindness.|CPM|46|49|lithium|72|79
12630660|Central pontine myelinolysis manifested by temporary blindness: a possible complication of lithium toxicity.|Central pontine myelinolysis|0|28|lithium|91|98
12630660|Central pontine myelinolysis manifested by temporary blindness: a possible complication of lithium toxicity.|temporary blindness|43|62|lithium|91|98
12635752|Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).|elevated hepatic enzymes|62|86|propylthiouracil|27|43
12635752|Antithyroid treatment with propylthiouracil (PTU) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).|elevated hepatic enzymes|62|86|PTU|45|48
12635752|Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report.|hepatic impairment|71|89|propylthiouracil|96|112
12639299|Interferon-alpha (IFN-alpha) may precipitate or exacerbate the occurrence of MPGN.|MPGN|77|81|IFN-alpha|18|27
12639299|Interferon-alpha (IFN-alpha) may precipitate or exacerbate the occurrence of MPGN.|MPGN|77|81|Interferon-alpha|0|16
12639299|Minimal change disease in a patient receiving IFN-alpha therapy for chronic hepatitis C virus infection.|Minimal change disease|0|22|IFN-alpha|46|55
12656748|A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia (CML) after continuous uneventful treatment with hydroxyurea for 18 yr.|chronic myeloid leukaemia|72|97|hydroxyurea|147|158
12656748|A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia (CML) after continuous uneventful treatment with hydroxyurea for 18 yr.|CML|99|102|hydroxyurea|147|158
12656748|Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia.|Philadelphia positive chronic myeloid leukaemia|13|60|hydroxyurea|83|94
12656748|There are no previous reports in the literature about the emergence of CML during treatment with hydroxyurea.|CML|71|74|hydroxyurea|97|108
12659609|His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.|chloroquine toxicity|71|91|chloroquine|71|82
12659609|OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.|severe chloroquine toxicity|31|58|chloroquine|38|49
12659609|Toxicity related to chloroquine treatment of resistant vivax malaria.|Toxicity|0|8|chloroquine|20|31
12661801|A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.|fever|84|89|carbimazole|115|126
12661801|A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and fever two weeks after starting carbimazole.|sore throat|68|79|carbimazole|115|126
12661801|Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.|agranulocytosis|33|48|carbimazole|13|24
12661801|Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor.|sepsis|53|59|carbimazole|13|24
12661801|We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).|agranulocytosis|29|44|carbimazole|81|92
12661801|We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor (G-CSF).|neutropenic sepsis|49|67|carbimazole|81|92
12665232|Comeoscleral perforation after pterygium excision and intraoperative mitomycin C.|Comeoscleral perforation|0|24|mitomycin C|69|80
12665232|To the best of our knowledge, corneoscleral melting in the first postoperative week after a single intraoperative application of mitomycin C has not been reported.|corneoscleral melting|30|51|mitomycin C|129|140
1267457|A 71-year-old man, who had a history of a previous bullous drug reaction to a sulfonamide, began receiving an ophthalmic preparation that contained sulfacetamide sodium.|bullous drug reaction|51|72|sulfonamide|78|89
1267457|The patient received only the ophthalmic sulfonamide, and it was used for one day, but he developed Stevens-Johnson syndrome.|Stevens-Johnson syndrome|100|124|sulfonamide|41|52
1267457|The sulfonamides are the best verified drug-trigger for erythema multiforme and Stevens-Johnson syndrome.|erythema multiforme|56|75|sulfonamides|4|16
1267457|The sulfonamides are the best verified drug-trigger for erythema multiforme and Stevens-Johnson syndrome.|Stevens-Johnson syndrome|80|104|sulfonamides|4|16
12680486|Based on these findings, the patient was diagnosed with diabetes insipidus secondary to lithium therapy and was treated successfully with amiloride.|diabetes insipidus|56|74|lithium|88|95
12680486|Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and nephrogenic diabetes insipidus.|lithium toxicity|30|46|lithium|30|37
12680486|Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and nephrogenic diabetes insipidus.|nephrogenic diabetes insipidus|150|180|lithium|30|37
12680486|Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and nephrogenic diabetes insipidus.|nephrogenic diabetes insipidus|150|180|lithium|121|128
12680486|Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and nephrogenic diabetes insipidus.|polyuria|137|145|lithium|30|37
12680486|Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and nephrogenic diabetes insipidus.|polyuria|137|145|lithium|121|128
12680486|Treatment of lithium-induced diabetes insipidus with amiloride.|diabetes insipidus|29|47|lithium|13|20
12692521|Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).|Systemic capillary leak syndrome|0|32|G-CSF|78|83
12692521|Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).|Systemic capillary leak syndrome|0|32|granulocyte colony-stimulating factor|39|76
12692521|We present two cases in which both patients suffered with CLS, which we believe was caused following administration of granulocyte colony-stimulating factor, to our knowledge not described in the intensive care patient previously.|CLS|58|61|granulocyte colony-stimulating factor|119|156
12699871|FK506, which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL) 1 day before neurologic abnormalities began.|neurologic abnormalities|124|148|FK506|0|5
12699871|Rapid identification of speech loss linked to FK506 may be important because reduction or cessation of the drug may be associated with reverse of speech loss.|speech loss|24|35|FK506|46|51
12699871|Tacrolimus (FK506), an immunosuppressant, has been associated with mutism in adults after liver transplant.|mutism|67|73|FK506|12|17
12699871|Tacrolimus (FK506), an immunosuppressant, has been associated with mutism in adults after liver transplant.|mutism|67|73|Tacrolimus|0|10
12699871|Tacrolimus (FK506)-induced mutism after liver transplant.|mutism|27|33|FK506|12|17
12699871|Tacrolimus (FK506)-induced mutism after liver transplant.|mutism|27|33|Tacrolimus|0|10
12702914|Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?|oedema|117|123|insulin|16|23
12702914|Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.|ascites|111|118|insulin|27|34
12702914|Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.|peripheral oedema|92|109|insulin|27|34
12702914|Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.|pleural effusion|123|139|insulin|27|34
12702914|Soon after introduction of insulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and pleural effusion.|severe anasarca|58|73|insulin|27|34
12702914|The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of insulin (> 110 units/day), suggesting the existence of insulin insensitivity and hyperinsulinaemia.|hyperinsulinaemia|169|186|insulin|88|95
12702914|The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of insulin (> 110 units/day), suggesting the existence of insulin insensitivity and hyperinsulinaemia.|insulin insensitivity|143|164|insulin|88|95
12702914|We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.|anti-natriuresis|57|73|insulin|40|47
12702914|We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.|hyperinsulinaemia|214|231|insulin|40|47
12702914|We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.|hypoalbuminaemia|236|252|insulin|40|47
12702914|We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.|increased vascular permeability|78|109|insulin|40|47
12702914|We conjectured that the side effects of insulin, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.|insulin insensitivity|191|212|insulin|40|47
12702914|While 40 mg/day of prednisolone improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.|diabetic milieu deteriorated|79|107|prednisolone|19|31
12707728|Intrathecal methotrexate-induced acute cerebellar syndrome.|acute cerebellar syndrome|33|58|methotrexate|12|24
12707728|We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously.|acute cerebellar syndrome|36|61|methotrexate|93|105
12729371|Angioimmunoblastic lymphadenopathy with dysproteinemia following doxycycline administration.|Angioimmunoblastic lymphadenopathy with dysproteinemia|0|54|doxycycline|65|76
12729371|We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.|AILD|20|24|doxycycline|133|144
12729371|We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.|fever|117|122|doxycycline|133|144
12729371|We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following doxycycline administration.|generalized pruritic maculopapular eruption|69|112|doxycycline|133|144
12751276|Anaphylaxis from isoniazid is a possible side effect to this commonly prescribed antibiotic.|Anaphylaxis|0|11|isoniazid|17|26
12751276|Isoniazid-induced anaphylaxis.|anaphylaxis|18|29|Isoniazid|0|9
1275625|A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.|low plasma parathyroid hormone|56|86|magnesium sulfate|145|162
1275625|A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.|PTH|88|91|magnesium sulfate|145|162
1275625|A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.|severe hypocalcemia|28|47|magnesium sulfate|145|162
12757344|Carbamazepine-related hyponatremia following cardiopulmonary bypass.|hyponatremia|22|34|Carbamazepine|0|13
12757344|We discuss the association between carbamazepine and hyponatremia and the causes of hyponatremia after cardiopulmonary bypass.|hyponatremia|53|65|carbamazepine|35|48
12763355|After 5-ASA was discontinued, the polyneuropathy symptoms recovered gradually.|polyneuropathy|34|48|5-ASA|6|11
12763355|Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.|Sensorimotor polyneuropathy|0|27|5-aminosalicylic acid|33|54
12763355|This clinical course suggests that the sensorimotor polyneuropathy may have been caused by 5-ASA.|sensorimotor polyneuropathy|39|66|5-ASA|91|96
12763355|When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.|atrophy|125|132|5-aminosalicylic acid|25|46
12763355|When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.|atrophy|125|132|5-ASA|48|53
12763355|When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.|gait disturbance|218|234|5-aminosalicylic acid|25|46
12763355|When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.|gait disturbance|218|234|5-ASA|48|53
12763355|When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.|weakness|112|120|5-aminosalicylic acid|25|46
12763355|When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.|weakness|112|120|5-ASA|48|53
12763355|When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.|worsening of the dysesthesia|173|201|5-aminosalicylic acid|25|46
12763355|When SASP was changed to 5-aminosalicylic acid (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.|worsening of the dysesthesia|173|201|5-ASA|48|53
12773807|Disseminated cellulitic cryptococcosis in the setting of prednisone monotherapy for pemphigus vulgaris.|Disseminated cellulitic cryptococcosis|0|38|prednisone|57|67
12786839|In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.|atypical lymphocytosis|60|82|SASP|133|137
12786839|In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.|high fever|15|25|SASP|133|137
12786839|In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.|liver dysfunction|38|55|SASP|133|137
12786839|In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.|skin rash|27|36|SASP|133|137
12786839|Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.|infectious mononucleosis-like syndrome|56|94|salazosulfapyridine|106|125
12786839|We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).|infectious mononucleosis-like syndrome|28|66|salazosulfapyridine|78|97
12786839|We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).|infectious mononucleosis-like syndrome|28|66|SASP|99|103
12792223|A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and methotrexate, developed a lupus-like syndrome eight months after her initial infusion.|lupus-like syndrome|149|168|infliximab|98|108
12792223|A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and methotrexate, developed a lupus-like syndrome eight months after her initial infusion.|lupus-like syndrome|149|168|methotrexate|123|135
12792223|A lupus-like syndrome associated with infliximab therapy.|lupus-like syndrome|2|21|infliximab|38|48
12792223|Infliximab therapy may cause a lupus-like syndrome that is reversible upon discontinuing this agent.|lupus-like syndrome|31|50|Infliximab|0|10
12792223|We report in detail an unusual adverse reaction to infliximab therapy, a drug-induced lupus-like clinical syndrome.|lupus-like clinical syndrome|86|114|infliximab|51|61
12796597|Chronic myelogenous leukemia (CML), hepatitis C, and interferon alpha (IFNalpha) have all been associated with renal dysfunction.|renal dysfunction|111|128|IFNalpha|71|79
12796597|Chronic myelogenous leukemia (CML), hepatitis C, and interferon alpha (IFNalpha) have all been associated with renal dysfunction.|renal dysfunction|111|128|interferon alpha|53|69
12796597|Despite the underlying hepatitis C, this case represents renal abnormalities consistent with IFNalpha therapy for CML.|renal abnormalities|57|76|IFNalpha|93|101
12796597|Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature.|focal segmental glomerulosclerosis|25|59|Interferon-alpha|0|16
12796597|The renal biopsy showed focal segmental glomerulosclerosis, which has only been previously reported in two cases of CML treated with IFNalpha.|focal segmental glomerulosclerosis|24|58|IFNalpha|133|141
12802933|Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.|autoimmune hemolytic anemia|7|34|rituximab|45|54
12802933|The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab.|destruction of CD20 positive cells|121|155|rituximab|159|168
12802933|The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab.|massive cytokines liberation|86|114|rituximab|159|168
12802933|We report the first case, to our knowledge, of rituximab-related autoimmune hemolytic anemia.|autoimmune hemolytic anemia|65|92|rituximab|47|56
12806509|Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report.|acute transverse myelitis|12|37|hepatitis B vaccination|48|71
12806509|In this paper, we report a case of 3 years-old boy who developed acute onset tetraparesia following a viral respiratory infecction and hepatitis B vaccination.|acute onset tetraparesia|65|89|hepatitis B vaccination|135|158
12811715|Although it would be expected that, like other type IA toxicities, diphenhydramine-induced cardiotoxicity could be responsive to hypertonic sodium bicarbonate, this finding is largely unappreciated.|cardiotoxicity|91|105|diphenhydramine|67|82
12811715|Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate.|dysrhythmia|37|48|Diphenhydramine|0|15
12811715|However, because diphenhydramine also exhibits type IA sodium channel blockade, cardiac toxicity is also possible.|cardiac toxicity|80|96|diphenhydramine|17|32
12811715|We describe 3 cases of diphenhydramine-induced cardiac toxicity that were responsive to bicarbonate.|cardiac toxicity|47|63|diphenhydramine|23|38
12823045|We describe a patient with extranodal non-Hodgkin lymphoma who developed systemic candidiasis after treatment with a cyclophosphamide-based chemotherapy regimen.|systemic candidiasis|73|93|cyclophosphamide|117|133
12836099|Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.|Stevens-Johnson syndrome|0|24|prednisolone|65|77
12836099|We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.|SJS|20|23|prednisolone|97|109
12847760|A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.|reversal reaction|86|103|dapsone|119|126
12847760|A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.|reversal reaction|86|103|rifampin|131|139
12852380|However, in order to avoid neuropathic side effects, patients under thalidomide therapy should be monitored every 6 months with nerve conduction studies while taking the drug.|neuropathic side effects|27|51|thalidomide|68|79
12854039|After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.|neurological manifestations|140|167|interferon alpha|69|85
12854039|Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.|bilateral optic neuritis|39|63|recombinant interferon alpha-2a|187|218
12854039|Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.|decreased sensation of vibration|69|101|recombinant interferon alpha-2a|187|218
12854039|Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.|increased deep tendon reflex|106|134|recombinant interferon alpha-2a|187|218
12854039|Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.|bilateral optic neuritis|39|63|recombinant interferon alpha-2b|177|208
12854039|Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.|bowel and bladder dysfunction|123|152|recombinant interferon alpha-2b|177|208
12854039|Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.|numbness of the lower extremities|78|111|recombinant interferon alpha-2b|177|208
12854039|CONCLUSIONS: Optic neuritis in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural interferon alpha administration.|neurological signs|54|72|interferon alpha|182|198
12854039|CONCLUSIONS: Optic neuritis in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural interferon alpha administration.|Optic neuritis|13|27|interferon alpha|182|198
12854039|Multiple sclerosis-like disease secondary to alpha interferon.|Multiple sclerosis-like disease|0|31|alpha interferon|45|61
12854039|PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.|bilateral optic neuritis|21|45|interferon alpha|108|124
12860350|Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen.|Acute abdomen|0|13|tamoxifen|67|76
12860350|Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen.|endometriosis|21|34|tamoxifen|67|76
12860350|We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery.|endometriosis|120|133|tamoxifen|52|61
12862258|A case report of fatal dapsone-induced agranulocytosis in an Indian mid-borderline leprosy patient.|agranulocytosis|39|54|dapsone|23|30
12862258|Fatal agranulocytosis in an Indian male receiving 100mg of dapsone daily, hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported.|Fatal agranulocytosis|0|21|dapsone|59|66
12862258|Various case reports concerning dapsone-induced agranulocytosis are reviewed.|agranulocytosis|48|63|dapsone|32|39
12869178|Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.|Massive pulmonary embolism|0|26|heparin|45|52
12869178|Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.|thrombocytopenia|61|77|heparin|45|52
12869178|Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.|thrombocytopenia|186|202|heparin|170|177
12875956|Acute psychosis associated with levetiracetam.|Acute psychosis|0|15|levetiracetam|32|45
12875956|A twelve year-old-girl with idiopathic partial epilepsy with secondary generalization, developed acute psychosis 10 days after the administration of levetiracetam.|acute psychosis|97|112|levetiracetam|149|162
12875956|The psychotic behavior resolved completely soon after the discontinuation of levetiracetam.|psychotic behavior|4|22|levetiracetam|77|90
12880504|CASES: "A" was an 8-year-old boy with attention deficit and chronic tic disorder who developed obsessive-compulsive symptoms within 2 weeks of starting risperidone.|obsessive-compulsive symptoms|95|124|risperidone|152|163
12880504|Obsessive-compulsive symptoms suddenly emerged 10 days after starting risperidone and resolved within 3 days of discontinuation.|Obsessive-compulsive symptoms|0|29|risperidone|70|81
12880504|Risperidone-induced obsessive-compulsive symptoms in two children.|obsessive-compulsive symptoms|20|49|Risperidone|0|11
1288290|Proliferation of abnormal bone marrow histiocytes, an undesired effect of granulocyte macrophage-colony-stimulating factor therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation.|Proliferation of abnormal bone marrow histiocytes|0|49|granulocyte macrophage-colony-stimulating factor|74|122
12885108|Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.|heart failure exacerbation|9|35|rosiglitazone|52|65
12889716|Enoxaparin-induced generalized exanthem.|generalized exanthem|19|39|Enoxaparin|0|10
12889716|Only one case of a generalized maculopapular rash with enoxaparin has been reported in Europe.|generalized maculopapular rash|19|49|enoxaparin|55|65
12889716|To our knowledge, this is the first case reported in the English literature of a generalized exanthem due to subcutaneous injection of enoxaparin.|generalized exanthem|81|101|enoxaparin|135|145
12908837|Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.|aggression|74|84|clonazepam|40|50
12908837|Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.|agitation|63|72|clonazepam|40|50
12908837|Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.|hyperactivity|86|99|clonazepam|40|50
12908837|Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.|irritability|101|113|clonazepam|40|50
12908837|Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.|property destruction|115|135|clonazepam|40|50
12908837|Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.|temper tantrums|141|156|clonazepam|40|50
12908837|This report describes an individual with mental retardation who experienced behavioral exacerbation associated with clonazepam prescribed at 2 mg/day (0.02 mg/kg/day) to treat aggression, self-injurious behavior, property destruction, and screaming, which was measured with a 15-minute partial interval recording measurement method.|behavioral exacerbation|76|99|clonazepam|116|126
12915840|Cefuroxime-induced immune hemolysis.|immune hemolysis|19|35|Cefuroxime|0|10
12915840|We report the first case of IHA associated with cefuroxime administration.|IHA|28|31|cefuroxime|48|58
12921505|After 39 hours on argatroban, the infusion was stopped when minor bleeding was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds.|bleeding|66|74|argatroban|18|28
12921505|Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.|thrombocytopenia|31|47|heparin|15|22
12921505|Argatroban is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant renal impairment, but conversely has prolonged effects in hepatic failure.|hepatic failure|174|189|Argatroban|0|10
12921505|OBJECTIVE: To report a case of significant hepatic and renal failure with the use of argatroban in a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD).|hepatic and renal failure|43|68|argatroban|85|95
12921505|OBJECTIVE: To report a case of significant hepatic and renal failure with the use of argatroban in a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD).|thrombocytopenia|130|146|heparin|114|121
12923827|Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.|Schneiderian first-rank symptoms|0|32|fluvoxamine|49|60
12923827|The patient, a 28-year-old man suffering from panic disorder, developed several first-rank symptoms during fluvoxamine administration.|first-rank symptoms|80|99|fluvoxamine|107|118
12923827|This communication describes a patient who developed Schneiderian first-rank symptoms in the course of treatment with fluvoxamine.|Schneiderian first-rank symptoms|53|85|fluvoxamine|118|129
12923827|This finding suggests that fluvoxamine can precipitate Schneiderian first-rank symptoms in some susceptible patients.|Schneiderian first-rank symptoms|55|87|fluvoxamine|27|38
12927328|We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.|EPS|100|103|clozapine|75|84
12932249|Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection.|Hyperpigmentation|0|17|interferon-alpha|25|41
12932249|These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN).|skin lesions|6|18|IFN|94|97
12932249|These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN).|skin lesions|6|18|interferon-alpha|76|92
12932249|We describe two dark-skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin.|hyperpigmented skin|52|71|IFN|123|126
12932249|We describe two dark-skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin.|hyperpigmented skin|52|71|ribavirin|131|140
12932249|We describe two dark-skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin.|tongue lesions|76|90|IFN|123|126
12932249|We describe two dark-skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin.|tongue lesions|76|90|ribavirin|131|140
12944250|It is concluded that simultaneous administration of ciprofloxacin and tazobactam/piperacillin may cause marked thrombocytosis.|thrombocytosis|111|125|ciprofloxacin|52|65
12944250|It is concluded that simultaneous administration of ciprofloxacin and tazobactam/piperacillin may cause marked thrombocytosis.|thrombocytosis|111|125|piperacillin|81|93
12944250|It is concluded that simultaneous administration of ciprofloxacin and tazobactam/piperacillin may cause marked thrombocytosis.|thrombocytosis|111|125|tazobactam|70|80
12944250|Since the thrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative.|thrombocyte count started to increase|10|47|ciprofloxacin|126|139
12944250|Since the thrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative.|thrombocyte count started to increase|10|47|piperacillin|155|167
12944250|Since the thrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative.|thrombocyte count started to increase|10|47|tazobactam|144|154
12944250|Thrombocytosis under ciprofloxacin and tazobactam/piperacillin.|Thrombocytosis|0|14|ciprofloxacin|21|34
12944250|Thrombocytosis under ciprofloxacin and tazobactam/piperacillin.|Thrombocytosis|0|14|piperacillin|50|62
12944250|Thrombocytosis under ciprofloxacin and tazobactam/piperacillin.|Thrombocytosis|0|14|tazobactam|39|49
129501|Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.|Anaphylaxis|0|11|chymopapain|35|46
129501|Both patients suddenly became hypotensive after injection of chymopapain into a disk.|hypotensive|30|41|chymopapain|61|72
12951892|Lethargy in a newborn: lithium toxicity or lab error?|Lethargy|0|8|lithium|23|30
12951892|Lethargy in a newborn: lithium toxicity or lab error?|lithium toxicity|23|39|lithium|23|30
12951892|The newborn manifested a four day course of lethargy with unexplained high lithium levels in the adult toxic range.|lethargy|44|52|lithium|75|82
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|fever|87|92|carbamazepine|180|193
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|fever|87|92|CBZ|195|198
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|fever|87|92|Tegretol|200|208
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|leukopenia|94|104|carbamazepine|180|193
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|leukopenia|94|104|CBZ|195|198
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|leukopenia|94|104|Tegretol|200|208
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|positive anti-nuclear antibody|109|139|carbamazepine|180|193
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|positive anti-nuclear antibody|109|139|CBZ|195|198
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|positive anti-nuclear antibody|109|139|Tegretol|200|208
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|rash|81|85|carbamazepine|180|193
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|rash|81|85|CBZ|195|198
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|rash|81|85|Tegretol|200|208
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|systemic lupus erythematosus (SLE)-like symptoms|31|79|carbamazepine|180|193
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|systemic lupus erythematosus (SLE)-like symptoms|31|79|CBZ|195|198
1295628|A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; Tegretol) used against benign Rolandic epilepsy.|systemic lupus erythematosus (SLE)-like symptoms|31|79|Tegretol|200|208
1295628|Carbamazepine-induced systemic lupus erythematosus-like disease.|systemic lupus erythematosus-like disease|22|63|Carbamazepine|0|13
1295628|The cases of CBZ-induced SLE reported in the literature were reviewed.|SLE|25|28|CBZ|13|16
12962465|After four months, while receiving RH, he developed painful bilateral gynaecomastia.|bilateral gynaecomastia|60|83|RH|35|37
12962465|Gynaecomastia is a rarely reported adverse drug reaction due to isoniazid therapy.|Gynaecomastia|0|13|isoniazid|64|73
12962465|Isoniazid associated, painful, bilateral gynaecomastia.|bilateral gynaecomastia|31|54|Isoniazid|0|9
1310879|A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.|acute renal failure|101|120|heparin|25|32
1310879|A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.|acute renal failure|101|120|heparin|151|158
1310879|A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.|HAT|62|65|heparin|25|32
1310879|A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.|HAT|62|65|heparin|151|158
1310879|A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.|recurrent arteriothromboses|68|95|heparin|25|32
1310879|A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.|recurrent arteriothromboses|68|95|heparin|151|158
1310879|A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.|thrombocytopenia|44|60|heparin|25|32
1310879|A patient suffering from heparin-associated thrombocytopenia (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.|thrombocytopenia|44|60|heparin|151|158
1310879|By means of the in vitro heparin-induced platelet activation (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.|platelet activation|257|276|Clexane|209|216
1310879|By means of the in vitro heparin-induced platelet activation (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.|platelet activation|257|276|Fragmin|130|137
1310879|By means of the in vitro heparin-induced platelet activation (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.|platelet activation|257|276|Fraxiparin|142|152
1310879|By means of the in vitro heparin-induced platelet activation (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.|platelet activation|257|276|heparin|101|108
1310879|Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.|thrombocytopenia|19|35|Heparin|0|7
1316047|Hemodynamic collapse following labetalol administration in preeclampsia.|Hemodynamic collapse|0|20|labetalol|31|40
1348483|A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy.|pleuropulmonary abnormalities|130|159|bromocriptine|59|72
1348483|A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy.|pleuropulmonary abnormalities|130|159|cabergoline|95|106
1348483|Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.|Pleuropulmonary changes|0|23|cabergoline|101|112
1348483|Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine.|pleuropulmonary abnormalities|35|64|bromocriptine|68|81
1348483|Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine.|pleuropulmonary abnormalities|35|64|cabergoline|5|16
1356045|Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium.|Acute myopathy|0|14|methylprednisolone|105|123
1356045|Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium.|Acute myopathy|0|14|vecuronium|128|138
1356045|Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium.|degeneration of myosin filaments|30|62|methylprednisolone|105|123
1356045|Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium.|degeneration of myosin filaments|30|62|vecuronium|128|138
1356045|Flaccid quadriparesis was noted after discontinuation of vecuronium.|Flaccid quadriparesis|0|21|vecuronium|57|67
1356045|This entity is probably related to a combination of high doses of corticosteroids, vecuronium administration and metabolic abnormalities associated with respiratory failure.|respiratory failure|153|172|vecuronium|83|93
1359782|A patient with ulcerative colitis developed skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology, while taking sulfasalazine.|diffuse pulmonary shadowing|66|93|sulfasalazine|143|156
1359782|A patient with ulcerative colitis developed skin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology, while taking sulfasalazine.|skin pigmentation|44|61|sulfasalazine|143|156
1359782|Pulmonary infiltrates and skin pigmentation associated with sulfasalazine.|Pulmonary infiltrates|0|21|sulfasalazine|60|73
1359782|Pulmonary infiltrates and skin pigmentation associated with sulfasalazine.|skin pigmentation|26|43|sulfasalazine|60|73
1359782|Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology.|lung disorder|22|35|Sulfasalazine|0|13
1359782|Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology.|ulcerative colitis|96|114|Sulfasalazine|0|13
1359782|Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology.|ulcerative colitis|96|114|sulfasalazine|133|146
13680140|Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.|sclerotic changes of lumbar spine and femur|11|54|isotretinoin|77|89
1378497|Although an association between exposure to bleomycin and the development of scleroderma has been suspected, few cases are reported.|scleroderma|77|88|bleomycin|44|53
1378497|Our series of 3 patients supports a causal connection between bleomycin and scleroderma.|scleroderma|76|87|bleomycin|62|71
1378497|Scleroderma in association with the use of bleomycin: a report of 3 cases.|Scleroderma|0|11|bleomycin|43|52
1378497|We describe the development of cutaneous scleroderma in 3 patients coincident with the use of bleomycin in low cumulative doses of less than 100 U.|cutaneous scleroderma|31|52|bleomycin|94|103
1389744|A patient presented with dilated cardiomyopathy after many years of overusing an adrenaline inhaler.|dilated cardiomyopathy|25|47|adrenaline|81|91
1389744|Dilated cardiomyopathy associated with chronic overuse of an adrenaline inhaler.|Dilated cardiomyopathy|0|22|adrenaline|61|71
1393348|A 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus (SLE) with characteristic laboratory findings, 18 months after starting carbamazepine maintenance treatment.|SLE|102|105|carbamazepine|173|186
1393348|A 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus (SLE) with characteristic laboratory findings, 18 months after starting carbamazepine maintenance treatment.|systemic lupus erythematosus|72|100|carbamazepine|173|186
1393348|Although both the spontaneous occurrence of SLE and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of carbamazepine.|SLE|44|47|carbamazepine|170|183
1393348|Although both the spontaneous occurrence of SLE and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of carbamazepine.|SLE|98|101|carbamazepine|170|183
1393348|Although both the spontaneous occurrence of SLE and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of carbamazepine.|SLE|122|125|carbamazepine|170|183
1393348|Carbamazepine-induced systemic lupus erythematosus.|systemic lupus erythematosus|22|50|Carbamazepine|0|13
1393348|SLE receded after withdrawal of carbamazepine and treatment with anti-inflammatory drugs.|SLE|0|3|carbamazepine|32|45
1401493|We report a case of acne fulminans occurring during treatment with 13-cis-retinoic acid for cystic acne.|acne fulminans|20|34|13-cis-retinoic acid|67|87
1414247|Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.|coma|82|86|valproic acid|60|73
1414247|Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.|coma|22|26|Valproic acid|0|13
1420650|Asterixis induced by carbamazepine therapy.|Asterixis|0|9|carbamazepine|21|34
1420650|In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.|asterixis|108|117|carbamazepine|149|162
1420650|In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.|asterixis|108|117|CBZ|164|167
1420650|We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.|asterixis|12|21|CBZ|197|200
1420650|We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.|asterixis|12|21|clozapine|158|167
1420650|We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.|asterixis|12|21|lithium|147|154
1420650|We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.|neurotoxicity|57|70|CBZ|197|200
1420650|We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.|neurotoxicity|57|70|clozapine|158|167
1420650|We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.|neurotoxicity|57|70|lithium|147|154
1422497|Encephalopathy and seizures induced by intravesical alum irrigations.|Encephalopathy|0|14|alum|52|56
1422497|Encephalopathy and seizures induced by intravesical alum irrigations.|seizures|19|27|alum|52|56
1422497|Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.|Hemorrhagic cystitis|0|20|cyclophosphamide|54|70
1422497|We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.|elevated aluminum levels|55|79|alum|178|182
1422497|We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.|encephalopathy|24|38|alum|178|182
1422497|We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.|seizures|117|125|alum|178|182
1433432|Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis.|hyponatremia|13|25|desmopressin|48|60
1433432|Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis.|Seizure|0|7|desmopressin|48|60
1433432|We report a case of hyponatremia associated with a grand mal seizure in a 28 month-old child after intra-nasal desmopressin administration for high fluid intake with nocturnal enuresis.|grand mal seizure|51|68|desmopressin|111|123
1433432|We report a case of hyponatremia associated with a grand mal seizure in a 28 month-old child after intra-nasal desmopressin administration for high fluid intake with nocturnal enuresis.|hyponatremia|20|32|desmopressin|111|123
1440123|This case report describes a 38-year-old male in whom SIADH was strongly suspected secondary to Tegretol therapy to control a seizure disorder.|SIADH|54|59|Tegretol|96|104
1445134|Gestational diabetes was no less severe (degree of hyperglycaemia, need for insulin therapy) when associated with norethisterone.|Gestational diabetes|0|20|norethisterone|114|128
1445134|However, follow-up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance.|diabetes mellitus|120|137|norethisterone|75|89
1445134|However, follow-up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance.|gestational diabetes|33|53|norethisterone|75|89
1445134|However, follow-up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance.|impaired glucose tolerance|142|168|norethisterone|75|89
1445134|In a single practice during the 21 years 1971-1991, the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take norethisterone (137 of 1,684) (p < 0.001).|gestational diabetes|69|89|norethisterone|114|128
1445134|Masculinization of a female fetus occurred in 5 of 39 (12.8%) exposed to norethisterone; all were cases of clitoral hypertrophy not requiring surgical treatment.|clitoral hypertrophy|107|127|norethisterone|73|87
1445134|Masculinization of a female fetus occurred in 5 of 39 (12.8%) exposed to norethisterone; all were cases of clitoral hypertrophy not requiring surgical treatment.|Masculinization of a female fetus|0|33|norethisterone|73|87
1445134|Norethisterone in these 69 pregnancies accounted for 33.3% (5 of 15) cases of clitoral hypertrophy diagnosed in 100,756 consecutive births.|clitoral hypertrophy|78|98|Norethisterone|0|14
1450506|An adverse reaction to IFN was strongly suspected as the cause of CHF.|CHF|66|69|IFN|23|26
1450506|Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon.|congestive heart failure|32|56|recombinant alpha-interferon|91|119
1450506|Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).|CHF|116|119|IFN|53|56
1450506|Sixteen hours after the first administration of IFN, IFN was suspended by the symptoms of congestive heart failure (CHF).|congestive heart failure|90|114|IFN|53|56
14514135|Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient: a complication of cyclophosphamide.|Neutrophilic eccrine hidradenitis|0|33|cyclophosphamide|103|119
14514135|We report a case of NEH masquerading as cutaneous vasculitis in a woman receiving cyclophosphamide for lupus nephritis.|NEH|20|23|cyclophosphamide|82|98
14522628|Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.|Generalised cutaneous rash|0|26|ganciclovir|43|54
14522628|Skin rash and splinter hemorrhages from ganciclovir.|Skin rash|0|9|ganciclovir|40|51
14522628|Skin rash and splinter hemorrhages from ganciclovir.|splinter hemorrhages|14|34|ganciclovir|40|51
14526130|Can roxithromycin and betamethasone induce acute pancreatitis? A case report.|acute pancreatitis|43|61|betamethasone|22|35
14526130|Can roxithromycin and betamethasone induce acute pancreatitis? A case report.|acute pancreatitis|43|61|roxithromycin|4|17
14526130|CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and betamethasone, manifested acute pancreatitis.|acute pancreatitis|137|155|betamethasone|111|124
14526130|CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and betamethasone, manifested acute pancreatitis.|acute pancreatitis|137|155|roxithromycin|93|106
14530108|Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.|Renal tubular acidosis|0|22|FK506|36|41
14530108|RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.|nephrotoxicity|19|33|FK506|45|50
14530108|RTA is one type of nephrotoxicity induced by FK506, and it is reversible in mild cases when appropriately treated.|RTA|0|3|FK506|45|50
14530108|Surgeons and physicians should therefore be aware of the potential for RTA to occur with FK506 after any organ transplantation.|RTA|71|74|FK506|89|94
14530108|The mechanism of RTA induced by FK506 has not yet been clearly elucidated.|RTA|17|20|FK506|32|37
14530108|The treatment for acidosis and hyperkalaemia should be started as soon as RTA is diagnosed, and the dosage of FK506 should also be reduced if possible.|RTA|74|77|FK506|110|115
14530108|We report a case of RTA secondary to FK506 administration in liver transplantation.|RTA|20|23|FK506|37|42
14557583|A 74-year-old patient with idiopathic Parkinson's disease was evaluated for unintended sleep episodes that occurred after long-term treatment with 400 mg/day of L-dopa.|unintended sleep episodes|76|101|L-dopa|161|167
14557583|L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.|daytime sleepiness|25|43|L-DOPA|0|6
14557583|The authors' results suggest that L-dopa may cause daytime somnolence in some patients with Parkinson's disease.|daytime somnolence|51|69|L-dopa|34|40
14561622|Neurotoxicity of intrathecal methotrexate: MR imaging findings.|Neurotoxicity|0|13|methotrexate|29|41
14561622|We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.|cytotoxic edema|55|70|methotrexate|96|108
14561622|We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.|aphasia|96|103|methotrexate|32|44
14561622|We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.|left arm weakness|74|91|methotrexate|32|44
14561622|We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.|neurotoxicity|45|58|methotrexate|32|44
14566215|In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.|Epstein's anomaly|154|171|lithium|234|241
14566215|In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.|Epstein's anomaly|154|171|lithium|88|95
14566215|In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.|teratogenicity|108|122|lithium|234|241
14566215|In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.|teratogenicity|108|122|lithium|88|95
14585456|We present a case of a 20-year-old woman who ingested 900 mg of glyburide causing refractory hypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide.|hypoglycemia|93|105|glyburide|64|73
14601701|Ocular ethambutol toxicity.|Ocular ethambutol toxicity|0|26|ethambutol|7|17
14601701|The most commonly recognized toxic effect of ethambutol is optic neuropathy, which generally is considered uncommon and reversible in medical literature.|optic neuropathy|59|75|ethambutol|45|55
14601701|This case and a review of the literature show the severe and unpredictable nature of ethambutol toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring.|ethambutol toxicity|85|104|ethambutol|85|95
14601701|This case and a review of the literature show the severe and unpredictable nature of ethambutol toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring.|vision loss|140|151|ethambutol|85|95
14601701|We describe a 43-year-old man who developed signs and symptoms of bilateral optic neuropathy during treatment with ethambutol.|bilateral optic neuropathy|66|92|ethambutol|115|125
14607011|The case history and toxicological findings of an infant fatality involving pseudoephedrine, brompheniramine, and dextromethorphan are presented.|fatality|57|65|brompheniramine|93|108
14607011|The case history and toxicological findings of an infant fatality involving pseudoephedrine, brompheniramine, and dextromethorphan are presented.|fatality|57|65|dextromethorphan|114|130
14607011|The case history and toxicological findings of an infant fatality involving pseudoephedrine, brompheniramine, and dextromethorphan are presented.|fatality|57|65|pseudoephedrine|76|91
14614357|Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.|overanticoagulation|6|25|acenocoumarol|31|44
14614357|We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.|overanticoagulation|67|86|acenocoumarol|102|115
14632592|Colchicine-induced myopathy in a teenager with familial Mediterranean fever.|myopathy|19|27|Colchicine|0|10
14632592|CONCLUSIONS: Colchicine-induced myopathy should be excluded in patients with FMF who present with generalized muscle weakness.|myopathy|32|40|Colchicine|13|23
14632592|DISCUSSION: Colchicine, the most important drug in treatment of FMF, can cause myopathy in patients with impaired renal and hepatic function.|myopathy|79|87|Colchicine|12|22
14632592|In our patient, an objective causality scale showed that therapeutic doses of colchicine for FMF were the definite cause of myopathy, even though his renal and hepatic function were normal.|myopathy|124|132|colchicine|78|88
14632592|OBJECTIVE: To report a case of colchicine-induced myopathy in a teenager with familial Mediterranean fever (FMF).|myopathy|50|58|colchicine|31|41
14641354|Angioedema and dysphagia caused by contact allergy to inhaled budesonide.|Angioedema|0|10|budesonide|62|72
14641354|Angioedema and dysphagia caused by contact allergy to inhaled budesonide.|dysphagia|15|24|budesonide|62|72
14641354|We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (Budefat) for treatment of bronchial asthma.|dysphagia|98|107|Budefat|152|159
14641354|We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (Budefat) for treatment of bronchial asthma.|dysphagia|98|107|budesonide|134|144
14641354|We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (Budefat) for treatment of bronchial asthma.|sore throat|44|55|Budefat|152|159
14641354|We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (Budefat) for treatment of bronchial asthma.|sore throat|44|55|budesonide|134|144
14641354|We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (Budefat) for treatment of bronchial asthma.|swelling of the lips and oral cavity|57|93|Budefat|152|159
14641354|We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (Budefat) for treatment of bronchial asthma.|swelling of the lips and oral cavity|57|93|budesonide|134|144
14660304|Infectious toxicity of dexamethasone during all remission-induction chemotherapy: report of two cases and literature review.|Infectious toxicity|0|19|dexamethasone|23|36
14660304|We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.|infectious complications|307|331|dexamethasone|337|350
14660304|We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.|infectious toxicities|16|37|dexamethasone|108|121
1467295|We describe a patient who developed NEH on three separate occasions provoked by two different chemotherapeutic agents--cytarabine and mitoxantrone.|NEH|36|39|cytarabine|119|129
1467295|We describe a patient who developed NEH on three separate occasions provoked by two different chemotherapeutic agents--cytarabine and mitoxantrone.|NEH|36|39|mitoxantrone|134|146
14674674|A diagnosis of infliximab-induced lupus was made and the drug treatment was withdrawn.|lupus|34|39|infliximab|15|25
14674674|Infliximab-induced lupus in Crohn's disease: a case report.|lupus|19|24|Infliximab|0|10
14674674|This is the first case, to our knowledge, of onset of prolonged infliximab-induced lupus.|lupus|83|88|infliximab|64|74
14674674|Treatment with infliximab is known to produce an increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease.|anti-double-stranded DNA|101|125|infliximab|15|25
14674674|Treatment with infliximab is known to produce an increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease.|antinuclear antibodies|77|99|infliximab|15|25
14674674|Treatment with infliximab is known to produce an increase of autoantibodies (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease.|increase of autoantibodies|49|75|infliximab|15|25
14677199|Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction.|Severe Raynaud's phenomenon|0|27|yohimbine|33|42
14677199|We describe a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) who paradoxically experienced worsening of Raynaud's phenomenon when using yohimbine for ED.|worsening of Raynaud's phenomenon|166|199|yohimbine|211|220
14684937|After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.|serum level of calcium and urinary excretion of calcium increased|117|182|vitamin D3|28|38
14684937|Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.|hypercalcemia|11|24|1,24(OH)2D3|53|64
14684937|Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.|hypercalcemia|11|24|thiazide|80|88
14684937|Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.|hypercalcemia|11|24|vitamin D3|32|42
14684937|The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.|hypercalcemia|40|53|thiazide|89|97
14684937|The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.|hypercalcemia|40|53|vitamin D3|65|75
14684937|We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.|hypercalcemia|177|190|tacalcitol|97|107
14684937|We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.|hypercalcemia|177|190|thiazide|121|129
14684937|We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.|hypercalciuria|158|172|tacalcitol|97|107
14684937|We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.|hypercalciuria|158|172|thiazide|121|129
14690166|2-CdA typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use.|immunodeficiency|47|63|2-CdA|0|5
14690166|2-CdA typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use.|secondary neoplasms|174|193|2-CdA|0|5
14690166|2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma.|non-Hodgkin's lymphoma|123|145|2-Chloro-deoxyadenosine|0|23
14690166|Therefore, it is reasonable to conclude that: 1) 2-CdA can induce durable complete remission in MCD patients but unfortunately it cannot cure the disease; 2) the possibility that 2-CdA may accelerate the transformation of MCD to NHL cannot be ruled out.|transformation of MCD to NHL|204|232|2-CdA|179|184
1469187|Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.|cardiac DGTX toxicity|81|102|DGTX|89|93
1469187|Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.|total AV-block|104|118|DGTX|89|93
14693027|All patients had taken phenytoin for variable time periods (range 16-80 days; mean: 40) and were on the medication when the skin lesions first appeared.|skin lesions|124|136|phenytoin|23|32
14693027|Erythema multiforme associated with phenytoin and cranial radiation therapy: a report of three patients and review of the literature.|Erythema multiforme|0|19|phenytoin|36|45
14697943|In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.|RSDS|15|19|CyA|115|118
14697943|In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.|RSDS|15|19|tacrolimus|122|132
14697943|Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.|Reflex sympathetic dystrophy syndrome|0|37|tacrolimus|98|108
14697943|We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.|RSDS|29|33|tacrolimus|79|89
14700673|CONCLUSIONS: Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma.|acute myopia|170|182|Topiramate|13|23
14700673|CONCLUSIONS: Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma.|angle-closure glaucoma|187|209|Topiramate|13|23
14700673|CONCLUSIONS: Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma.|anterior chamber shallowing|128|155|Topiramate|13|23
14700673|CONCLUSIONS: Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma.|ciliochoroidal effusion|47|70|Topiramate|13|23
14700673|CONCLUSIONS: Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma.|displacement of the lens-iris diaphragm|84|123|Topiramate|13|23
14700673|Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma.|acute-onset myopia|32|50|topiramate|13|23
14700673|Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma.|angle closure glaucoma|55|77|topiramate|13|23
14700673|METHODS: In an institutional practice setting, two women, aged 25 and 45, developed acute myopia after starting topiramate for epilepsy.|acute myopia|84|96|topiramate|112|122
14711147|Doxycycline-induced photo-onycholysis.|photo-onycholysis|20|37|Doxycycline|0|11
14711147|We present a case of photo-onycholysis in a patient treated with doxycycline for acne vulgaris.|photo-onycholysis|21|38|doxycycline|65|76
14723711|A new type of minocycline-induced cutaneous hyperpigmentation.|cutaneous hyperpigmentation|34|61|minocycline|14|25
14723711|Pigmentary disorders are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, minocycline.|Pigmentary disorders|0|20|minocycline|110|121
14723711|This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.|hyperpigmentation|42|59|minocycline|30|41
14723711|Three distinct types of minocycline-induced cutaneous pigmentation have been described.|cutaneous pigmentation|44|66|minocycline|24|35
14723711|We report two patients with acne vulgaris with a fourth type of minocycline-induced cutaneous pigmentation.|cutaneous pigmentation|84|106|minocycline|64|75
14735388|Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus.|toxic epidermal necrolysis|22|48|Ciprofloxacin|0|13
14735388|We report here a case of TEN after administration of ciprofloxacin.|TEN|25|28|ciprofloxacin|53|66
14740795|A 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed fever concurrent with the administration of amifostine.|fever|115|120|amifostine|159|169
14740795|Amifostine-induced fever: case report and review of the literature.|fever|19|24|Amifostine|0|10
14740795|Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug.|fever|47|52|amifostine|19|29
14740795|Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug.|fevers of neutropenia|129|150|amifostine|19|29
14740795|Patients receiving amifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug.|sepsis|118|124|amifostine|19|29
14740795|To our knowledge, this is the first case report that demonstrates the occurrence of fever with low-dose amifostine therapy without the manifestation of accompanying rash or hypotension.|fever|84|89|amifostine|104|114
14742791|Acute interstitial nephritis due to pantoprazole.|Acute interstitial nephritis|0|28|pantoprazole|36|48
14742791|After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.|general malaise|65|80|pantoprazole|45|57
14742791|OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.|acute interstitial nephritis|117|145|pantoprazole|159|171
14742791|The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.|AIN|78|81|pantoprazole|86|98
14742791|There have been several reported cases of omeprazole-induced AIN.|AIN|61|64|omeprazole|42|52
14746605|It was highly suspected that finasteride was associated with the anterior subcapsular opacity on the lens, and the patient therefore discontinued use of finasteride.|anterior subcapsular opacity on the lens|65|105|finasteride|29|40
14746605|It was highly suspected that finasteride was associated with the anterior subcapsular opacity on the lens, and the patient therefore discontinued use of finasteride.|anterior subcapsular opacity on the lens|65|105|finasteride|153|164
14746605|Propecia-associated bilateral cataract.|bilateral cataract|20|38|Propecia|0|8
14746605|To the best of the authors' knowledge, this is the first reported case of Propecia-associated cataract.|cataract|94|102|Propecia|74|82
14760958|Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a.|Scleromyxedema|0|14|interferon beta-1a|81|99
1477441|CASE SUMMARY: Two children with attention deficit disorder treated with methylphenidate as a simple drug developed fixed drug eruption of the scrotum.|fixed drug eruption of the scrotum|115|149|methylphenidate|72|87
1477441|CONCLUSIONS: Fixed drug rash induced by methylphenidate is a possible but rare phenomenon.|Fixed drug rash|13|28|methylphenidate|40|55
1477441|Fixed drug eruption of the scrotum due to methylphenidate.|Fixed drug eruption of the scrotum|0|34|methylphenidate|42|57
1477441|OBJECTIVE: To report two cases of fixed drug eruption induced by methylphenidate.|fixed drug eruption|34|53|methylphenidate|65|80
1495728|Methotrexate pneumonitis in nonsurgical treatment of ectopic pregnancy.|pneumonitis|13|24|Methotrexate|0|12
1495728|We describe a case of pneumonitis following local administration of methotrexate for nonsurgical termination of an ectopic pregnancy.|pneumonitis|22|33|methotrexate|68|80
14960440|BACKGROUND: The risk/benefit ratio of warfarin therapy changes in the over 75s, when haemorrhagic side-effects become more common.|haemorrhagic side-effects|85|110|warfarin|38|46
14960440|CASE REPORT: A woman of 80 years, on long-term warfarin therapy presented with an acute dissecting thoracic aortic aneurysm; on investigation the only precipitating factor found was an international normalised ratio of 4.8.|acute dissecting thoracic aortic aneurysm|82|123|warfarin|47|55
14960440|Warfarin-associated thoracic aortic dissection in an elderly woman.|thoracic aortic dissection|20|46|Warfarin|0|8
14964753|Cutaneous vasculitis secondary to ramipril.|Cutaneous vasculitis|0|20|ramipril|34|42
14964753|Here we report ramipril-induced cutaneous vasculitis in a patient who required steroid therapy to control it.|cutaneous vasculitis|32|52|ramipril|15|23
14964753|Ramipril-induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before.|cutaneous vasculitis|17|37|Ramipril|0|8
14968106|CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.|severe myelopathy|59|76|doxorubicin|128|139
14968106|Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.|toxic myelopathy|64|80|doxorubicin|113|124
14968106|RESULTS: Evidence of neurological improvement and rehabilitation potential after severe myelopathy due to intrathecal injection of doxorubicin.|severe myelopathy|81|98|doxorubicin|131|142
14968106|STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.|toxic myelopathy|68|84|doxorubicin|122|133
14971874|After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.|increase in the number of apneic events|65|104|infliximab|6|16
14971874|After infliximab treatment, additional sleep studies revealed an increase in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.|SaO2 dips|109|118|infliximab|6|16
14971874|Thus, clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab.|sleep disordered breathing|30|56|infliximab|144|154
14996269|Hypernatraemia induced by sodium polystyrene sulphonate (Kayexalate) in two extremely low birth weight newborns.|Hypernatraemia|0|14|Kayexalate|57|67
14996269|Hypernatraemia induced by sodium polystyrene sulphonate (Kayexalate) in two extremely low birth weight newborns.|Hypernatraemia|0|14|sodium polystyrene sulphonate|26|55
14996269|We describe two ELBW infants affected by hyperkalaemia, treated with Kayexalate, who developed serious hypernatraemia, that has never been reported before in preterm infants.|hypernatraemia|103|117|Kayexalate|69|79
15013892|Bull's-eye maculopathy associated with quinacrine therapy for malaria.|Bull's-eye maculopathy|0|22|quinacrine|39|49
15013892|CONCLUSIONS: Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe maculopathy indistinguishable from chloroquine maculopathy in certain patients.|maculopathy|156|167|chloroquine|144|155
15013892|CONCLUSIONS: Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe maculopathy indistinguishable from chloroquine maculopathy in certain patients.|severe maculopathy|102|120|quinacrine|28|38
15013892|RESULTS: A patient developed a bilaterally symmetric bull's-eye maculopathy 45 years after taking quinacrine for 18 months as prophylaxis against malaria.|bilaterally symmetric bull's-eye maculopathy|31|75|quinacrine|98|108
15013892|The clinical picture was identical to that of chloroquine and hydroxychloroquine maculopathy.|maculopathy|81|92|chloroquine|46|57
15013892|The clinical picture was identical to that of chloroquine and hydroxychloroquine maculopathy.|maculopathy|81|92|hydroxychloroquine|62|80
15028328|Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication.|Cerebral infarcts|0|17|phenylpropanolamine|54|73
15028328|Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.|neurologic events|95|112|Phenylpropanolamine|0|19
15028328|Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.|neurologic events|95|112|PPA|21|24
15028328|Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.|stroke|78|84|Phenylpropanolamine|0|19
15028328|Phenylpropanolamine (PPA) recently has been publicly implicated as a cause of stroke and other neurologic events.|stroke|78|84|PPA|21|24
15028328|The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.|extremely elevated levels of PPA|63|95|PPA|92|95
15028328|The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid.|occipital infarcts|22|40|PPA|92|95
15028328|We present a case of stroke after PPA ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.|stroke|21|27|PPA|34|37
1504404|Central nervous system effects secondary to ciprofloxacin treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and hallucinations have been reported.|hallucinations|185|199|ciprofloxacin|44|57
1504404|Central nervous system effects secondary to ciprofloxacin treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and hallucinations have been reported.|mild headache|128|141|ciprofloxacin|44|57
1504404|Central nervous system effects secondary to ciprofloxacin treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and hallucinations have been reported.|minor dizziness|109|124|ciprofloxacin|44|57
1504404|Central nervous system effects secondary to ciprofloxacin treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and hallucinations have been reported.|seizures|172|180|ciprofloxacin|44|57
1504404|Ciprofloxacin-induced psychosis.|psychosis|22|31|Ciprofloxacin|0|13
1504404|DATA SYNTHESIS: A 49-year-old man developed symptoms of severe psychosis concomitant with ciprofloxacin (250 mg bid) treatment.|severe psychosis|56|72|ciprofloxacin|90|103
1504404|OBJECTIVE: To report a case of ciprofloxacin-induced psychosis and to discuss occurrence rates, risk factors, possible etiologies, preventive measures, and treatment courses for this adverse reaction.|psychosis|53|62|ciprofloxacin|31|44
15053046|Agranulocytosis induced by vancomycin in an ESRD patient on CAPD.|Agranulocytosis|0|15|vancomycin|27|37
15053046|Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.|Agranulocytosis|0|15|vancomycin|67|77
15053046|We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed vancomycin-induced agranulocytosis during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.|agranulocytosis|105|120|vancomycin|86|96
15061230|It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.|osteonecrosis|111|124|dexamethasone|27|40
15061230|Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.|Osteonecrosis|0|13|dexamethasone|68|81
15061230|Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.|osteonecrosis|46|59|dexamethasone|72|85
15072497|Development of Peyronie's disease during long-term colchicine treatment.|Peyronie's disease|15|33|colchicine|51|61
15072497|However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).|PD|55|57|colchicine|75|85
150825|A patient developed cholestatic hepatitis while being treated with nitrofurantoin.|cholestatic hepatitis|20|41|nitrofurantoin|67|81
150825|A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime.|jaundice|20|28|furazolidone|86|98
150825|A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime.|jaundice|20|28|nifuroxime|103|113
1509179|A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy.|exacerbation of a preexisting maladaptive behavior|24|74|phenobarbital|10|23
1509179|Ten years of behavioral data are presented to support the hypothesis that phenobarbital was exacerbating maladaptive behaviors.|maladaptive behaviors|105|126|phenobarbital|74|87
1509179|This profile should trigger a "red flag" as to the possibility of phenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors.|behavioral side effects|80|103|phenobarbital|66|79
1509179|This profile should trigger a "red flag" as to the possibility of phenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors.|exacerbation of preexisting maladaptive behaviors|107|156|phenobarbital|66|79
15093850|Pilocarpine toxicity and the treatment of xerostomia.|Pilocarpine toxicity|0|20|Pilocarpine|0|11
15093850|We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.|bradycardia|88|99|pilocarpine|51|62
15093850|We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.|mild hypotension|101|117|pilocarpine|51|62
15093850|We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.|muscarinic symptoms|123|142|pilocarpine|51|62
15097937|Although combinations of belladonna, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome.|anticonvulsant hypersensitivity syndrome|204|244|belladonna|25|35
15097937|Although combinations of belladonna, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome.|anticonvulsant hypersensitivity syndrome|204|244|ergotamine|37|47
15097937|Although combinations of belladonna, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome.|anticonvulsant hypersensitivity syndrome|204|244|phenobarbital|53|66
15097937|Anticonvulsant hypersensitivity syndrome associated with Bellamine S, a therapy for menopausal symptoms.|Anticonvulsant hypersensitivity syndrome|0|40|Bellamine S|57|68
15097937|We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes.|anticonvulsant hypersensitivity syndrome|77|117|belladonna alkaloids|144|164
15097937|We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes.|anticonvulsant hypersensitivity syndrome|77|117|Bellamine S|131|142
15097937|We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes.|anticonvulsant hypersensitivity syndrome|77|117|ergotamine|166|176
15097937|We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes.|anticonvulsant hypersensitivity syndrome|77|117|phenobarbital|178|191
15107195|A case of heatstroke is reported in a 32-year-old man diagnosed with schizophrenia and on clozapine monotherapy.|heatstroke|10|20|clozapine|90|99
15107195|Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management.|Heat stroke|0|11|clozapine|36|45
15112258|Gemcitabine-related radiation recall preferentially involves internal tissue and organs.|radiation recall|20|36|Gemcitabine|0|11
15112258|The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.|myositis|47|55|gemcitabine|259|270
15112258|The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.|radiation recall|167|183|gemcitabine|259|270
15112258|The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13.|radiation recall|239|255|gemcitabine|259|270
15112258|The literature search found 12 cases of radiation recall caused by gemcitabine.|radiation recall|40|56|gemcitabine|67|78
15112258|The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs.|radiation recall reactions|16|42|gemcitabine|57|68
15126179|Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost.|Cystoid macular edema|0|21|bimatoprost|80|91
15126179|Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost.|Cystoid macular edema|0|21|latanoprost|65|76
15126179|METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.|cystoid macula edema|72|92|bimatoprost|129|140
15126179|METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.|cystoid macula edema|72|92|latanoprost|114|125
15126179|METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.|cystoid macular edema|204|225|bimatoprost|129|140
15126179|METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.|cystoid macular edema|204|225|latanoprost|114|125
15126179|METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.|intense conjunctival hyperemia|37|67|bimatoprost|129|140
15126179|METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.|intense conjunctival hyperemia|37|67|latanoprost|114|125
15126179|PURPOSE: To report a case of angiographically documented cystoid macula edema occurring after switching a pseudophakic patient from latanoprost to bimatoprost.|cystoid macula edema|57|77|bimatoprost|147|158
15126179|PURPOSE: To report a case of angiographically documented cystoid macula edema occurring after switching a pseudophakic patient from latanoprost to bimatoprost.|cystoid macula edema|57|77|latanoprost|132|143
15157248|An immediate hemolytic reaction induced by repeated administration of oxaliplatin.|hemolytic reaction|13|31|oxaliplatin|70|81
15157248|CASE REPORT: We report a patient who developed a DAT-positive hemolytic episode after a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin.|DAT-positive hemolytic episode|49|79|oxaliplatin|170|181
15162903|Although neurotoxicity is a frequent complication of methotrexate therapy, fatal acute neurotoxicity is extremely uncommon, especially in adults.|fatal acute neurotoxicity|75|100|methotrexate|53|65
15162903|Although neurotoxicity is a frequent complication of methotrexate therapy, fatal acute neurotoxicity is extremely uncommon, especially in adults.|neurotoxicity|9|22|methotrexate|53|65
15162903|Clinicians should be aware of the signs and symptoms of neurotoxicity during treatment, as well as predisposing factors that put patients receiving methotrexate at risk for neurotoxic effects.|neurotoxicity|56|69|methotrexate|148|160
15162903|Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate.|Fatal acute encephalomyelitis|0|29|methotrexate|65|77
15162903|The day after methotrexate administration, the patient complained of severe back pain and urinary retention.|severe back pain|69|85|methotrexate|14|26
15162903|The day after methotrexate administration, the patient complained of severe back pain and urinary retention.|urinary retention|90|107|methotrexate|14|26
15162903|This patient rapidly progressed from mild neurotoxicity to fatal encephalopathy after one dose of intrathecal methotrexate during his third cycle of chemotherapy.|fatal encephalopathy|59|79|methotrexate|110|122
15162903|This patient rapidly progressed from mild neurotoxicity to fatal encephalopathy after one dose of intrathecal methotrexate during his third cycle of chemotherapy.|mild neurotoxicity|37|55|methotrexate|110|122
1517501|We report a third case of a 6-week-old infant with Escherichia coli sepsis who received ampicillin and other antibiotics and subsequently developed TEN.|TEN|148|151|ampicillin|88|98
15176542|One patient developed large intramural esophageal hematoma as a complication of heparin therapy.|large intramural esophageal hematoma|22|58|heparin|80|87
15183980|Eosinophilic cystitis after bladder instillation with dimethyl sulfoxide.|Eosinophilic cystitis|0|21|dimethyl sulfoxide|54|72
15183980|We report the first case of an acute flare of eosinophilic cystitis in a 51-year-old woman after bladder instillation with dimethyl sulfoxide (DMSO) for presumed interstitial cystitis.|eosinophilic cystitis|46|67|dimethyl sulfoxide|123|141
15183980|We report the first case of an acute flare of eosinophilic cystitis in a 51-year-old woman after bladder instillation with dimethyl sulfoxide (DMSO) for presumed interstitial cystitis.|eosinophilic cystitis|46|67|DMSO|143|147
15190230|Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection.|Acute dystonia|0|14|pegylated interferon alpha|22|48
15190230|In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed acute dystonia soon after the first dose of pegylated interferon alpha.|acute dystonia|115|129|pegylated interferon alpha|159|185
15190230|Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders.|akathisia|107|116|IFN-alpha|13|22
15190230|Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders.|depressive disorders|131|151|IFN-alpha|13|22
15190230|Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders.|neuropsychiatric symptoms|58|83|IFN-alpha|13|22
15190230|Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders.|Parkinsonism|93|105|IFN-alpha|13|22
15190230|Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders.|seizure|118|125|IFN-alpha|13|22
15197722|A patient developed restless legs symptoms paralleling the course of interferon-alpha (IFN alpha) therapy for chronic hepatitis C.|restless legs symptoms|20|42|IFN alpha|87|96
15197722|A patient developed restless legs symptoms paralleling the course of interferon-alpha (IFN alpha) therapy for chronic hepatitis C.|restless legs symptoms|20|42|interferon-alpha|69|85
15197722|Restless legs syndrome due to interferon-alpha.|Restless legs syndrome|0|22|interferon-alpha|30|46
15197722|Restless legs syndrome may thus be an adverse effect of IFN alpha treatment.|Restless legs syndrome|0|22|IFN alpha|56|65
15203443|Many clinicians appear to be concerned about the potential hepatotoxicity of the opiate antagonist naltrexone (NTX) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers.|hepatotoxicity|59|73|naltrexone|99|109
15203443|Many clinicians appear to be concerned about the potential hepatotoxicity of the opiate antagonist naltrexone (NTX) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers.|hepatotoxicity|59|73|NTX|111|114
15203443|We describe a heroin abuser in whom clinical and laboratory manifestations of acute hepatitis B and C appeared a few days after the insertion of a subcutaneous naltrexone implant.|acute hepatitis B and C|78|101|naltrexone|160|170
15224368|Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment.|Sweet's syndrome|0|16|sargramostim|33|45
15224368|Sweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation.|acute febrile neutrophilic dermatosis|23|60|filgrastim|115|125
15224368|Sweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation.|Sweet's syndrome|0|16|filgrastim|115|125
15224368|We report a case of Sweet's syndrome in association with sargramostim treatment following chemotherapy for acute myelogenous leukemia.|Sweet's syndrome|20|36|sargramostim|57|69
15235919|Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.|hypersensitivity myocarditis|28|56|clozapine|64|73
15235919|Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment.|Sudden cardiac death|0|20|clozapine|64|73
15235919|The autopsy findings and a detailed medical history supported the conclusion that clozapine-induced hypersensitivity myocarditis was the most likely cause of death.|hypersensitivity myocarditis|100|128|clozapine|82|91
15235919|The case concerns the sudden death of a 29-year-old male during clozapine therapy started 2 weeks before.|sudden death|22|34|clozapine|64|73
15239684|Purple glove syndrome, named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous phenytoin administration through small dorsal veins of the hands.|purple discoloration|49|69|phenytoin|171|180
15239684|Purple glove syndrome, named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous phenytoin administration through small dorsal veins of the hands.|Purple glove syndrome|0|21|phenytoin|171|180
15239684|Purple glove syndrome, named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous phenytoin administration through small dorsal veins of the hands.|swelling of the hands|74|95|phenytoin|171|180
15239684|The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of phenytoin, also termed purple glove syndrome.|purple glove syndrome|135|156|phenytoin|112|121
15239684|The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of phenytoin, also termed purple glove syndrome.|soft-tissue injury|47|65|phenytoin|112|121
15261876|Our patient was a 72-year-old man with advanced Parkinson's disease (PD) who received levodopa and anti-cholinergic drugs and whose head had become almost completely bald.|completely bald|155|170|levodopa|86|94
15266150|A patient with monocular open-angle glaucoma had trichiasis, a condition associated with the use of a prostaglandin analog.|trichiasis|49|59|prostaglandin|102|115
15266150|Increased lash length, thickness, and pigmentation are well-documented side effects of prostaglandin analog glaucoma drops.|Increased lash length|0|21|prostaglandin|87|100
15266150|Increased lash length, thickness, and pigmentation are well-documented side effects of prostaglandin analog glaucoma drops.|pigmentation|38|50|prostaglandin|87|100
15266150|Trichiasis associated with prostaglandin analog use.|Trichiasis|0|10|prostaglandin|27|40
15286697|Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.|Fatal pulmonary fibrosis|0|24|BCNU|41|45
15286697|Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.|Pulmonary fibrosis|0|18|BCNU|83|87
15286697|Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.|Pulmonary fibrosis|0|18|bis-chloronitrosourea|60|81
15286697|These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.|pulmonary fibrosis|96|114|BCNU|80|84
15286697|We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.|pulmonary fibrosis|266|284|BCNU|253|257
15286697|We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).|severe pulmonary fibrosis|83|108|BCNU|155|159
15289139|Dorzolamide-induced choroidal detachment in a surgically untreated eye.|choroidal detachment|20|40|Dorzolamide|0|11
15289139|METHODS: A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery developed a choroidal detachment 12 hours after initiation of therapy with dorzolamide eye drops.|choroidal detachment|107|127|dorzolamide|170|181
15289139|We document the abrupt development of an extensive choroidal detachment after initiation of dorzolamide therapy in a surgically untreated eye with primary open-angle glaucoma.|choroidal detachment|51|71|dorzolamide|92|103
15300114|Deepening of lid sulcus from topical bimatoprost therapy.|Deepening of lid sulcus|0|23|bimatoprost|37|48
15300114|In each of the three reported patients, alteration of eyelid appearance with deepening of the lid sulcus was evident as the result of topical bimatoprost therapy.|alteration of eyelid appearance|40|71|bimatoprost|142|153
15300114|In each of the three reported patients, alteration of eyelid appearance with deepening of the lid sulcus was evident as the result of topical bimatoprost therapy.|deepening of the lid sulcus|77|104|bimatoprost|142|153
15304176|Lichen planus induced by hepatitis B vaccination: a new case and review of the literature.|Lichen planus|0|13|hepatitis B vaccination|25|48
15307435|Case report: life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug.|life-threatening hypoglycaemia|13|43|sulfadoxine-pyrimethamine|60|85
15307435|In this report, we present a case of hypoglycaemic coma associated with SP, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases.|hypoglycaemic coma|37|55|SP|72|74
15307435|In this report, we present a case of hypoglycaemic coma associated with SP, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases.|hypoglycaemic coma|37|55|SP|190|192
15311565|Initial treatment with heparin was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by fatal intracerebral haemorrhage.|fatal intracerebral haemorrhage|165|196|heparin|23|30
15316423|Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction.|Extensive forearm deep venous thrombosis|0|40|infliximab|60|70
15316423|Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.|IIR|101|104|infliximab|71|81
15316423|Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.|IIR|101|104|infliximab|201|211
15316423|Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.|severe infliximab infusion reaction|64|99|infliximab|71|81
15316423|Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.|severe infliximab infusion reaction|64|99|infliximab|201|211
15316423|Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.|severe swelling of the forearm and hand ipsilateral|134|185|infliximab|71|81
15316423|Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.|severe swelling of the forearm and hand ipsilateral|134|185|infliximab|201|211
15316423|The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case.|hypersensitivity|84|100|infliximab|104|114
15316423|The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case.|IIR|67|70|infliximab|104|114
15316423|The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case.|venous thrombosis|139|156|infliximab|104|114
15331204|After 3- to 13-month period of therapy without indapamide, glucose levels of all patients decreased and diabetes disappeared.|diabetes|104|112|indapamide|47|57
15331204|After stopping indapamide, glucose tolerance impairing may be reversed.|glucose tolerance impairing|27|54|indapamide|15|25
15331204|CONCLUSION: Therapy with indapamide may induce diabetes in essential hypertension patients.|diabetes|47|55|indapamide|25|35
15331204|OBJECTIVE: To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide.|diabetes|172|180|indapamide|33|43
15331204|OBJECTIVE: To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide.|diabetes|172|180|indapamide|192|202
15331204|OBJECTIVE: To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide.|impairing carbohydrate metabolism|44|77|indapamide|33|43
15331204|Possible induction of diabetes by treatment of hypertension with indapamide (with four case reports).|diabetes|22|30|indapamide|65|75
15331204|RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses.|diabetes|285|293|fosinopril|100|110
15331204|RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses.|diabetes|285|293|indapamide|72|82
15331204|RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of diabetes diagnoses.|diabetes|285|293|indapamide|180|190
15338554|CONTEXT: Previous investigators have reported discrepancies between hematologic, marrow morphologic, and cytogenetic responses to imatinib mesylate among patients with chronic myeloid leukemia (CML).|discrepancies between hematologic, marrow morphologic, and cytogenetic responses|46|126|imatinib mesylate|130|147
15338554|Despite a hematologic response in all 3 patients, none of them achieved cytogenetic remission, and all progressed to blast crisis at 7 to 10 months of imatinib therapy.|blast crisis|117|129|imatinib|151|159
15338554|In addition to disease refractoriness, rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported.|blast crisis|99|111|imatinib|119|127
15338554|OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature.|blast crisis|123|135|imatinib|149|157
15338554|Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.|progression of marrow reticulin fibrosis|38|78|imatinib|86|94
15338554|Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.|blast crisis|43|55|imatinib mesylate|78|95
15359206|Easily reversible hypoxemia and hypotension induced by nimodipine.|hypotension|32|43|nimodipine|55|65
15359206|Easily reversible hypoxemia and hypotension induced by nimodipine.|hypoxemia|18|27|nimodipine|55|65
15359206|In this paper we report a case of nimodipine overdosage resulting in prolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate.|hypoxemia|95|104|nimodipine|34|44
15359206|In this paper we report a case of nimodipine overdosage resulting in prolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate.|prolonged hypotension|69|90|nimodipine|34|44
15362597|Refractory hypoglycemia from ciprofloxacin and glyburide interaction.|Refractory hypoglycemia|0|23|ciprofloxacin|29|42
15362597|Refractory hypoglycemia from ciprofloxacin and glyburide interaction.|Refractory hypoglycemia|0|23|glyburide|47|56
15362597|We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.|prolonged hypoglycemia|104|126|ciprofloxacin|76|89
15362597|We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia, which persisted for over 24 hours.|prolonged hypoglycemia|104|126|glyburide|47|56
1536494|Aminophylline hypersensitivity apparently due to ethylenediamine.|Aminophylline hypersensitivity|0|30|Aminophylline|0|13
1536494|Aminophylline hypersensitivity apparently due to ethylenediamine.|Aminophylline hypersensitivity|0|30|ethylenediamine|49|64
1536494|We present a case of ethylenediamine-induced delayed hypersensitivity reaction in a 46-year-old woman who received parenteral aminophylline for an acute asthma exacerbation.|delayed hypersensitivity reaction|45|78|aminophylline|126|139
1536494|We present a case of ethylenediamine-induced delayed hypersensitivity reaction in a 46-year-old woman who received parenteral aminophylline for an acute asthma exacerbation.|delayed hypersensitivity reaction|45|78|ethylenediamine|21|36
15368548|L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.|lethal complication|65|84|L-asparaginase|0|14
15368548|L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.|pancreatitis|23|35|L-asparaginase|0|14
15368548|L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.|severe necrotizing pancreatitis|23|54|L-asparaginase|0|14
15368548|Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.|pancreatitis|14|26|L-asparaginase|43|57
15368548|Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.|Pancreatitis|0|12|L-asparaginase|96|110
15368548|We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.|necrotizing pancreatitis|82|106|L-asparaginase|59|73
15379082|Disulfiram-induced fulminant hepatic failure in an active duty soldier.|fulminant hepatic failure|19|44|Disulfiram|0|10
15379082|Fulminant hepatic failure is a rare complication of disulfiram treatment for alcoholism.|Fulminant hepatic failure|0|25|disulfiram|52|62
15379082|This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence.|fulminant hepatic failure|20|45|disulfiram|66|76
15388215|Tiagabine overdose causes an unusual array of neurological symptoms, many similar to reported adverse effects during therapeutic use.|unusual array of neurological symptoms|29|67|Tiagabine|0|9
15454180|A case of sideroblastic anemia is presented in a patient with a left ventricular assist device drive-line infection who was receiving linezolid, an antibiotic used for serious infections with gram-positive organisms.|sideroblastic anemia|10|30|linezolid|134|143
15454180|As linezolid has been shown to have hematologic side effects, blood count monitoring is recommended in patients receiving this drug for long-term therapy.|hematologic side effects|36|60|linezolid|3|12
15454180|Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device.|Sideroblastic anemia|0|20|linezolid|28|37
15461766|In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.|harlequin color change|78|100|prostaglandin E1|174|190
15461766|The harlequin color change and association with prostaglandin E1.|harlequin color change|4|26|prostaglandin E1|48|64
15463865|Acute renal insufficiency is known to occur in patients who are taking ciprofloxacin, particularly the elderly.|Acute renal insufficiency|0|25|ciprofloxacin|71|84
15463865|Ciprofloxacin-induced renal insufficiency in cystic fibrosis.|renal insufficiency|22|41|Ciprofloxacin|0|13
15463865|Multiple mechanisms for ciprofloxacin-induced nephrotoxicity have been proposed.|nephrotoxicity|46|60|ciprofloxacin|24|37
15463865|We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2-3 weeks of oral ciprofloxacin therapy.|acute renal insufficiency|69|94|ciprofloxacin|119|132
15468380|Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.|necrotizing vasculitis|29|51|infliximab|59|69
15468380|Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.|Sensory neuropathy|0|18|infliximab|59|69
15468380|We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.|necrotizing vasculitis|181|203|infliximab|113|123
15468380|We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.|peripheral neuropathy|152|173|infliximab|113|123
15468380|We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.|progression of preexisting mononeuritis multiplex|226|275|infliximab|113|123
15479299|Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.|Progressive anemia|0|18|interferon-alpha|54|70
15479299|Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.|Progressive anemia|0|18|interleukin-2|75|88
15479299|We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving IL-2 plus IFN-alpha for metastatic renal cell carcinoma.|severe anemia|20|33|IFN-alpha|109|118
15479299|We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving IL-2 plus IFN-alpha for metastatic renal cell carcinoma.|severe anemia|20|33|IL-2|99|103
15482394|An objective causality assessment indicated a probable relationship between clotting abnormality and warfarin administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure.|clotting abnormality|76|96|warfarin|101|109
15482394|Based on the clinical status of the patient, it was suspected that several conditions contributed to the abnormal hypersensitivity to warfarin.|abnormal hypersensitivity|105|130|warfarin|134|142
15482394|Despite the low dosage of warfarin, international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and bleeding symptoms concurrently developed.|bleeding symptoms|135|152|warfarin|26|34
15482394|In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage.|fatal haemorrhage|173|190|warfarin|208|216
15482394|Unusual hypersensitivity to warfarin in a critically ill patient.|hypersensitivity|8|24|warfarin|28|36
15489872|We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.|CMV infection|71|84|cidofovir|151|160
15489872|We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.|CMV infection|71|84|foscarnet|136|145
15489872|We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir, foscarnet, and cidofovir.|CMV infection|71|84|ganciclovir|123|134
15494638|5-fluorouracil (5-FU)-associated peripheral neuropathy is an uncommon event.|peripheral neuropathy|33|54|5-fluorouracil|0|14
15494638|5-fluorouracil (5-FU)-associated peripheral neuropathy is an uncommon event.|peripheral neuropathy|33|54|5-FU|16|20
15494638|During analysis of 28 patients receiving CAP with concomitant radiation (XRT) for pancreatic cancer (resected or locally advanced), two patients developed signs and symptoms consistent with peripheral neuropathy.|peripheral neuropathy|190|211|CAP|41|44
15494638|Knowledge regarding potential adverse effects of CAP is paramount and dose modification is indicated with development of neurotoxicity.|neurotoxicity|121|134|CAP|49|52
15494638|Neurologic symptoms resolved after stopping CAP for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at 2000 mg/m2.|Neurologic symptoms|0|19|CAP|44|47
15494638|Neurologic symptoms resolved after stopping CAP for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at 2000 mg/m2.|Neurologic symptoms|0|19|CAP|112|115
15494638|Patient A reported right leg weakness (foot drop) during week 4 of CAP-XRT (1600 mg/m2).|foot drop|39|48|CAP-XRT|67|74
15494638|Patient A reported right leg weakness (foot drop) during week 4 of CAP-XRT (1600 mg/m2).|right leg weakness|19|37|CAP-XRT|67|74
15494638|Patient B developed perioral and upper extremity paresthesias during the fourth cycle of CAP alone (2500 mg/m2).|perioral and upper extremity paresthesias|20|61|CAP|89|92
15494638|Peripheral neuropathy associated with capecitabine.|Peripheral neuropathy|0|21|capecitabine|38|50
15494638|We conclude peripheral neuropathy with 5-FU is rare.|peripheral neuropathy|12|33|5-FU|39|43
15504988|Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.|Severe hypo-alpha-lipoproteinemia|0|33|rosiglitazone|56|69
15504988|We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy.|reduction in plasma HDL cholesterol and apolipoprotein AI levels|99|163|rosiglitazone|193|206
15507779|Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.|mild hepatotoxicity|34|53|nevirapine|85|95
15507779|Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.|Severe leukopenia|0|17|nevirapine|85|95
15507779|We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.|leukopenia|51|61|nevirapine|85|95
15507779|We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.|leukopenia|197|207|nevirapine|85|95
15507779|We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.|skin and hepatic toxicity|141|166|nevirapine|85|95
15516308|In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.|death|98|103|quetiapine|127|137
15516308|These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.|deaths|56|62|quetiapine|115|125
15516308|We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.|suicidal overdose deaths|98|122|quetiapine|144|154
15522120|After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.|intense itching sensation|66|91|sertraline|33|43
15522120|Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.|Itch|0|4|fluoxetine|41|51
15522120|Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.|Itch|0|4|sertraline|56|66
15522120|Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.|skin rash|9|18|fluoxetine|41|51
15522120|Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.|skin rash|9|18|sertraline|56|66
15529178|Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.|Pulmonary lymphohistiocytic reactions|0|37|etanercept|60|70
15529178|This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of pulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of etanercept therapy.|pulmonary signs and symptoms with alveolar infiltrates|125|179|etanercept|221|231
15533031|Paradoxical cerebral cortical hyperexcitability following flupirtine overdose.|Paradoxical cerebral cortical hyperexcitability|0|47|flupirtine|58|68
15533031|We report the case of a patient with increased cerebral cortical excitability following intoxication with flupirtine, a centrally acting analgesic and antispastic drug.|increased cerebral cortical excitability|37|77|flupirtine|106|116
15543388|AIM: Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C.|celiac disease|55|69|pegylated interferon alpha-2a|76|105
15543388|AIM: Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C.|celiac disease|55|69|ribavirin|110|119
15543388|Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C.|Celiac disease|0|14|pegylated interferon|27|47
15543388|Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C.|Celiac disease|0|14|ribavirin|52|61
15543388|PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment.|anemia|180|186|pegylated interferon alpha-2a|88|117
15543388|PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment.|anemia|180|186|ribavirin|122|131
15543388|PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment.|progressive malaise|156|175|pegylated interferon alpha-2a|88|117
15543388|PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment.|progressive malaise|156|175|ribavirin|122|131
15549981|We present two cases of anaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist metaraminol.|anaphylaxis|24|35|metaraminol|188|199
15554737|In this article, we describe another case of subcutaneous changes following repeated glatiramer acetate injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.|localized panniculitis|128|150|glatiramer acetate|85|103
15554737|In this article, we describe another case of subcutaneous changes following repeated glatiramer acetate injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.|localized panniculitis|128|150|glatiramer acetate|244|262
15554737|In this article, we describe another case of subcutaneous changes following repeated glatiramer acetate injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.|subcutaneous changes|45|65|glatiramer acetate|85|103
15554737|Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.|lipoatrophy|38|49|Copaxone|88|96
15554737|Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.|lipoatrophy|38|49|glatiramer acetate|68|86
15554737|Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.|Localized panniculitis|0|22|Copaxone|88|96
15554737|Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.|Localized panniculitis|0|22|glatiramer acetate|68|86
1557089|In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.|exacerbation in myasthenic weakness|95|130|verapamil|69|78
15571949|In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.|hepatic veno-occlusive disease|61|91|busulfan|146|154
15571949|In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.|HVOD|93|97|busulfan|146|154
15571949|In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.|thrombosis|18|28|busulfan|146|154
15571949|PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.|HVOD|158|162|busulfan|123|131
15571949|PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.|PVT|0|3|busulfan|123|131
15580406|Here, we describe a case of Vogt-Koyanagi-Harada disease occurring 4 months after the start of interferon alpha treatment, probably induced by the immunomodulatory effects of interferon.|Vogt-Koyanagi-Harada disease|28|56|interferon|175|185
15580406|Here, we describe a case of Vogt-Koyanagi-Harada disease occurring 4 months after the start of interferon alpha treatment, probably induced by the immunomodulatory effects of interferon.|Vogt-Koyanagi-Harada disease|28|56|interferon alpha|95|111
15580406|Retinal abnormalities, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C.|"cotton-wool" spots|56|75|interferon|131|141
15580406|Retinal abnormalities, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C.|Retinal abnormalities|0|21|interferon|131|141
15580406|Retinal abnormalities, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C.|retinal hemorrhage|33|51|interferon|131|141
15580406|Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.|Vogt-Koyanagi-Harada disease|0|28|interferon alpha|46|62
15588385|Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.|Acute hepatic failure|0|21|propylthiouracil|71|87
15588385|Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.|Acute hepatic failure|0|21|PTU|89|92
15588385|After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.|fulminant hepatitis|186|205|PTU|174|177
15588385|Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.|acute hepatic failure|99|120|propylthiouracil|74|90
15588385|We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.|fulminant hepatitis|86|105|PTU|74|77
15595320|Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?|Epstein-Barr virus-associated lymphoproliferative disorder|0|58|methotrexate|101|113
15595320|Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?|Epstein-Barr virus-associated lymphoproliferative disorder|0|58|rofecoxib|118|127
15595320|Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.|Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder|110|192|Methotrexate|0|12
15595320|Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.|Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder|110|192|MTX|14|17
15595320|Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.|Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder|110|192|MTX|196|199
15595320|Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.|acute renal failure|170|189|MTX|54|57
15595320|Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.|diarrhea|215|223|MTX|54|57
15595320|Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.|elevated liver transaminases|225|253|MTX|54|57
15595320|Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.|jaundice|255|263|MTX|54|57
15595320|Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.|mucosal ulcerations|265|284|MTX|54|57
15595320|Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.|pancytopenia|191|203|MTX|54|57
15595320|Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.|pyrexia|290|297|MTX|54|57
15595320|Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.|vomiting|205|213|MTX|54|57
15595320|We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.|EBV-associated lymphoproliferative disease|164|206|MTX|51|54
15595320|We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.|hematopoietic toxicity|107|129|MTX|51|54
15595320|We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.|immunosuppression|134|151|MTX|51|54
15611427|OBSERVATIONS: We observed aggravation and spreading of a psoriatic plaque when treated topically with the toll-like receptor (TLR) 7 agonist imiquimod.|aggravation and spreading of a psoriatic plaque|26|73|imiquimod|141|150
15611427|Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.|Psoriasis|0|9|imiquimod|52|61
15611427|Since imiquimod induces large amounts of type I interferon production from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin.|large amounts of type I interferon production|24|69|imiquimod|6|15
15611427|The exacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after imiquimod therapy.|exacerbation of psoriasis|4|29|imiquimod|142|151
15623719|Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.|Vision declined|0|15|methylprednisolone|37|55
15628319|Allergic side effects of AZA are rare, and reported allergic skin eruptions from AZA are very limited in Japan.|allergic skin eruptions|52|75|AZA|25|28
15628319|Allergic side effects of AZA are rare, and reported allergic skin eruptions from AZA are very limited in Japan.|allergic skin eruptions|52|75|AZA|81|84
15628319|DLST is a good diagnostic tool for AZA allergy, especially for severe drug allergy cases.|allergy|39|46|AZA|35|38
15628319|Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis.|Drug eruption|0|13|azathioprine|24|36
15628319|We report AZA-induced drug eruption that developed in two cases of systemic scleroderma with polymyositis.|drug eruption|22|35|AZA|10|13
15644988|Tardive dyskinesia in 2 patients treated with ziprasidone.|Tardive dyskinesia|0|18|ziprasidone|46|57
15644988|Two of our patients developed TD after 23 months and 34 months of ziprasidone monotherapy, respectively.|TD|30|32|ziprasidone|66|77
15644988|Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD).|extrapyramidal symptoms|101|124|Ziprasidone|0|11
15644988|Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD).|tardive dyskinesia|136|154|Ziprasidone|0|11
15644988|Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD).|TD|156|158|Ziprasidone|0|11
15661067|Asthenozoospermia: possible association with long-term exposure to an anti-epileptic drug of carbamazepine.|Asthenozoospermia|0|17|carbamazepine|93|106
15661067|The patient was found to have no motile sperm with a normal sperm count, while taking a dose of 400 mg/day of carbamazepine.|no motile sperm|30|45|carbamazepine|110|123
15663666|Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.|Scrotal ulceration|0|18|retinoic acid|40|53
15663666|The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.|ulcer|4|9|ATRA|87|91
15663666|We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.|scrotal ulcer|29|42|ATRA|129|133
15671134|A case of clozapine-induced tonic-clonic seizures managed with valproate: implications for clinical care.|tonic-clonic seizures|28|49|clozapine|10|19
15671134|Following discontinuation of clozapine, she was rechallenged and again was observed to have seizures.|seizures|92|100|clozapine|29|38
15671134|These findings suggest that clozapine-induced seizures can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of seizures and that concomitant use of a suitable mood stabilizer/anti-epileptic medication can improve the outcome of treatment-resistant schizophrenia.|seizures|46|54|clozapine|28|37
15671134|We describe a case of clozapine-induced seizures in a patient with treatment-resistant schizophrenia.|seizures|40|48|clozapine|22|31
15681911|CONCLUSIONS: Symptoms and pathologic changes of colitis are associated with exposure to rofecoxib.|colitis|48|55|rofecoxib|88|97
15681911|OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib.|lower gastrointestinal symptoms|86|117|rofecoxib|134|143
15681911|RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.|IBD|78|81|rofecoxib|90|99
15681911|RESULTS: Three patients who developed symptoms of inflammatory bowel disease (IBD) during rofecoxib exposure are described along with pathology findings.|inflammatory bowel disease|50|76|rofecoxib|90|99
15685264|After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication.|Carbamazepine intoxication|155|181|Carbamazepine|155|168
15685264|After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication.|Carbamazepine intoxication|155|181|Dantrolene|81|91
15685264|After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication.|Carbamazepine intoxication|155|181|Oxybutynin|24|34
15685264|Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report.|Carbamazepine toxicity|0|22|Carbamazepine|0|13
15685264|Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report.|Carbamazepine toxicity|0|22|Dantrolene|48|58
15685264|Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report.|Carbamazepine toxicity|0|22|Oxybutynin|33|43
15685264|OBJECTIVE: To report a case of Carbamazepine toxicity following the administration of Oxybutynin and Dantrolene.|Carbamazepine toxicity|31|53|Carbamazepine|31|44
15685264|OBJECTIVE: To report a case of Carbamazepine toxicity following the administration of Oxybutynin and Dantrolene.|Carbamazepine toxicity|31|53|Dantrolene|101|111
15685264|OBJECTIVE: To report a case of Carbamazepine toxicity following the administration of Oxybutynin and Dantrolene.|Carbamazepine toxicity|31|53|Oxybutynin|86|96
1569260|To the best of our knowledge, this is the first reported patient with captopril-induced pemphigus in whom no new lesions developed after subsequent treatment with enalapril.|pemphigus|88|97|captopril|70|79
1569260|We report a case of drug-induced pemphigus caused by an angiotensin-converting enzyme inhibitor, captopril.|pemphigus|33|42|captopril|97|106
15694139|Neuropathy is a significant side effect of thalidomide therapy, which may limit its clinical use.|Neuropathy|0|10|thalidomide|43|54
15694139|Thalidomide neuropathy in childhood.|neuropathy|12|22|Thalidomide|0|11
15694139|Thalidomide neuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'.|neuropathy|12|22|Thalidomide|0|11
15694139|Thalidomide neuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'.|proximal weakness|48|65|Thalidomide|0|11
15694139|Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects.|teratogenic effects|82|101|Thalidomide|0|11
15694139|We report four cases of sensorimotor axonal neuropathy in children aged 10-15 years, treated with thalidomide for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration.|sensorimotor axonal neuropathy|24|54|thalidomide|98|109
15701285|Cerebral edema associated with Gliadel wafers: two case studies.|Cerebral edema|0|14|Gliadel|31|38
15701285|Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers.|cerebral edema|63|77|Gliadel|110|117
15701285|While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.|cerebral edema|202|216|carmustine|26|36
15701285|While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect.|cerebral edema|202|216|Gliadel|45|52
15719254|Cis-retinoic acid (RA) may further increase the risk of developing BMTN.|BMTN|67|71|Cis-retinoic acid|0|17
15719254|Cis-retinoic acid (RA) may further increase the risk of developing BMTN.|BMTN|67|71|RA|19|21
15719254|It is likely that RA contributed to the deterioration in renal function in these patients.|deterioration in renal function|40|71|RA|18|20
15719254|Retinoic acid may increase the risk of bone marrow transplant nephropathy.|bone marrow transplant nephropathy|39|73|Retinoic acid|0|13
15719254|The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental.|BMTN|18|22|RA|52|54
15727358|He developed a late secondary infection in some sites treated with imiquimod.|secondary infection|20|39|imiquimod|67|76
15729090|A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine.|myoclonic jerks|47|62|quetiapine|90|100
15729090|Quetiapine-induced myoclonus.|myoclonus|19|28|Quetiapine|0|10
15729090|We report a case of myoclonus induced by quetiapine.|myoclonus|20|29|quetiapine|41|51
15735923|Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.|myelodysplastic syndrome|18|42|temozolomide|49|61
15735923|We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ).|refractory anemia with excess blasts|42|78|temozolomide|141|153
15735923|We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ).|refractory anemia with excess blasts|42|78|TMZ|155|158
1575118|Typically, drug-induced neutropenia occurs in a patient receiving a semisynthetic penicillin for two weeks or more.|neutropenia|24|35|penicillin|82|92
15752306|Livedo reticularis associated with interferon alpha therapy in two melanoma patients.|Livedo reticularis|0|18|interferon alpha|35|51
15752306|These cases highlight the occurrence of livedo reticularis as an uncommon side-effect of interferon alpha treatment.|livedo reticularis|40|58|interferon alpha|89|105
15752306|We report two patients who developed intense livedo reticularis clearly related to the administration of interferon alpha 2b as an adjuvant therapy for melanoma.|livedo reticularis|45|63|interferon alpha 2b|105|124
15760792|CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.|ANCA-associated vasculitis|42|68|PTU|30|33
15760792|CONCLUSION: This rare case of PTU-induced ANCA-associated vasculitis manifested with ototoxicity in combination with systemic involvement.|ototoxicity|85|96|PTU|30|33
15760792|OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.|antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis|140|204|propylthiouracil|109|125
15760792|OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.|antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis|140|204|PTU|127|130
15760792|OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.|ototoxicity|76|87|propylthiouracil|109|125
15760792|OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.|ototoxicity|76|87|PTU|127|130
15760792|Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.|antineutrophil cytoplasmic antibodies|68|105|Propylthiouracil|0|16
15760792|Propylthiouracil-induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies.|sensorineural hearing loss|25|51|Propylthiouracil|0|16
15760792|RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.|hearing impairment in the left ear (with progression to the right ear)|69|139|PTU|193|196
15760792|RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.|tinnitus|59|67|PTU|193|196
15760792|RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with PTU.|vertigo|145|152|PTU|193|196
15760792|The hearing impairment and tinnitus were gradually reduced after PTU withdrawal and corticosteroid and azathioprine treatment.|hearing impairment|4|22|PTU|65|68
15760792|The hearing impairment and tinnitus were gradually reduced after PTU withdrawal and corticosteroid and azathioprine treatment.|tinnitus|27|35|PTU|65|68
15770343|Anti-tuberculous drugs had been stopped on the 2nd day of therapy due to development of optic neuritis secondary to ethambutol administration at another hospital.|optic neuritis|88|102|ethambutol|116|126
15770343|During the anti-tuberculous therapy, visual loss can be related to ethambutol toxicity or the tuberculosis infection itself.|visual loss|37|48|ethambutol|67|77
15770343|In addition, ethambutol rarely causes visual loss during the early period or when given at lower doses.|visual loss|38|49|ethambutol|13|23
15773973|Flucloxacillin-induced aplastic anaemia and liver failure.|aplastic anaemia|23|39|Flucloxacillin|0|14
15773973|Flucloxacillin-induced aplastic anaemia and liver failure.|liver failure|44|57|Flucloxacillin|0|14
15773973|It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.|fatal hepatic injury|69|89|flucloxacillin|27|41
15773973|We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.|aplastic anaemia|86|102|flucloxacillin|130|144
15773973|We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.|fulminant hepatic failure|56|81|flucloxacillin|130|144
15779196|Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.|bronchospasm|125|137|Zoledronic acid|28|43
15779196|Four days after intravenous Zoledronic acid, the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm.|carpopedal spasm|104|120|Zoledronic acid|28|43
15779196|Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.|severe hypocalcaemia|24|44|Zoledronic acid|0|15
1577957|This case report describes an adolescent with severe lupus erythematosus who received cyclophosphamide (CY) paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli.|severe lupus erythematosus|46|72|CY|104|106
1577957|This case report describes an adolescent with severe lupus erythematosus who received cyclophosphamide (CY) paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli.|severe lupus erythematosus|46|72|cyclophosphamide|86|102
15785053|Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus.|Mucosal pigmentation|0|20|tacrolimus|69|79
15785053|The relation between tacrolimus treatment and staining was suggested by the appearance of pigmentation during topical tacrolimus treatment and its clinical disappearance when treatment was stopped.|pigmentation|90|102|tacrolimus|21|31
15785053|The relation between tacrolimus treatment and staining was suggested by the appearance of pigmentation during topical tacrolimus treatment and its clinical disappearance when treatment was stopped.|pigmentation|90|102|tacrolimus|118|128
15785053|We report the first histopathologically documented case of oral mucosa pigmentation after OLP treatment with topical tacrolimus.|oral mucosa pigmentation|59|83|tacrolimus|117|127
15790469|Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate (MTX) and malignant lymphoma developing.|malignant lymphoma|148|166|Methotrexate|125|137
15790469|Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate (MTX) and malignant lymphoma developing.|malignant lymphoma|148|166|MTX|139|142
15795553|Risperidone is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia (TD).|tardive dyskinesia|268|286|Risperidone|0|11
15795553|Risperidone is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia (TD).|TD|288|290|Risperidone|0|11
15795553|Risperidone withdrawal-related respiratory dyskinesia: a case diagnosed by spirography and fibroscopy.|respiratory dyskinesia|31|53|Risperidone|0|11
15795553|The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of risperidone therapy.|limb dyskinesia|135|150|risperidone|209|220
15795553|The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of risperidone therapy.|orofacial dyskinesia|156|176|risperidone|209|220
15795553|The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of risperidone therapy.|RD|130|132|risperidone|209|220
15795553|The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of risperidone therapy.|respiratory dyskinesia|106|128|risperidone|209|220
15795553|The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of risperidone therapy.|TD|73|75|risperidone|209|220
15795553|Therefore, clinicians should pay close attention to possible onset of RD in patients with multiple risk factors for TD, even when SDA therapy is used.|RD|70|72|SDA|130|133
15806568|In this study, we report on three individual patients who received BTX-B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX-B at remote sites.|parasympathetic dysfunction of the visual system|104|152|BTX-B|67|72
15806568|In this study, we report on three individual patients who received BTX-B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX-B at remote sites.|parasympathetic dysfunction of the visual system|104|152|BTX-B|173|178
15806568|To date, there have been few reports of visual disturbances associated with BTX-B use.|visual disturbances|40|59|BTX-B|76|81
15806568|Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections.|parasympathetic dysfunction|37|64|botulinum toxin type B|71|93
15806568|Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections.|Visual system side effects|0|26|botulinum toxin type B|71|93
1580986|Enalapril-induced anemia in two kidney transplant recipients.|anemia|18|24|Enalapril|0|9
1580986|Two renal transplant patients developed anemia during treatment of hypertension with enalapril medication.|anemia|40|46|enalapril|85|94
15811174|A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.|muscle pain|131|142|cerivastatin|50|62
15811174|A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.|muscle weakness|111|126|cerivastatin|50|62
15811174|Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.|rhabdomyolysis|83|97|cerivastatin|62|74
15811174|We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.|acute rhabdomyolysis|37|57|cerivastatin|71|83
15823103|Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.|hypersensitivity|12|28|Carboplatin|0|11
15823103|Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.|hypersensitivity|12|28|carboplatin|60|71
15823103|Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.|hypersensitivity|12|28|paclitaxel|49|59
15823103|However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.|apnea|94|99|CBDCA|206|211
15823103|However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.|cardiac arrest|75|89|CBDCA|206|211
15823103|However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.|eruptions|137|146|CBDCA|206|211
15823103|However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.|hypotension|148|159|CBDCA|206|211
15823103|However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.|severe hypersensitivity reactions|31|64|CBDCA|206|211
15823103|However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of CBDCA.|tachycardia|165|176|CBDCA|206|211
15823103|Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.|hypersensitivity|32|48|CBDCA|26|31
15823103|Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.|hypersensitivity|32|48|CBDCA|271|276
15823103|Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.|hypersensitivity|277|293|CBDCA|271|276
15823103|Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.|hypersensitivity|277|293|CBDCA|323|328
15823103|We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.|hypersensitivity|44|60|carboplatin|24|35
15823103|We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.|hypersensitivity|44|60|CBDCA|37|42
15823103|We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.|hypersensitivity|44|60|paclitaxel|83|93
15827670|TREATMENT/OUTCOME: Standard anti-tuberculosis therapy was administered but was complicated by interaction with cyclosporine and drug-induced cholestasis.|cholestasis|141|152|cyclosporine|111|123
15836666|Chronic fentanyl application induces adrenocortical insufficiency.|adrenocortical insufficiency|37|65|fentanyl|8|16
15836666|We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.|adrenocortical insufficiency|53|81|fentanyl|120|128
15840734|Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient.|neuroleptic malignant syndrome|21|51|Fluphenazine|0|12
15840734|OBJECTIVE: To report a case of neuroleptic malignant syndrome (NMS) associated with fluphenazine in a schizophrenic patient and review the literature related to this condition.|neuroleptic malignant syndrome|31|61|fluphenazine|84|96
15840734|OBJECTIVE: To report a case of neuroleptic malignant syndrome (NMS) associated with fluphenazine in a schizophrenic patient and review the literature related to this condition.|NMS|63|66|fluphenazine|84|96
1584367|Intraventricular vancomycin-induced cerebrospinal fluid eosinophilia: report of two patients.|cerebrospinal fluid eosinophilia|36|68|vancomycin|17|27
1584367|We propose a mechanism of vancomycin-induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE.|CSFE|139|143|vancomycin|26|36
1584367|We report two cases of cerebrospinal fluid eosinophilia (CSFE) secondary to the intraventricular administration of vancomycin.|cerebrospinal fluid eosinophilia|23|55|vancomycin|115|125
1584367|We report two cases of cerebrospinal fluid eosinophilia (CSFE) secondary to the intraventricular administration of vancomycin.|CSFE|57|61|vancomycin|115|125
15852680|Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.|interstitial pneumonitis|25|49|bicalutamide|62|74
15852680|Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.|interstitial pneumonitis|25|49|leuprorelin acetate|79|98
15852680|We report a case of interstitial pneumonitis induced by bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment.|interstitial pneumonitis|20|44|bicalutamide|56|68
15852680|We report a case of interstitial pneumonitis induced by bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment.|interstitial pneumonitis|20|44|leuprorelin acetate|76|95
15857283|CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.|corneal endothelial deposits|70|98|rifabutin|135|144
15857283|Corneal endothelial deposits associated with rifabutin use.|Corneal endothelial deposits|0|28|rifabutin|45|54
15857283|PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.|corneal endothelial deposits|76|104|rifabutin|131|140
15857283|RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.|corneal endothelial deposits|29|57|rifabutin|80|89
15863610|CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.|malignant mixed mesodermal tumor|8|40|raloxifene|124|134
15863610|CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.|malignant mixed mesodermal tumor|82|114|raloxifene|48|58
15863610|Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.|Malignant mixed mullerian tumor of the uterus|0|45|raloxifene|66|76
15863610|We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.|malignant mixed mesodermal tumor|38|70|raloxifene|106|116
15866658|Herein we report four patients who underwent liver transplantation and developed neutropenia while receiving MMF.|neutropenia|81|92|MMF|109|112
15866658|Mycophenolate mofetil-induced neutropenia in liver transplantation.|neutropenia|30|41|Mycophenolate mofetil|0|21
15866658|The mean time from starting MMF to the development of neutropenia was 4 months.|neutropenia|54|65|MMF|28|31
15866658|The side effects of MMF, such as bone marrow toxicity, have been reported.|bone marrow toxicity|33|53|MMF|20|23
15878975|A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or secondary thrombocytopenia.|acute hemoglobinemia|64|84|anti-D IGIV|113|124
15878975|A previous review described data on 15 patients who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or secondary thrombocytopenia.|hemoglobinuria|88|102|anti-D IGIV|113|124
15878975|Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura.|acute hemoglobinemia|55|75|Rh(0)(D) immune globulin|104|128
15878975|Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura.|Disseminated intravascular coagulation|0|38|Rh(0)(D) immune globulin|104|128
15878975|Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura.|hemoglobinuria|79|93|Rh(0)(D) immune globulin|104|128
15878975|That review suggested that patients receiving anti-D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation (DIC).|DIC|187|190|anti-D IGIV|46|57
15878975|That review suggested that patients receiving anti-D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation (DIC).|disseminated intravascular coagulation|147|185|anti-D IGIV|46|57
15878975|That review suggested that patients receiving anti-D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation (DIC).|hemoglobinemia|118|132|anti-D IGIV|46|57
15878975|The purpose of this review is to increase awareness among physicians and other health care professionals that DIC may be a rare but potentially severe complication of anti-D IGIV treatment.|DIC|110|113|anti-D IGIV|167|178
15878975|This review presents the first case series of DIC associated with acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP.|acute hemoglobinemia|66|86|anti-D IGIV|115|126
15878975|This review presents the first case series of DIC associated with acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP.|DIC|46|49|anti-D IGIV|115|126
15878975|This review presents the first case series of DIC associated with acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP.|hemoglobinuria|90|104|anti-D IGIV|115|126
15895899|After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).|severe transient neutropenia|61|89|infliximab|17|27
15895899|Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.|agranulocytosis|13|28|infliximab|51|61
15895899|These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.|autoimmune agranulocytosis|127|153|infliximab|26|36
15895899|These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.|production of granulocyte and neutrophil autoantibodies|56|111|infliximab|26|36
15907341|However, peripheral neuropathy and bone marrow depression led to linezolid withdrawal in seven patients, and neuropathy may not be fully reversible in all patients.|bone marrow depression|35|57|linezolid|65|74
15907341|However, peripheral neuropathy and bone marrow depression led to linezolid withdrawal in seven patients, and neuropathy may not be fully reversible in all patients.|neuropathy|109|119|linezolid|65|74
15907341|However, peripheral neuropathy and bone marrow depression led to linezolid withdrawal in seven patients, and neuropathy may not be fully reversible in all patients.|peripheral neuropathy|9|30|linezolid|65|74
15907341|Six patients developed peripheral neuropathy and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of linezolid.|bone marrow depression|63|85|linezolid|211|220
15907341|Six patients developed peripheral neuropathy and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of linezolid.|peripheral neuropathy|23|44|linezolid|211|220
15920338|A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant tamoxifen.|high-grade endometrial stromal sarcoma|10|48|tamoxifen|170|179
15920338|A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant tamoxifen.|intrauterine polypoid growth|67|95|tamoxifen|170|179
15920338|High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer.|High-grade endometrial stromal sarcoma|0|38|tamoxifen|45|54
15920338|In deciding if tamoxifen therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma.|endometrial adenocarcinoma|153|179|tamoxifen|15|24
15920338|In deciding if tamoxifen therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma.|endometrial adenocarcinoma|153|179|tamoxifen|111|120
15920338|In deciding if tamoxifen therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma.|uterine sarcoma|183|198|tamoxifen|15|24
15920338|In deciding if tamoxifen therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma.|uterine sarcoma|183|198|tamoxifen|111|120
15927910|After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.|heart rate had decreased|74|98|pentamidine|29|40
15927910|Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.|cardiotoxicity|55|69|pentamidine|35|46
15927910|Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.|second-degree heart block|108|133|pentamidine|35|46
15927910|Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.|cardiotoxicity|50|64|pentamidine|87|98
15927910|Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.|second-degree heart block|35|60|pentamidine|12|23
15927910|Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.|sinus bradycardia|65|82|pentamidine|12|23
1592841|Falling backward in two elderly patients taking bupropion.|Falling backward|0|16|bupropion|48|57
1592841|RESULTS: Both patients experienced a previously unreported side effect--falling backward--associated with bupropion use.|falling backward|72|88|bupropion|106|115
15941649|Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero.|Ophthalmologic and neurologic findings|0|38|vigabatrin|66|76
15941649|The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.|visual dysfunction|40|58|VGB|25|28
15941649|Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug.|visual field defects|19|39|Vigabatrin|0|10
15941649|We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.|ophthalmic and neurologic findings|12|46|VGB|99|102
15944830|BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.|cotton wool spots|106|123|IFN|24|27
15944830|BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.|cotton wool spots|106|123|Interferon|12|22
15944830|BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.|retinal hemorrhages|82|101|IFN|24|27
15944830|BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.|retinal hemorrhages|82|101|Interferon|12|22
15944830|BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.|retinopathy|40|51|IFN|24|27
15944830|BACKGROUND: Interferon (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.|retinopathy|40|51|Interferon|12|22
15944830|Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.|macular edema|19|32|interferon|49|59
15944830|Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography.|retinopathy|71|82|interferon|49|59
15944830|CONCLUSION: During and after IFN therapy, OCT is a useful examination technique for revealing macular edema in patients who have decreased vision.|decreased vision|129|145|IFN|29|32
15944830|CONCLUSION: During and after IFN therapy, OCT is a useful examination technique for revealing macular edema in patients who have decreased vision.|macular edema|94|107|IFN|29|32
15944830|Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.|hypoalbuminemia|137|152|IFN|63|66
15944830|Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.|ocular side effects|40|59|IFN|63|66
15944830|Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.|thrombocytopenia|157|173|IFN|63|66
15944830|The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.|visual acuity had decreased|48|75|IFN|101|104
15944830|The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.|visual acuity had decreased|182|209|IFN|161|164
15944830|With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.|macular edema|115|128|IFN|70|73
15944830|With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.|macular edema|115|128|IFN|185|188
15944830|With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.|reduced visual acuity|133|154|IFN|70|73
15944830|With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.|reduced visual acuity|133|154|IFN|185|188
15944830|With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.|retinopathy|85|96|IFN|70|73
15944830|With the use of optical coherence tomography (OCT), two patients with IFN-associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.|retinopathy|85|96|IFN|185|188
15961942|Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.|diabetes mellitus|20|37|interferon-alfa|44|59
15961942|Late development of diabetes mellitus after interferon-alfa and ribavirin therapy for chronic hepatitis C: a case report.|diabetes mellitus|20|37|ribavirin|64|73
15961942|OBJECTIVE: To report the late development of immune-mediated diabetes mellitus after completion of alfa-interferon therapy for hepatitis C in an Asian patient.|immune-mediated diabetes mellitus|45|78|alfa-interferon|99|114
15965422|Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.|Cutaneous necrosis|0|18|interferon alfa|67|82
15965422|Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.|Cutaneous necrosis|0|18|interferon alfa|34|49
15965422|We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.|local cutaneous reactions|200|225|pegylated interferon alfa-2b|310|338
15965422|We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.|local cutaneous reactions|200|225|pegylated interferon alfa-2b|71|99
15965422|We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed local cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.|local cutaneous reactions|200|225|ribavirin|125|134
15965422|We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.|cutaneous necrosis|57|75|interferon alfa|104|119
15965422|We review the literature on previously reported cases of cutaneous necrosis after injection of standard interferon alfa or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.|cutaneous necrosis|57|75|pegylated interferon alfa-2b|123|151
15977922|Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed.|ischemic colitis|51|67|tegaserod|90|99
15977922|Tegaserod-associated ischemic colitis.|ischemic colitis|21|37|Tegaserod|0|9
15977922|We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.|irritable bowel syndrome|161|185|tegaserod|80|89
15977922|We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.|irritable bowel syndrome|161|185|tegaserod|142|151
15977922|We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.|ischemic colitis|31|47|tegaserod|80|89
15977922|We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.|ischemic colitis|31|47|tegaserod|142|151
15977922|We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.|ischemic colitis|124|140|tegaserod|80|89
15977922|We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.|ischemic colitis|124|140|tegaserod|142|151
16001348|A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.|chronic, watery diarrhea|28|52|lansoprazole|120|132
16001348|A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease.|chronic, watery diarrhea|28|52|lansoprazole|145|157
16001348|Lansoprazole-associated collagenous colitis: a case report.|collagenous colitis|24|43|Lansoprazole|0|12
16001348|The reported case represents an unusual association between medication with the proton pump inhibitor lansoprazole and the development of collagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis.|collagenous colitis|138|157|lansoprazole|102|114
16008658|46-year-old woman developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta-1b subcutaneously for multiple sclerosis.|painful ulcers|28|42|interferon beta-1b|117|135
16008658|46-year-old woman developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta-1b subcutaneously for multiple sclerosis.|reticulate erythema|81|100|interferon beta-1b|117|135
16008658|Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b.|Abdominal wall ulceration|0|25|recombinant human interferon-beta-1b|53|89
16008658|Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b.|mucinosis|30|39|recombinant human interferon-beta-1b|53|89
16012330|Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.|vincristine neurotoxicity|31|56|Itraconazole|0|12
16012330|Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.|vincristine neurotoxicity|31|56|vincristine|31|42
16012330|Nineteen cases of unusual enhanced vincristine neurotoxicity related to itraconazole have been reported in children.|neurotoxicity|47|60|itraconazole|72|84
16012330|Nineteen cases of unusual enhanced vincristine neurotoxicity related to itraconazole have been reported in children.|neurotoxicity|47|60|vincristine|35|46
16012330|Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.|absence of deep reflexes|113|137|itraconazole|15|27
16012330|Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.|mild left ptosis|91|107|itraconazole|15|27
16012330|Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.|mild weakness of the upper extremities|190|228|itraconazole|15|27
16012330|Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.|neurogenic bladder|71|89|itraconazole|15|27
16012330|Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.|paralytic ileus|54|69|itraconazole|15|27
16012330|Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.|severe paralysis of the lower extremities|144|185|itraconazole|15|27
16012330|The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially fatal toxicities, the combination use of these drugs should be avoided.|fatal toxicities|186|202|itraconazole|65|77
16012330|The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially fatal toxicities, the combination use of these drugs should be avoided.|fatal toxicities|186|202|vincristine|135|146
16018164|CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.|intracerebral hemorrhage|33|57|pseudoephedrine|148|163
16018164|Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.|intracerebral hemorrhage|60|84|phenylpropanolamine|22|41
16018164|Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.|cerebral vascular malformation|53|83|Pseudoephedrine|0|15
16018164|Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.|hemorrhage|24|34|Pseudoephedrine|0|15
16018164|Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.|stroke|108|114|phenylpropanolamine|84|103
16018164|This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.|intracerebral hemorrhage|42|66|pseudoephedrine|18|33
16025424|Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report.|diabetic ketoacidosis|34|55|quetiapine|15|25
16025424|We report a case of reversible DKA and new-onset DM that developed in a demented patient who was treated with quetiapine for 14 days.|DKA|31|34|quetiapine|110|120
16025424|We report a case of reversible DKA and new-onset DM that developed in a demented patient who was treated with quetiapine for 14 days.|DM|49|51|quetiapine|110|120
1602800|Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.|Pulmonary leukostasis|0|21|all-trans retinoic acid|35|58
16029707|Eruptive epidermoid cysts resulting from treatment with imiquimod.|Eruptive epidermoid cysts|0|25|imiquimod|56|65
16029707|METHODS: A 79-year-old woman being treated with imiquimod 5 days per week for a nodular basal cell developed a verrucous plaque over the treatment area after 7 weeks of therapy.|verrucous plaque|111|127|imiquimod|48|57
16029707|The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy.|multiple comedones|4|22|imiquimod|91|100
16029707|The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy.|ruptured epidermoid cysts|27|52|imiquimod|91|100
16035204|We report an unusual case of massive fluoxetine ingestion resulting in neurological and cardiovascular toxicity resulting in death.|death|125|130|fluoxetine|37|47
16035204|We report an unusual case of massive fluoxetine ingestion resulting in neurological and cardiovascular toxicity resulting in death.|neurological and cardiovascular toxicity|71|111|fluoxetine|37|47
16044093|Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child.|Hepatocellular damage|0|21|iron sucrose|56|68
16044093|The case reported here is of a child given a large dose of intravenous iron sucrose (16 mg/kg) over 3 hours, who subsequently developed features of systemic iron toxicity.|systemic iron toxicity|148|170|iron sucrose|71|83
160443|Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature.|acute amnestic episode|33|55|clioquinol|95|105
160443|The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.|retrograde amnesia|174|192|clioquinol|95|105
160443|The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.|transient global amnesia|48|72|clioquinol|95|105
160443|Transient global amnesia after clioquinol: five personal observations from outside Japan.|Transient global amnesia|0|24|clioquinol|31|41
16046172|In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.|Neisseria mucosa knee arthritis|43|74|sodium hyaluronate|99|117
16046172|One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.|Staphylococcus aureus knee arthritis|58|94|corticosteroids|161|176
16046172|One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.|Staphylococcus aureus knee arthritis|58|94|sodium hyaluronate|138|156
16046172|Septic knee arthritis after intra-articular hyaluronate injection.|Septic knee arthritis|0|21|hyaluronate|44|55
16062101|Acute dystonia induced by lamivudine.|Acute dystonia|0|14|lamivudine|26|36
16062101|ADR induced by drug treatment can be a side effect of treatment with antipsychotic drugs and other drugs; however, there have been no reports of lamivudine-induced ADR in the English literature.|ADR|164|167|lamivudine|145|155
16062101|The authors report two cases of acute dystonic reactions (ADRs) as a side effect of lamivudine.|acute dystonic reactions|32|56|lamivudine|84|94
16062101|The authors report two cases of acute dystonic reactions (ADRs) as a side effect of lamivudine.|ADRs|58|62|lamivudine|84|94
16062101|The authors think that although lamivudine is widely used and well tolerated, it can cause ADRs, which are reversible after drug withdrawal.|ADRs|91|95|lamivudine|32|42
16087771|Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.|Pleuropulmonary fibrosis|0|24|pergolide|77|86
16092915|CONCLUSIONS: This observation of "on-off" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.|psychiatric and physical manifestations|113|152|risperidone|42|53
16092915|CONCLUSIONS: This observation of "on-off" risperidone treatment suggests that risperidone may have worsened both psychiatric and physical manifestations of the mitochondrial disorder in this adolescent.|psychiatric and physical manifestations|113|152|risperidone|78|89
16092915|OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and increased mood symptoms during treatment with risperidone.|increased mood symptoms|179|202|risperidone|225|236
16092915|Risperidone-induced psychosis and depression in a child with a mitochondrial disorder.|depression|34|44|Risperidone|0|11
16092915|Risperidone-induced psychosis and depression in a child with a mitochondrial disorder.|psychosis|20|29|Risperidone|0|11
16097572|Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.|Fatal radiation myelopathy|0|26|busulfan|43|51
16097572|Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.|Fatal radiation myelopathy|0|26|melphalan|56|65
16109609|Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation.|pericardial effusion|20|40|Gemcitabine|0|11
16109609|Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation.|tamponade|45|54|Gemcitabine|0|11
16109609|Gemcitabine therapy has been associated with radiation recall reactions when used in the treatment of carcinoma.|radiation recall reactions|45|71|Gemcitabine|0|11
16109609|Physicians should be aware of the potential for developing a gemcitabine-induced radiation recall reaction resulting in hemodynamically significant pericardial effusion.|pericardial effusion|148|168|gemcitabine|61|72
16109609|Physicians should be aware of the potential for developing a gemcitabine-induced radiation recall reaction resulting in hemodynamically significant pericardial effusion.|radiation recall reaction|81|106|gemcitabine|61|72
16109609|We report four cases of hemodynamically significant pericardial effusion in patients with refractory lymphoma who were receiving gemcitabine, all of whom had a history of mediastinal radiation without subcarinal blocking.|pericardial effusion|52|72|gemcitabine|129|140
16116136|A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment.|CNS lymphoma|76|88|MM|59|61
16116136|Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with MM may be associated with increased risk of lymphoproliferative disorders.|lymphoproliferative disorders|136|165|MM|92|94
16116136|Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.|CNS lymphoma|8|20|mycophenolate mofetil|70|91
16116136|Primary CNS lymphoma regressed on withdrawal of MM.|CNS lymphoma|8|20|MM|48|50
16119501|Baclofen withdrawal: a cause of prolonged fever in the intensive care unit.|fever|42|47|Baclofen|0|8
16119501|Baclofen withdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit.|withdrawal syndrome|9|28|Baclofen|0|8
16119501|Baclofen withdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit.|withdrawal syndrome|9|28|baclofen|64|72
16119501|The patient continued to have fever and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral baclofen.|autonomic instability|40|61|baclofen|185|193
16119501|The patient continued to have fever and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral baclofen.|fever|30|35|baclofen|185|193
16119501|We report a case of baclofen withdrawal syndrome resulting from oral baclofen underdosing.|withdrawal syndrome|29|48|baclofen|20|28
16119501|We report a case of baclofen withdrawal syndrome resulting from oral baclofen underdosing.|withdrawal syndrome|29|48|baclofen|69|77
16132305|After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.|eosinophilia|107|119|captopril|20|29
16132305|After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.|radiographic abnormalities|124|150|captopril|20|29
16132305|Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.|pulmonary infiltrates with eosinophilia|18|57|Captopril|0|9
16132305|We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.|pulmonary infiltrates with eosinophilia|173|212|captopril|86|95
16146480|Can propofol precipitate pancreatitis in patients with Cushing's syndrome?|pancreatitis|25|37|propofol|4|12
16146480|Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to acute pancreatitis following propofol administration.|acute pancreatitis|168|186|propofol|197|205
16156485|Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a focal seizure) of severe lithium-induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.|focal seizure|169|182|lithium|194|201
16156485|Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a focal seizure) of severe lithium-induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.|prolonged seizure|123|140|lithium|194|201
16156485|Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a focal seizure) of severe lithium-induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.|serotonin syndrome|144|162|lithium|194|201
16160485|CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.|CD20-negative T-cell-rich B-cell lymphoma|0|41|rituximab|127|136
16160485|Recently, CD20-negative tumors have been described after Rituximab therapy.|CD20-negative tumors|10|30|Rituximab|57|66
16164579|A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.|angio-oedema|47|59|irbesartan|88|98
16164579|A 51-year old physically fit woman experienced angio-oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion.|hypotensive shock|64|81|irbesartan|88|98
16164579|To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.|angio-oedema|62|74|irbesartan|80|90
16164579|To our knowledge, our report is one of the first on shock and angio-oedema from irbesartan.|shock|52|57|irbesartan|80|90
16167682|She died within six weeks of developing congestive heart failure coupled with liver failure due to haemosiderosis despite regular use of desferrioxamine.|congestive heart failure|40|64|desferrioxamine|137|152
16167682|She died within six weeks of developing congestive heart failure coupled with liver failure due to haemosiderosis despite regular use of desferrioxamine.|haemosiderosis|99|113|desferrioxamine|137|152
16167682|She died within six weeks of developing congestive heart failure coupled with liver failure due to haemosiderosis despite regular use of desferrioxamine.|liver failure|78|91|desferrioxamine|137|152
16167682|Transfusion haemosiderosis inspite of regular use of desferrioxamine: case report.|Transfusion haemosiderosis|0|26|desferrioxamine|53|68
16181292|One of the side-effects of intravitreal triamcinolone is the development of cataract, and it is known that cataract extraction can exacerbate macular degeneration.|cataract|76|84|triamcinolone|40|53
16181292|Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.|cataract|39|47|triamcinolone|71|84
16181292|Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.|Severe loss of vision|0|21|triamcinolone|71|84
16192734|Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.|Rhabdomyolysis|0|14|ritodrine hydrochloride|45|68
16192734|Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.|Rhabdomyolysis|0|14|ritodrine hydrochloride|79|102
16192734|We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.|rhabdomyolysis|62|76|ritodrine-hydrochloride|30|53
16196187|Acute myocardial ischemia following accidental intravenous administration of epinephrine in high concentration.|Acute myocardial ischemia|0|25|epinephrine|77|88
16196187|Inadvertent and accidental epinephrine overdose might result in potentially lethal complications.|lethal complications|76|96|epinephrine|27|38
16196187|We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously.|acute myocardial ischemia|61|86|epinephrine|27|38
16196187|We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously.|severe allergic reaction|165|189|epinephrine|27|38
16196187|We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously.|severe allergic reaction|165|189|epinephrine|248|259
16200540|Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.|restless legs syndrome|82|104|levodopa|49|57
16200540|Symptoms and signs of augmentation were related to low plasma levodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration.|augmentation|22|34|levodopa|62|70
16200540|Symptoms and signs of augmentation were related to low plasma levodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration.|augmentation|22|34|levodopa|109|117
16200540|Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia.|anarchic discharges of motor unit potentials|158|202|levodopa|76|84
16200540|Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia.|flexor spasms|233|246|levodopa|76|84
16200540|Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia.|marked motor hyperactivity|105|131|levodopa|76|84
16200540|Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia.|painful dysesthesia|264|283|levodopa|76|84
16200540|Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia.|tonic grouped discharges|204|228|levodopa|76|84
16200540|We describe a patient with idiopathic RLS who developed augmentation after 8 months of levodopa treatment.|augmentation|56|68|levodopa|87|95
16204273|The major side effect of infliximab is infection.|infection|39|48|infliximab|25|35
16204273|This report describes a probable case of infliximab-induced membranous nephropathy.|membranous nephropathy|60|82|infliximab|41|51
16207263|Linezolid-induced dyserythropoiesis: chloramphenicol toxicity revisited.|dyserythropoiesis|18|35|Linezolid|0|9
16207263|We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to chloramphenicol-associated myelotoxicity.|dyserythropoietic anaemia|28|53|linezolid|80|89
16207263|We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to chloramphenicol-associated myelotoxicity.|myelotoxicity|157|170|chloramphenicol|130|145
1621023|A selective association between fluoxetine and extensive, prominent eye movements in nonrapid eye movement (NREM) sleep was detected, utilizing Fisher's exact one-tailed statistic (p less than 0.00001 for each comparison).|eye movements in nonrapid eye movement (NREM) sleep|68|119|fluoxetine|32|42
1621023|In addition, a 31-year-old man with obsessive-compulsive disorder developed RBD soon after starting fluoxetine therapy, which persisted at PSG study 19 months after fluoxetine discontinuation.|RBD|76|79|fluoxetine|100|110
1621023|In addition, a 31-year-old man with obsessive-compulsive disorder developed RBD soon after starting fluoxetine therapy, which persisted at PSG study 19 months after fluoxetine discontinuation.|RBD|76|79|fluoxetine|165|175
1621023|Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder.|Prominent eye movements during NREM sleep|0|41|fluoxetine|90|100
1621023|Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder.|REM sleep behavior disorder|46|73|fluoxetine|90|100
16211208|Because of serious side effects of an increase in the QT interval causing torsades de pointes, dofetilide must be initiated with close monitoring of the QT interval in an inpatient setting.|increase in the QT interval|38|65|dofetilide|95|105
16211208|Because of serious side effects of an increase in the QT interval causing torsades de pointes, dofetilide must be initiated with close monitoring of the QT interval in an inpatient setting.|torsades de pointes|74|93|dofetilide|95|105
16211208|Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.|acute ischemia|60|74|dofetilide|100|110
16211208|Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.|Marked QT prolongation|0|22|dofetilide|100|110
16211208|Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.|torsades de pointes|27|46|dofetilide|100|110
16211208|We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with dofetilide for atrial fibrillation.|acute myocardial ischemia|110|135|dofetilide|176|186
16211208|We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with dofetilide for atrial fibrillation.|flash pulmonary edema|73|94|dofetilide|176|186
16211208|We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with dofetilide for atrial fibrillation.|QT prolongation|17|32|dofetilide|176|186
16211208|We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with dofetilide for atrial fibrillation.|torsades de pointes|37|56|dofetilide|176|186
16216617|Prominent positive U waves appearing with high-dose intravenous phenylephrine.|positive U waves|10|26|phenylephrine|64|77
16216617|While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.|positive U waves|65|81|phenylephrine|27|40
16221163|Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems.|Hepatoxicity|0|12|SRL|39|42
16221163|Sirolimus-associated hepatotoxicity in the kidney graft recipient.|hepatotoxicity|21|35|Sirolimus|0|9
16221163|The aim of our paper was to describe hepatotoxicity of sirolimus (SRL) in a kidney graft recipient.|hepatotoxicity|37|51|sirolimus|55|64
16225183|CASE REPORT: We present a case of a 28-yr-old male who developed a severe case of nephrotic syndrome while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of interferon beta 1a.|nephrotic syndrome|82|100|interferon beta 1a|197|215
16225183|Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a.|Nephrotic syndrome|0|18|interferon beta 1a|64|82
16225183|SUBSEQUENT COURSE: The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment.|nephrosis|23|32|interferon|69|79
16225183|This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS.|renal toxicity|127|141|interferons|145|156
16237130|Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.|multifocal leukoencephalopathy|21|51|Capecitabine|0|12
16237130|The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.|multifocal leukoencephalopathy|65|95|capecitabine|44|56
16239768|A 56-year-old white woman with a diagnosis of reactive depression developed severe UI after a 30 days' treatment with venlafaxine 75 mg/day.|UI|83|85|venlafaxine|118|129
16239768|The authors report a case of urinary incontinence (UI) that occurred in a woman after administration of venlafaxine.|UI|51|53|venlafaxine|104|115
16239768|The authors report a case of urinary incontinence (UI) that occurred in a woman after administration of venlafaxine.|urinary incontinence|29|49|venlafaxine|104|115
16239768|Venlafaxine-induced urinary incontinence resolved after switching to sertraline.|urinary incontinence|20|40|Venlafaxine|0|11
1624172|Diagnosis of hypothyroidism during treatment can be difficult because of the common side effects of alpha interferon.|hypothyroidism|13|27|alpha interferon|100|116
1624172|Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.|Sustained hypothyroidism|0|24|recombinant alpha interferon|36|64
1624172|Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon.|Thyroid dysfunction|0|19|recombinant alpha interferon|86|114
1624172|Two cases of hypothyroidism in patients with chronic hepatitis C treated with recombinant alpha interferon are reported.|hypothyroidism|13|27|recombinant alpha interferon|78|106
16244351|Atrial fibrillation after vardenafil therapy.|Atrial fibrillation|0|19|vardenafil|26|36
16244351|We report a case admitted with a first-detected, symptomatic paroxysmal atrial fibrillation in a healthy patient after self-medication with vardenafil.|symptomatic paroxysmal atrial fibrillation|49|91|vardenafil|140|150
16249064|We describe a case of infection with Mycobacterium abscessus in a 67-year-old woman receiving infliximab as a component of her therapy for RA.|Mycobacterium abscessus|37|60|infliximab|94|104
16265343|DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.|cardiomyopathy|39|53|Interferon alpha-2b|11|30
16265343|Reversible cardiomyopathy caused by administration of interferon alpha.|Reversible cardiomyopathy|0|25|interferon alpha|54|70
16268429|In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury.|liver injury|132|144|senna|13|18
16268429|In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury.|subacute cholestatic hepatitis|45|75|senna|13|18
16268429|Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation.|Subacute cholestatic hepatitis|0|30|senna|60|65
16268429|We report a case of senna-induced cholestatic hepatitis which was not diagnosed at presentation.|cholestatic hepatitis|34|55|senna|20|25
16284443|Based on the history and clinical features, a diagnosis of insulin-induced lipohypertrophy was made.|lipohypertrophy|75|90|insulin|59|66
16284443|Insulin-induced lipohypertrophy: report of a case with histopathology.|lipohypertrophy|16|31|Insulin|0|7
16284443|Thus, the possible in vivo effects of insulin on adipocytes were clearly observed in this case of insulin-induced lipohypertrophy.|lipohypertrophy|114|129|insulin|98|105
16284443|To our knowledge, this is the first report of insulin-induced lipohypertrophy with detailed histological examinations.|lipohypertrophy|62|77|insulin|46|53
1628669|A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.|diabetes mellitus|28|45|azathioprine|136|148
1628669|A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.|diabetes mellitus|28|45|prednisone|156|166
1628669|A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.|exocrine pancreatic insufficiency|50|83|azathioprine|136|148
1628669|A 7-year-old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto-immune haemolytic anaemia.|exocrine pancreatic insufficiency|50|83|prednisone|156|166
16288069|An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.|JHR|52|55|penicillin|95|105
16288069|CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.|JHR|126|129|penicillin G|167|179
16288069|Penicillin-induced Jarisch-Herxheimer reaction.|Jarisch-Herxheimer reaction|19|46|Penicillin|0|10
16288069|The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.|chills|63|69|penicillin|129|139
16288069|The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.|feeling cold|22|34|penicillin|129|139
16288069|The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.|worsening headache|40|58|penicillin|129|139
16298824|Acute respiratory distress syndrome after rituximab infusion.|Acute respiratory distress syndrome|0|35|rituximab|42|51
16298824|ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.|ARDS|0|4|gemtuzumab ozogamicin|101|122
16298824|ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.|ARDS|0|4|infliximab|89|99
16298824|ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.|ARDS|0|4|OKT3|128|132
16298824|ARDS is rarely associated with rituximab infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.|ARDS|0|4|rituximab|31|40
16298824|ARDS is rarely associated with rituximab infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.|ARDS|0|4|rituximab|137|146
16298824|ARDS is rarely associated with rituximab infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.|severe pulmonary symptoms|183|208|rituximab|137|146
16298824|Dyspnea, hypoxemia, and pleuritic chest pain occurred within 24 hours of rituximab administration, and there was no other apparent explanation.|Dyspnea|0|7|rituximab|73|82
16298824|Dyspnea, hypoxemia, and pleuritic chest pain occurred within 24 hours of rituximab administration, and there was no other apparent explanation.|hypoxemia|9|18|rituximab|73|82
16298824|Dyspnea, hypoxemia, and pleuritic chest pain occurred within 24 hours of rituximab administration, and there was no other apparent explanation.|pleuritic chest pain|24|44|rituximab|73|82
16298824|Progressive hypoxemia mandated endotracheal intubation 1 week after rituximab administration and led to death 4 weeks after admission.|Progressive hypoxemia|0|21|rituximab|68|77
16298824|We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome (ARDS) after a single infusion of rituximab.|acute respiratory distress syndrome|117|152|rituximab|187|196
16298824|We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome (ARDS) after a single infusion of rituximab.|ARDS|154|158|rituximab|187|196
16313549|Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.|renal impairment|30|46|bisphosphonate|63|77
16313549|Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.|Symptomatic hypocalcaemia|0|25|bisphosphonate|63|77
16313549|We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma.|severe hypocalcaemia|25|45|bisphosphonate|67|81
16317298|Gemcitabine-related radiation recall in a patient with pancreatic cancer.|radiation recall|20|36|Gemcitabine|0|11
16317298|Gemcitabine should be added to the list of drugs known to cause radiation recall.|radiation recall|64|80|Gemcitabine|0|11
16317298|Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.|Radiation recall|0|16|gemcitabine|22|33
16317298|Radiation recall related to gemcitabine has been reported in lung and breast cancer.|Radiation recall|0|16|gemcitabine|28|39
16317298|We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.|gastrointestinal bleeding|68|93|gemcitabine|135|146
16317298|We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.|radiation-recall|107|123|gemcitabine|135|146
16317298|We suggest discontinuing gemcitabine if radiation recall is observed.|radiation recall|40|56|gemcitabine|25|36
16326413|A 17-year-old boy with acute lymphoblastic leukemia developed acute renal failure within 48 h of an intravenous high-dose methotrexate (5 g/m2) infusion.|acute renal failure|62|81|methotrexate|122|134
16326413|High-dose methotrexate-associated acute renal failure may be an avoidable complication.|acute renal failure|34|53|methotrexate|10|22
16326413|Methotrexate-associated nephropathy is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development.|nephropathy|24|35|Methotrexate|0|12
16341621|Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.|prolapse of the urethral mucosa|8|39|calcium hydroxylapatite|76|99
16341621|The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.|granulomatous reaction|39|61|calcium hydroxylapatite|138|161
16341621|The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.|urethral prolapse|73|90|calcium hydroxylapatite|138|161
16341621|To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.|granulomatous reaction|36|58|calcium hydroxylapatite|75|98
16352777|CASE SUMMARY: A 57-year-old female with cardiomyopathy and "sulfa" (trimethoprim/sulfamethoxazole) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide.|pancreatitis|174|186|furosemide|200|210
16352777|In addition, while cases of loop diuretic-induced pancreatitis, including furosemide, have been published, the allergic manifestations with both sulfonamide antibiotics and non-antibiotics in our patient suggest possible cross-reactivity between these 2 drug classes.|pancreatitis|50|62|furosemide|74|84
16352777|Torsemide appears to also be a part of a long list of agents that can cause pancreatitis.|pancreatitis|76|88|Torsemide|0|9
16355099|Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.|massive thrombosis of the inferior vena cava|50|94|Heparin|0|7
16355099|Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement.|thrombocytopenia|16|32|Heparin|0|7
16355099|On the 3rd day, an inferior vena cava (IVC) filter was placed with a heparin flush, after which massive IVC thrombosis developed.|IVC thrombosis|104|118|heparin|69|76
16355099|The patient was positive for antibody against complexes of heparin and platelet factor 4, and was diagnosed as heparin-induced thrombocytopenia with thrombosis syndrome (HITTS).|thrombocytopenia|127|143|heparin|111|118
16355099|The patient was positive for antibody against complexes of heparin and platelet factor 4, and was diagnosed as heparin-induced thrombocytopenia with thrombosis syndrome (HITTS).|thrombosis syndrome|149|168|heparin|111|118
16355099|When thrombosis develops during heparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.|thrombosis|5|15|heparin|32|39
1635565|After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication.|gastric-outlet obstruction|6|32|prostaglandin E1|80|96
1635565|CONCLUSIONS: The administration of prostaglandin E1 to neonates can cause gastric-outlet obstruction due to antral hyperplasia.|antral hyperplasia|108|126|prostaglandin E1|35|51
1635565|CONCLUSIONS: The administration of prostaglandin E1 to neonates can cause gastric-outlet obstruction due to antral hyperplasia.|gastric-outlet obstruction|74|100|prostaglandin E1|35|51
16357738|Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.|RPLS|149|153|cisplatin|71|80
16357738|Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.|RPLS|149|153|cyclosporine|57|69
16357738|Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.|RPLS|149|153|interferon-alpha|98|114
16357738|Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.|RPLS|149|153|tacrolimus|82|92
16357738|Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.|Reversible posterior leukoencephalopathy syndrome|0|49|cyclosporine|117|129
16357738|We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.|headache|100|108|cyclosporine|138|150
16357738|We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.|seizure|114|121|cyclosporine|138|150
16357738|We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.|severe perspiration|79|98|cyclosporine|138|150
16368918|OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.|mania|45|50|lopinavir|97|106
16368918|OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.|mania|45|50|ritonavir|107|116
16368918|OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.|mania|45|50|valproic acid|121|134
16368918|OBJECTIVE: To describe a case of exacerbated mania potentially related to an interaction between lopinavir/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.|mania|45|50|VPA|136|139
16368918|Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder.|bipolar disorder|79|95|lopinavir|29|38
16368918|Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder.|bipolar disorder|79|95|ritonavir|39|48
16368918|Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder.|bipolar disorder|79|95|valproic Acid|53|66
16371793|After intravitreal injection of triamcinolone acetonide, cataract may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years.|cataract|57|65|triamcinolone acetonide|32|55
16393774|Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.|Arthritis|0|9|interferon-beta|67|82
16393774|Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.|bursitis|14|22|interferon-beta|67|82
16393774|Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.|inflammatory arthritis|67|89|IFN-beta|115|123
16393774|The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.|monoarthritis|30|43|IFN-beta|72|80
16393774|Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.|autoimmune disorders|73|93|IFN-beta|13|21
16393774|The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.|autoimmune thyroid disease|34|60|IFN-beta|119|127
16393774|The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.|refractory pre-patellar bursitis|67|99|IFN-beta|119|127
16393774|We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.|inflammatory musculoskeletal manifestations|119|162|IFN-beta|174|182
16396068|Trimethoprim-sulfamethoxazole-induced aseptic meningitis.|aseptic meningitis|38|56|Trimethoprim-sulfamethoxazole|0|29
16396068|We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of meningitis after using trimethoprim/sulfamethoxazole (TMP/SMX).|meningitis|145|155|SMX|203|206
16396068|We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of meningitis after using trimethoprim/sulfamethoxazole (TMP/SMX).|meningitis|145|155|sulfamethoxazole|181|197
16396068|We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of meningitis after using trimethoprim/sulfamethoxazole (TMP/SMX).|meningitis|145|155|TMP|199|202
16396068|We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of meningitis after using trimethoprim/sulfamethoxazole (TMP/SMX).|meningitis|145|155|trimethoprim|168|180
16396068|We reviewed the literature in an attempt to characterize the pattern and predictors of TMP/SMX-induced aseptic meningitis.|aseptic meningitis|103|121|SMX|91|94
16396068|We reviewed the literature in an attempt to characterize the pattern and predictors of TMP/SMX-induced aseptic meningitis.|aseptic meningitis|103|121|TMP|87|90
16404563|In this paper, we report a patient with primary anti-phospholipid syndrome treated by corticosteroid, who developed disseminated nocardiosis.|disseminated nocardiosis|116|140|corticosteroid|86|100
16405935|Chloroquine-induced bilateral ptosis.|bilateral ptosis|20|36|Chloroquine|0|11
16405935|Ptosis occurring 24 h after chloroquine therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously.|Ptosis|0|6|chloroquine|28|39
16405935|Ptosis occurring 24 h after chloroquine therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously.|Ptosis|0|6|chloroquine|92|103
16405935|This report describes a case of bilateral ptosis induced by chloroquine.|bilateral ptosis|32|48|chloroquine|60|71
16411025|DESIGN: We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a central neurological syndrome within days of intrathecal MTX.|central neurological syndrome|136|165|MTX|193|196
16411025|Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.|neurotoxicity|67|80|methotrexate|46|58
16411025|OBJECTIVES: A delayed stroke-like leukoencephalopathy has been observed in patients receiving methotrexate (MTX) for childhood leukemia.|stroke-like leukoencephalopathy|22|53|methotrexate|94|106
16411025|OBJECTIVES: A delayed stroke-like leukoencephalopathy has been observed in patients receiving methotrexate (MTX) for childhood leukemia.|stroke-like leukoencephalopathy|22|53|MTX|108|111
16411025|Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX.|subacute neurotoxicity|103|125|MTX|144|147
16416684|This is a rare case of ARDS associated with lithium intoxication.|ARDS|23|27|lithium|44|51
16421117|CONCLUSION: The present findings suggest that: (i) amantadine probably exerts its anti-dyskinetic effect by acting on the "indirect" pathway; (ii) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in L-dopa induced dyskinesias; (iii) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop.|dyskinesias|268|279|L-dopa|253|259
16421117|Prior to surgery, levodopa induced dyskinesia had improved (< or = 50%) under treatment with amantadine (400 mg/day, po) in all three patients.|dyskinesia|35|45|levodopa|18|26
1642627|A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent triazolam-induced eating disorder.|eating disorder|127|142|triazolam|109|118
1642627|Triazolam-induced nocturnal bingeing with amnesia.|amnesia|42|49|Triazolam|0|9
1642627|Triazolam-induced nocturnal bingeing with amnesia.|nocturnal bingeing|18|36|Triazolam|0|9
16432996|Although interferon gamma has been implicated in the pathogenesis of sarcoidosis, only a few cases of sarcoidosis associated with interferon alpha therapy have been reported.|sarcoidosis|102|113|interferon alpha|130|146
16432996|Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature.|sarcoidosis|15|26|interferon alpha 2b|34|53
16432996|Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature.|sarcoidosis|15|26|ribavirin|58|67
16432996|We report a case with chronic hepatitis C (CHC) who developed sarcoidosis after the treatment by interferon alpha and ribavirin.|sarcoidosis|62|73|interferon alpha|97|113
16432996|We report a case with chronic hepatitis C (CHC) who developed sarcoidosis after the treatment by interferon alpha and ribavirin.|sarcoidosis|62|73|ribavirin|118|127
16432996|We suggest that sarcoidosis may develop in chronic hepatitis C patients during interferon alpha and/or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups.|sarcoidosis|16|27|interferon alpha|79|95
16432996|We suggest that sarcoidosis may develop in chronic hepatitis C patients during interferon alpha and/or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups.|sarcoidosis|16|27|ribavirin|103|112
16436462|Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer.|Neutropenic colitis|0|19|irinotecan|86|96
16436462|Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer.|Neutropenic colitis|0|19|nedaplatin|71|81
16441824|In this paper, we report a case of severe hypercalcemia of immobilization in a 40-year-old hemodialyzed woman treated by cinacalcet HCl for a severe HPTH-II (PTH>1,000 pg/mL).|severe hypercalcemia|35|55|cinacalcet HCl|121|135
16446228|Here, we present a case of sirolimus-associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.|interstitial pneumonitis|48|72|sirolimus|27|36
16446228|Reversible sirolimus-associated pneumonitis after heart transplantation.|pneumonitis|32|43|sirolimus|11|20
16446228|Two cases of sirolimus-associated pneumonitis have been reported after cardiac transplantation.|pneumonitis|34|45|sirolimus|13|22
16449538|An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable.|NCSE|88|92|ifosfamide|100|110
16449538|CASE SUMMARIES: Two patients who received ifosfamide-containing chemotherapy developed NCSE.|NCSE|87|91|ifosfamide|42|52
16449538|CONCLUSIONS: Among the many presentations of ifosfamide neurotoxicity, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.|neurotoxicity|56|69|ifosfamide|45|55
16449538|NCSE, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving ifosfamide.|NCSE|0|4|ifosfamide|134|144
16449538|Nonconvulsive status epilepticus due to ifosfamide.|Nonconvulsive status epilepticus|0|32|ifosfamide|40|50
16449538|OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.|NCSE|66|70|ifosfamide|94|104
16449538|OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide.|nonconvulsive status epilepticus|32|64|ifosfamide|94|104
16453964|We describe a case of intraoperative gelatine-induced anaphylaxis whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records.|anaphylaxis|54|65|gelatine|37|45
16453964|We describe a case of intraoperative gelatine-induced anaphylaxis whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records.|anaphylaxis|54|65|gelatine|108|116
16459502|Cutaneous mycobacterial infection post intravesical BCG installation.|Cutaneous mycobacterial infection|0|33|BCG|52|55
16459502|Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly.|Disseminated tuberculous lesions|0|32|BCG|51|54
16463436|Some patients develop hypersensitivity rash in response to HCQ.|hypersensitivity rash|22|43|HCQ|59|62
16472339|Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.|symptomatic cerebral vasospasm|120|150|sumatriptan|18|29
16480245|METHOD: We describe two patients who presented with diabetic ketoacidosis after treatment with quetiapine and risperidone, respectively.|diabetic ketoacidosis|52|73|quetiapine|95|105
16480245|METHOD: We describe two patients who presented with diabetic ketoacidosis after treatment with quetiapine and risperidone, respectively.|diabetic ketoacidosis|52|73|risperidone|110|121
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|atypical lymphocytosis|192|214|SMX|296|299
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|atypical lymphocytosis|192|214|sulfamethoxazole|278|294
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|atypical lymphocytosis|192|214|TMP|273|276
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|atypical lymphocytosis|192|214|trimethoprim|259|271
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|cervical lymphadenopathy|146|170|SMX|296|299
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|cervical lymphadenopathy|146|170|sulfamethoxazole|278|294
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|cervical lymphadenopathy|146|170|TMP|273|276
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|cervical lymphadenopathy|146|170|trimethoprim|259|271
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|eosinophilia|220|232|SMX|296|299
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|eosinophilia|220|232|sulfamethoxazole|278|294
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|eosinophilia|220|232|TMP|273|276
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|eosinophilia|220|232|trimethoprim|259|271
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|fever|123|128|SMX|296|299
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|fever|123|128|sulfamethoxazole|278|294
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|fever|123|128|TMP|273|276
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|fever|123|128|trimethoprim|259|271
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|hepatosplenomegaly|172|190|SMX|296|299
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|hepatosplenomegaly|172|190|sulfamethoxazole|278|294
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|hepatosplenomegaly|172|190|TMP|273|276
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|hepatosplenomegaly|172|190|trimethoprim|259|271
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|skin eruptions|130|144|SMX|296|299
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|skin eruptions|130|144|sulfamethoxazole|278|294
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|skin eruptions|130|144|TMP|273|276
16484748|A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (SMX) treatment.|skin eruptions|130|144|trimethoprim|259|271
16484748|This is the first case of TMP-SMX-induced hypersensitivity syndrome associated with the reactivation of a latent viral infection.|hypersensitivity syndrome|42|67|TMP-SMX|26|33
16484748|Trimethoprim-sulfamethoxazole-induced hypersensitivity syndrome associated with reactivation of human herpesvirus-6.|hypersensitivity syndrome|38|63|Trimethoprim-sulfamethoxazole|0|29
16490518|PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.|glaucoma|59|67|corticosteroid|36|50
16490518|PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.|glaucoma|59|67|triamcinolone acetate|100|121
16490518|RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.|severe vision loss|61|79|triamcinolone|125|138
16490518|RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.|visual field defects|36|56|triamcinolone|125|138
16490518|Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.|glaucoma|23|31|steroid|7|14
16490518|Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.|glaucoma|23|31|triamcinolone acetonide|68|91
16490518|This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.|glaucoma|111|119|corticosteroid|88|102
16490518|This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.|severe vision loss|42|60|corticosteroid|88|102
16498048|Autoimmune thyroid disease is a common side-effect of interferon-alpha (IFN-alpha) treatment of viral hepatitis C.|Autoimmune thyroid disease|0|26|IFN-alpha|72|81
16498048|Autoimmune thyroid disease is a common side-effect of interferon-alpha (IFN-alpha) treatment of viral hepatitis C.|Autoimmune thyroid disease|0|26|interferon-alpha|54|70
16498048|Destructive thyrotoxicosis appeared 4-6 months after starting IFN-alpha, followed by Graves' hyperthyroidism within 8 to 11 months.|Graves' hyperthyroidism|85|108|IFN-alpha|62|71
16498048|Destructive thyrotoxicosis appeared 4-6 months after starting IFN-alpha, followed by Graves' hyperthyroidism within 8 to 11 months.|thyrotoxicosis|12|26|IFN-alpha|62|71
16498048|Hence, hyperthyroidism induced by IFN-alpha could correspond to the first phase of silent thyroiditis, to Graves' disease or to the succession of both.|hyperthyroidism|7|22|IFN-alpha|34|43
16498048|Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease.|hyperthyroidism|25|40|Interferon-alpha|0|16
16498048|We have described three patients with hepatitis C for whom IFN-alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves' disease.|hyperthryroidism|173|189|IFN-alpha|59|68
16498048|We have described three patients with hepatitis C for whom IFN-alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves' disease.|hyperthryroidism|173|189|ribavirin|73|82
16498048|We have described three patients with hepatitis C for whom IFN-alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves' disease.|thyroiditis|149|160|IFN-alpha|59|68
16498048|We have described three patients with hepatitis C for whom IFN-alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves' disease.|thyroiditis|149|160|ribavirin|73|82
16503727|Dipyrone, also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with agranulocytosis.|agranulocytosis|171|186|Dipyrone|0|8
16503727|Dipyrone, also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with agranulocytosis.|agranulocytosis|171|186|metamizole|24|34
16503727|Dipyrone-induced granulocytopenia: a case for awareness.|granulocytopenia|17|33|Dipyrone|0|8
16503727|We describe a patient who developed granulocytopenia and fever after taking dipyrone and discuss the available literature.|granulocytopenia|36|52|dipyrone|76|84
16507211|Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.|CD8+ cutaneous lymphoproliferative disorders|53|97|efalizumab|119|129
16507211|Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab.|CD8+ cutaneous lymphoproliferative disorders|53|97|infliximab|134|144
16511396|A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.|abdominal pain|172|186|pyrimethamine|52|65
16511396|A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.|abdominal pain|172|186|sulfadiazine|70|82
16511396|A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.|fever|125|130|pyrimethamine|52|65
16511396|A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.|fever|125|130|sulfadiazine|70|82
16511396|A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.|severe cutaneous involvement|132|160|pyrimethamine|52|65
16511396|A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.|severe cutaneous involvement|132|160|sulfadiazine|70|82
16511396|A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.|swelling|162|170|pyrimethamine|52|65
16511396|A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.|swelling|162|170|sulfadiazine|70|82
16511396|A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.|transaminitis|191|204|pyrimethamine|52|65
16511396|A 7-year-old with congenital toxoplasmosis who took pyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.|transaminitis|191|204|sulfadiazine|70|82
16511396|Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis.|hypersensitivity|20|36|sulfadiazine|7|19
16511396|This case underscores problems in clinical management with sulfadiazine hypersensitivity, potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis.|hypersensitivity|72|88|sulfadiazine|59|71
16515630|Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.|Fatal lung fibrosis|0|19|carboplatin|174|185
16515630|Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.|Fatal lung fibrosis|0|19|paclitaxel|30|40
16515630|Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.|Fatal lung fibrosis|0|19|paclitaxel|159|169
16515630|Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.|Fatal pulmonary fibrosis|0|24|paclitaxel|36|46
16515630|Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.|lung fibrosis|107|120|paclitaxel|52|62
16515630|Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.|pneumonitis|91|102|paclitaxel|52|62
16515630|Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.|Pulmonary fibrosis|0|18|paclitaxel|40|50
16521231|Infections are a major adverse effect during the treatment with anti-TNF-alpha.|Infections|0|10|anti-TNF-alpha|64|78
16521231|In this case report, we have described a patient with Crohn's disease who developed subfulminant hepatitis B after the fourth infusion of infliximab due to an unrecognized HBs-antigen carrier state.|subfulminant hepatitis B|84|108|infliximab|138|148
16521231|Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?|Subfulminant hepatitis B|0|24|infliximab|31|41
16527771|Acute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia: a case report.|Acute unilateral total visual loss|0|34|phenol|56|62
16527771|The visual loss in this patient seems to result from phenol neurotoxicity rather than mechanical compression of the intraorbital optic nerve.|neurotoxicity|60|73|phenol|53|59
16527771|The visual loss in this patient seems to result from phenol neurotoxicity rather than mechanical compression of the intraorbital optic nerve.|visual loss|4|15|phenol|53|59
16527771|We report a 78-year-old man who had acute unilateral total visual loss after retrogasserian phenol injection for the treatment of trigeminal neuralgia.|acute unilateral total visual loss|36|70|phenol|92|98
16531969|Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.|liver injury|13|25|IFN-beta|56|64
16531969|Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.|liver injury|13|25|interferon-beta|39|54
16531969|Grade 3 hepatotoxicity (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFN beta.|Grade 3 hepatotoxicity|0|22|IFN beta|131|139
16531969|Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.|hepatotoxicity|133|147|IFN beta|43|51
16531969|Post marketing studies of Interferon-beta (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity.|hepatotoxicity|133|147|Interferon-beta|26|41
16531969|We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.|hepatitis|42|51|IFN beta|25|33
16531969|We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.|liver injury|133|145|IFN beta|25|33
16540070|A 55-year-old woman presented an episode of acute urticaria and labial angioedema 60 minutes after ingesting 500 mg of cloxacillin for a skin abscess.|acute urticaria|44|59|cloxacillin|119|130
16540070|A 55-year-old woman presented an episode of acute urticaria and labial angioedema 60 minutes after ingesting 500 mg of cloxacillin for a skin abscess.|labial angioedema|64|81|cloxacillin|119|130
16540070|Allergy to cloxacillin with normal tolerance to amoxicillin and cefuroxime.|Allergy|0|7|cloxacillin|11|22
16540070|Several hypersensitivity reactions to cloxacillin have been reported, although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy.|hypersensitivity|8|24|cloxacillin|38|49
16540070|Several hypersensitivity reactions to cloxacillin have been reported, although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy.|IgE-mediated allergic reactions|79|110|cloxacillin|38|49
1655228|Cardiac toxicity related to BCNU has not been described well.|Cardiac toxicity|0|16|BCNU|28|32
1655228|Myocardial ischemia associated with high-dose carmustine infusion.|Myocardial ischemia|0|19|carmustine|46|56
1655228|Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.|myocardial ischemia|119|138|BCNU|168|172
16599252|Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.|asthma|51|57|aspirin|35|42
16599252|We present a case of hypereosinophilia related to zafirlukast therapy.|hypereosinophilia|21|38|zafirlukast|50|61
16603845|Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.|edema|130|135|pegfilgrastim|47|60
16603845|Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.|pain in his right forearm|141|166|pegfilgrastim|47|60
16603845|Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.|rapidly progressive erythema|100|128|pegfilgrastim|47|60
16609346|A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.|myasthenic syndrome|59|78|statin|102|108
16609346|Statin-associated myasthenia gravis: report of 4 cases and review of the literature.|myasthenia gravis|18|35|Statin|0|6
16609346|We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.|myasthenia gravis|47|64|statin|109|115
1661260|Reactivation of cytomegalovirus probably followed the treatment of Wegener's granulomatosis with corticosteroids and azathioprine.|Reactivation of cytomegalovirus|0|31|azathioprine|117|129
16615675|After excluding other causes of long QT syndrome, the HCQ was suspected as the cause of her ventricular tachycardia.|ventricular tachycardia|92|115|HCQ|54|57
16615675|Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.|QT prolongation|47|62|hydroxychloroquine|8|26
16615675|Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.|refractory ventricular arrhythmia|67|100|hydroxychloroquine|8|26
16615675|CONCLUSION: The chronic use of HCQ for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal cardiac arrhythmias.|cardiac arrhythmias|157|176|HCQ|31|34
16615675|We report a case of chronic use of HCQ associated with torsade de pointes.|torsade de pointes|55|73|HCQ|35|38
16620273|CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.|lactic acidosis|121|136|metformin|81|90
16620273|Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.|Severe acidosis|0|15|metformin|35|44
16623611|Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.|diabetes|32|40|olanzapine|116|126
16623611|Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.|weight gain|45|56|olanzapine|116|126
16623611|The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and weight gain.|uncontrolled diabetes mellitus|197|227|olanzapine|151|161
16623611|The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and weight gain.|weight gain|232|243|olanzapine|151|161
16623611|The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted. Subsequently, olanzapine was discontinued because of weight gain and uncontrolled diabetes.|uncontrolled diabetes|163|184|olanzapine|108|118
16623611|The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted. Subsequently, olanzapine was discontinued because of weight gain and uncontrolled diabetes.|weight gain|147|158|olanzapine|108|118
16629074|PURPOSE: To report a case of traumatic flap dehiscence and Enterobacter keratitis 34 months after LASIK.|Enterobacter keratitis|59|81|LASIK|98|103
16629074|PURPOSE: To report a case of traumatic flap dehiscence and Enterobacter keratitis 34 months after LASIK.|traumatic flap dehiscence|29|54|LASIK|98|103
16629074|Traumatic late flap dehiscence and Enterobacter keratitis following LASIK.|Enterobacter keratitis|35|57|LASIK|68|73
16629074|Traumatic late flap dehiscence and Enterobacter keratitis following LASIK.|Traumatic late flap dehiscence|0|30|LASIK|68|73
16632429|We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor.|BOOP|99|103|docetaxel|128|137
16632429|We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor.|BOOP|99|103|gemcitabine|142|153
16632429|We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor.|progression of the tumor|215|239|docetaxel|128|137
16632429|We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor.|progression of the tumor|215|239|gemcitabine|142|153
16632429|We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor.|severe respiratory insufficiency|164|196|docetaxel|128|137
16632429|We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor.|severe respiratory insufficiency|164|196|gemcitabine|142|153
16637972|A 65-year-old man on warfarin therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with bloody tears was assessed in the clinic following a referral from an optometrist.|bloody tears|116|128|warfarin|21|29
16637972|A 65-year-old man on warfarin therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with bloody tears was assessed in the clinic following a referral from an optometrist.|sub-conjunctival haematoma|73|99|warfarin|21|29
16637972|An unusual presentation of spontaneous sub-conjunctival haematoma in a patient receiving warfarin.|sub-conjunctival haematoma|39|65|warfarin|89|97
16637972|Due to discomfort, diplopia and lagophthalmos, the haematoma necessitated suspension of warfarin therapy and a surgical evacuation.|diplopia|19|27|warfarin|88|96
16637972|Due to discomfort, diplopia and lagophthalmos, the haematoma necessitated suspension of warfarin therapy and a surgical evacuation.|discomfort|7|17|warfarin|88|96
16637972|Due to discomfort, diplopia and lagophthalmos, the haematoma necessitated suspension of warfarin therapy and a surgical evacuation.|haematoma|51|60|warfarin|88|96
16637972|Due to discomfort, diplopia and lagophthalmos, the haematoma necessitated suspension of warfarin therapy and a surgical evacuation.|lagophthalmos|32|45|warfarin|88|96
16637972|The sub-conjunctival haematoma in a patient receiving warfarin can pose a significant management challenge.|sub-conjunctival haematoma|4|30|warfarin|54|62
16641839|Angioedema and maculopapular eruptions associated with carbamazepine administration.|Angioedema|0|10|carbamazepine|55|68
16641839|Angioedema and maculopapular eruptions associated with carbamazepine administration.|maculopapular eruptions|15|38|carbamazepine|55|68
16641839|Angioedema, a rare side effect of carbamazepine, involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins.|Angioedema|0|10|carbamazepine|34|47
16641839|Cutaneous eruptions occur in 3% of individuals administered carbamazepine.|Cutaneous eruptions|0|19|carbamazepine|60|73
16641839|Cutaneous rashes and eruptions can be caused by many medications, including carbamazepine.|Cutaneous rashes|0|16|carbamazepine|76|89
16641839|Cutaneous rashes and eruptions can be caused by many medications, including carbamazepine.|eruptions|21|30|carbamazepine|76|89
16641839|We report the case of a 27-year-old Indian woman who developed maculopapular rash and angioedema secondary to carbamazepine administration.|angioedema|86|96|carbamazepine|110|123
16641839|We report the case of a 27-year-old Indian woman who developed maculopapular rash and angioedema secondary to carbamazepine administration.|maculopapular rash|63|81|carbamazepine|110|123
16678268|Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.|AVP|29|32|infliximab|44|54
16678268|Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.|Severe adenovirus pneumonia|0|27|infliximab|44|54
16678268|We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).|severe AVP|20|30|infliximab|75|85
16682062|First case of ivermectin-induced severe hepatitis.|severe hepatitis|33|49|ivermectin|14|24
16682062|To our knowledge, this is the first case of ivermectin-induced severe liver disease published in the literature.|severe liver disease|63|83|ivermectin|44|54
16682062|We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis, identified 1 month after a single dose of ivermectin.|severe hepatitis|121|137|ivermectin|181|191
16685112|CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.|myositis|72|80|gemcitabine|94|105
16685112|CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.|radiation recall dermatitis|40|67|gemcitabine|94|105
16685112|CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.|radiation recall|79|95|gemcitabine|59|70
16685112|Gemcitabine-induced rectus abdominus radiation recall.|rectus abdominus radiation recall|20|53|Gemcitabine|0|11
16688722|Sporadic rippling muscle disease unmasked by simvastatin.|Sporadic rippling muscle disease|0|32|simvastatin|45|56
16688722|We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.|rippling muscle disease|42|65|simvastatin|96|107
16688722|We report a 53-year-old-man who developed rippling muscle disease (RMD) 2 months after starting simvastatin therapy for hypercholesterolemia.|RMD|67|70|simvastatin|96|107
16697705|Acute coronary syndrome induced by capecitabine therapy.|Acute coronary syndrome|0|23|capecitabine|35|47
16697705|This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.|acute coronary syndrome|49|72|Capecitabine|93|105
16708747|Acute severe intoxication with carbamazepine is associated with seizures, coma and respiratory depression.|coma|74|78|carbamazepine|31|44
16708747|Acute severe intoxication with carbamazepine is associated with seizures, coma and respiratory depression.|respiratory depression|83|105|carbamazepine|31|44
16708747|Acute severe intoxication with carbamazepine is associated with seizures, coma and respiratory depression.|seizures|64|72|carbamazepine|31|44
16728538|After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.|hepatic enzyme disturbances|61|88|pegvisomant|35|46
16728538|After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.|hepatic enzyme disturbances|61|88|pegvisomant|148|159
16728538|After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.|hepatitis|294|303|pegvisomant|148|159
16728538|Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.|hepatitis|13|22|octreotide|96|106
16728538|Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.|hepatitis|13|22|pegvisomant|155|166
16728538|Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.|hepatitis|13|22|pegvisomant|80|91
16728538|The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.|hepatic enzyme disturbances|4|31|pegvisomant|68|79
16728538|We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.|hepatitis|73|82|octreotide|150|160
16728538|We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.|hepatitis|73|82|pegvisomant|192|203
1673494|Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.|anaemia|89|96|AmB|16|19
1673494|Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.|anaemia|89|96|Amphotericin B|0|14
1673494|Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.|fever|98|103|AmB|16|19
1673494|Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.|fever|98|103|Amphotericin B|0|14
1673494|Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.|hypokalaemia|118|130|AmB|16|19
1673494|Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.|hypokalaemia|118|130|Amphotericin B|0|14
1673494|Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.|malaise|105|112|AmB|16|19
1673494|Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.|malaise|105|112|Amphotericin B|0|14
1673494|Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.|renal impairment|71|87|AmB|16|19
1673494|Amphotericin B (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and hypokalaemia are common.|renal impairment|71|87|Amphotericin B|0|14
16757971|DIAGNOSIS: Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.|brain abscess with Listeria monocytogenes|207|248|temozolomide|18|30
16757971|DIAGNOSIS: Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.|cutaneous Kaposi's sarcoma|254|280|temozolomide|18|30
16757971|DIAGNOSIS: Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.|immunosuppression|39|56|temozolomide|18|30
16757971|DIAGNOSIS: Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.|infections with Pneumocystis jiroveci pneumonia|158|205|temozolomide|18|30
16757971|DIAGNOSIS: Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.|T-cell lymphocytopenia|104|126|temozolomide|18|30
16757971|Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.|Kaposi's sarcoma|51|67|temozolomide|74|86
16757971|Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.|Listeria brain abscess|0|22|temozolomide|74|86
16757971|Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.|Pneumocystis pneumonia|24|46|temozolomide|74|86
16765687|PURPOSE: Topiramate-induced angle-closure glaucoma (TiACG) is believed to be related to its sulfonamide moiety.|angle-closure glaucoma|28|50|Topiramate|9|19
16765687|Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol.|angle-closure glaucoma|39|61|mannitol|90|98
16765687|Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol.|angle-closure glaucoma|39|61|methylprednisolone|67|85
16765687|Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol.|angle-closure glaucoma|39|61|topiramate|20|30
16767537|Spontaneous splenic infarction associated with sumatriptan use.|Spontaneous splenic infarction|0|30|sumatriptan|47|58
16767537|Though they are generally considered safe, there have been a few reports of myocardial infarction and stroke associated with triptan use.|myocardial infarction|76|97|triptan|125|132
16767537|Though they are generally considered safe, there have been a few reports of myocardial infarction and stroke associated with triptan use.|stroke|102|108|triptan|125|132
16767537|We report a patient who developed spontaneous splenic infarction after the use of sumatriptan for the treatment of migraine headache.|spontaneous splenic infarction|34|64|sumatriptan|82|93
16791713|Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.|Acute myocardial infarction|0|27|methylprednisolone|45|63
16791713|Except hypothyroidism after radioiodine treatment (euthyroid under substitutional therapy), she suffered from no other diseases.|hypothyroidism|7|21|radioiodine|28|39
16791713|Here we present the case of a woman who received high doses of methylprednisolone (1 g iv daily) for active Graves' ophthalmopathy, and developed severe hypertension followed by myocardial infarction on the fifth day of treatment.|myocardial infarction|178|199|methylprednisolone|63|81
16791713|Here we present the case of a woman who received high doses of methylprednisolone (1 g iv daily) for active Graves' ophthalmopathy, and developed severe hypertension followed by myocardial infarction on the fifth day of treatment.|severe hypertension|146|165|methylprednisolone|63|81
16791713|We conclude that myocardial infarction may develop in patients treated with high-dose glucocorticoids for Graves' ophthalmopathy, and increased blood pressure may herald this complication.|myocardial infarction|17|38|glucocorticoids|86|101
1680596|Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.|psoriasis-like skin reaction|162|190|SASP|117|121
1680596|Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.|psoriasis-like skin reaction|162|190|sulphasalazine|101|115
1680596|Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.|Psoriasis-like skin reaction|0|28|sulphasalazine|74|88
16816519|Five days after the fourth dose of vincristine, she presented with bilateral ptosis.|bilateral ptosis|67|83|vincristine|35|46
16816519|Vincristine induced cranial polyneuropathy.|cranial polyneuropathy|20|42|Vincristine|0|11
16816519|We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment.|cranial polyneuropathy|69|91|vincristine|49|60
16843118|Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.|Acute generalized exanthematous pustulosis|0|42|morphine|53|61
16843118|Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.|facial flushing|86|101|Morphine|0|8
16843118|Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.|hyperhidrosis|68|81|Morphine|0|8
16854757|We describe a case of a man treated with an EGFR-inhibitor (erlotinib) for a cell lung cancer who developed skin manifestations localized in an uncommon area and with an atypical evolution.|skin manifestations|108|127|erlotinib|60|69
16863495|Olanzapine-associated neuroleptic malignant syndrome.|neuroleptic malignant syndrome|22|52|Olanzapine|0|10
16882109|Allergic contact angioedema to benzoyl peroxide.|Allergic contact angioedema|0|27|benzoyl peroxide|31|47
16882109|Factors that suggested an association between the severe angioedematous reaction and BP topical application include the strong reaction to BP in the patch-test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations.|severe angioedematous reaction|50|80|BP|85|87
16884425|A 35-year-old woman presented with neurotoxicity correlated to an i.v. regimen of 5-fluorouracil as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum.|acute confusional state|112|135|5-fluorouracil|82|96
16884425|A 35-year-old woman presented with neurotoxicity correlated to an i.v. regimen of 5-fluorouracil as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum.|neurotoxicity|35|48|5-fluorouracil|82|96
16884425|Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity.|neurotoxicity|62|75|5-fluorouracil|47|61
1688693|We present the case of a 58-year-old woman who ingested more than 35 g of caffeine in a suicide attempt.|suicide attempt|88|103|caffeine|74|82
16889287|It may cause a severe adverse drug reaction with multiorgan involvement known as dapsone hypersensitivity syndrome.|hypersensitivity syndrome|89|114|dapsone|81|88
16889287|Severe dapsone hypersensitivity syndrome.|hypersensitivity syndrome|15|40|dapsone|7|14
16889287|We report the case of a 21-year-old female patient with dapsone hypersensitivity syndrome.|hypersensitivity syndrome|64|89|dapsone|56|63
16901609|Anaphylaxis to intrathecal diamorphine.|Anaphylaxis|0|11|diamorphine|27|38
16901609|We believe this is the first report of intrathecal diamorphine causing anaphylaxis.|anaphylaxis|71|82|diamorphine|51|62
16914372|We highlight two instances of systemic allergic reaction, and discuss the potential side effects of local aprotinin injections in the orthopaedic setting as well as the evidence base for its use.|systemic allergic reaction|30|56|aprotinin|106|115
16923659|METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.|NMS|148|151|carbamazepine|108|121
16923659|METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.|NMS|148|151|divalproex sodium|72|89
16923659|METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.|NMS|148|151|risperidone|91|102
16923659|METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.|NMS|148|151|topiramate|60|70
16923659|METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.|NMS|148|151|venlafaxine|47|58
16923659|METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.|SS|145|147|carbamazepine|108|121
16923659|METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.|SS|145|147|divalproex sodium|72|89
16923659|METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.|SS|145|147|risperidone|91|102
16923659|METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.|SS|145|147|topiramate|60|70
16923659|METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.|SS|145|147|venlafaxine|47|58
16935446|Fever and maculopapular rashes appeared at 10 days after phenytoin initiation, and then the drug was discontinued.|Fever|0|5|phenytoin|57|66
16935446|Fever and maculopapular rashes appeared at 10 days after phenytoin initiation, and then the drug was discontinued.|maculopapular rashes|10|30|phenytoin|57|66
16939867|Localized purpura associated with lamotrigine.|Localized purpura|0|17|lamotrigine|34|45
16939867|This case study is the second report of localized purpura after prolonged lamotrigine treatment suggesting this may be an atypical lamotrigine-induced drug reaction.|localized purpura|40|57|lamotrigine|74|85
16939867|This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy.|localized purpura|125|142|lamotrigine|162|173
16945058|Acute renal failure during lisinopril and losartan therapy for proteinuria.|Acute renal failure|0|19|lisinopril|27|37
16945058|Acute renal failure during lisinopril and losartan therapy for proteinuria.|Acute renal failure|0|19|losartan|42|50
16945058|This report describes a case of acute compromise of renal function associated with hypotension in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB losartan.|hypotension|83|94|lisinopril|146|156
16945058|This report describes a case of acute compromise of renal function associated with hypotension in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB losartan.|hypotension|83|94|losartan|169|177
1694575|Reversible corneal keratinization following trabeculectomy and treatment with 5-fluorouracil.|Reversible corneal keratinization|0|33|5-fluorouracil|78|92
16948177|Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.|Bronchiolitis obliterans with organizing pneumonia|0|50|rituximab|57|66
16948177|Moreover, these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated.|BOOP|55|59|rituximab|70|79
16948177|This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.|BOOP|35|39|rituximab|69|78
16948177|This is the first reported case of BOOP associated with single-agent rituximab, and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.|BOOP|159|163|rituximab|190|199
16948177|We describe a case of an NHL patient who received rituximab and developed symptomatic, biopsy-proven multinodular bronchiolitis obliterans with organizing pneumonia (BOOP).|bronchiolitis obliterans with organizing pneumonia|114|164|rituximab|50|59
16960880|Despite a very low complication rate, several severe arterial thrombotic events have been reported following thrombin injection of pseudoaneurysms.|severe arterial thrombotic events|46|79|thrombin|109|117
16960880|Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm.|arterial thrombosis|16|35|thrombin|69|77
16960880|Native arterial thrombosis, though recognized as a severe complication of thrombin injection, has not been well described in the literature.|arterial thrombosis|7|26|thrombin|74|82
16960880|We report a case of successful surgical management of arterial thrombosis after percutaneous thrombin injection of a femoral artery pseudoaneurysm in a 69-year-old woman.|arterial thrombosis|54|73|thrombin|93|101
16968538|A small number of oxaliplatin-related hemolytic and/or thrombocytopenic reactions have been reported.|hemolytic and/or thrombocytopenic reactions|38|81|oxaliplatin|18|29
16968538|Hemolytic uremic syndrome following the infusion of oxaliplatin: case report.|Hemolytic uremic syndrome|0|25|oxaliplatin|52|63
16968538|We present a case of hemolytic-uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin.|hemolytic-uremic syndrome|21|46|5-fluorouracil|129|143
16968538|We present a case of hemolytic-uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin.|hemolytic-uremic syndrome|21|46|leucovorin|148|158
16968538|We present a case of hemolytic-uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin.|hemolytic-uremic syndrome|21|46|oxaliplatin|116|127
16978752|First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.|agranulocytosis|80|95|olanzapine|118|128
16978752|First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.|agranulocytosis|80|95|Zyprexa|130|137
16978752|First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.|neutropenia|65|76|olanzapine|118|128
16978752|First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.|neutropenia|65|76|Zyprexa|130|137
16978752|Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.|agranulocytosis|16|31|clozapine|81|90
16978752|Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.|agranulocytosis|16|31|phenothiazines|62|76
16978752|Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.|Neutropenia|0|11|clozapine|81|90
16978752|Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.|Neutropenia|0|11|phenothiazines|62|76
16978752|Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.|neutropenia|28|39|olanzapine|103|113
16978752|Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.|neutropenia|28|39|thiazide|118|126
16978752|Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.|severe neutropenia|17|35|olanzapine|69|79
16986159|We present a depressive patient who developed mild parkinsonian signs and camptocormia after the introduction of olanzapine.|camptocormia|74|86|olanzapine|113|123
16986159|We present a depressive patient who developed mild parkinsonian signs and camptocormia after the introduction of olanzapine.|mild parkinsonian signs|46|69|olanzapine|113|123
16997047|Five months after initiating mirtazapine therapy, she developed symptomatic hyponatremia.|symptomatic hyponatremia|64|88|mirtazapine|29|40
16997047|In this case, unlike those previously reported, hyponatremia recurred 5 months after switching from citalopram to mirtazapine, which is believed to be a safe antidepressant.|hyponatremia|48|60|citalopram|100|110
16997047|In this case, unlike those previously reported, hyponatremia recurred 5 months after switching from citalopram to mirtazapine, which is believed to be a safe antidepressant.|hyponatremia|48|60|mirtazapine|114|125
16997047|Recurrent hyponatremia associated with citalopram and mirtazapine.|Recurrent hyponatremia|0|22|citalopram|39|49
16997047|Recurrent hyponatremia associated with citalopram and mirtazapine.|Recurrent hyponatremia|0|22|mirtazapine|54|65
17009081|A 43-year-old woman with multiple sclerosis (MS) had nephrotic syndrome 21 months after starting treatment with interferon (IFN)-beta-1b (subcutaneous administration).|nephrotic syndrome|53|71|interferon (IFN)-beta-1b|112|136
17009081|Because nephrotic syndrome may be induced by IFN therapy, the IFN was stopped.|nephrotic syndrome|8|26|IFN|45|48
17009081|Because nephrotic syndrome may be induced by IFN therapy, the IFN was stopped.|nephrotic syndrome|8|26|IFN|62|65
17009081|Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis.|Nephrotic syndrome|0|18|interferon-beta-1b|35|53
17009081|Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN-beta-1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.|nephrotic syndrome|23|41|IFN-beta-1b|70|81
17009081|Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN-beta-1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.|proteinuria|7|18|IFN-beta-1b|70|81
17016002|A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.|dyspnea|58|65|homochlorcyclizine hydrochloride|104|136
17016002|Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.|Acute eosinophilic pneumonia|0|28|calcium stearate|39|55
17016002|Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.|pulmonary disease|44|61|calcium stearate|76|92
17026827|Scleritis complicating zoledronic acid infusion.|Scleritis|0|9|zoledronic acid|23|38
17026827|We present a case of severe unilateral posterior scleritis associated with zoledronic acid administration that was recognized and treated in a timely manner.|severe unilateral posterior scleritis|21|58|zoledronic acid|75|90
17034541|Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.|hepatitis B virus reactivation|12|42|rituximab|49|58
17034541|Several such HBV reactivations were reported after combined rituximab and multiagent chemotherapy for B-cell lymphomas.|HBV reactivations|13|30|rituximab|60|69
17034541|This is the first case of HBV reactivation occurring during the year following rituximab monotherapy in the absence of any other immunosuppressive factor.|HBV reactivation|26|42|rituximab|79|88
1703754|This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.|cryptococcal meningitis|31|54|azathioprine|136|148
1703754|This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.|cryptococcal meningitis|31|54|prednisolone|119|131
17039658|An intertrigo-like eruption from pegylated liposomal doxorubicin.|intertrigo-like eruption|3|27|doxorubicin|53|64
17039658|This eruption appears to be a distinct cutaneous toxicity of PLD.|eruption|5|13|PLD|61|64
17039658|We report the case of a 60-year-old woman who developed erythema and erosions in the axilla and groin while on PLD for breast cancer.|erosions in the axilla and groin|69|101|PLD|111|114
17039658|We report the case of a 60-year-old woman who developed erythema and erosions in the axilla and groin while on PLD for breast cancer.|erythema|56|64|PLD|111|114
17044380|Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma.|skin necrosis|66|79|warfarin|49|57
17044380|Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma.|thrombocytopenia|100|116|heparin|84|91
17044380|Warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for marantic endocarditis.|skin necrosis|17|30|Warfarin|0|8
17044380|Warfarin-induced skin necrosis and heparin-induced thrombocytopenia following mitral valve replacement for marantic endocarditis.|thrombocytopenia|51|67|heparin|35|42
17060191|Exposure of the fetus to indomethacin by administration of the drug to the mother may cause many side effects, including premature closure of the ductus arteriosus.|premature closure of the ductus arteriosus|121|163|indomethacin|25|37
17060191|Hypoxia is a predisposing factor for premature ductal closure and often occurs after maternal indomethacin therapy.|Hypoxia|0|7|indomethacin|94|106
17060191|Hypoxia is a predisposing factor for premature ductal closure and often occurs after maternal indomethacin therapy.|premature ductal closure|37|61|indomethacin|94|106
17060191|Premature closure of the ductus arteriosus: variable response among monozygotic twins after in utero exposure to indomethacin.|Premature closure of the ductus arteriosus|0|42|indomethacin|113|125
17060191|This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to ductal closure in response to indomethacin exposure.|ductal closure|140|154|indomethacin|170|182
17060191|This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to ductal closure in response to indomethacin exposure.|hypoxia|99|106|indomethacin|170|182
17068466|CONCLUSION: These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers.|corneal ulcers|84|98|moxifloxacin|37|49
17068466|RESULTS: Both cases presented here describe corneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with moxifloxacin.|corneal ulcers|44|58|moxifloxacin|149|161
17068466|Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases.|Severe corneal toxicity|0|23|fluoroquinolone|38|53
17083900|Acute generalized exanthematous pustulosis induced by nimesulide.|Acute generalized exanthematous pustulosis|0|42|nimesulide|54|64
17083900|We report a case of acute generalized exanthematous pustulosis (AGEP) in a 50-year-old woman that was attributed to the ingestion of nimesulide.|acute generalized exanthematous pustulosis|20|62|nimesulide|133|143
17083900|We report a case of acute generalized exanthematous pustulosis (AGEP) in a 50-year-old woman that was attributed to the ingestion of nimesulide.|AGEP|64|68|nimesulide|133|143
17090724|DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.|bradycardia|132|143|Amphotericin B deoxycholate|12|39
17090724|DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.|cardiac toxicity|81|97|Amphotericin B deoxycholate|12|39
17090724|DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.|ventricular arrhythmias|104|127|Amphotericin B deoxycholate|12|39
17090724|OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.|fatal cardiac arrhythmia|129|153|amphotericin B|181|195
17090724|Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.|cardiac toxicity|99|115|amphotericin B deoxycholate|120|147
17109650|The authors describe a case of valvular heart disease in a 48-year-old woman receiving benfluorex (150 mg t.i.d. for 8 years) and leading to surgical mitral valve replacement.|valvular heart disease|31|53|benfluorex|87|97
17109650|Valvular heart disease in a patient taking benfluorex.|Valvular heart disease|0|22|benfluorex|43|53
1711090|The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.|liver dysfunction|109|126|Lp-TAE|25|31
1711090|The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.|localized pain|71|85|Lp-TAE|25|31
1711090|The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.|low-grade fever|54|69|Lp-TAE|25|31
1711090|The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.|myelo-suppression|87|104|Lp-TAE|25|31
17123120|Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.|acute renal failure|44|63|Tacrolimus|0|10
17123120|Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.|HUS|19|22|Tacrolimus|0|10
17123120|Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.|ARF|48|51|tacrolimus|6|16
17123120|Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.|HUS|25|28|tacrolimus|6|16
17133571|Liver transplantation for fulminant hepatitis related to nevirapine therapy.|fulminant hepatitis|26|45|nevirapine|57|67
17133571|We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation.|fulminant hepatitis|31|50|nevirapine|62|72
17133571|We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation.|fulminant hepatitis|31|50|Viramune|74|82
17163271|Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin.|Cholelithiasis|0|14|cyclosporin|103|114
17163271|Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin.|thrombosis of the central retinal vein|19|57|cyclosporin|103|114
17163271|In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine, developed thrombosis of the central retinal vein 5 years following the transplantation.|thrombosis|214|224|azathioprine|190|202
17163271|In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine, developed thrombosis of the central retinal vein 5 years following the transplantation.|thrombosis|214|224|cyclosporin|162|173
17163271|In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and azathioprine, developed thrombosis of the central retinal vein 5 years following the transplantation.|thrombosis|214|224|prednisone|175|185
17163271|The use of cyclosporin has been associated with the development of cholelithiasis in transplant recipients.|cholelithiasis|67|81|cyclosporin|11|22
17167851|Hepatotoxicity induced by cyproterone acetate: a report of three cases.|Hepatotoxicity|0|14|cyproterone acetate|26|45
17167851|Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.|severe hepatotoxic reactions|60|88|CPA|103|106
17176478|CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.|cutaneous leishmaniasis|330|353|CS|373|375
17176478|CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.|Leishmania infantum leishmaniasis|34|67|corticosteroid|71|85
17176478|CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.|Leishmania infantum leishmaniasis|34|67|CS|181|183
17176478|CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.|lingual leishmaniasis|134|155|corticosteroid|71|85
17176478|CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.|lingual leishmaniasis|134|155|CS|181|183
17176478|Leishmania infantum leishmaniasis in corticosteroid--treated patients.|Leishmania infantum leishmaniasis|0|33|corticosteroid|37|51
17182354|However, an association of Ritalin with glaucoma has been reported.|glaucoma|40|48|Ritalin|27|34
17182354|Large dose of methylphenidate may cause cataract and glaucoma.|cataract|40|48|methylphenidate|14|29
17182354|Large dose of methylphenidate may cause cataract and glaucoma.|glaucoma|53|61|methylphenidate|14|29
17182354|Methylphenidate (Ritalin)-associated cataract and glaucoma.|cataract|37|45|Methylphenidate|0|15
17182354|Methylphenidate (Ritalin)-associated cataract and glaucoma.|cataract|37|45|Ritalin|17|24
17182354|Methylphenidate (Ritalin)-associated cataract and glaucoma.|glaucoma|50|58|Methylphenidate|0|15
17182354|Methylphenidate (Ritalin)-associated cataract and glaucoma.|glaucoma|50|58|Ritalin|17|24
17182354|We report a case of Ritalin-associated cataract and glaucoma.|cataract|39|47|Ritalin|20|27
17182354|We report a case of Ritalin-associated cataract and glaucoma.|glaucoma|52|60|Ritalin|20|27
17188061|CONCLUSIONS: We report a typical symptoms of Charles-Bonnet syndrome (CBS) in patients with severe AMD after intravitreal Avastin-injections.|CBS|70|73|Avastin|122|129
17188061|CONCLUSIONS: We report a typical symptoms of Charles-Bonnet syndrome (CBS) in patients with severe AMD after intravitreal Avastin-injections.|Charles-Bonnet syndrome|45|68|Avastin|122|129
17188061|PURPOSE: To describe transient structured visual hallucinations in a patient with vascular age-related macular degeneration (AMD), following an intravitreal Avastin-injection.|transient structured visual hallucinations|21|63|Avastin|157|164
17188061|Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration.|Visual hallucinations|0|21|bevacizumab|54|65
17195428|A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis.|oculogyric crisis|33|50|metoclopramide|10|24
17195428|A case of oculogyric crisis induced by metoclopramide is described in this paper.|oculogyric crisis|10|27|metoclopramide|39|53
17199845|However, cyclosporine dependency is associated with the risk of nephrotoxicity.|nephrotoxicity|64|78|cyclosporine|9|21
17205927|Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.|prolonged hypotension|97|118|Quinapril|0|9
17205927|Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.|transient renal impairment|141|167|Quinapril|0|9
172214|Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.|Cardiomyopathy|0|14|actinomycin-D|75|88
172214|Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.|Cardiomyopathy|0|14|adriamycin|49|59
172214|Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.|Cardiomyopathy|0|14|mithramycin|93|104
172214|Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-0) and mithramycin (NSC-0).|Exacerbations of the heart failure|0|34|actinomycin-D|110|123
172214|Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-0) and mithramycin (NSC-0).|Exacerbations of the heart failure|0|34|mithramycin|139|150
172214|Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-0) and mithramycin (NSC-0).|Exacerbations of the heart failure|0|34|NSC-0|152|161
172214|Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-0) and mithramycin (NSC-0).|Exacerbations of the heart failure|0|34|NSC-0|125|133
172214|The pathogenic mechanisms involved in the development of adriamycin cardiomyopathy are reviewed, and the possible synergistic effect of other antitumor antibiotics is discussed.|cardiomyopathy|68|82|adriamycin|57|67
17224428|Cardiac hypersensitivity and myopericarditis have been reported during long-term treatment with mesalazine.|Cardiac hypersensitivity|0|24|mesalazine|96|106
17224428|Cardiac hypersensitivity and myopericarditis have been reported during long-term treatment with mesalazine.|myopericarditis|29|44|mesalazine|96|106
17224428|We report the case of a man, treated with mesalazine for Crohn's disease who developed drug-induced pericarditis.|pericarditis|100|112|mesalazine|42|52
17228132|Acute drug induced hepatitis due to erlotinib.|hepatitis|19|28|erlotinib|36|45
17228132|CASE REPORT: We report a case of acute severe hepatitis resulting from erlotinib monotherapy in a patient with locally advanced pancreatic cancer.|acute severe hepatitis|33|55|erlotinib|71|80
17228132|CONCLUSIONS: Acute severe hepatitis though rare is occasionally observed with EGFR inhibitors gefitinib or erlotinib.|Acute severe hepatitis|13|35|erlotinib|107|116
17228132|CONCLUSIONS: Acute severe hepatitis though rare is occasionally observed with EGFR inhibitors gefitinib or erlotinib.|Acute severe hepatitis|13|35|gefitinib|94|103
17228132|Hepatotoxicity resolved once erlotinib was discontinued and serum transaminases returned to baseline normal values.|Hepatotoxicity|0|14|erlotinib|29|38
1722991|Heparin-associated thrombocytopenia and thrombosis is a severe complication of systemic heparin therapy.|thrombocytopenia|19|35|Heparin|0|7
1722991|Heparin-associated thrombocytopenia and thrombosis is a severe complication of systemic heparin therapy.|thrombocytopenia|19|35|heparin|88|95
1722991|Heparin-associated thrombocytopenia and thrombosis is a severe complication of systemic heparin therapy.|thrombosis|40|50|Heparin|0|7
1722991|Heparin-associated thrombocytopenia and thrombosis is a severe complication of systemic heparin therapy.|thrombosis|40|50|heparin|88|95
1722991|This experience supports the hypothesis that heparin can be readministered early to patients with heparin-associated thrombocytopenia and thrombosis, provided antiplatelet therapy is given.|thrombocytopenia|117|133|heparin|98|105
1722991|This experience supports the hypothesis that heparin can be readministered early to patients with heparin-associated thrombocytopenia and thrombosis, provided antiplatelet therapy is given.|thrombosis|138|148|heparin|98|105
1722991|Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis.|thrombocytopenia|73|89|heparin|54|61
1722991|Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis.|thrombosis|94|104|heparin|54|61
17241588|RESULTS: A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil (Cialis) was made.|fixed drug eruption|33|52|Cialis|99|105
17241588|RESULTS: A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil (Cialis) was made.|fixed drug eruption|33|52|tadalafil|88|97
17260498|Even though only a few cases of this adverse event have been reported in the literature, severe docetaxel-induced pulmonary toxicity needs to be considered in the differential diagnosis when such patients present with respiratory symptoms.|pulmonary toxicity|114|132|docetaxel|96|105
17260498|Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer.|Fatal interstitial pneumonitis|0|30|docetaxel|47|56
17260498|The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 docetaxel who developed subacute interstitial pneumonitis-related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment.|subacute interstitial pneumonitis-related pulmonary fibrosis|145|205|docetaxel|121|130
17266059|The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole.|fulminant microangiopathic hemolytic anemia|27|70|sulfamethoxazole|145|161
17266059|The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole.|fulminant microangiopathic hemolytic anemia|27|70|trimethoprim|132|144
17266059|The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole.|thrombocytopenia|75|91|sulfamethoxazole|145|161
17266059|The patient presented with fulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-sulfamethoxazole.|thrombocytopenia|75|91|trimethoprim|132|144
17266059|Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness.|Thrombotic thrombocytopenic purpura|0|35|sulfamethoxazole|60|76
17266059|Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness.|Thrombotic thrombocytopenic purpura|0|35|trimethoprim|47|59
17266059|We report a case of Thrombotic Thrombocytopenic Purpura occurring as an allergic response to trimethoprim-sulfamethoxazole therapy (Bactrim, Septra) in a Jehovah's Witness patient.|Thrombotic Thrombocytopenic Purpura|20|55|sulfamethoxazole|106|122
17266059|We report a case of Thrombotic Thrombocytopenic Purpura occurring as an allergic response to trimethoprim-sulfamethoxazole therapy (Bactrim, Septra) in a Jehovah's Witness patient.|Thrombotic Thrombocytopenic Purpura|20|55|trimethoprim|93|105
17275666|Juvenile absence epilepsy exacerbated by valproic acid.|Juvenile absence epilepsy|0|25|valproic acid|41|54
17275666|This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.|seizure exacerbation|79|99|paradoxical|32|43
17275666|This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.|seizure exacerbation|79|99|valproic acid|57|70
17277758|Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection.|Acute endophthalmitis|0|21|Avastin|58|65
17277758|Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection.|Acute endophthalmitis|0|21|bevacizumab|45|56
17277758|CONCLUSIONS: Infectious endophthalmitis is a potential complication of intravitreal bevacizumab injection.|Infectious endophthalmitis|13|39|bevacizumab|84|95
17277758|METHODS: Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of bevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later.|age-related macular degeneration|37|69|bevacizumab|130|141
17277758|METHODS: Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of bevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later.|painless infectious endophthalmitis|176|211|bevacizumab|130|141
17277758|PURPOSE: To report two cases of acute endophthalmitis following intravitreal bevacizumab injection.|acute endophthalmitis|32|53|bevacizumab|77|88
17285101|Pulmonary hypertension during lithium therapy: clinical case study.|Pulmonary hypertension|0|22|lithium|30|37
17285101|The authors presented a case of pulmonary hypertension during lithium therapy, while she has been on lithium for 6 years.|pulmonary hypertension|32|54|lithium|62|69
17285101|This is the first report of pulmonary hypertension in an adult patient during lithium therapy.|pulmonary hypertension|28|50|lithium|78|85
17298107|The patient's arthritis flared after the second infusion of infliximab, which was discontinued.|arthritis|14|23|infliximab|60|70
17301517|A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.|circulatory collapse|83|103|perospirone hydrochloride|149|174
17301517|A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride, a recently developed atypical antipsychotic agent available only in Japan.|deep coma|108|117|perospirone hydrochloride|149|174
17301517|The risk of new-onset diabetic ketoacidosis in patients with diabetic risk factors who are taking perospirone hydrochloride or other atypical antipsychotics should be kept in mind.|diabetic ketoacidosis|22|43|perospirone hydrochloride|98|123
17310853|Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.|Fatal venous thrombembolism|0|27|imatinib|41|49
17310853|The possibility of deep vein thrombosis caused by the compression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with imatinib.|deep vein thrombosis|19|39|imatinib|207|215
17316891|We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.|status epilepticus|99|117|cisplatin|142|151
17316891|We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.|status epilepticus|99|117|gemcitabine|156|167
17319250|Of particular interest in this patient is the fluctuation of the QT interval at a stable dose of methadone, suggesting that a single normal electrocardiogram (ECG) does not guarantee that the patient is not at risk of ventricular arrhythmias.|fluctuation of the QT interval|46|76|methadone|97|106
17319250|We present a case report of a patient who developed a prolonged QT while being treated with oral methadone for a chronic pain syndrome.|prolonged QT|54|66|methadone|97|106
17324248|AIMS: To present a case of piloerection after replacing fluvoxamine maleate with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory.|piloerection|27|39|fluvoxamine maleate|56|75
17324248|AIMS: To present a case of piloerection after replacing fluvoxamine maleate with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory.|piloerection|27|39|milnacipran hydrochloride|81|106
17324248|CONCLUSIONS: The piloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran.|piloerection|17|29|fluvoxamine|64|75
17324248|CONCLUSIONS: The piloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran.|piloerection|17|29|milnacipran|81|92
17324248|Piloerection induced by replacing fluvoxamine with milnacipran.|Piloerection|0|12|fluvoxamine|34|45
17324248|Piloerection induced by replacing fluvoxamine with milnacipran.|Piloerection|0|12|milnacipran|51|62
17331261|CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.|recurrent eosinophilia|61|83|tobramycin|174|184
17331261|CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age.|severe persistent bronchospasm|88|118|tobramycin|174|184
17331261|CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.|deterioration of pulmonary function|110|145|tobramycin|167|177
17331261|CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.|recurrent eosinophilia|83|105|tobramycin|167|177
17331261|Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.|recurrent eosinophilia|39|61|tobramycin|8|18
17331261|Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.|severe persistent bronchospasm|66|96|tobramycin|8|18
17346586|The most serious dental side effect of bisphosphonate treatment (particularly when it is administered intravenously) is, paradoxically, osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone.|osteonecrosis of the mandible|136|165|bisphosphonate|39|53
17352036|Adverse effects of amiodarone including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood.|aggravation of arrhythmia|76|101|amiodarone|19|29
17352036|Adverse effects of amiodarone including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood.|hepatotoxicity|60|74|amiodarone|19|29
17352036|Adverse effects of amiodarone including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood.|pulmonary toxicity|40|58|amiodarone|19|29
17352036|Adverse effects of amiodarone including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood.|thyroid diseases|107|123|amiodarone|19|29
17352036|Pancreatitis is a very rare adverse effect associated with the use of amiodarone, and only four cases of amiodarone-induced pancreatitis have been reported in literature.|Pancreatitis|0|12|amiodarone|70|80
17352036|Pancreatitis is a very rare adverse effect associated with the use of amiodarone, and only four cases of amiodarone-induced pancreatitis have been reported in literature.|pancreatitis|124|136|amiodarone|105|115
17352036|Under the suspicion of amiodarone-induced acute pancreatitis, amiodarone was substituted by propafenone.|acute pancreatitis|42|60|amiodarone|23|33
17352036|We report a patient who developed acute pancreatitis during amiodarone therapy.|acute pancreatitis|34|52|amiodarone|60|70
17364199|DISCUSSION: To our knowledge this is the first reported case of tuberculous uveitis following treatment with etanercept.|tuberculous uveitis|64|83|etanercept|109|119
17364199|Tuberculous uveitis after treatment with etanercept.|Tuberculous uveitis|0|19|etanercept|41|51
17364199|We report the first case of tuberculous uveitis due to etanercept.|tuberculous uveitis|28|47|etanercept|55|65
17366681|A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer.|melanonychia|21|33|pemetrexed|71|81
17366681|A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer.|onycholysis|38|49|pemetrexed|71|81
17373180|Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.|osteomyelitis|77|90|Infliximab|0|10
17373180|Infliximab and its serious adverse effects are discussed, and other cases of osteomyelitis with infliximab use are also reviewed.|osteomyelitis|77|90|infliximab|96|106
17373180|Osteomyelitis occurring during infliximab treatment of severe psoriasis.|Osteomyelitis|0|13|infliximab|31|41
17381671|Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co-administration of citalopram and fentanyl.|serotonin syndrome|40|58|citalopram|128|138
17381671|Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co-administration of citalopram and fentanyl.|serotonin syndrome|40|58|fentanyl|143|151
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|agitation|143|152|citalopram|111|121
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|agitation|143|152|fentanyl|271|279
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|agitation|143|152|fentanyl|346|354
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|confusion|132|141|citalopram|111|121
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|confusion|132|141|fentanyl|271|279
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|confusion|132|141|fentanyl|346|354
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|myoclonic jerks|176|191|citalopram|111|121
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|myoclonic jerks|176|191|fentanyl|271|279
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|myoclonic jerks|176|191|fentanyl|346|354
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|serotonin syndrome|227|245|citalopram|111|121
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|serotonin syndrome|227|245|fentanyl|271|279
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|serotonin syndrome|227|245|fentanyl|346|354
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|tachycardia|154|165|citalopram|111|121
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|tachycardia|154|165|fentanyl|271|279
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|tachycardia|154|165|fentanyl|346|354
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|tremors|167|174|citalopram|111|121
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|tremors|167|174|fentanyl|271|279
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|tremors|167|174|fentanyl|346|354
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|unsteady gait|196|209|citalopram|111|121
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|unsteady gait|196|209|fentanyl|271|279
17381671|CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.|unsteady gait|196|209|fentanyl|346|354
17381671|CONCLUSION: Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs.|serotonin syndrome|84|102|fentanyl|138|146
17381671|OBJECTIVE: To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.|serotonin syndrome|31|49|citalopram|99|109
17381671|OBJECTIVE: To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.|serotonin syndrome|31|49|fentanyl|86|94
17381671|OBJECTIVE: To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.|serotonin syndrome|31|49|fentanyl|207|215
17381671|Serotonin syndrome caused by interaction between citalopram and fentanyl.|Serotonin syndrome|0|18|citalopram|49|59
17381671|Serotonin syndrome caused by interaction between citalopram and fentanyl.|Serotonin syndrome|0|18|fentanyl|64|72
17387702|Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.|Renal failure|0|13|methotrexate|30|42
17387702|We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).|renal failure|98|111|HDMTX|166|171
17387702|We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).|renal failure|98|111|methotrexate|152|164
17404582|Docetaxel induced Meibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past.|Meibomian duct inflammation and blockage|18|58|Docetaxel|0|9
17404582|Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation.|chalazion|70|79|Docetaxel|0|9
17404582|Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation.|Meibomian duct inflammation and blockage|18|58|Docetaxel|0|9
17404582|We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly docetaxel for 12 weeks and developed significant eye irritation and dryness during treatment.|eye irritation and dryness|155|181|docetaxel|106|115
17406804|A case of recall pneumonitis induced by gemcitabine is reported.|recall pneumonitis|10|28|gemcitabine|40|51
17406804|After having received gemcitabine on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and dyspnea within 48 h.|dry cough|87|96|gemcitabine|22|33
17406804|After having received gemcitabine on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and dyspnea within 48 h.|dyspnea|126|133|gemcitabine|22|33
17406804|After having received gemcitabine on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and dyspnea within 48 h.|subfebrile temperatures|98|121|gemcitabine|22|33
17406804|CONCLUSION: Gemcitabine-induced recall pneumonitis is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy.|recall pneumonitis|32|50|Gemcitabine|12|23
17406804|Radiation recall pneumonitis induced by gemcitabine.|Radiation recall pneumonitis|0|28|gemcitabine|40|51
17426073|CONCLUSIONS: For all patients with vancomycin-induced neutropenia, possible cross-reactivity of teicoplanin should be monitored.|neutropenia|54|65|vancomycin|35|45
17426073|However, a new episode of neutropenia, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after teicoplanin initiation.|neutropenia|26|37|teicoplanin|128|139
17426073|OBJECTIVE: To report teicoplanin-related neutropenia that developed after an episode of neutropenia induced by vancomycin therapy.|neutropenia|41|52|teicoplanin|21|32
17426073|OBJECTIVE: To report teicoplanin-related neutropenia that developed after an episode of neutropenia induced by vancomycin therapy.|neutropenia|88|99|vancomycin|111|121
17426073|Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.|agranulocytosis|20|35|Teicoplanin|0|11
17426073|Teicoplanin-induced agranulocytosis that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.|agranulocytosis|69|84|vancomycin|50|60
1743388|Cutaneous ulceration: an unusual complication of intravenous pentamidine therapy.|Cutaneous ulceration|0|20|pentamidine|61|72
1743388|This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and ulceration following the extravasation of intravenous pentamidine into the soft tissues of the left hand and forearm.|chemical cellulitis|89|108|pentamidine|167|178
1743388|This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and ulceration following the extravasation of intravenous pentamidine into the soft tissues of the left hand and forearm.|ulceration|113|123|pentamidine|167|178
17438184|OBSERVATIONS: A 48-year-old woman presented with disfiguring facial edema 10 weeks after she began antiviral therapy with peginterferon alfa-2a and ribavirin for chronic hepatitis C infection.|disfiguring facial edema|49|73|peginterferon alfa-2a|122|143
17438184|OBSERVATIONS: A 48-year-old woman presented with disfiguring facial edema 10 weeks after she began antiviral therapy with peginterferon alfa-2a and ribavirin for chronic hepatitis C infection.|disfiguring facial edema|49|73|ribavirin|148|157
17444802|Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia.|Tumor-volume increase|0|21|interferon alpha 2-beta|69|92
17448102|Flecainide overdose can rapidly result in profound cardiovascular collapse, and is associated with a relatively high mortality.|cardiovascular collapse|51|74|Flecainide|0|10
17448102|Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy.|cardiovascular collapse|9|32|flecainide|43|53
17458405|Ezetimibe-induced acute pancreatitis.|acute pancreatitis|18|36|Ezetimibe|0|9
17458405|Since its FDA approval in 2002, there are no known citations of ezetimibe-induced pancreatitis.|pancreatitis|82|94|ezetimibe|64|73
17473493|Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis.|aggravation of nonalcoholic steatohepatitis|60|103|raloxifene|38|48
17473493|This is the first histologically confirmed case of NASH that was aggravated by raloxifene.|NASH|51|55|raloxifene|79|89
1747495|A case of liver damage following treatment with Danazol for fibrocystic breast disease is reported.|liver damage|10|22|Danazol|48|55
1747495|Hepatic damage after danazol treatment.|Hepatic damage|0|14|danazol|21|28
17494808|Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.|Hypersensitivity pneumonitis-like syndrome|0|42|lenalidomide|70|82
17494808|In this report, we describe a patient receiving lenalidomide in whom dyspnea, fever, hypoxia, and diffuse pulmonary infiltrates developed.|diffuse pulmonary infiltrates|98|127|lenalidomide|48|60
17494808|In this report, we describe a patient receiving lenalidomide in whom dyspnea, fever, hypoxia, and diffuse pulmonary infiltrates developed.|dyspnea|69|76|lenalidomide|48|60
17494808|In this report, we describe a patient receiving lenalidomide in whom dyspnea, fever, hypoxia, and diffuse pulmonary infiltrates developed.|fever|78|83|lenalidomide|48|60
17494808|In this report, we describe a patient receiving lenalidomide in whom dyspnea, fever, hypoxia, and diffuse pulmonary infiltrates developed.|hypoxia|85|92|lenalidomide|48|60
17494808|Physicians should be cognizant of this potential complication in patients receiving thalidomide or thalidomide-like drugs who present with fever and pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics.|fever|139|144|thalidomide|84|95
17494808|Physicians should be cognizant of this potential complication in patients receiving thalidomide or thalidomide-like drugs who present with fever and pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics.|pulmonary infiltrates|149|170|thalidomide|84|95
17494808|Thus, the patient's clinical course and workup strongly support a diagnosis of lenalidomide-induced hypersensitivity pneumonitis-like syndrome.|hypersensitivity pneumonitis-like syndrome|100|142|lenalidomide|79|91
17505739|Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient.|exacerbation of retinochoroiditis|60|93|triamcinolone|13|26
17509184|A 40-year-old man with advanced HIV infection and Mycobacterium avium complex infection experienced rapid cognitive decline after commencement of ethambutol, and symptoms fully resolved with cessation.|rapid cognitive decline|100|123|ethambutol|146|156
17509184|Ethambutol toxicity manifesting as acute onset psychosis.|acute onset psychosis|35|56|Ethambutol|0|10
1751354|Psoriasis induced by interferon-alpha.|Psoriasis|0|9|interferon-alpha|21|37
1751354|Recombinant human interferon-alpha has been used in the treatment of several cancers, but there have been several reports that it may exacerbate psoriasis or trigger off its onset.|exacerbate psoriasis or trigger off its onset|134|179|Recombinant human interferon-alpha|0|34
1751354|We report four patients, three of whom first developed psoriasis and one who had an aggravation of the condition during treatment with interferon-alpha.|psoriasis|55|64|interferon-alpha|135|151
17519584|A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed generalized erythema with high fever 3 weeks after taking sulfamethoxazole/trimethoprim.|generalized erythema|122|142|sulfamethoxazole|180|196
17519584|A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed generalized erythema with high fever 3 weeks after taking sulfamethoxazole/trimethoprim.|generalized erythema|122|142|trimethoprim|197|209
17522786|INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and raised intracranial pressure (ICP) after severe sodium valproic acid (VPA) intoxication.|raised intracranial pressure|114|142|sodium valproic acid|162|182
17522786|INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and raised intracranial pressure (ICP) after severe sodium valproic acid (VPA) intoxication.|raised intracranial pressure|114|142|VPA|184|187
17522786|INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and raised intracranial pressure (ICP) after severe sodium valproic acid (VPA) intoxication.|severe cerebral swelling|85|109|sodium valproic acid|162|182
17522786|INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and raised intracranial pressure (ICP) after severe sodium valproic acid (VPA) intoxication.|severe cerebral swelling|85|109|VPA|184|187
17522786|Neurointensive care management of raised intracranial pressure caused by severe valproic acid intoxication.|raised intracranial pressure|34|62|valproic acid|80|93
17526968|Bleomycin induced hyperpigmentation with yolk sac tumor.|hyperpigmentation|18|35|Bleomycin|0|9
17526968|The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the skin toxicity of bleomycin.|skin toxicity|128|141|bleomycin|145|154
17526968|We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin.|localized pigmentation|52|74|bleomycin|161|170
17526968|We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin.|localized pigmentation|52|74|cisplatin|136|145
17526968|We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and bleomycin.|localized pigmentation|52|74|etoposide|147|156
17536204|A cause-effect relationship to capecitabine was suggested due to resolution of headache with capecitabine withdrawal and reappearance with capecitabine rechallenge.|headache|79|87|capecitabine|93|105
17536204|BACKGROUND: Headaches have been reported as a potential side effect of capecitabine therapy.|Headaches|12|21|capecitabine|71|83
17536204|Capecitabine-induced headache responding to diltiazem.|headache|21|29|Capecitabine|0|12
17536204|CCBs should be considered in the treatment of 5-FU or capecitabine-induced headaches.|headaches|75|84|5-FU|46|50
17536204|CCBs should be considered in the treatment of 5-FU or capecitabine-induced headaches.|headaches|75|84|capecitabine|54|66
17536204|The patient developed grade 3 capecitabine-induced headache.|headache|51|59|capecitabine|30|42
17536204|We hypothesize that capecitabine-induced headache is vascular in nature.|headache|41|49|capecitabine|20|32
17547624|Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome.|Brugada type electrocardiographic changes|0|41|lithium|72|79
17547624|Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff-Parkinson-White syndrome.|Brugada type electrocardiographic changes|0|41|propafenone|84|95
17547624|We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels.|ST elevation in right precordial leads|20|58|propafenone|127|138
17547624|We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels.|type 1 Brugada syndrome|75|98|propafenone|127|138
17551408|We postulate that gastritis caused by dexamethasone, mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event.|gastritis|18|27|dexamethasone|38|51
17551408|We postulate that gastritis caused by dexamethasone, mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event.|mucositis|53|62|doxorubicin|73|84
17556909|Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.|gastrointestinal side effect|50|78|Bortezomib|0|10
17556909|Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.|paralytic ileus|19|34|Bortezomib|0|10
17556909|Paralytic ileus in patients undergoing bortezomib treatment has been reported, although a definite attribution to bortezomib administration has not been established.|Paralytic ileus|0|15|bortezomib|39|49
17556909|We report a myeloma patient who developed severe paralytic ileus during bortezomib therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship.|severe paralytic ileus|42|64|bortezomib|72|82
1756352|A woman developed delusional parasitosis when taking phenelzine.|delusional parasitosis|18|40|phenelzine|53|63
1756352|Delusional parasitosis associated with phenelzine.|Delusional parasitosis|0|22|phenelzine|39|49
17596682|Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature.|alveolar hemorrhage|29|48|rituximab|69|78
17596682|Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature.|Interstitial pneumonitis|0|24|rituximab|69|78
17596682|The use of rituximab has been uncommonly associated with delayed pulmonary toxicity.|delayed pulmonary toxicity|57|83|rituximab|11|20
1759924|Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene.|neuroleptic malignant syndrome|33|63|metoclopramide|10|24
1759924|We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six-hourly intravenous metoclopramide.|neuroleptic malignant syndrome|30|60|metoclopramide|140|154
17610180|The clinical symptoms of gastric mucosa foveolar hyperplasia due to long-term PGE1 therapy simulate hypertrophic pyloric stenosis.|gastric mucosa foveolar hyperplasia|25|60|PGE1|78|82
17610180|The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of gastric mucosa foveolar hyperplasia due to prolonged PGE1 therapy.|gastric mucosa foveolar hyperplasia|96|131|PGE1|149|153
17619811|A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.|fatigue|162|169|colchicine|236|246
17619811|A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.|leg weakness|184|196|colchicine|236|246
17619811|A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.|myalgia|171|178|colchicine|236|246
17619811|A case of colchicine-induced rhabdomyolysis is reported.|rhabdomyolysis|29|43|colchicine|10|20
17619811|Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.|rhabdomyolysis|19|33|Colchicine|0|10
17619811|Colchicine-induced rhabdomyolysis.|rhabdomyolysis|19|33|Colchicine|0|10
17619811|Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.|rhabdomylysis|154|167|colchicine|80|90
17624096|5-Fluorouracil cardiotoxicity complicating treatment of stage IIB cervical cancer--case report.|cardiotoxicity|15|29|5-Fluorouracil|0|14
17627694|CONCLUSION: Acetic acid is corrosive and may cause vagina bleeding.|vagina bleeding|51|66|Acetic acid|12|23
1765991|Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis.|systemic lupus erythematosus|13|41|interferon-gamma|45|61
1765991|The development of systemic lupus erythematosus (SLE) after 38 months of therapy with recombinant human interferon gamma (rIFN-gamma) was observed in a patient with rheumatoid arthritis.|SLE|49|52|recombinant human interferon gamma|86|120
1765991|The development of systemic lupus erythematosus (SLE) after 38 months of therapy with recombinant human interferon gamma (rIFN-gamma) was observed in a patient with rheumatoid arthritis.|SLE|49|52|rIFN-gamma|122|132
1765991|The development of systemic lupus erythematosus (SLE) after 38 months of therapy with recombinant human interferon gamma (rIFN-gamma) was observed in a patient with rheumatoid arthritis.|systemic lupus erythematosus|19|47|recombinant human interferon gamma|86|120
1765991|The development of systemic lupus erythematosus (SLE) after 38 months of therapy with recombinant human interferon gamma (rIFN-gamma) was observed in a patient with rheumatoid arthritis.|systemic lupus erythematosus|19|47|rIFN-gamma|122|132
1765991|We assume that rIFN-gamma induced the de novo development of SLE in our patient.|SLE|61|64|rIFN-gamma|15|25
17660778|Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour.|osteochemonecrosis of the jaw|23|52|Bisphosphonate|0|14
17665812|Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.|eosinophilia|18|30|Clozapine|0|9
17665812|Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.|eosinophilia|13|25|clozapine|65|74
17665812|Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.|agranulocytosis|113|128|clozapine|49|58
17667216|Metformin-associated lactic acidosis (MALA) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure.|lactic acidosis|21|36|metformin|103|112
17667216|Metformin-associated lactic acidosis (MALA) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure.|lactic acidosis|21|36|Metformin|0|9
17667216|Metformin-associated lactic acidosis precipitated by diarrhea.|lactic acidosis|21|36|Metformin|0|9
17671884|An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia.|red blood cell anemia|120|141|MMF|49|52
17671884|An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia.|red blood cell anemia|120|141|prednisone|58|68
17671884|Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone.|Red blood cell anemia|0|21|mycophenolate mofetil|81|102
17671884|Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone.|Red blood cell anemia|0|21|prednisone|107|117
17671884|The dermatology literature heretofore has not noted that anemia is a side effect of patients taking MMF to treat pemphigus.|anemia|57|63|MMF|100|103
17671884|This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.|anemia|26|32|cyclosporine|203|215
17671884|This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.|anemia|26|32|MMF|50|53
17671884|This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.|anemia|26|32|MMF|198|201
17671884|This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.|anemia|26|32|prednisone|91|101
17671884|This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.|anemia|26|32|prednisone|220|230
17675030|A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of oxcarbazepine-associated angioedema in pediatric patients aged 16 years and younger.|angioedema|142|152|oxcarbazepine|117|130
17675030|Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review.|angioneurotic edema|42|61|oxcarbazepine|20|33
17675030|Oxcarbazepine-associated angioedema manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing (or both) is a rare but potentially life-threatening reaction for which early recognition and management are vital.|angioedema|25|35|Oxcarbazepine|0|13
17675030|We describe in detail the first U.S. case report, of a 4(1/2)-year-old boy who experienced angioedema during treatment with oxcarbazepine.|angioedema|91|101|oxcarbazepine|124|137
17697264|Here we describe another case of VOD occurring after LT, but in which the causative role was played by azathioprine.|VOD|33|36|azathioprine|103|115
17697264|One case of tacrolimus-induced hepatic VOD developing after lung transplantation (LT) has been recently reported.|hepatic VOD|31|42|tacrolimus|12|22
17705565|Carbamazepine hypersensitivity syndrome is a rare, life-threatening condition.|hypersensitivity syndrome|14|39|Carbamazepine|0|13
17710018|A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide.|pulmonary toxicity|70|88|etoposide|115|124
17710018|Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.|pulmonary toxicity|26|44|etoposide|8|17
17710018|PET scintigraphy of etoposide-induced pulmonary toxicity.|pulmonary toxicity|38|56|etoposide|20|29
1772299|Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome.|eosinophilia-myalgia syndrome|88|117|L-tryptophan|67|79
1772299|The Center for Disease Control has received numerous reports of an eosinophilia-myalgia syndrome related to products containing L-tryptophan.|eosinophilia-myalgia syndrome|67|96|L-tryptophan|128|140
17725438|Here, we report a case of RFP-induced hypothyroidism without underlying thyroid disease.|hypothyroidism|38|52|RFP|26|29
17725438|Rifampin-induced hypothyroidism without underlying thyroid disease.|hypothyroidism|17|31|Rifampin|0|8
17725438|Rifampin (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with Hashimoto's thyroiditis.|Hashimoto's thyroiditis|139|162|RFP|10|13
17725438|Rifampin (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with Hashimoto's thyroiditis.|Hashimoto's thyroiditis|139|162|Rifampin|0|8
17725438|Rifampin (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with Hashimoto's thyroiditis.|hypothyroidism|103|117|RFP|10|13
17725438|Rifampin (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with Hashimoto's thyroiditis.|hypothyroidism|103|117|Rifampin|0|8
1775411|A patient is described who developed a rapid onset of pulmonary fibrosis following treatment with a new non-steroidal anti-inflammatory drug, nabumetone.|pulmonary fibrosis|54|72|nabumetone|142|152
1775411|Pulmonary fibrosis associated with nabumetone.|Pulmonary fibrosis|0|18|nabumetone|35|45
17763133|Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.|rhabdomyolysis|111|125|Cyclosporine|0|12
17763133|Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced rhabdomyolysis.|rhabdomyolysis|111|125|simvastatin|91|102
17763133|Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.|rhabdomyolysis|74|88|cyclosporine|35|47
17763133|Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function.|rhabdomyolysis|74|88|simvastatin|19|30
17763133|Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.|rhabdomyolysis|20|34|cyclosporine|45|57
17763133|Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis.|rhabdomyolysis|20|34|Simvastatin|0|11
17823522|Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.|Generalized lichen nitidus|0|26|interferon alpha|67|83
17823522|Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.|generalized lichen nitidus|30|56|interferon alpha|147|163
17823522|Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.|generalized lichen nitidus|30|56|ribavirin|168|177
17823522|It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.|lichen nitidus|89|103|interferon alpha|33|49
17827517|Sirolimus-eluting stent thrombosis several years after clopidogrel discontinuation.|Sirolimus-eluting stent thrombosis|0|34|clopidogrel|55|66
17852449|Treatment of APL in pregnancy is controversial as the use of ATRA has been questioned due to the teratogenic effect of retinoids.|teratogenic effect|97|115|ATRA|61|65
17873198|Interstitial lung disease (ILD) related to therapy with the drug gefitinib has been well reported.|ILD|27|30|gefitinib|65|74
17873198|Interstitial lung disease (ILD) related to therapy with the drug gefitinib has been well reported.|Interstitial lung disease|0|25|gefitinib|65|74
17873198|Pulmonary toxicity associated with erlotinib.|Pulmonary toxicity|0|18|erlotinib|35|44
17873198|Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity.|pulmonary fibrosis|126|144|erlotinib|175|184
17873198|Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity.|pulmonary toxicity|185|203|erlotinib|175|184
17873198|This case and other published evidence should alert physicians to the possibility of fatal erlotinib-induced ILD.|ILD|109|112|erlotinib|91|100
17873198|We report a case of fatal pulmonary toxicity in a patient with advanced non-small cell lung cancer who received erlotinib.|fatal pulmonary toxicity|20|44|erlotinib|112|121
17876386|It has been reported that fluoroquinolone antimicrobials prolong the corrected QT interval but rarely cause torsade de pointes.|torsade de pointes|108|126|fluoroquinolone|26|41
17876386|Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.|Torsade de pointes|0|18|moxifloxacin|35|47
17880357|AIM: To report three cases of extensive skin necrosis in cirrhotic patients treated with the vasoconstrictor agent terlipressin (Glypressin).|skin necrosis|40|53|Glypressin|129|139
17880357|AIM: To report three cases of extensive skin necrosis in cirrhotic patients treated with the vasoconstrictor agent terlipressin (Glypressin).|skin necrosis|40|53|terlipressin|115|127
17921794|Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.|myopathy|58|66|colchicine|5|15
17921794|Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.|myopathy|58|66|statin|20|26
17921794|Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.|muscle weakness|15|30|colchicine|100|110
17921794|Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.|muscle weakness|15|30|simvastatin|84|95
17921794|Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.|rhabdomyolysis|32|46|colchicine|100|110
17921794|Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.|rhabdomyolysis|32|46|simvastatin|84|95
17921794|The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.|muscle weakness|99|114|colchicine|33|43
17921794|The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.|muscle weakness|99|114|statin|48|54
17921794|We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.|acute weakness|130|144|colchicine|194|204
17921794|We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.|acute weakness|130|144|simvastatin|88|99
17921794|We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.|mild chronic renal insufficiency|35|67|simvastatin|88|99
1792646|Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma.|Pneumocystis carinii pneumonia|0|30|methotrexate|52|64
1792646|Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, pulmonary infiltrates, and hypoxia.|fever|103|108|methotrexate|73|85
1792646|Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, pulmonary infiltrates, and hypoxia.|hypoxia|137|144|methotrexate|73|85
1792646|Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, pulmonary infiltrates, and hypoxia.|Pneumocystis pneumonia|0|22|methotrexate|73|85
1792646|Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever, pulmonary infiltrates, and hypoxia.|pulmonary infiltrates|110|131|methotrexate|73|85
17931455|CASE REPORT: A six-year-old boy with transfusion-dependent beta-thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy.|unilateral hearing loss|89|112|desferrioxamine|138|153
17937473|Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).|abdominal sepsis|209|225|leflunomide|75|86
17937473|Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).|cellulitis|138|148|leflunomide|75|86
17937473|Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).|disseminated herpes zoster|154|180|leflunomide|75|86
17937473|Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).|gastroenteritis|256|271|leflunomide|75|86
17937473|Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).|infection|26|35|leflunomide|75|86
17937473|Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).|lower respiratory tract infections|98|132|leflunomide|75|86
17937473|Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).|mycotic aneurysm|231|247|leflunomide|75|86
17937473|Eleven patients developed infection requiring hospitalization while taking leflunomide including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).|TB liver|195|203|leflunomide|75|86
17937473|Leflunomide-associated infections in rheumatoid arthritis.|infections|23|33|Leflunomide|0|11
17937473|The NZ Pharmacovigilance Centre has received 7 additional reports of severe infections in patients with RA taking leflunomide.|severe infections|69|86|leflunomide|114|125
17952482|A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.|fever|61|66|sulfasalazine|151|164
17952482|A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.|leukocytopenia|84|98|sulfasalazine|151|164
17952482|A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.|skin eruptions|68|82|sulfasalazine|151|164
17952482|A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with sulfasalazine.|thrombocytopenia|104|120|sulfasalazine|151|164
17952482|Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.|hemophagocytic syndrome|52|75|Sulfasalazine|0|13
17952482|Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.|hypersensitivity syndrome|22|47|Sulfasalazine|0|13
17952482|This case illustrates that the hemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking sulfasalazine.|hemophagocytic syndrome|31|54|sulfasalazine|166|179
17955169|The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into status migrainosus after the introduction of oxcarbazepine (OXC), as part of a switch off from carbamazepine (CBZ).|status migrainosus|128|146|carbamazepine|223|236
17955169|The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into status migrainosus after the introduction of oxcarbazepine (OXC), as part of a switch off from carbamazepine (CBZ).|status migrainosus|128|146|CBZ|238|241
17955169|The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into status migrainosus after the introduction of oxcarbazepine (OXC), as part of a switch off from carbamazepine (CBZ).|status migrainosus|128|146|OXC|188|191
17955169|The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into status migrainosus after the introduction of oxcarbazepine (OXC), as part of a switch off from carbamazepine (CBZ).|status migrainosus|128|146|oxcarbazepine|173|186
17955169|Uncontrolled headache induced by oxcarbazepine.|headache|13|21|oxcarbazepine|33|46
17959575|CONCLUSION: A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v. infusion.|myoclonic muscle spasms|50|73|dobutamine|90|100
17959575|Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease.|Myoclonus|0|9|dobutamine|37|47
17959575|PURPOSE: The occurrence of myoclonus associated with continuous i.v. infusion of dobutamine in a patient with end-stage renal disease (ESRD) is described.|myoclonus|27|36|dobutamine|81|91
17965530|Reports of colonic perforation as a result of the administration of calcium polystyrene sulfonate and sorbitol are rare.|colonic perforation|11|30|calcium polystyrene sulfonate|68|97
17965530|Reports of colonic perforation as a result of the administration of calcium polystyrene sulfonate and sorbitol are rare.|colonic perforation|11|30|sorbitol|102|110
17965530|We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol.|colonic ulcer|22|35|calcium polystyrene sulfonate|109|138
17965530|We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol.|colonic ulcer|22|35|sorbitol|143|151
17965530|We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol.|sigmoidovesical fistula|44|67|calcium polystyrene sulfonate|109|138
17965530|We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol.|sigmoidovesical fistula|44|67|sorbitol|143|151
17968817|Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz.|Psychosis|0|9|efavirenz|86|95
17968817|We report (to our knowledge, for the first time in a child) the emergence of psychosis in a 12-year old white girl with an increased efavirenz concentration and heterozygous gene polymorphism of the CYP2B6-G516T.|psychosis|77|86|efavirenz|133|142
17983451|Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab.|Mycobacterium marinum infection|0|31|infliximab|75|85
18006091|Sustained monomorphic ventricular tachycardia after adenosine infusion.|Sustained monomorphic ventricular tachycardia|0|45|adenosine|52|61
18006091|We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion.|sustained monomorphic ventricular tachycardia|23|68|adenosine|79|88
18020545|Surprisingly, we found that three patients appeared to develop tardive OGC while taking clozapine.|tardive OGC|63|74|clozapine|88|97
18020545|Tardive oculogyric crisis during treatment with clozapine: report of three cases.|Tardive oculogyric crisis|0|25|clozapine|48|57
180258|Metronidazole neuropathy.|neuropathy|14|24|Metronidazole|0|13
180258|Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively.|sensory neuropathy|41|59|metronidazole|98|111
18034202|We report a case of a patient with rheumatoid arthritis treated with low-dose methotrexate (15 mg/week) who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip.|infection with both M. tuberculosis and M. chelonae|118|169|methotrexate|78|90
18037876|DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.|Sustained ventricular tachycardia|11|44|thalidomide|63|74
18037876|Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.|Multiple syncopal episodes|0|26|thalidomide|51|62
18037876|Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.|sustained ventricular tachycardia|155|188|thalidomide|51|62
18037876|Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.|Sustained ventricular tachycardia|0|33|thalidomide|39|50
18042092|A patient developed typical ECM after subcutaneous selfinjection of glatiramer acetate for multiple sclerosis.|ECM|28|31|glatiramer acetate|68|86
18042092|Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.|Embolia cutis medicamentosa|0|27|glatiramer acetate|64|82
18042092|This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.|skin necrosis|193|206|glatiramer acetate|163|181
18067642|Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case, it is reasonable to presume that this histopathology is associated with amiodarone-induced hypothyroidism and that involution changes represent the hypofunctional status of this drug-induced disorder.|hypothyroidism|194|208|amiodarone|175|185
18067642|Amiodarone is well recognized as an anti-arrhythmic drug containing a high dose of iodine with considerable potential to cause thyroid dysfunction.|thyroid dysfunction|127|146|Amiodarone|0|10
18067642|Histopathology of the thyroid in amiodarone-induced hypothyroidism.|hypothyroidism|52|66|amiodarone|33|43
18067642|This is the first report on the histopathological findings of thyroid tissue from a patient with amiodarone-induced hypothyroidism.|hypothyroidism|116|130|amiodarone|97|107
18071101|Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.|leucocytopenia|77|91|quetiapine|118|128
18071101|Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.|thrombocytopenia|96|112|quetiapine|118|128
18071101|Quetiapine-induced leucopenia and thrombocytopenia.|leucopenia|19|29|Quetiapine|0|10
18071101|Quetiapine-induced leucopenia and thrombocytopenia.|thrombocytopenia|34|50|Quetiapine|0|10
18076602|Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.|cutaneous leucocytoclastic vasculitis|23|60|Amphotericin B|0|14
18076602|Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.|Palpable purpuric skin lesions|0|30|amphotericin B|96|110
18076602|We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.|cutaneous leucocytoclastic vasculitis|21|58|amphotericin B|68|82
18079582|The incidence of 5-fluorouracil (5-FU)-related cardiotoxicity seems to be dosage and schedule dependent.|cardiotoxicity|47|61|5-fluorouracil|17|31
18079582|The incidence of 5-fluorouracil (5-FU)-related cardiotoxicity seems to be dosage and schedule dependent.|cardiotoxicity|47|61|5-FU|33|37
18079582|Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil.|Transient asymptomatic bradycardia|0|34|5-fluorouracil|61|75
18079582|We report such a series of patients who had transient asymptomatic bradycardia after being treated with continuous infusion 5-FU.|transient asymptomatic bradycardia|44|78|5-FU|124|128
18094347|According to the Naranjo probability scale, the papular eruption was probably caused by methotrexate.|papular eruption|48|64|methotrexate|88|100
18094347|CONCLUSIONS: The pathogenesis of methotrexate-induced papular eruption in collagen vascular diseases may suggest cutaneous small-vessel vasculitis.|papular eruption|54|70|methotrexate|33|45
18094347|DISCUSSION: Methotrexate-induced papular eruption is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases.|papular eruption|33|49|Methotrexate|12|24
18094347|Methotrexate-induced papular eruption following treatment of psoriasis has not been previously reported.|papular eruption|21|37|Methotrexate|0|12
18094347|Methotrexate-induced papular eruption following treatment of psoriasis.|papular eruption|21|37|Methotrexate|0|12
18094347|OBJECTIVE: To report a case of a diffuse papular eruption following treatment of psoriasis with methotrexate injections.|diffuse papular eruption|33|57|methotrexate|96|108
18094347|Pathogenesis of methotrexate-induced papular eruption in psoriasis may involve immune mechanisms other than those of methotrexate-induced cutaneous vasculitis in collagen vascular disease.|cutaneous vasculitis|138|158|methotrexate|117|129
18094347|Pathogenesis of methotrexate-induced papular eruption in psoriasis may involve immune mechanisms other than those of methotrexate-induced cutaneous vasculitis in collagen vascular disease.|papular eruption|37|53|methotrexate|16|28
18094347|Ten hours after the second methotrexate injection, the patient experienced a diffuse pruritic papular eruption located mainly on the limbs.|diffuse pruritic papular eruption|77|110|methotrexate|27|39
1814986|Metabolic acidosis induced by acetazolamide.|Metabolic acidosis|0|18|acetazolamide|30|43
18160579|Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.|Pericardial hemorrhage|0|22|acetylsalicylic acid|30|50
18160579|The authors describe pericardial hemorrhage, which is related to the use of low-dose acetylsalicylic acid in a patient with essential thrombocythemia.|pericardial hemorrhage|21|43|acetylsalicylic acid|85|105
18176653|From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss).|cutaneous rash|128|142|nelfinavir|116|126
18176653|From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss).|fever|108|113|indinavir|81|90
18176653|From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss).|nausea|160|166|efavirenz|149|158
18176653|From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss).|renal colic|92|103|indinavir|81|90
18176653|From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss).|temporary memory loss|171|192|efavirenz|149|158
18191947|Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity.|sub-acute neurotoxicity|73|96|methotrexate|52|64
18191947|This case demonstrates the value of DWI in evaluation and diagnosis of sub-acute toxic leukoencephalopathy in patients being treated with methotrexate.|sub-acute toxic leukoencephalopathy|71|106|methotrexate|138|150
18191947|We describe longitudinal diffusion-weighted MRI findings of sub-acute leukoencephalopathy following methotrexate therapy in a 24-year-old man diagnosed with pre-B-cell acute lymphoblastic leukemia (ALL), presenting with right-sided paralysis and aphasia after second consolidation with intrathecal triple-drug therapy given intrathecally.|sub-acute leukoencephalopathy|60|89|methotrexate|100|112
18203308|New onset of CD may be considered as an immune-mediated injury induced by etanercept.|CD|13|15|etanercept|74|84
18203308|New onset of CD may be considered as an immune-mediated injury induced by etanercept.|immune-mediated injury|40|62|etanercept|74|84
18203308|New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.|Crohn's disease|13|28|etanercept|84|94
18203308|Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.|CD|27|29|etanercept|76|86
18203308|We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.|CD|91|93|etanercept|39|49
18252776|Upper gastrointestinal haemorrhage is a serious complication of aspirin and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality.|Upper gastrointestinal haemorrhage|0|34|aspirin|64|71
18252776|Upper gastrointestinal haemorrhage is a serious complication of aspirin and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality.|Upper gastrointestinal haemorrhage|0|34|clopidogrel|76|87
18258513|While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.|breathing distress|76|94|doxorubicin|6|17
18258513|While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.|thoracic pain|58|71|doxorubicin|6|17
1827039|Severe hepatocellular dysfunction following cyproterone acetate therapy.|Severe hepatocellular dysfunction|0|33|cyproterone acetate|44|63
1827039|We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.|fatal fulminant hepatitis|82|107|CPA|62|65
1827039|We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.|severe hepatocellular damage|26|54|CPA|62|65
18277922|She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.|VZV antigen-positive zoster|58|85|acyclovir|21|30
18294121|According to the Naranjo adverse drug reaction probability scale, the likelihood that temozolomide was responsible for the adverse drug reaction of fever was probable (score of 6).|fever|148|153|temozolomide|86|98
18294121|Clinicians should be aware that an erythematous and exfoliative rash may be induced by temozolomide, and be familiar with the pharmacologic and supportive measures necessary for its treatment.|exfoliative rash|52|68|temozolomide|87|99
18294121|Due to the severity of the rash, temozolomide was permanently discontinued.|rash|27|31|temozolomide|33|45
18294121|Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.|desquamative skin rash|21|43|Temozolomide|0|12
18294121|Temozolomide was restarted 2 months later; the patient again developed a fever.|fever|73|78|Temozolomide|0|12
1829999|Exfoliative dermatitis secondary to tobramycin sulfate.|Exfoliative dermatitis|0|22|tobramycin sulfate|36|54
1829999|We report a case of exfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of tobramycin.|exfoliative dermatitis|20|42|tobramycin|111|121
18306483|Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.|interstitial pneumonitis|23|47|Rituximab-CHOP|0|14
18315788|Phenytoin toxicity: an easily missed cause of cerebellar syndrome.|cerebellar syndrome|46|65|Phenytoin|0|9
18343993|A diagnosis of trastuzumab-induced pneumonitis was made.|pneumonitis|35|46|trastuzumab|15|26
18343993|A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a plural effusion dyspnoea after several months of trastuzumab treatment.|plural effusion dyspnoea|106|130|trastuzumab|155|166
18343993|A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a plural effusion dyspnoea after several months of trastuzumab treatment.|pulmonary infiltrates|77|98|trastuzumab|155|166
18343993|Life-threatening interstitial lung disease associated with trastuzumab: case report.|interstitial lung disease|17|42|trastuzumab|59|70
1834424|A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).|acute allergic contact dermatitis|39|72|4-chloro-7-nitrobenzofurazan|80|108
1834424|A 30-year-old pharmacist suffered from acute allergic contact dermatitis due to 4-chloro-7-nitrobenzofurazan (NBD-Cl).|acute allergic contact dermatitis|39|72|NBD-Cl|110|116
1834424|Allergic contact dermatitis from 4-chloro-7-nitrobenzofurazan.|Allergic contact dermatitis|0|27|4-chloro-7-nitrobenzofurazan|33|61
18344734|Photo-onycholysis caused by olanzapine and aripiprazole.|Photo-onycholysis|0|17|aripiprazole|43|55
18344734|Photo-onycholysis caused by olanzapine and aripiprazole.|Photo-onycholysis|0|17|olanzapine|28|38
18344734|We report the case of a woman who developed photo-onycholysis on multiple nails after uptake of olanzapine.|photo-onycholysis|44|61|olanzapine|96|106
18347524|Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.|Diffuse alveolar hemorrhage|0|27|leflunomide|34|45
18347524|We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.|hemoptysis|113|123|leflunomide|188|199
18347524|We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.|severe weakness|129|144|leflunomide|188|199
18347524|We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.|short-of-breath|96|111|leflunomide|188|199
18354950|Hyponatraemia developed after rechallenge with controlled release carbamazepine.|Hyponatraemia|0|13|carbamazepine|66|79
18354950|Hyponatraemia during low-dose carbamazepine therapy.|Hyponatraemia|0|13|carbamazepine|30|43
18354950|We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.|antidiuresis|40|52|carbamazepine|86|99
18359591|In the present paper, we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine.|severe systemic CMV infection|78|107|cyclosporine|162|174
18362995|A short review on imatinib-related hepatotoxicity is also presented.|hepatotoxicity|35|49|imatinib|18|26
18362995|Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.|fatal acute hepatic failure|26|53|Imatinib mesylate|0|17
18362995|Up to four percent of patients treated with imatinib may develop hepatotoxicity, which usually resolves with discontinuation of the drug.|hepatotoxicity|65|79|imatinib|44|52
18362995|We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on imatinib treatment, presenting with herpetic rash and acute liver failure.|acute liver failure|143|162|imatinib|89|97
18362995|We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on imatinib treatment, presenting with herpetic rash and acute liver failure.|herpetic rash|125|138|imatinib|89|97
18364401|CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.|hyperglycemia|122|135|olanzapine|55|65
18364401|OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.|hyperglycemia|49|62|olanzapine|128|138
18364401|Rapidly developing hyperglycemia during treatment with olanzapine.|hyperglycemia|19|32|olanzapine|55|65
18364401|Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.|hyperglycemia|27|40|olanzapine|94|104
18364401|There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.|hyperglycemia|41|54|olanzapine|60|70
18371508|Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.|Adult respiratory distress syndrome|0|35|pegylated interferon alpha-2a|57|86
18371508|Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.|Adult respiratory distress syndrome|0|35|ribavirin|91|100
18371508|We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.|adult respiratory distress syndrome|38|73|pegIFNalpha-2a|128|142
18371508|We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.|adult respiratory distress syndrome|38|73|pegylated interferon alpha-2a|97|126
18371508|We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.|adult respiratory distress syndrome|38|73|ribavirin|148|157
18371508|We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.|ARDS|75|79|pegIFNalpha-2a|128|142
18371508|We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.|ARDS|75|79|pegylated interferon alpha-2a|97|126
18371508|We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.|ARDS|75|79|ribavirin|148|157
18379937|Bilateral anterior uveitis associated with clomiphene citrate.|Bilateral anterior uveitis|0|26|clomiphene citrate|43|61
18379937|PURPOSE: To report a case of bilateral anterior uveitis associated with ovulation induction therapy using clomiphene citrate.|bilateral anterior uveitis|29|55|clomiphene citrate|106|124
18408649|Development of tics in a thirteen-year-old male following atomoxetine use.|tics|15|19|atomoxetine|58|69
18408649|There are, however, case studies describing patients experiencing recurrences of tics following treatment with atomoxetine.|tics|81|85|atomoxetine|111|122
18421192|A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C.|type 1 diabetes mellitus|28|52|alpha-2b peginterferon|102|124
18421192|A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C.|type 1 diabetes mellitus|28|52|ribavirin|130|139
18421192|The clinical course suggested that recombinant alpha-2b peginterferon plus ribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.|type 1 diabetes mellitus|94|118|recombinant alpha-2b peginterferon|35|69
18421192|The clinical course suggested that recombinant alpha-2b peginterferon plus ribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.|type 1 diabetes mellitus|94|118|ribavirin|75|84
18421192|Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.|Type 1 diabetes mellitus|0|24|peginterferon alpha-2b|37|59
18421192|Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.|Type 1 diabetes mellitus|0|24|ribavirin|65|74
18425523|BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.|ocular hypertension|42|61|ranibizumab|102|113
18425523|CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.|sustained ocular hypertension|23|52|ranibizumab|82|93
18425523|Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.|Ocular hypertension|0|19|ranibizumab|54|65
18425523|Persisent ocular hypertension following intravitreal ranibizumab.|Persisent ocular hypertension|0|29|ranibizumab|53|64
18431096|Methylphenidate and dextroamphetamine-induced peripheral vasculopathy.|peripheral vasculopathy|46|69|dextroamphetamine|20|37
18431096|Methylphenidate and dextroamphetamine-induced peripheral vasculopathy.|peripheral vasculopathy|46|69|Methylphenidate|0|15
18431096|We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon.|acral cyanosis|89|103|dextroamphetamine|52|69
18431096|We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon.|acral cyanosis|89|103|methylphenidate|27|42
18431096|We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon.|livedo reticularis|105|123|dextroamphetamine|52|69
18431096|We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon.|livedo reticularis|105|123|methylphenidate|27|42
18431096|We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon.|Raynaud phenomenon|128|146|dextroamphetamine|52|69
18431096|We report 4 patients, 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or Raynaud phenomenon.|Raynaud phenomenon|128|146|methylphenidate|27|42
18446030|Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy.|Disseminated eruptive giant mollusca contagiosa|0|47|efalizumab|85|95
18446030|We report a 45-year-old psoriasis patient who developed eruptive mollusca contagiosa during an antipsoriatic treatment with efalizumab.|eruptive mollusca contagiosa|56|84|efalizumab|124|134
18459568|Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.|cervical adenocarcinoma|41|64|tamoxifen|108|117
18459568|Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.|endometrial carcinoma|15|36|tamoxifen|108|117
18459568|Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer.|Gastric tumor|0|13|tamoxifen|108|117
18465737|Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema.|Incomplete posterior hyaloid detachment|0|39|pegaptanib|59|69
18465737|The authors report one case of incomplete posterior hyaloid detachment (PHD) following intravitreal pegaptanib to treat DME.|incomplete posterior hyaloid detachment|31|70|pegaptanib|100|110
18472517|Enalaprilat induced acute parotitis.|acute parotitis|20|35|Enalaprilat|0|11
18472517|We present here a female patient who developed acute bilateral parotitis within minutes of i.v. enalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.|acute bilateral parotitis|47|72|enalaprilat|96|107
18476934|We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.|acute bilateral blindness|47|72|oxybutynin|132|142
18476934|We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.|focal seizure|76|89|oxybutynin|132|142
18476934|We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis.|hypertension|94|106|oxybutynin|132|142
18487000|Severe symptomatic hyponatremia during sibutramine therapy: a case report.|Severe symptomatic hyponatremia|0|31|sibutramine|39|50
18487000|The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.|hypertension|43|55|sibutramine|26|37
18487000|The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects.|tachycardia|60|71|sibutramine|26|37
18487000|We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman.|hyponatremia|39|51|sibutramine|68|79
18492617|Our findings reveal that even in patients without a history of seizures, pregabalin can cause a cortical negative myoclonus.|cortical negative myoclonus|96|123|pregabalin|73|83
18492617|Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.|cortical negative myoclonus|19|46|Pregabalin|0|10
18492617|We describe a patient who, after receiving his first dose of pregabalin to relieve neuropathic pain, presented with a negative myoclonus.|negative myoclonus|118|136|pregabalin|61|71
1849334|Muzolimine-induced severe neuromyeloencephalopathy: report of seven cases.|severe neuromyeloencephalopathy|19|50|Muzolimine|0|10
1849334|We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy.|fatal neuromyeloencephalopathy|165|195|muzolimine|123|133
18504683|L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.|posterior reversible encephalopathy|23|58|L-asparaginase|0|14
18504683|The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome (PRES) associated with L-asparaginase treatment.|posterior reversible encephalopathy syndrome|67|111|L-asparaginase|135|149
18504683|The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome (PRES) associated with L-asparaginase treatment.|PRES|113|117|L-asparaginase|135|149
18504683|We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L-asparaginase therapy.|altered sensorium|91|108|L-asparaginase|115|129
18504683|We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L-asparaginase therapy.|seizures|78|86|L-asparaginase|115|129
18515982|Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer.|sclerosing glomerulonephritis|23|52|Anastrozole|0|11
18515982|CONCLUSIONS: Anastrozole may be the causative factor in patients with sclerosing glomerulonephritis.|sclerosing glomerulonephritis|70|99|Anastrozole|13|24
18515982|Diagnosis of sclerosing glomerulonephritis occurred in this patient during anastrozole use, suggesting a newly defined side effect of anastrozole.|sclerosing glomerulonephritis|13|42|anastrozole|75|86
18515982|Renal injury due to anastrozole has not been published in the English literature.|Renal injury|0|12|anastrozole|20|31
18515982|There are major side effects of anastrozole including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level.|decrease in both lumbar spine|54|83|anastrozole|32|43
18515982|There are major side effects of anastrozole including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level.|increase in the cholesterol level|236|269|anastrozole|32|43
18515982|There are major side effects of anastrozole including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level.|increase in the incidence of all bone fractures|120|167|anastrozole|32|43
18515982|There are major side effects of anastrozole including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level.|joint disorders|216|231|anastrozole|32|43
18515982|We believe that the acute renal failure in our patient was associated with anastrozole.|acute renal failure|20|39|anastrozole|75|86
18523232|CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.|acute hepatitis|91|106|itraconazole|168|180
18523232|CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.|severe and irreversible hepatotoxic events|117|159|itraconazole|35|47
18523232|Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.|Fatal hepatitis|0|15|itraconazole|38|50
18523232|OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.|acute cytolytic hepatitis|39|64|itraconazole|95|107
18523232|OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.|hepatitis|209|218|itraconazole|188|200
18523232|Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.|severe symptomatic hepatitis|17|45|itraconazole|81|93
18533420|CONCLUSIONS: Intrathecal baclofen can impair sexual function and ejaculation in some patients.|impair sexual function|38|60|baclofen|25|33
18533420|RESULTS: A male and a female patient with spasticity treated with intrathecal baclofen were recognized to have sexual dysfunction side effects from treatment.|sexual dysfunction|111|129|baclofen|78|86
18533420|Sexual dysfunction associated with intrathecal baclofen use: a report of two cases.|Sexual dysfunction|0|18|baclofen|47|55
18556970|Anaphylactic reaction to recombinant insulin-like growth factor-I.|Anaphylactic reaction|0|21|recombinant insulin-like growth factor-I|25|65
18556970|We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.|anaphylaxis|60|71|Increlex|95|103
18562412|Increasing the olanzapine dosage severely aggravated the symptoms of RLS.|RLS|69|72|olanzapine|15|25
18562412|Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.|periodic limb movements during sleep|27|63|olanzapine|89|99
18562412|Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.|Restless legs syndrome|0|22|olanzapine|89|99
18562412|The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.|agitation|45|54|olanzapine|65|75
18562412|The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation.|paraesthesia|28|40|olanzapine|65|75
18562412|The fourth patient showed RLS symptoms that were initially caused by a 20-mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.|RLS symptoms|26|38|olanzapine|83|93
18562412|The second patient exhibited sudden PLMS following olanzapine injection.|PLMS|36|40|olanzapine|51|61
18562412|The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.|akathisia|50|59|olanzapine|115|125
18562412|The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.|akathisia|50|59|risperidone|69|80
18562412|The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.|RLS|168|171|olanzapine|115|125
18562412|The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.|RLS|168|171|risperidone|69|80
18562412|We report five cases of restless legs syndrome (RLS) and periodic limb movements during sleep (PLMS) that were probably associated with olanzapine.|periodic limb movements during sleep|57|93|olanzapine|136|146
18562412|We report five cases of restless legs syndrome (RLS) and periodic limb movements during sleep (PLMS) that were probably associated with olanzapine.|PLMS|95|99|olanzapine|136|146
18562412|We report five cases of restless legs syndrome (RLS) and periodic limb movements during sleep (PLMS) that were probably associated with olanzapine.|restless legs syndrome|24|46|olanzapine|136|146
18562412|We report five cases of restless legs syndrome (RLS) and periodic limb movements during sleep (PLMS) that were probably associated with olanzapine.|RLS|48|51|olanzapine|136|146
18569796|CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.|nodular scleritis|31|48|Alendronate|12|23
18569796|CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.|scleritis|86|95|Alendronate|12|23
18569796|Nodular scleritis following alendronate therapy.|Nodular scleritis|0|17|alendronate|28|39
18569796|PURPOSE: To report a case of nodular scleritis following alendronate sodium.|nodular scleritis|29|46|alendronate sodium|57|75
18569796|Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.|scleritis|86|95|alendronate sodium|37|55
18580694|In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.|prolonged ECT seizure|34|55|ciprofloxacin|67|80
18580694|Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.|tardive seizures|6|22|cefotiam|82|90
18580694|Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.|tardive seizures|6|22|piperacillin|65|77
18585545|Acute delirium resulting from levofloxacin therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients.|Acute delirium|0|14|levofloxacin|30|42
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|dizziness|271|280|gatifloxacin|101|113
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|dizziness|271|280|grepafloxacin|71|84
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|dizziness|271|280|levofloxacin|43|55
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|dizziness|271|280|moxifloxacin|118|130
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|dizziness|271|280|sparfloxacin|57|69
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|dizziness|271|280|trovafloxacin|86|99
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|headache|261|269|gatifloxacin|101|113
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|headache|261|269|grepafloxacin|71|84
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|headache|261|269|levofloxacin|43|55
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|headache|261|269|moxifloxacin|118|130
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|headache|261|269|sparfloxacin|57|69
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|headache|261|269|trovafloxacin|86|99
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|insomnia|285|293|gatifloxacin|101|113
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|insomnia|285|293|grepafloxacin|71|84
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|insomnia|285|293|levofloxacin|43|55
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|insomnia|285|293|moxifloxacin|118|130
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|insomnia|285|293|sparfloxacin|57|69
18585545|CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia.|insomnia|285|293|trovafloxacin|86|99
18585545|Here, we describe levofloxacin-induced delirium with psychotic features in a relatively young, otherwise healthy female.|delirium with psychotic features|39|71|levofloxacin|18|30
18585545|Levofloxacin-induced delirium with psychotic features.|delirium with psychotic features|21|53|Levofloxacin|0|12
18585545|RESULTS: A previously healthy 42-year-old woman presented with acute-onset delirium with psychotic features as a consequence of levofloxacin therapy.|acute-onset delirium with psychotic features|63|107|levofloxacin|128|140
18607107|CONCLUSIONS: Clinicians should be aware that Crohn's disease is a potential novel adverse drug effect of Copaxone.|Crohn's disease|45|60|Copaxone|105|113
18607107|Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone.|Crohn's disease|15|30|copaxone|81|89
18607107|RESULTS: Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression.|Crohn's disease|31|46|Copaxone|56|64
18607107|RESULTS: Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression.|long-term immunosuppression|95|122|Copaxone|56|64
18607107|She had been on Copaxone 20 mg/day treatment for 2 years when she first exhibited gastrointestinal symptoms.|gastrointestinal symptoms|82|107|Copaxone|16|24
1860779|The authors present a case study of a mentally healthy man who repeatedly experienced short-lived, obsessional-like suicidal ideas and images after ingestion of the anti-fungal drug ketoconazole.|obsessional-like suicidal ideas and images|99|141|ketoconazole|182|194
18609153|During intravenous treatment with terlipressin for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and torsade de pointes.|prolonged QT interval|163|184|terlipressin|34|46
18609153|During intravenous treatment with terlipressin for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and torsade de pointes.|torsade de pointes|189|207|terlipressin|34|46
18609153|Terlipressin-induced ventricular arrhythmia.|ventricular arrhythmia|21|43|Terlipressin|0|12
18622319|Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.|Spontaneous nasal septal perforation|0|36|bevacizumab|57|68
18622319|This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.|spontaneous nasal septal perforation|62|98|bevacizumab|136|147
18628507|A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed angio-oedema 10 days after starting therapy.|angio-oedema|107|119|VRC|89|92
18628507|Angio-oedema as an unusual tolerable side effect of voriconazole therapy.|Angio-oedema|0|12|voriconazole|52|64
18628507|Here, we report a case of angio-oedema associated with VRC therapy.|angio-oedema|26|38|VRC|55|58
18628507|To our knowledge, this is the first report of an angio-oedema associated with VRC.|angio-oedema|49|61|VRC|78|81
18628507|Voriconazole (VRC) has not previously been reported to cause angio-oedema.|angio-oedema|61|73|Voriconazole|0|12
18628507|Voriconazole (VRC) has not previously been reported to cause angio-oedema.|angio-oedema|61|73|VRC|14|17
18633310|Multiple seizures after bupropion overdose in a small child.|Multiple seizures|0|17|bupropion|24|33
18633310|The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release bupropion.|agitation|40|49|bupropion|141|150
18633310|The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release bupropion.|hallucinations|24|38|bupropion|141|150
18633310|The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release bupropion.|seizures|77|85|bupropion|141|150
18633310|The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release bupropion.|tachycardia|61|72|bupropion|141|150
18633310|The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release bupropion.|vomiting|51|59|bupropion|141|150
18633310|We report a case of pediatric bupropion ingestion resulting in multiple seizures.|multiple seizures|63|80|bupropion|30|39
18644535|Methylphenidate-associated enuresis in attention deficit hyperactivity disorder.|enuresis|27|35|Methylphenidate|0|15
18644535|This is a case report of possible association of methylphenidate and enuresis in an 11-year-old boy with attention deficit hyperactivity disorder.|enuresis|69|77|methylphenidate|49|64
18648015|Cephalosporin-induced leukopenia following rechallenge with cefoxitin.|leukopenia|22|32|Cephalosporin|0|13
18648015|CONCLUSIONS: Cefazolin was a probable cause of this patient's leukopenia.|leukopenia|62|72|Cefazolin|13|22
18648015|OBJECTIVE: To describe a case of cefazolin-induced leukopenia in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin.|leukopenia|51|61|cefazolin|33|42
18648015|Use of the Naranjo probability scale determined the association between cephalosporin use and leukopenia to be probable.|leukopenia|94|104|cephalosporin|72|85
18661248|Posterior reversible encephalopathy syndrome (PRES) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis.|cyclosporine|63|75|PRES|46|50
18661248|Posterior reversible encephalopathy syndrome (PRES) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis.|Posterior reversible encephalopathy syndrome|0|44|PRES|46|50
18661248|We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).|PRES|22|26|CSA|156|159
18661248|We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).|PRES|22|26|cyclosporine|142|154
18665833|Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency.|Stuttering priapism|0|19|warfarin|33|41
18665833|This therapy was also complicated by Warfarin-induced skin necrosis.|skin necrosis|54|67|Warfarin|37|45
18665833|We report a rare case of recurrent (stuttering) priapism in a patient with protein C deficiency while maintained on Warfarin therapy.|priapism|48|56|Warfarin|116|124
18665833|We report a rare case of recurrent (stuttering) priapism in a patient with protein C deficiency while maintained on Warfarin therapy.|stuttering|36|46|Warfarin|116|124
18672645|The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.|pulmonary fibrosis|82|100|bleomycin|126|135
18675768|CASE SUMMARY: An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.|mild cognitive impairment|80|105|propafenone|123|134
18675768|CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.|coronary artery disease|177|200|citalopram|88|98
18675768|CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.|coronary artery disease|177|200|propafenone|72|83
18675768|CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.|dizziness|146|155|citalopram|88|98
18675768|CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.|dizziness|146|155|propafenone|72|83
18675768|CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.|falls|157|162|citalopram|88|98
18675768|CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.|falls|157|162|propafenone|72|83
18675768|Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.|chest tightness|68|83|citalopram|28|38
18675768|Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.|dizziness|88|97|citalopram|28|38
18682542|CONCLUSIONS: Clinicians should be aware of this adverse reaction when facing similar complex neurologic symptoms in patients who are receiving the antibiotic treatment described here, especially vancomycin.|neurologic symptoms|93|112|vancomycin|195|205
18682542|DISCUSSION: To our knowledge, this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin/tazobactam.|neuralgic amyotrophy|73|93|piperacillin|163|175
18682542|DISCUSSION: To our knowledge, this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin/tazobactam.|neuralgic amyotrophy|73|93|tazobactam|176|186
18682542|DISCUSSION: To our knowledge, this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin/tazobactam.|neuralgic amyotrophy|73|93|tobramycin|147|157
18682542|DISCUSSION: To our knowledge, this is the first case report illustrating neuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin/tazobactam.|neuralgic amyotrophy|73|93|vancomycin|135|145
1868481|Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.|Seizures|0|8|methylprednisolone|61|79
1868481|Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.|transient blindness|13|32|methylprednisolone|61|79
1868481|Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.|seizures|126|134|methylprednisolone|195|213
1868481|Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.|transient blindness|139|158|methylprednisolone|195|213
18691992|BACKGROUND: Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation.|mucocutaneous adverse events|132|160|Hydroxyurea|12|23
18691992|BACKGROUND: Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation.|nail hyperpigmentation|165|187|Hydroxyurea|12|23
18691992|Based on the Naranjo algorithm, the adverse reaction observed was probably related to the hydroxyurea treatment (score = 6); however, the hydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder.|myeloproliferative disorder|204|231|hydroxyurea|138|149
18691992|Both the longitudinal melanonychia and the multiple skin cancers first appeared after approximately 6 months of hydroxyurea treatment.|longitudinal melanonychia|9|34|hydroxyurea|112|123
18691992|Both the longitudinal melanonychia and the multiple skin cancers first appeared after approximately 6 months of hydroxyurea treatment.|multiple skin cancers|43|64|hydroxyurea|112|123
18691992|CONCLUSIONS: We report this case of the concomitant appearance of multiple skin cancers and nail changes associated with hydroxyurea use.|multiple skin cancers|66|87|hydroxyurea|121|132
18691992|CONCLUSIONS: We report this case of the concomitant appearance of multiple skin cancers and nail changes associated with hydroxyurea use.|nail changes|92|104|hydroxyurea|121|132
18691992|Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject.|diffuse longitudinal melanonychia|54|87|Hydroxyurea|0|11
18691992|Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject.|multiple squamous cell carcinomas|92|125|Hydroxyurea|0|11
18691992|OBJECTIVE: The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and diffuse nail hyperpigmentation associated with hydroxyurea treatment, and to describe a successful therapeutic approach using imiquimod 5%.|diffuse nail hyperpigmentation|119|149|hydroxyurea|166|177
18691992|OBJECTIVE: The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and diffuse nail hyperpigmentation associated with hydroxyurea treatment, and to describe a successful therapeutic approach using imiquimod 5%.|multiple squamous cell carcinomas|81|114|hydroxyurea|166|177
18691992|The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a painful hand ulcer, possibly associated with the hydroxyurea, and new skin cancers were observed at the last follow-up visit.|painful hand ulcer|137|155|hydroxyurea|186|197
18691992|The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a painful hand ulcer, possibly associated with the hydroxyurea, and new skin cancers were observed at the last follow-up visit.|skin cancers|207|219|hydroxyurea|186|197
18698687|It is the first case of ciprofloxacin-induced VBDS successfully treated with tacrolimus.|VBDS|46|50|ciprofloxacin|24|37
18698687|Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.|Stevens-Johnson syndrome|24|48|ciprofloxacin|65|78
18698687|Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.|Vanishing bile duct|0|19|ciprofloxacin|65|78
18698687|We report a case of a patient with ciprofloxacin-induced SJS and acute onset of VBDS, and reviewed the related literature.|SJS|57|60|ciprofloxacin|35|48
18698687|We report a case of a patient with ciprofloxacin-induced SJS and acute onset of VBDS, and reviewed the related literature.|VBDS|80|84|ciprofloxacin|35|48
18707772|A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving aspirin and clopidogrel.|intracranial bleeding|116|137|aspirin|154|161
18707772|A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving aspirin and clopidogrel.|intracranial bleeding|116|137|clopidogrel|166|177
18715650|Disseminated salmonellosis in a patient treated with temozolomide.|Disseminated salmonellosis|0|26|temozolomide|53|65
18715650|We describe the first case of disseminated salmonellosis in a patient treated with temozolomide.|disseminated salmonellosis|30|56|temozolomide|83|95
18717612|Ceftriaxone-induced fixed drug eruption: first report.|fixed drug eruption|20|39|Ceftriaxone|0|11
18717612|FDE from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone-induced FDE in the literature.|FDE|0|3|cephalosporins|9|23
18717612|FDE from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone-induced FDE in the literature.|FDE|135|138|ceftriaxone|115|126
18717612|We report the first case of a 54-year-old Turkish woman who presented with ceftriaxone-induced FDE.|FDE|95|98|ceftriaxone|75|86
18721173|CONCLUSION: All doctors need to be aware of the need to review the indications for gabapentin use during periods of acute illness, especially with regard to renal impairment.|renal impairment|157|173|gabapentin|83|93
18721173|Gabapentin toxicity in renal failure: the importance of dose adjustment.|renal failure|23|36|Gabapentin|0|10
18721173|OBJECTIVE: This case report outlines a significant type of morbidity due to continued use of gabapentin during an episode of acute renal failure.|acute renal failure|125|144|gabapentin|93|103
18751717|Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.|Acute syphilitic posterior placoid chorioretinitis|0|50|triamcinolone acetonide|74|97
18751717|BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.|acute syphilitic posterior placoid chorioretinitis|84|134|IVTA|202|206
18751717|BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.|acute syphilitic posterior placoid chorioretinitis|84|134|triamcinolone acetonide|177|200
18751717|BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.|ASPPC|136|141|IVTA|202|206
18751717|BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.|ASPPC|136|141|triamcinolone acetonide|177|200
18751717|CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.|ASPPC|71|76|IVTA|83|87
18751717|RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.|severe chorioretinitis|75|97|IVTA|104|108
18755414|Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.|intratumoral hemorrhage|45|68|aspirin|72|79
18755414|Hemorrhage from a falx meningioma after internal use of low-dose aspirin.|Hemorrhage|0|10|aspirin|65|72
18755414|On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.|enlargement of spontaneous hemorrhage|49|86|aspirin|19|26
18755414|Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.|hemorrhage|36|46|aspirin|90|97
18755414|We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.|hemorrhage|26|36|aspirin|134|141
18765315|Acute coronary syndromes can be associated with the infusion of rituximab.|Acute coronary syndromes|0|24|rituximab|64|73
18765315|Acute coronary syndromes complicating the first infusion of rituximab.|Acute coronary syndromes|0|24|rituximab|60|69
18765315|The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions.|acute coronary syndromes|56|80|rituximab|95|104
18765315|The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively.|acute coronary syndrome|56|79|rituximab|130|139
18765315|We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab.|acute coronary syndromes|89|113|rituximab|156|165
18775393|CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.|laryngeal hematoma|181|199|acenocoumarol|107|120
18775393|CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient.|laryngeal hematoma|181|199|econazole|83|92
18775393|Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.|Laryngeal dyspnea|0|17|acenocoumarol|56|69
18775393|Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.|Laryngeal dyspnea|0|17|econazole|82|91
18784429|Adrenal suppression in a fetus due to administration of methylprednisolone has hitherto been rarely published.|Adrenal suppression in a fetus|0|30|methylprednisolone|56|74
18784429|CONCLUSIONS: Life-threatening adrenal suppression, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high-dose methylprednisolone in late pregnancy.|adrenal suppression|30|49|methylprednisolone|203|221
18784429|High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn.|adrenal suppression|74|93|methylprednisolone|10|28
18795|A 10-year-old asthmatic boy began to suffer from urticarial rash and moderately severe bronchospasm after 8 weeks' treatment with disodium cromoglycate.|moderately severe bronchospasm|69|99|disodium cromoglycate|130|151
18795|A 10-year-old asthmatic boy began to suffer from urticarial rash and moderately severe bronchospasm after 8 weeks' treatment with disodium cromoglycate.|urticarial rash|49|64|disodium cromoglycate|130|151
18795|Asthma and urticaria during disodium cromoglycate treatment.|Asthma|0|6|disodium cromoglycate|28|49
18795|Asthma and urticaria during disodium cromoglycate treatment.|urticaria|11|20|disodium cromoglycate|28|49
18795|When DSCG was withdrawn, urticaria vanished and the child remained symptom-free.|urticaria|25|34|DSCG|5|9
1879988|After the first oral dose of propranolol, syncope developed together with atrioventricular block.|atrioventricular block|74|96|propranolol|29|40
1879988|After the first oral dose of propranolol, syncope developed together with atrioventricular block.|syncope|42|49|propranolol|29|40
1879988|Syncope induced by propranolol in hypertrophic cardiomyopathy.|Syncope|0|7|propranolol|19|30
18801826|Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.|hyperglycaemic coma|19|38|Olanzapine|0|10
18801826|Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.|neuroleptic malignant syndrome|43|73|Olanzapine|0|10
18805724|DISCUSSION: The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.|allergic skin reactions|133|156|leflunomide|40|51
18805724|DISCUSSION: The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.|alopecia|119|127|leflunomide|40|51
18805724|DISCUSSION: The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.|diarrhea|63|71|leflunomide|40|51
18805724|DISCUSSION: The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.|hypertension|105|117|leflunomide|40|51
18805724|DISCUSSION: The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.|liver enzyme elevation|81|103|leflunomide|40|51
18805724|DISCUSSION: The main adverse effects of leflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.|nausea|73|79|leflunomide|40|51
18805724|Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis.|toxic epidermal necrolysis|20|46|Leflunomide|0|11
18810448|In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment.|mediastinal lymphadenopathy|136|163|Etanercept|217|227
18810448|In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment.|pleurisy|168|176|Etanercept|217|227
18810448|In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment.|thymic enlargement|90|108|Etanercept|217|227
18810448|In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment.|thymic hyperplasia|115|133|Etanercept|217|227
18810448|Thymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy.|Thymic enlargement|0|18|etanercept|74|84
18821094|Oxcarbazepine-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).|DRESS|77|82|Oxcarbazepine|0|13
18821094|Oxcarbazepine-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).|Drug Reaction with Eosinophilia and Systemic Symptoms|22|75|Oxcarbazepine|0|13
18821094|This is an image and brief case report of a 13-year-old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine.|severe rash|79|90|oxcarbazepine|128|141
18836269|After treatment with a beta-sympathomimetic drug (Partusisten) one fetus developed supraventricular tachycardia.|supraventricular tachycardia|83|111|Partusisten|50|61
18837734|Rosaceiform eruption induced by erlotinib.|Rosaceiform eruption|0|20|erlotinib|32|41
18837734|The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.|rosaceiform eruption|47|67|erlotinib|79|88
18855892|In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.|anaphylaxis|38|49|methotrexate|17|29
18855892|Management and successful desensitization in methotrexate-induced anaphylaxis.|anaphylaxis|66|77|methotrexate|45|57
18855892|Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.|anaphylaxis|122|133|methotrexate|101|113
18855892|We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.|anaphylactic/anaphylactoid reaction|79|114|methotrexate|118|130
1888256|Drug-induced fever due to diltiazem.|fever|13|18|diltiazem|26|35
1888256|Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.|fever|13|18|diltiazem|98|107
1888256|To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.|fever|31|36|diltiazem hydrochloride|75|98
189279|A case of congestive heart failure in a child with Wilms' tumor treated Adriamycin is presented and discussed.|congestive heart failure|10|34|Adriamycin|72|82
189279|Radiologic recognition of adriamycin cardiotoxicity.|cardiotoxicity|37|51|adriamycin|26|36
189279|The role of Adriamycin in the production of cardiotoxicity is reviewed.|cardiotoxicity|44|58|Adriamycin|12|22
1893404|Carbamazepine-induced Diabetes mellitus.|Diabetes mellitus|22|39|Carbamazepine|0|13
1893404|Diabetes Mellitus was observed in a patient given carbamazepine.|Diabetes Mellitus|0|17|carbamazepine|50|63
18950384|The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.|unusual weight fluctuation|46|72|aripiprazole|143|155
18950384|The present study describes a patient who had unusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and aripiprazole.|unusual weight fluctuation|46|72|mianserin|129|138
18957000|Although heparin-dependent antibodies (HDAs) typically manifest with thrombocytopenia as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.|thrombocytopenia|108|124|heparin|92|99
18957000|Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing thrombosis who are receiving heparin therapy.|thrombosis|109|119|heparin|138|145
18957000|Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.|thrombocytopenia|68|84|heparin|52|59
18977778|Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.|venous thromboembolism|69|91|heparin|135|142
18983414|Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for progressive liver failure and severe hepatocellular necrosis thought to be due to tacrolimus.|progressive liver failure|95|120|tacrolimus|177|187
18983414|Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for progressive liver failure and severe hepatocellular necrosis thought to be due to tacrolimus.|severe hepatocellular necrosis|125|155|tacrolimus|177|187
18983414|Initiation of posaconazole led to clinical improvement until the patient's demise from bacteremic vancomycin-resistant enterococcal peritonitis.|enterococcal peritonitis|119|143|posaconazole|14|26
18991509|Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.|Iatrogenic Cushing syndrome|0|27|triamcinolone|43|56
18991509|We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed Cushing syndrome with profound complications after epidural triamcinolone injections.|Cushing syndrome|180|196|triamcinolone|240|253
19003750|A 22-year-old drug-abuser injected flunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of acute ischaemia of the left leg.|acute ischaemia of the left leg|146|177|flunitrazepam|35|48
19003750|Acute ischaemia of the leg following accidental intra-arterial injection of dissolved flunitrazepam tablets.|Acute ischaemia of the leg|0|26|flunitrazepam|86|99
19017039|A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a syringotropic hypersensitivity reaction after 9 months of therapy with infliximab and leflunomide is described.|syringotropic hypersensitivity reaction|105|144|infliximab|176|186
19017039|A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a syringotropic hypersensitivity reaction after 9 months of therapy with infliximab and leflunomide is described.|syringotropic hypersensitivity reaction|105|144|leflunomide|191|202
19017039|Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis.|Syringotropic hypersensitivity reaction|0|39|infliximab|56|66
19017039|Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis.|Syringotropic hypersensitivity reaction|0|39|leflunomide|71|82
19018868|A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.|severe aplastic anemia|10|32|lenalidomide|61|73
19018868|Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, aplastic anemia has not previously been reported to be associated with this agent.|aplastic anemia|97|112|lenalidomide|83|95
19018868|We describe a case of severe aplastic anemia (AA) that was probably induced by lenalidomide.|AA|46|48|lenalidomide|79|91
19018868|We describe a case of severe aplastic anemia (AA) that was probably induced by lenalidomide.|severe aplastic anemia|22|44|lenalidomide|79|91
19034138|After cessation of amantadine, the edema resolved, and the endothelial cell densities were <or=600/mm.|edema|35|40|amantadine|19|29
19034138|CONCLUSIONS: Amantadine can cause reversible corneal edema but can irreversibly reduce the density of endothelial cells.|reversible corneal edema|34|58|Amantadine|13|23
19034138|Corneal edema recurred when the administration of amantadine was resumed.|Corneal edema|0|13|amantadine|50|60
19034138|Corneal endothelial dysfunction associated with amantadine toxicity.|Corneal endothelial dysfunction|0|31|amantadine|48|58
19034138|PURPOSE: To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long-term amantadine.|bilateral corneal endothelial dysfunction|21|62|amantadine|130|140
19034138|RESULTS: A 52-year-old woman with Parkinson disease who had taken amantadine for 6 years had bilateral corneal edema for 2 months at baseline.|bilateral corneal edema|93|116|amantadine|66|76
19034138|Therefore, amantadine was permanently discontinued and the cornea cleared again.|cornea|59|65|amantadine|11|21
19039026|Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?|acute interstitial nephritis|14|42|sunitinib|89|98
19039026|We report the first biopsy confirmed occurrence of acute interstitial nephritis in a patient receiving treatment with Sunitinib for metastatic renal cell cancer.|acute interstitial nephritis|51|79|Sunitinib|118|127
19047493|Extrapyramidal symptoms are well-documented complications of therapy with haloperidol, even when small doses are used.|Extrapyramidal symptoms|0|23|haloperidol|74|85
19047493|This report highlights a case of drug-induced dysphagia in a patient receiving haloperidol for obsessive nocturnal thoughts and auditory disturbances.|dysphagia|46|55|haloperidol|79|90
19058340|A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate.|iron deficiency anemia|81|103|methotrexate|135|147
19058340|Methotrexate induced sprue-like syndrome.|sprue-like syndrome|21|40|Methotrexate|0|12
19097599|Only 3 cases of imatinib-induced tumor lysis syndrome have been reported.|tumor lysis syndrome|33|53|imatinib|16|24
19097599|We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.|tumor lysis syndrome|114|134|imatinib|163|171
19104709|IFNalpha-induced recurrence of Graves' disease ten years after thyroidectomy in chronic viral hepatitis C.|Graves' disease|31|46|IFNalpha|0|8
19104709|In contrast to chronic or subacute thyroiditis, Graves' disease rarely complicates IFN-alpha therapy for chronic viral C hepatitis.|Graves' disease|48|63|IFN-alpha|83|92
19104709|In contrast to chronic or subacute thyroiditis, Graves' disease rarely complicates IFN-alpha therapy for chronic viral C hepatitis.|subacute thyroiditis|26|46|IFN-alpha|83|92
19104709|We report the case of a 51-year-old man in whom IFN-alpha treatment was followed by recurrence of Graves' disease 10 years after thyroidectomy was performed and the patient was declared cured.|Graves' disease|98|113|IFN-alpha|48|57
19112808|Interstitial granulomatous dermatitis associated with darifenacin.|Interstitial granulomatous dermatitis|0|37|darifenacin|54|65
19112808|The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.|interstitial granulomatous dermatitis|31|68|darifenacin|85|96
19116715|Gemcitabine is a known risk factor for hemolytic uremic syndrome (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis.|hemolytic uremic syndrome|39|64|Gemcitabine|0|11
19116715|Gemcitabine is a known risk factor for hemolytic uremic syndrome (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis.|HUS|66|69|Gemcitabine|0|11
19116715|METHODS: A retrospective report of the first case of gemcitabine-related HUS, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented.|HUS|73|76|gemcitabine|53|64
19116715|Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.|hemolytic uremic syndrome|48|73|gemcitabine|28|39
19122478|Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia.|Drug rash with eosinophilia and systemic symptoms|0|49|chlorambucil|56|68
19122478|He developed recurrent skin rash, fever, hypereosinophilia, and acute renal failure after rechallenge with chlorambucil.|acute renal failure|64|83|chlorambucil|107|119
19122478|He developed recurrent skin rash, fever, hypereosinophilia, and acute renal failure after rechallenge with chlorambucil.|fever|34|39|chlorambucil|107|119
19122478|He developed recurrent skin rash, fever, hypereosinophilia, and acute renal failure after rechallenge with chlorambucil.|hypereosinophilia|41|58|chlorambucil|107|119
19122478|He developed recurrent skin rash, fever, hypereosinophilia, and acute renal failure after rechallenge with chlorambucil.|skin rash|23|32|chlorambucil|107|119
19122478|We report the first case of chlorambucil-induced DRESS syndrome in a 70-year-old man recently diagnosed with chronic lymphocytic leukaemia.|DRESS syndrome|49|63|chlorambucil|28|40
19131789|A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.|acute renal failure|324|343|methotrexate|271|283
19131789|A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.|acute renal failure|324|343|MTX|285|288
19131789|A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.|elevation of aspartate aminotrasferase|133|171|methotrexate|271|283
19131789|A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.|elevation of aspartate aminotrasferase|133|171|MTX|285|288
19131789|A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.|renal toxicity|106|120|methotrexate|271|283
19131789|A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.|renal toxicity|106|120|MTX|285|288
19131789|Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.|renal toxicity|187|201|MTX|270|273
19131789|Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.|renal toxicity|21|35|methotrexate|49|61
19145124|Multifocal electroretinographic abnormalities in ethambutol-induced visual loss.|visual loss|68|79|ethambutol|49|59
19145124|These are the first reported patients to show mfERG abnormalities that correspond to bitemporal visual field defects and add to the growing evidence that ethambutol damages the retina.|bitemporal visual field defects|85|116|ethambutol|154|164
19145124|These are the first reported patients to show mfERG abnormalities that correspond to bitemporal visual field defects and add to the growing evidence that ethambutol damages the retina.|mfERG abnormalities|46|65|ethambutol|154|164
19145124|Two patients who developed decreased visual acuity after several months of ethambutol treatment for Mycobacterium avium-intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage.|bitemporal visual field defects|149|180|ethambutol|75|85
19145124|Two patients who developed decreased visual acuity after several months of ethambutol treatment for Mycobacterium avium-intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage.|decreased visual acuity|27|50|ethambutol|75|85
19183077|Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.|nephrotoxicity|21|35|Tenofovir|0|9
19183077|To our knowledge, these cases represent the first reports of TDF-associated irreversible renal failure and rickets in pediatric patients.|irreversible renal failure|76|102|TDF|61|64
19183077|To our knowledge, these cases represent the first reports of TDF-associated irreversible renal failure and rickets in pediatric patients.|rickets|107|114|TDF|61|64
19183077|We report two cases of tenofovir (TDF)-associated nephrotoxicity in perinatally HIV-infected adolescents.|nephrotoxicity|50|64|TDF|34|37
19183077|We report two cases of tenofovir (TDF)-associated nephrotoxicity in perinatally HIV-infected adolescents.|nephrotoxicity|50|64|tenofovir|23|32
1918672|In this case, discontinuing piroxicam, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's ulcers.|ulcers|146|152|piroxicam|28|37
19203515|Acute renal failure following intravenous immunoglobulin therapy in a HIV-infected patient.|Acute renal failure|0|19|immunoglobulin|42|56
19203515|Acute renal failure is a rare complication following the administration of intravenous immunoglobulin (IVIG).|Acute renal failure|0|19|immunoglobulin|87|101
19203515|The exact mechanism of IVIG-associated acute renal failure remains unclear.|acute renal failure|39|58|IVIG|23|27
19212144|A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.|proteinuria|71|82|temsirolimus|165|177
19212144|Temsirolimus-induced glomerulopathy.|glomerulopathy|21|35|Temsirolimus|0|12
19217693|Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause hypoglycemia, such as sulfonylureas, meglitinides, and insulin.|Hypoglycemia|0|12|etanercept|45|55
19217693|Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause hypoglycemia, such as sulfonylureas, meglitinides, and insulin.|hypoglycemia|119|131|etanercept|45|55
19217693|Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause hypoglycemia, such as sulfonylureas, meglitinides, and insulin.|hypoglycemia|119|131|insulin|174|181
19217693|Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause hypoglycemia, such as sulfonylureas, meglitinides, and insulin.|hypoglycemia|119|131|meglitinides|156|168
19217693|Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause hypoglycemia, such as sulfonylureas, meglitinides, and insulin.|hypoglycemia|119|131|sulfonylureas|141|154
19217693|Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis.|Persistent hypoglycemia|0|23|etanercept|58|68
19217693|We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen.|persistent hypoglycemia|177|200|etanercept|125|135
19224802|We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. glycopyrrolate (5.0 microg/kg) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure.|bradycardia|70|81|dexmedetomidine|46|61
19224802|We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. glycopyrrolate (5.0 microg/kg) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure.|exaggerated increase of arterial blood pressure|196|243|glycopyrrolate|92|106
19235747|Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is reported in up to 18.6% of patients treated with intravenous bisphosphonates and can result in significant morbidity.|osteonecrosis of the jaw|23|47|Bisphosphonate|0|14
19235747|Bisphosphonate-related osteonecrosis of the skull base.|osteonecrosis of the skull base|23|54|Bisphosphonate|0|14
19260037|A previous study of patients with "quinine-associated TTP/HUS" found that ADAMTS13 activities were not abnormal in 12/12 patients.|TTP/HUS|54|61|quinine|35|42
19260037|A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.|thrombotic microangiopathy|63|89|quinine|44|51
19260037|A retrospective review of TTP patients with quinine-associated thrombotic microangiopathy (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.|TMA|91|94|quinine|44|51
19260037|Thrombocytopenia with or without microangiopathy following quinine is often referred to as quinine "hypersensitivity." When schistocytes are present it is frequently termed "quinine-associated TTP/HUS." A severe deficiency of the vWF-cleaving protease, ADAMTS13, is associated with idiopathic TTP.|Thrombocytopenia|0|16|quinine|59|66
19260037|Thrombocytopenia with or without microangiopathy following quinine is often referred to as quinine "hypersensitivity." When schistocytes are present it is frequently termed "quinine-associated TTP/HUS." A severe deficiency of the vWF-cleaving protease, ADAMTS13, is associated with idiopathic TTP.|TTP/HUS|193|200|quinine|174|181
19260037|We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).|schistocytosis|44|58|quinine|74|81
19260037|We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).|thrombocytopenia|23|39|quinine|74|81
19260037|We conclude that while thrombocytopenia and schistocytosis can be seen in quinine-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).|TTP/HUS|93|100|quinine|74|81
19260037|We recommend that a TMA in association with quinine be consistently referred to as quinine-associated thrombotic microangiopathy (quinine-TMA) to better distinguish this entity from idiopathic TTP.|thrombotic microangiopathy|102|128|quinine|83|90
19266307|Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.|primary and secondary perforation of the bladder|30|78|epirubicin|116|126
19266307|MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.|primary and secondary perforation of the bladder|80|128|epirubicin|160|170
19281746|Aliskiren-associated acute renal failure with hyperkalemia.|acute renal failure|21|40|Aliskiren|0|9
19281746|We report the first case of acute renal failure with hyperkalemia associated with the recently marketed direct renin inhibitor aliskiren.|acute renal failure|28|47|aliskiren|127|136
19281746|We report the first case of acute renal failure with hyperkalemia associated with the recently marketed direct renin inhibitor aliskiren.|hyperkalemia|53|65|aliskiren|127|136
19296063|A case of acute cardiomyopathy and pericarditis associated with methylphenidate.|acute cardiomyopathy|10|30|methylphenidate|64|79
19296063|A case of acute cardiomyopathy and pericarditis associated with methylphenidate.|pericarditis|35|47|methylphenidate|64|79
19296063|However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.|acute cardiomyopathy|9|29|methylphenidate|60|75
19296063|However, acute cardiomyopathy and pericarditis secondary to methylphenidate use has been rarely reported.|pericarditis|34|46|methylphenidate|60|75
19296063|We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.|acute left ventricular dysfunction|100|134|methylphenidate|162|177
19296063|We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.|chest pain|55|65|methylphenidate|162|177
19296063|We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of methylphenidate.|elevated cardiac biomarkers|67|94|methylphenidate|162|177
19299370|According to the Naranjo et al. adverse-reaction probability scale, enoxaparin was the probable cause of hepatotoxicity in this patient.|hepatotoxicity|105|119|enoxaparin|68|78
19299370|CONCLUSION: A woman receiving enoxaparin every 12 hours developed signs and symptoms of hepatotoxicity after the second dose.|hepatotoxicity|88|102|enoxaparin|30|40
19299370|Probable enoxaparin-induced hepatotoxicity.|hepatotoxicity|28|42|enoxaparin|9|19
19299370|PURPOSE: A case of probable enoxaparin-induced hepatotoxicity is described.|hepatotoxicity|47|61|enoxaparin|28|38
19307676|Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings.|Posterior reversible encephalopathy syndrome|0|44|methotrexate|61|73
19307676|The addition of intrathecal methotrexate to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of neurotoxicity.|neurotoxicity|186|199|methotrexate|28|40
19307676|We describe a 15-year-old female patient diagnosed with acute lymphoblastic leukemia presenting with status epilepticus after receiving intrathecal methotrexate.|acute lymphoblastic leukemia|56|84|methotrexate|148|160
19318596|Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.|pain syndrome|21|34|Cyclosporine|0|12
19318596|In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.|CIPS|14|18|cyclosporine|65|77
19318596|OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).|pain syndrome|51|64|calcineurin|31|42
19318596|With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.|leg pain|60|68|cyclosporine|15|27
19318596|With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.|leg pain|60|68|cyclosporine|101|113
19331262|Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome.|Neuroleptic malignant syndrome|0|30|risperidone|38|49
19331262|This report describes a case of neuroleptic malignant syndrome due to risperidone in a child with Joubert syndrome.|neuroleptic malignant syndrome|32|62|risperidone|70|81
19336028|A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.|tuberculosis|10|22|Efalizumab|39|49
19336028|A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.|tuberculosis|10|22|Etanercept|54|64
19354059|The most common complication of warfarin use is adverse bleeding.|bleeding|56|64|warfarin|32|40
19357764|CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda.|symptomatic hyperlactatemia|91|118|stavudine|145|154
19357764|CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda.|symptomatic hyperlactatemia|91|118|zidovudine|158|168
19357764|DISCUSSION: This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse.|hyperlactatemia relapse|83|106|zidovudine|46|56
19357764|INTRODUCTION: In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative.|hyperlactatemia|110|125|stavudine|92|101
19363904|Anaphylactic reaction to bacitracin ointment.|Anaphylactic reaction|0|21|bacitracin|25|35
19363904|We report a case of an 11-year-old boy who experienced an anaphylactic reaction after administration of bacitracin ointment.|anaphylactic reaction|58|79|bacitracin|104|114
19365885|Herein, we present a patient with severe and prolonged hypoglycemia after long-acting octreotide treatment.|prolonged hypoglycemia|45|67|octreotide|86|96
19365885|Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor.|Hypoglycemia|0|12|somatostatin|36|48
19365885|In these patients, long-acting octreotide may trigger serious hypoglycemia.|serious hypoglycemia|54|74|octreotide|31|41
19390192|Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine.|Leukopenia|0|10|azathioprine|68|80
19390192|The uncomplicated long-term use of adequately-dosed AZA and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the leukopenia.|leukopenia|159|169|AZA|52|55
19390192|We present the case of an adult Crohn's disease patient with a parvovirus B19 infection and leukopenia during long-term AZA therapy.|leukopenia|92|102|AZA|120|123
19402273|Isoniazid causing breast tissue enlargement has been very rarely reported.|breast tissue enlargement|18|43|Isoniazid|0|9
19402273|Isoniazid induced gynaecomastia: a case report.|gynaecomastia|18|31|Isoniazid|0|9
19423476|Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.|Cryptococcus neoformans fatal sepsis|0|36|alemtuzumab|92|103
19423476|The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.|fungal infections|142|159|alemtuzumab|101|112
19423476|The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed.|opportunistic infections|39|63|alemtuzumab|101|112
19434733|Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis.|acute myeloid leukemia|10|32|etoposide|39|48
19434733|The risk of developing sAML is estimated to be between 1% and 5%, 2-20 years after exposure to etoposide but may also be related to cumulative drug doses, treatment schedules, host factors and co-administration of other antineoplastic agents.|sAML|23|27|etoposide|95|104
19434733|Two patients with HLH developed etoposide-related secondary acute myeloid leukemia (sAML) following therapy for HLH.|sAML|84|88|etoposide|32|41
19434733|Two patients with HLH developed etoposide-related secondary acute myeloid leukemia (sAML) following therapy for HLH.|secondary acute myeloid leukemia|50|82|etoposide|32|41
19448237|Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.|Polymyoclonus seizure|0|21|tranexamic acid|61|76
19474653|Rhabdomyolysis following clarithromycin monotherapy.|Rhabdomyolysis|0|14|clarithromycin|25|39
19474653|We report the first case of rhabdomyolysis related to the administration of clarithromycin without concurrent use of other medications.|rhabdomyolysis|28|42|clarithromycin|76|90
19499966|At the end of his fifth cycle of sunitinib therapy, the patient complained of the development of abnormally large mammary glands associated with pain and peri-areolar erythema.|development of abnormally large mammary glands|82|128|sunitinib|33|42
19499966|At the end of his fifth cycle of sunitinib therapy, the patient complained of the development of abnormally large mammary glands associated with pain and peri-areolar erythema.|pain|145|149|sunitinib|33|42
19499966|At the end of his fifth cycle of sunitinib therapy, the patient complained of the development of abnormally large mammary glands associated with pain and peri-areolar erythema.|peri-areolar erythema|154|175|sunitinib|33|42
19499966|However, re-initiation of sunitinib treatment was followed by bilateral breast enlargement again.|bilateral breast enlargement|62|90|sunitinib|26|35
19499966|Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma.|gynaecomastia|14|27|sunitinib|54|63
19499966|The mechanism by which sunitinib induces gynaecomastia is thought to be associated with an unknown direct action on breast hormonal receptors.|gynaecomastia|41|54|sunitinib|23|32
19499966|The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, hand-foot syndrome, elevated lipase and lymphopenia.|elevated lipase|109|124|sunitinib|48|57
19499966|The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, hand-foot syndrome, elevated lipase and lymphopenia.|fatigue|80|87|sunitinib|48|57
19499966|The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, hand-foot syndrome, elevated lipase and lymphopenia.|hand-foot syndrome|89|107|sunitinib|48|57
19499966|The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, hand-foot syndrome, elevated lipase and lymphopenia.|hypertension|66|78|sunitinib|48|57
19499966|The more common grade 3 or 4 adverse effects of sunitinib include hypertension, fatigue, hand-foot syndrome, elevated lipase and lymphopenia.|lymphopenia|129|140|sunitinib|48|57
19512997|Divalproex sodium-induced eosinophilic pleural effusion.|eosinophilic pleural effusion|26|55|Divalproex sodium|0|17
19512997|We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.|dyspnea|111|118|Depakote|82|90
19512997|We report a case of 48-year-old woman with seizure disorder on divalproex sodium (Depakote) who presented with dyspnea.|dyspnea|111|118|divalproex sodium|63|80
19512997|Withdrawal of Depakote resulted in resolution of the effusion.|effusion|53|61|Depakote|14|22
1951476|Flurbiprofen-associated acute tubulointerstitial nephritis.|acute tubulointerstitial nephritis|24|58|Flurbiprofen|0|12
1951476|We report a case of biopsy-proven acute tubulointerstitial nephritis associated with a second course of flurbiprofen, a nonsteroidal anti-inflammatory drug of the propionic acid class.|acute tubulointerstitial nephritis|34|68|flurbiprofen|104|116
19520277|Stupor and fast activity on electroencephalography in a child treated with valproate.|Stupor|0|6|valproate|75|84
19520277|The case of a 4-year-old girl with valproate-induced stupor and electroencephalographic pattern of increased fast activity is reported.|stupor|53|59|valproate|35|44
19537383|Localized dyskeratotic plaque with milia associated with sorafenib.|Localized dyskeratotic plaque|0|29|sorafenib|57|66
19537383|Localized dyskeratotic plaque with milia associated with sorafenib.|milia|35|40|sorafenib|57|66
19537383|This article presents a case of an atypical localized cutaneous eruption with an unusual course and protracted resolution time associated with sorafenib therapy.|atypical localized cutaneous eruption|35|72|sorafenib|143|152
19540093|According to the Naranjo adverse drug reaction probability scale, tigecycline was the probable cause of her acute pancreatitis.|acute pancreatitis|108|126|tigecycline|66|77
19540093|Following 7 days of tigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis.|acute pancreatitis|111|129|tigecycline|20|31
19540093|Following 7 days of tigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis.|elevated pancreatic enzymes|72|99|tigecycline|20|31
19540093|Following 7 days of tigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis.|severe abdominal pain|46|67|tigecycline|20|31
19540093|Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about tigecycline-induced acute pancreatitis have recently been raised.|acute pancreatitis|115|133|tigecycline|95|106
19540093|Tigecycline-induced acute pancreatitis: case report and literature review.|acute pancreatitis|20|38|Tigecycline|0|11
19540093|We recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including abdominal pain, during treatment with tigecycline.|abdominal pain|96|110|tigecycline|134|145
19540093|We recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including abdominal pain, during treatment with tigecycline.|pancreatitis|72|84|tigecycline|134|145
1954704|Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma.|polymyositis|13|25|leuprolide acetate|39|57
1954704|Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma.|polymyositis|13|25|Lupron|59|65
1954704|We report a case of biopsy proven myositis whose symptoms began within 10 days of receiving leuprolide acetate therapy for prostate cancer.|myositis|34|42|leuprolide acetate|92|110
19555801|Aripiprazole-induced hiccups: a case report.|hiccups|21|28|Aripiprazole|0|12
19555801|We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.|hiccups|72|79|aripiprazole|112|124
19567656|CONCLUSIONS: This patient's rhabdomyolysis was probably induced by sertraline therapy.|rhabdomyolysis|28|42|sertraline|67|77
19567656|DISCUSSION: The Naranjo probability scale indicated a probable relationship between sertraline treatment and the onset of rhabdomyolysis.|rhabdomyolysis|122|136|sertraline|84|94
19567656|OBJECTIVE: To describe a case of sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.|rhabdomyolysis|52|66|sertraline|33|43
19567656|Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.|rhabdomyolysis|19|33|Sertraline|0|10
19567656|The patient's other comorbidities and medications have not been suggested as possible interactions with sertraline that can cause rhabdomyolysis.|rhabdomyolysis|130|144|sertraline|104|114
19570088|Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma.|Tumor lysis syndrome|0|20|cisplatin|62|71
19579947|He had priapism following the use of olanzapine.|priapism|7|15|olanzapine|37|47
19579947|Priapism associated with olanzapine.|Priapism|0|8|olanzapine|25|35
19648225|Can ketamine prescribed for pain cause damage to the urinary tract?|damage to the urinary tract|39|66|ketamine|4|12
19648225|Possible mechanisms for damage to the urothelium by ketamine are suggested.|damage to the urothelium|24|48|ketamine|52|60
19648225|Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms.|urological symptoms|143|162|ketamine|62|70
19653965|These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.|arrhythmias|84|95|lopinavir|56|65
19653965|These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.|arrhythmias|84|95|ritonavir|66|75
19653965|Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.|Transient cardiac arrhythmias|0|29|lopinavir|41|50
19653965|Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.|Transient cardiac arrhythmias|0|29|ritonavir|51|60
19660974|Colitis as a manifestation of infliximab-associated disseminated cryptococcosis.|Colitis|0|7|infliximab|30|40
19660974|Colitis as a manifestation of infliximab-associated disseminated cryptococcosis.|disseminated cryptococcosis|52|79|infliximab|30|40
19667003|After three weeks of carbamazepine therapy, the patient arrived at the emergency department (ED) with severe agitation and aggressive behavior.|aggressive behavior|123|142|carbamazepine|21|34
19667003|After three weeks of carbamazepine therapy, the patient arrived at the emergency department (ED) with severe agitation and aggressive behavior.|severe agitation|102|118|carbamazepine|21|34
19667003|Carbamazepine-induced hyperammonemia.|hyperammonemia|22|36|Carbamazepine|0|13
19667003|CONCLUSION: A 26-year-old man with bipolar disorder developed hyperammonemia three weeks after initiating carbamazepine therapy.|hyperammonemia|62|76|carbamazepine|106|119
19667003|He had also developed elevated serum ammonia levels while on valproic acid.|elevated serum ammonia levels|22|51|valproic acid|61|74
19667003|PURPOSE: A case of carbamazepine-induced hyperammonemia is presented.|hyperammonemia|41|55|carbamazepine|19|32
1966850|Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.|cardiomyopathy|19|33|Adriamycin|0|10
1966850|Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.|nephrotoxicity|61|75|cis-platinum|48|60
1966850|Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.|cardiotoxicity|129|143|adriamycin|118|128
1966850|Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.|nephrotoxicity|99|113|cisplatinum|87|98
19669617|A 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of adalimumab.|jaundice|44|52|adalimumab|183|193
19669617|A 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of adalimumab.|severe dyspnea|78|92|adalimumab|183|193
19669617|A 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of adalimumab.|tachypnea|97|106|adalimumab|183|193
19669617|A case of acute respiratory failure due to diaphragmatic weakness following adalimumab therapy for psoriasis is described.|acute respiratory failure|10|35|adalimumab|76|86
19669617|Acute bilateral phrenic neuropathy following treatment with adalimumab.|Acute bilateral phrenic neuropathy|0|34|adalimumab|60|70
19687711|The potential development of SJS/TEN, a severe life-threatening illness, emphasizes the need for judicious use of TMP-Sx and close monitoring and follow-up for patients who were given TMP-Sx for SSTIs.|SJS|29|32|TMP-Sx|114|120
19687711|The potential development of SJS/TEN, a severe life-threatening illness, emphasizes the need for judicious use of TMP-Sx and close monitoring and follow-up for patients who were given TMP-Sx for SSTIs.|TEN|33|36|TMP-Sx|114|120
19687711|We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.|SJS|73|76|TMP-Sx|126|132
19687711|We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.|SJS|73|76|trimethoprim-sulfamethoxazole|95|124
19687711|We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.|Stevens-Johnson syndrome|20|44|TMP-Sx|126|132
19687711|We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.|Stevens-Johnson syndrome|20|44|trimethoprim-sulfamethoxazole|95|124
19687711|We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.|TEN|77|80|TMP-Sx|126|132
19687711|We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.|TEN|77|80|trimethoprim-sulfamethoxazole|95|124
19687711|We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.|toxic epidermal necrolysis|45|71|TMP-Sx|126|132
19687711|We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.|toxic epidermal necrolysis|45|71|trimethoprim-sulfamethoxazole|95|124
19690222|CONCLUSIONS: Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of LMWH.|Spontaneous hemothorax|13|35|LMWH|77|81
19690222|On day 4, following 3 doses of dalteparin, the patient developed acute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.|acute respiratory distress|65|91|dalteparin|31|41
19690222|Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.|Spontaneous hemothorax|0|22|heparin|75|82
19707032|Acute ocular ischemic change may be associated with intravitreal injection of bevacizumab in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery.|Acute ocular ischemic change|0|28|bevacizumab|78|89
19707032|Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome.|Acute vision loss|0|17|avastin|63|70
19707032|Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome.|Acute vision loss|0|17|bevacizumab|50|61
19707032|Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome.|ocular ischemic syndrome|88|112|avastin|63|70
19707032|Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome.|ocular ischemic syndrome|88|112|bevacizumab|50|61
19707032|AIM: To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab.|acute retinal ischemic change|66|95|bevacizumab|139|150
19707032|AIM: To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab.|stroke|100|106|bevacizumab|139|150
19707032|CONCLUSIONS: Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus.|carotid insufficiency|135|156|bevacizumab|59|70
19707032|CONCLUSIONS: Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus.|coagulopathy|158|170|bevacizumab|59|70
19707032|CONCLUSIONS: Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and poorly controlled diabetes mellitus.|poorly controlled diabetes mellitus|175|210|bevacizumab|59|70
19707032|Three days after intravitreal injection of bevacizumab, acute ocular ischemic syndrome occurred.|acute ocular ischemic syndrome|56|86|bevacizumab|43|54
19707032|Three days after receiving intravitreal injection of bevacizumab (1.25 mg in 0.1 ml), he developed acute vision loss and change of consciousness.|acute vision loss|99|116|bevacizumab|53|64
19707032|Three days after receiving intravitreal injection of bevacizumab (1.25 mg in 0.1 ml), he developed acute vision loss and change of consciousness.|change of consciousness|121|144|bevacizumab|53|64
19717383|Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.|pancytopenia|80|92|cyclophosphamide|161|177
19717383|Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.|pancytopenia|80|92|doxorubicin|179|190
19717383|Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.|pancytopenia|80|92|etoposide|125|134
19717383|Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.|pancytopenia|80|92|prednisone|136|146
19717383|Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.|pancytopenia|80|92|rituximab|196|205
19717383|Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.|pancytopenia|80|92|vincristine|148|159
19725909|Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy.|hepatitis B infection|29|50|adefovir|99|107
19725909|Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy.|hepatitis B infection|29|50|lamivudine|84|94
19733945|Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome.|acute interstitial nephritis|21|49|Linezolid|0|9
19733945|Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome.|DRESS|105|110|Linezolid|0|9
19733945|Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome.|drug rash with eosinophilia and systemic symptoms|54|103|Linezolid|0|9
19733945|On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.|eosinophilia|100|112|linezolid|12|21
19733945|On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.|facial edema|86|98|linezolid|12|21
19733945|On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.|macular rash|72|84|linezolid|12|21
19733945|On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.|marked increase in serum creatinine level|114|155|linezolid|12|21
19733945|On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.|mild hepatitis|161|175|linezolid|12|21
19733945|On day 7 of linezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.|severe pruritus|55|70|linezolid|12|21
19733945|This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.|acute interstitial nephritis|34|62|linezolid|180|189
19733945|This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.|acute interstitial nephritis|34|62|linezolid|13|22
19733945|This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.|DRESS|138|143|linezolid|180|189
19733945|This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.|DRESS|138|143|linezolid|13|22
19733945|This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.|drug rash with eosinophilia and systemic symptoms|87|136|linezolid|180|189
19733945|This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.|drug rash with eosinophilia and systemic symptoms|87|136|linezolid|13|22
19745701|Increased awareness is needed on the possible occurrence of LPD resembling gastric cancer in rheumatoid arthritis patients treated with MTX.|LPD|60|63|MTX|136|139
19745701|Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis.|lymphoproliferative disorder|35|63|methotrexate|11|23
19745701|She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to immunodeficiency caused by MTX administration.|Epstein-Barr virus-associated polymorphic lymphoproliferative disorder|23|93|MTX|134|137
19745701|She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to immunodeficiency caused by MTX administration.|immunodeficiency|107|123|MTX|134|137
19745701|She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to immunodeficiency caused by MTX administration.|LPD|95|98|MTX|134|137
19745701|To our knowledge, this is the first case of spontaneous remission of MTX-associated gastric LPD after discontinuation of MTX therapy.|gastric LPD|84|95|MTX|69|72
19764104|However, he developed acute renal failure, hyperkalemia, and hyperuricemia 30 d after receiving the sorafenib treatment.|acute renal failure|22|41|sorafenib|100|109
19764104|However, he developed acute renal failure, hyperkalemia, and hyperuricemia 30 d after receiving the sorafenib treatment.|hyperkalemia|43|55|sorafenib|100|109
19764104|However, he developed acute renal failure, hyperkalemia, and hyperuricemia 30 d after receiving the sorafenib treatment.|hyperuricemia|61|74|sorafenib|100|109
19764104|Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.|tumor lysis syndrome|18|38|Sorafenib|0|9
19775485|Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope.|syncope|77|84|oxymetazoline|55|68
19775485|We report here a case of cardiovascular and neurological depression induced by oxymetalzoline in a toddler.|neurological depression|44|67|oxymetalzoline|79|93
19789166|Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of toxic liver damage caused by nitrofurantoin.|toxic liver damage|216|234|nitrofurantoin|245|259
19789166|Nitrofurantoin-induced acute liver damage in pregnancy.|acute liver damage|23|41|Nitrofurantoin|0|14
19798640|A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy.|PCNSL|118|123|natalizumab|159|170
19798640|A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy.|primary central nervous system lymphoma|77|116|natalizumab|159|170
19798640|Primary central nervous system lymphoma in a patient treated with natalizumab.|Primary central nervous system lymphoma|0|39|natalizumab|66|77
19815480|The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue and hypertension.|fatigue|104|111|sunitinib|71|80
19815480|The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue and hypertension.|hypertension|116|128|sunitinib|71|80
19826099|OBJECTIVE: To report a case of severe apnea in an infant exposed to lamotrigine through breast-feeding.|severe apnea|31|43|lamotrigine|68|79
19826099|Severe apnea in an infant exposed to lamotrigine in breast milk.|Severe apnea|0|12|lamotrigine|37|48
19826099|The Naranjo probability scale indicated a probable relationship between apnea and exposure to lamotrigine through breast-feeding in this infant.|apnea|72|77|lamotrigine|94|105
19838099|Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.|pleural effusion|163|179|dasatinib|145|154
19838099|Dasatinib-induced pleural effusions: a lymphatic network disorder?|pleural effusions|18|35|Dasatinib|0|9
19844714|RESULTS: One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin-based regimen, developed a platinum hypersensitivity.|platinum hypersensitivity|125|150|carboplatin|86|97
19875411|One week after the initial-dose of adalimumab (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy.|fulminant cardiomyopathy|149|173|adalimumab|35|45
19875411|Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.|Severe cardiomyopathy|0|21|adalimumab|90|100
19884751|Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.|severe hypocalcemia|51|70|Amikacin|0|8
19884751|Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.|type 5 Bartter-like syndrome|17|45|Amikacin|0|8
19884751|Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.|tubular dysfunction|16|35|Amikacin|92|100
19884751|We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.|hypocalcemia|152|164|Amikacin|105|113
19884751|We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.|hypomagnesemia|166|180|Amikacin|105|113
19884751|We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.|metabolic alkalosis|182|201|Amikacin|105|113
19884751|We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.|polyuria|207|215|Amikacin|105|113
19884751|We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.|refractory hypokalemia|128|150|Amikacin|105|113
19884751|We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.|severe renal tubular dysfunction|35|67|Amikacin|105|113
1988604|Postoperatively, the first two patients treated with 1 to 2 cc of thrombin were slow to awaken; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension.|multiple infarcts|173|190|thrombin|66|74
1988604|Postoperatively, the first two patients treated with 1 to 2 cc of thrombin were slow to awaken; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension.|slow to awaken|80|94|thrombin|66|74
1988604|Postoperatively, the first two patients treated with 1 to 2 cc of thrombin were slow to awaken; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension.|vasospasm|116|125|thrombin|66|74
1988604|Thrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the cerebral infarctions in one patient.|cerebral infarctions|181|201|Thrombin|0|8
19892516|Ciprofloxacin-induced hemorrhagic vasculitis.|hemorrhagic vasculitis|22|44|Ciprofloxacin|0|13
19892516|Ciprofloxacin-induced hemorrhagic vasculitis is a rare side effect.|hemorrhagic vasculitis|22|44|Ciprofloxacin|0|13
19892516|Ciprofloxacin is among the standard treatments for infected ischemic ulcers; in the rare case of ciprofloxacin-induced hemorrhagic vasculitis, it might be interpreted as progression of infection, instead of a complication of the treatment, thus leading to faulty diagnosis and treatment.|hemorrhagic vasculitis|119|141|ciprofloxacin|97|110
19892516|In one patient the vasculitis resolved after termination of the ciprofloxacin therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation.|below-knee amputation|244|265|ciprofloxacin|112|125
19892516|In one patient the vasculitis resolved after termination of the ciprofloxacin therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation.|hemorrhagic vasculitis|134|156|ciprofloxacin|112|125
19892516|In one patient the vasculitis resolved after termination of the ciprofloxacin therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation.|progressive gangrene|217|237|ciprofloxacin|112|125
19892516|In one patient the vasculitis resolved after termination of the ciprofloxacin therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation.|severe forefoot infection|179|204|ciprofloxacin|112|125
19892516|In one patient the vasculitis resolved after termination of the ciprofloxacin therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation.|vasculitis|19|29|ciprofloxacin|64|77
19897274|However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib.|interstitial pneumonia|63|85|sorafenib|157|166
19897274|Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.|Interstitial pneumonia|0|22|sorafenib|48|57
19897274|In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma.|severe interstitial pneumonia|53|82|sorafenib|102|111
19897274|Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences.|interstitial lung disease|137|162|sorafenib|96|105
19904536|Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.|pulmonary toxicity|26|44|gemcitabine|6|17
19904536|Gemcitabine-induced pulmonary toxicity is usually a dramatic condition.|pulmonary toxicity|20|38|Gemcitabine|0|11
19904536|In this report, we describe a fatal gemcitabine-induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma.|pulmonary toxicity|56|74|gemcitabine|36|47
19915794|He had hypokalemia (K 2.3 mmol/L) induced by licorice and also had received disopyramide for arrhythmia, bicalutamide for prostate cancer, and silodosin for prostate hypertrophy.|hypokalemia|7|18|licorice|45|53
19915794|Therefore, although garenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP.|cardiac rhythms|78|93|garenoxacin|20|31
19915794|Therefore, although garenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP.|hypokalemia|202|213|garenoxacin|20|31
19915794|Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.|Torsades de Pointes|0|19|disopyramide|64|76
19915794|Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.|Torsades de Pointes|0|19|garenoxacin|48|59
19915794|We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (TdP) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia.|TdP|92|95|garenoxacin|126|137
19915794|We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (TdP) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia.|Torsades de Pointes|71|90|garenoxacin|126|137
19915794|We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (TdP) after oral administration of garenoxacin, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia.|ventricular tachycardia|43|66|garenoxacin|126|137
1993143|Of 371 patients treated with 8MOP, three (0.8%) developed an acute dermatitis in the PUVA-treated areas.|acute dermatitis|61|77|8MOP|29|33
19935411|Hepatotoxicity after high-dose methylprednisolone for demyelinating disease.|Hepatotoxicity|0|14|methylprednisolone|31|49
19935411|We observed 2 cases of hepatotoxicity after a high-dose methylprednisolone treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence.|hepatotoxicity|23|37|methylprednisolone|56|74
19949685|Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient.|Colonic mucosal necrosis|0|24|calcium polystryrene sulfonate|53|83
19949685|Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient.|Colonic mucosal necrosis|0|24|Kalimate|85|93
19949685|Colonic necrosis is known as a rare complication following the administration of Kayexalate (sodium polystryrene sulfonate) in sorbitol.|Colonic necrosis|0|16|Kayexalate|81|91
19949685|Colonic necrosis is known as a rare complication following the administration of Kayexalate (sodium polystryrene sulfonate) in sorbitol.|Colonic necrosis|0|16|sodium polystryrene sulfonate|93|122
19949685|Two days after administration of Kalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon.|colonic mucosal necrosis in the rectum|113|151|Kalimate|33|41
19949685|Two days after administration of Kalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon.|profuse hematochezia|56|76|Kalimate|33|41
19949685|We report a rare case of colonic mucosal necrosis following Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man.|colonic mucosal necrosis|25|49|calcium polystryrene sulfonate|70|100
19949685|We report a rare case of colonic mucosal necrosis following Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man.|colonic mucosal necrosis|25|49|Kalimate|60|68
19949685|We report a rare case of colonic mucosal necrosis following Kalimate (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man.|colonic mucosal necrosis|25|49|Kayexalate|118|128
19995222|Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.|tardive dyskinesia|18|36|Clozapine|0|9
19995222|CONCLUSIONS: These results suggest that clozapine may cause TD; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported discomfort.|discomfort|162|172|clozapine|40|49
19995222|CONCLUSIONS: These results suggest that clozapine may cause TD; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported discomfort.|TD|60|62|clozapine|40|49
19995222|However, several case reports have suggested that clozapine could also cause TD.|TD|77|79|clozapine|50|59
19995222|OBJECTIVE: Clozapine causes few extrapyramidal symptoms and is recommended as a treatment drug for severe tardive dyskinesia (TD).|extrapyramidal symptoms|32|55|Clozapine|11|20
20009973|All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.|focal myositis|32|46|All-trans retinoic acid|0|23
20009973|All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.|mononeuritis|63|75|All-trans retinoic acid|0|23
20009973|All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.|synovitis|48|57|All-trans retinoic acid|0|23
20009973|Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.|acute focal myositis|89|109|all-trans retinoic acid|163|186
20009973|Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.|possible vasculitis|126|145|all-trans retinoic acid|163|186
20009973|Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and possible vasculitis, after receiving all-trans retinoic acid therapy.|synovitis|111|120|all-trans retinoic acid|163|186
20020238|BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.|retinopathy|65|76|pegylated interferon|93|113
20020238|BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.|retinopathy|65|76|ribavirin|118|127
20020238|CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.|irreversible decrease of visual acuity|56|94|pegylated interferon|132|152
20020238|CONCLUSION: Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon.|ocular complications|24|44|pegylated interferon|132|152
20020238|Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.|Retinopathy|0|11|pegylated interferon|68|88
20020238|Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.|Retinopathy|0|11|ribavirin|93|102
20038831|Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?|hypersensitivity|63|79|carboplatin|51|62
20038831|Hypersensitivity to carboplatin has been reported in up to 44% of patients receiving this antineoplastic agent, usually occurring after several courses of treatment.|Hypersensitivity|0|16|carboplatin|20|31
20038831|Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and severe hypersensitivity reactions to carboplatin.|severe hypersensitivity|152|175|carboplatin|189|200
20065266|Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.|Aseptic meningitis|0|18|sulfamethoxazole|116|132
20065266|Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.|Aseptic meningitis|0|18|trimethoprim|103|115
20065266|Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.|hemolytic anemia|20|36|sulfamethoxazole|116|132
20065266|Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.|hemolytic anemia|20|36|trimethoprim|103|115
20065266|Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.|hepatitis|38|47|sulfamethoxazole|116|132
20065266|Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.|hepatitis|38|47|trimethoprim|103|115
20065266|Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.|orthostatic hypotension|53|76|sulfamethoxazole|116|132
20065266|Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole.|orthostatic hypotension|53|76|trimethoprim|103|115
20065266|CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.|aseptic meningitis|137|155|sulfamethoxazole|196|212
20065266|CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.|aseptic meningitis|137|155|trimethoprim|183|195
20065266|CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.|hemolytic anemia|79|95|sulfamethoxazole|196|212
20065266|CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.|hemolytic anemia|79|95|trimethoprim|183|195
20065266|CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.|hepatitis|97|106|sulfamethoxazole|196|212
20065266|CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.|hepatitis|97|106|trimethoprim|183|195
20065266|CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.|orthostatic hypotension|108|131|sulfamethoxazole|196|212
20065266|CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-sulfamethoxazole.|orthostatic hypotension|108|131|trimethoprim|183|195
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|difficulty with speech|155|177|sulfamethoxazole|32|48
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|difficulty with speech|155|177|trimethoprim|19|31
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|dizziness|144|153|sulfamethoxazole|32|48
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|dizziness|144|153|trimethoprim|19|31
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|headaches|133|142|sulfamethoxazole|32|48
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|headaches|133|142|trimethoprim|19|31
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|itching on the trunk|193|213|sulfamethoxazole|32|48
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|itching on the trunk|193|213|trimethoprim|19|31
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|maculopapular rash|244|262|sulfamethoxazole|32|48
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|maculopapular rash|244|262|trimethoprim|19|31
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|weakness|179|187|sulfamethoxazole|32|48
20065266|He had been taking trimethoprim-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.|weakness|179|187|trimethoprim|19|31
20065266|PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.|aseptic meningitis|45|63|sulfamethoxazole|172|188
20065266|PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.|aseptic meningitis|45|63|trimethoprim|159|171
20065266|PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.|hemolytic anemia|65|81|sulfamethoxazole|172|188
20065266|PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.|hemolytic anemia|65|81|trimethoprim|159|171
20065266|PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.|hepatitis|83|92|sulfamethoxazole|172|188
20065266|PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.|hepatitis|83|92|trimethoprim|159|171
20065266|PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.|orthostatic hypotension|98|121|sulfamethoxazole|172|188
20065266|PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-sulfamethoxazole is described.|orthostatic hypotension|98|121|trimethoprim|159|171
2006943|A patient, while on intravenous ritodrine therapy for preterm labor, experienced an episode of acute chest pain.|acute chest pain|95|111|ritodrine|32|41
2006943|The electrocardiogram (ECG), which was read as normal prior to ritodrine infusion, demonstrated a type I second-degree AV block which disappeared upon discontinuation of ritodrine therapy.|type I second-degree AV block|98|127|ritodrine|63|72
2006943|The electrocardiogram (ECG), which was read as normal prior to ritodrine infusion, demonstrated a type I second-degree AV block which disappeared upon discontinuation of ritodrine therapy.|type I second-degree AV block|98|127|ritodrine|170|179
2006943|Type I second-degree AV block (Mobitz type I, Wenckebach AV block) during ritodrine therapy for preterm labor.|Mobitz type I|31|44|ritodrine|74|83
2006943|Type I second-degree AV block (Mobitz type I, Wenckebach AV block) during ritodrine therapy for preterm labor.|Type I second-degree AV block|0|29|ritodrine|74|83
2006943|Type I second-degree AV block (Mobitz type I, Wenckebach AV block) during ritodrine therapy for preterm labor.|Wenckebach AV block|46|65|ritodrine|74|83
20098333|Exacerbation of anthracycline-induced early chronic cardiomyopathy with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction.|early chronic cardiomyopathy|38|66|anthracycline|16|29
20098333|We report the case of a 14-year-old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA).|symptomatic cardiomyopathy|91|117|all-trans retinoic acid|184|207
20098333|We report the case of a 14-year-old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA).|symptomatic cardiomyopathy|91|117|ATRA|209|213
20098333|We report the case of a 14-year-old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA).|symptomatic cardiomyopathy|91|117|daunomycin|169|179
20110001|CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with imatinib 400 mg/d.|KS|67|69|imatinib|110|118
20110001|Flare of Kaposi's sarcoma (KS) is well described in immunosuppressed patients treated with corticosteroids and rituximab, but has not yet been reported during treatment with imatinib.|Kaposi's sarcoma|9|25|rituximab|111|120
20110001|Flare of Kaposi's sarcoma (KS) is well described in immunosuppressed patients treated with corticosteroids and rituximab, but has not yet been reported during treatment with imatinib.|KS|27|29|rituximab|111|120
20110001|Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.|Kaposi's sarcoma|0|16|imatinib mesylate|43|60
20110001|OBJECTIVE: We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib.|cutaneous KS lesions|31|51|imatinib|94|102
2011096|Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia.|Bulbar|0|6|cytosine arabinoside|66|86
2011096|Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia.|pseudobulbar palsy|11|29|cytosine arabinoside|66|86
20118434|Interferon-based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including neuropsychiatric symptoms.|neuropsychiatric symptoms|129|154|Interferon|0|10
20118434|Interferon-induced psychosis as a "psychiatric contraindication" to hepatitis C treatment: a review and case-based discussion.|psychosis|19|28|Interferon|0|10
20118434|METHOD: The authors followed a patient with chronic HCV who received interferon and ribavirin and who developed hallucinations ultimately requiring psychiatric hospitalization.|hallucinations|112|126|interferon|69|79
20118434|METHOD: The authors followed a patient with chronic HCV who received interferon and ribavirin and who developed hallucinations ultimately requiring psychiatric hospitalization.|hallucinations|112|126|ribavirin|84|93
20118434|OBJECTIVE: The authors described a case of interferon-induced psychosis as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C.|psychosis|62|71|interferon|43|53
20120657|CONCLUSION: Zidovudine is well a known cause of anaemia and thus should be used with caution in the initiation of antiretroviral therapy.|anaemia|48|55|Zidovudine|12|22
20120657|We report a case of Zidovudine induced anaemia and bone marrow aplasia in a patient infected with HIV.|anaemia|39|46|Zidovudine|20|30
20120657|We report a case of Zidovudine induced anaemia and bone marrow aplasia in a patient infected with HIV.|bone marrow aplasia|51|70|Zidovudine|20|30
20120657|Zidovudine induced pure red cell aplasia: a case report.|pure red cell aplasia|19|40|Zidovudine|0|10
20126479|CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss.|objective visual field loss|254|281|hydroxychloroquine|109|127
20126479|CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from hydroxychloroquine toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss.|visual field loss|86|103|hydroxychloroquine|109|127
20126479|PURPOSE: To describe spectral-domain optical coherence tomography (SD-OCT) and adaptive optics (AO) imaging in hydroxychloroquine retinal toxicity.|retinal toxicity|130|146|hydroxychloroquine|111|129
20126479|Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss.|retinal toxicity|95|111|hydroxychloroquine|76|94
2012922|Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.|hypomanic symptoms|28|46|trazodone|10|19
2012922|Trazodone-induced transient hypomanic symptoms and their management.|transient hypomanic symptoms|18|46|Trazodone|0|9
20130478|Introduction of etanercept was also clinically effective but followed by development of severe heart failure.|severe heart failure|88|108|etanercept|16|26
20130478|Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis.|Reversible heart failure|0|24|etanercept|48|58
20154441|Combining methylephedrine and Chinese herbal drugs might carry a risk of stroke.|stroke|73|79|methylephedrine|10|25
2016556|We describe a patient who experienced chronic nausea and an episode of confusion while treated with a small, stable dose of oral morphine in the setting of mild renal insufficiency.|chronic nausea|38|52|morphine|129|137
2016556|We describe a patient who experienced chronic nausea and an episode of confusion while treated with a small, stable dose of oral morphine in the setting of mild renal insufficiency.|confusion|71|80|morphine|129|137
20171144|Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).|ataxia|144|150|lacosamide|41|51
20171144|Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).|diplopia|152|160|lacosamide|41|51
20171144|Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).|dizziness|133|142|lacosamide|41|51
20171144|Common adverse events (frequency 10%) of lacosamide doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).|somnolence|166|176|lacosamide|41|51
20178709|A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy.|aseptic pleuropericarditis|10|36|methotrexate|86|98
20178709|Methotrexate may rarely provoke serositis, even with low doses and after just a few weeks of therapy.|serositis|32|41|Methotrexate|0|12
20178709|We report here a rare case of pleuropericarditis due to methotrexate.|pleuropericarditis|30|48|methotrexate|56|68
20185472|The authors report five cases of tremor related to itraconazole therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following itraconazole withdrawal.|tremor|33|39|itraconazole|51|63
20185472|The authors report five cases of tremor related to itraconazole therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following itraconazole withdrawal.|tremor|33|39|itraconazole|164|176
20185472|Tremor: a newly described adverse event with long-term itraconazole therapy.|Tremor|0|6|itraconazole|55|67
20190474|Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome.|Acute kidney injury|0|19|zonisamide|30|40
20190474|Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome.|hypersensitivity syndrome|49|74|zonisamide|30|40
20190474|Hypersensitivity to zonisamide was confirmed by the skin patch test.|Hypersensitivity|0|16|zonisamide|20|30
20190474|The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.|acute kidney injury|127|146|zonisamide|54|64
20190474|The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.|an increase in antihuman herpesvirus-6 immunoglobulin G titer|219|280|zonisamide|54|64
20190474|The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.|eosinophilia|166|178|zonisamide|54|64
20190474|The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.|high-grade fever|148|164|zonisamide|54|64
20190474|The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.|liver dysfunction|180|197|zonisamide|54|64
20190474|The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.|lymphadenopathy|199|214|zonisamide|54|64
20190474|The current report describes a man who was prescribed zonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.|skin rash|116|125|zonisamide|54|64
20190474|This is the first report of acute kidney injury due to zonisamide-induced DRESS/DIHS.|acute kidney injury|28|47|zonisamide|55|65
20190474|This is the first report of acute kidney injury due to zonisamide-induced DRESS/DIHS.|DIHS|80|84|zonisamide|55|65
20190474|This is the first report of acute kidney injury due to zonisamide-induced DRESS/DIHS.|DRESS|74|79|zonisamide|55|65
20199429|Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.|allergic contact dermatitis|212|239|bisabolol|243|252
20203465|Case report: acute renal failure after administering intravenous immunoglobulin.|acute renal failure|13|32|immunoglobulin|65|79
20203465|The hospital course of the acute renal failure is presented with a review of the literature on cases of acute renal failure after IVIG.|acute renal failure|104|123|IVIG|130|134
20203465|We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG).|azotemia|120|128|immunoglobulin|196|210
20203465|We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG).|azotemia|120|128|IVIG|212|216
20203465|We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG).|hyperkalemia|134|146|immunoglobulin|196|210
20203465|We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG).|hyperkalemia|134|146|IVIG|212|216
20203465|We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG).|nausea|91|97|immunoglobulin|196|210
20203465|We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG).|nausea|91|97|IVIG|212|216
20203465|We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG).|shortness of breath|99|118|immunoglobulin|196|210
20203465|We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (IVIG).|shortness of breath|99|118|IVIG|212|216
2022118|However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.|cardiac toxicity|171|187|lithium|20|27
2022118|However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.|loss of intracellular potassium|107|138|lithium|20|27
20234160|Severe vancomycin-induced anaphylactic reaction.|anaphylactic reaction|26|47|vancomycin|7|17
20234160|Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis.|anaphylactoid|271|284|Vancomycin|0|10
20234160|Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis.|anaphylaxis|326|337|Vancomycin|0|10
20234160|Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis.|blood disorders|205|220|Vancomycin|0|10
20234160|Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis.|gastrointestinal disturbances|174|203|Vancomycin|0|10
20234160|Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis.|hypersensitivity reactions|239|265|Vancomycin|0|10
20234160|Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis.|nephrotoxicity|145|159|Vancomycin|0|10
20234160|Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis.|ototoxicity|161|172|Vancomycin|0|10
20234160|Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis.|red man syndrome|304|320|Vancomycin|0|10
20234160|We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.|anaphylactic reaction|73|94|vancomycin|54|64
2028358|Four patients in whom pulmonary oedema developed during tocolysis with hexoprenaline are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed.|pulmonary oedema|22|38|hexoprenaline|71|84
2028358|Pulmonary oedema after hexoprenaline administration in preterm labour.|Pulmonary oedema|0|16|hexoprenaline|23|36
20298401|Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.|Fatal interstitial lung disease|0|31|erlotinib|38|47
20298401|High-resolution computed tomography scan findings were consistent with ILD, which was sufficient to diagnose as erlotinib-induced ILD.|ILD|130|133|erlotinib|112|121
20298401|INTRODUCTION: Although gefitinib used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (ILD), few case reports on erlotinib-induced ILD have been issued.|ILD|138|141|gefitinib|23|32
20298401|INTRODUCTION: Although gefitinib used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (ILD), few case reports on erlotinib-induced ILD have been issued.|ILD|182|185|erlotinib|164|173
20298401|INTRODUCTION: Although gefitinib used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (ILD), few case reports on erlotinib-induced ILD have been issued.|interstitial lung disease|111|136|gefitinib|23|32
20298401|RESULTS: We recently experienced a case of fatal erlotinib-induced ILD, diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis.|ILD|67|70|erlotinib|49|58
20298401|This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of ILD in patients taking erlotinib.|ILD|120|123|erlotinib|143|152
20338114|One patient suffered coronary artery vasospasm, attributed to the use of topical 1:1000 epinephrine during surgery.|coronary artery vasospasm|21|46|epinephrine|88|99
20338114|The other patient developed transient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated epinephrine.|transient intraoperative hypertension|28|65|epinephrine|133|144
20349794|Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.|SIADH|66|71|Cisplatin|0|9
20349794|Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.|syndrome of inappropriate antidiuretic hormone|18|64|Cisplatin|0|9
20349794|We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.|SIADH|73|78|cisplatin|93|102
20349794|We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.|syndrome of inappropriate antidiuretic hormone|25|71|cisplatin|93|102
20367573|However, to our knowledge, in newborns there have been no reported cases to date of thrombocytosis induced by enoxaparin.|thrombocytosis|84|98|enoxaparin|110|120
20367573|Thrombocytosis associated with enoxaparin: A very rare cause in newborns.|Thrombocytosis|0|14|enoxaparin|31|41
20367573|Thrombocytosis induced by enoxaparin has been reported as a rare adverse effect of this medication in adults.|Thrombocytosis|0|14|enoxaparin|26|36
20378385|OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, splenomegaly, and extreme hyperferritinemia.|extreme hyperferritinemia|136|161|adalimumab|72|82
20378385|OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, splenomegaly, and extreme hyperferritinemia.|fever|97|102|adalimumab|72|82
20378385|OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, splenomegaly, and extreme hyperferritinemia.|pancytopenia|104|116|adalimumab|72|82
20378385|OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever, pancytopenia, splenomegaly, and extreme hyperferritinemia.|splenomegaly|118|130|adalimumab|72|82
20378385|Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab.|macrophagic activation syndrome|27|58|adalimumab|119|129
20378385|Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab.|Visceral leishmaniasis|0|22|adalimumab|119|129
2038845|This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an oro-pharyngeal dystonic reaction to prochlorperazine.|epiglottitis|74|86|prochlorperazine|144|160
2038845|This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an oro-pharyngeal dystonic reaction to prochlorperazine.|oro-pharyngeal dystonic reaction|108|140|prochlorperazine|144|160
20397038|Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up.|retinopathy|143|154|hydroxychloroquine|124|142
20412003|After other potential causes of liver toxicity were excluded, TMP-SMX was determined to be the cause of his acute liver toxicity.|acute liver toxicity|108|128|TMP-SMX|62|69
20412003|After other potential causes of liver toxicity were excluded, TMP-SMX was determined to be the cause of his acute liver toxicity.|liver toxicity|32|46|TMP-SMX|62|69
20412003|Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of TMP-SMX-induced hepatotoxicity are rare.|cutaneous skin eruptions|95|119|TMP-SMX|140|147
20412003|Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of TMP-SMX-induced hepatotoxicity are rare.|hepatotoxicity|156|170|TMP-SMX|140|147
20412003|Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of TMP-SMX-induced hepatotoxicity are rare.|hypersensitivity syndrome|59|84|TMP-SMX|140|147
20412003|Due to the increasing use of TMP-SMX in children, clinicians should be aware of this potentially life-threatening, immunemediated hypersensitivity reaction.|immunemediated hypersensitivity reaction|115|155|TMP-SMX|29|36
20412003|Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a pediatric patient.|hepatotoxicity|38|52|Trimethoprim-sulfamethoxazole|0|29
20412003|Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between the patient's development of hepatotoxicity and the TMP-SMX therapy.|hepatotoxicity|143|157|TMP-SMX|166|173
20412003|We describe a relatively healthy, 9-year-old boy who developed a CA-MRSA skin and soft tissue infection and was treated with TMP-SMX.|soft tissue infection|82|103|TMP-SMX|125|132
2042691|Amiodarone was discontinued, and thyrotoxicosis gradually abated.|thyrotoxicosis|33|47|Amiodarone|0|10
2042691|Goiter and hypothyroidism during re-treatment with amiodarone in a patient who previously experienced amiodarone-induced thyrotoxicosis.|Goiter|0|6|amiodarone|51|61
2042691|Goiter and hypothyroidism during re-treatment with amiodarone in a patient who previously experienced amiodarone-induced thyrotoxicosis.|hypothyroidism|11|25|amiodarone|51|61
2042691|Goiter and hypothyroidism during re-treatment with amiodarone in a patient who previously experienced amiodarone-induced thyrotoxicosis.|thyrotoxicosis|121|135|amiodarone|102|112
20465622|BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.|Aphthous stomatitis|12|31|sirolimus|101|110
20465622|CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.|worsening of chronic aphthous ulcers|88|124|sirolimus|188|197
20465622|CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.|worsening of chronic aphthous ulcers|88|124|tacrolimus|174|184
20465622|Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.|Severe aphthous stomatitis|0|26|calcineurin|48|59
2048579|These findings mean that the effect of the MP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an MP therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal-change nephrotic syndrome, may be responsible for the MP-induced transient renal failure.|transient renal failure|544|567|MP|533|535
2048579|Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of MP developed transient renal failure following an MP pulse therapy.|transient renal failure|163|186|MP|150|152
2048579|Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of MP developed transient renal failure following an MP pulse therapy.|transient renal failure|163|186|MP|200|202
2051906|A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.|severe cholestasis|144|162|azathioprine|192|204
2051906|It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.|cholestasis|87|98|azathioprine|66|78
2051906|Reversible cholestasis with bile duct injury following azathioprine therapy.|bile duct injury|28|44|azathioprine|55|67
2051906|Reversible cholestasis with bile duct injury following azathioprine therapy.|cholestasis|11|22|azathioprine|55|67
2063999|A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment.|acute encephalopathy|33|53|calcium hopantenate|69|88
2063999|We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).|acute encephalopathy|48|68|calcium hopantenate|89|108
2063999|We report a girl with the Rett syndrome who had acute encephalopathy probably induced by calcium hopantenate (HOPA).|acute encephalopathy|48|68|HOPA|110|114
2076372|Persistent light reactivity from systemic quinine.|Persistent light reactivity|0|27|quinine|42|49
2076372|The photosensitivity is still present 3 years after the withdrawal of quinine.|photosensitivity|4|20|quinine|70|77
2104570|Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.|hematologic malignancy|51|73|doxorubicin|166|177
2104570|Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.|hematologic malignancy|51|73|etoglucid|155|164
2104570|Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C.|hematologic malignancy|51|73|mitomycin C|183|194
2113320|A patient with Wegener's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.|circumferential subglottic stenosis|60|95|cyclophosphamide|107|123
2113320|Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy.|Subglottic stenosis|0|19|cyclophosphamide|68|84
2116935|A case is described of severe splenic hemorrhage and rupture which developed 3 h after completion of tPA infusion for suspected acute myocardial infarction.|severe splenic hemorrhage and rupture|23|60|tPA|101|104
2116935|Splenic hemorrhage: a complication of tissue plasminogen activator treatment.|Splenic hemorrhage|0|18|tissue plasminogen activator|38|66
2116935|Thrombolytic therapy with tissue plasminogen activator (tPA) for acute myocardial infarction may result in major bleeding complications such as gastrointestinal or intracranial bleeding.|gastrointestinal or intracranial bleeding|144|185|tissue plasminogen activator|26|54
2116935|Thrombolytic therapy with tissue plasminogen activator (tPA) for acute myocardial infarction may result in major bleeding complications such as gastrointestinal or intracranial bleeding.|gastrointestinal or intracranial bleeding|144|185|tPA|56|59
2140997|A case of severe acute hepatitis caused by cyproterone acetate in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug.|severe acute hepatitis|10|32|cyproterone acetate|43|62
2140997|Monitoring of liver function tests should be mandatory in patients receiving high doses of cyproterone acetate; the drug should be withdrawn immediately if abnormal liver function tests are found.|abnormal liver function tests|156|185|cyproterone acetate|91|110
2140997|Severe hepatitis caused by cyproterone acetate.|Severe hepatitis|0|16|cyproterone acetate|27|46
2144305|A unique case of a transient, nonpigmenting fixed drug eruption caused by the radiopaque contrast medium iothalamate is reported.|fixed drug eruption|44|63|iothalamate|105|116
2147700|One patient with systemic lupus erythematosus developed erythema multiforme after taking griseofulvin.|erythema multiforme|56|75|griseofulvin|89|101
2154663|Aminoglutethimide was discontinued until completion of radiotherapy, and the rash resolved.|rash|77|81|Aminoglutethimide|0|17
2154663|Concomitant irradiation apparently enhanced the skin toxicity of aminoglutethimide or possibly aminoglutethimide had a radiosensitizing role in this patient.|skin toxicity|48|61|aminoglutethimide|65|82
2154663|We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer.|skin toxicity|60|73|aminoglutethimide|42|59
2161782|Data have been published regarding the possibility that tamoxifen may be responsible for the subsequent development of carcinoma of the corpus uteri in these patients.|carcinoma of the corpus uteri|119|148|tamoxifen|56|65
2161782|The authors intend to carry out a case-control study on patients treated with tamoxifen for breast carcinoma to reveal the possible presence of endometrial carcinoma.|endometrial carcinoma|144|165|tamoxifen|78|87
2196696|Disulfiram-induced hepatitis.|hepatitis|19|28|Disulfiram|0|10
2196696|Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.|eosinophilia|66|78|disulfiram|96|106
2196696|Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.|headache|16|24|disulfiram|96|106
2196696|Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.|mild fever|26|36|disulfiram|96|106
2196696|Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.|nausea|38|44|disulfiram|96|106
2196696|Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.|rash|56|60|disulfiram|96|106
2196696|Our patient had headache, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of disulfiram therapy.|vomiting|46|54|disulfiram|96|106
2196696|We reported a case of disulfiram-induced hepatitis with unique clinical features and compared our case with others in the literature.|hepatitis|41|50|disulfiram|22|32
2204409|An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.|leukoencephalopathy|14|33|methotrexate|220|232
2204409|An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal methotrexate.|leukoencephalopathy|14|33|methotrexate|255|267
2204409|Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: a case report and analysis of the literature.|leukoencephalopathy|21|40|Methotrexate|0|12
2212262|Severe heparin associated thrombocytopenia is a rare complication of heparin therapy.|thrombocytopenia|26|42|heparin|69|76
2212262|Severe heparin associated thrombocytopenia is a rare complication of heparin therapy.|thrombocytopenia|26|42|heparin|7|14
2212262|We report a patient who developed heparin associated thrombocytopenia during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment.|thrombocytopenia|53|69|heparin|34|41
2219619|Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.|aluminum toxicity|6|23|alum|54|58
2219619|An encephalopathy and cardiomyopathy developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical aluminum infusion for hemorrhagic cystitis.|cardiomyopathy|22|36|aluminum|148|156
2219619|An encephalopathy and cardiomyopathy developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical aluminum infusion for hemorrhagic cystitis.|encephalopathy|3|17|aluminum|148|156
2224786|A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related hemolytic-uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate.|hemolytic-uremic syndrome|124|149|bleomycin|227|236
2224786|A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related hemolytic-uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate.|hemolytic-uremic syndrome|124|149|cisplatin|216|225
2224786|A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related hemolytic-uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate.|hemolytic-uremic syndrome|124|149|methotrexate|242|254
2229534|Awareness of this route of intoxication might be important in patients in whom neurologic or psychiatric symptoms develop while large amounts of lidocaine cream are being used.|psychiatric symptoms|93|113|lidocaine|145|154
2234880|Nitrendipine-induced gingival hyperplasia.|gingival hyperplasia|21|41|Nitrendipine|0|12
2234880|Nitrendipine is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced gingival hyperplasia.|gingival hyperplasia|122|142|Nitrendipine|0|12
2241449|Physicians using this "new" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.|injury to the urinary tract|94|121|sulfonamide|74|85
2241449|Sulfadiazine crystalluria revisited.|crystalluria|13|25|Sulfadiazine|0|12
2241449|We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.|crystalluria|46|58|sulfadiazine|25|37
2241449|We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.|renal failure|63|76|sulfadiazine|25|37
2250853|Glaucoma secondary to epithelial downgrowth and 5-fluorouracil.|Glaucoma|0|8|5-fluorouracil|48|62
2250853|We report a case of secondary glaucoma caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival 5-fluorouracil.|glaucoma|30|38|5-fluorouracil|152|166
2257522|Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature.|hypophosphatemic osteomalacia|31|60|sucralfate|12|22
2276822|Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.|hypersensitivity reaction|13|38|gentamicin|78|88
2276822|Because of a hypersensitivity reaction, initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin.|hypersensitivity reaction|13|38|penicillin G|61|73
228648|Prenatal cytomegalovirus (CMV) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus (SLE).|brain damage|64|76|azathioprine|155|167
228648|Prenatal cytomegalovirus (CMV) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus (SLE).|brain damage|64|76|prednisolone|138|150
228648|Prenatal cytomegalovirus (CMV) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus (SLE).|Prenatal cytomegalovirus (CMV) infection|0|40|azathioprine|155|167
228648|Prenatal cytomegalovirus (CMV) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus (SLE).|Prenatal cytomegalovirus (CMV) infection|0|40|prednisolone|138|150
2292051|Acute coronary events following cisplatin-based chemotherapy.|Acute coronary events|0|21|cisplatin|32|41
2292051|Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/infarction shortly after cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy.|acute coronary ischemia|96|119|cis-diamine-dichloroplatinum II|145|176
2292051|Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/infarction shortly after cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy.|acute coronary ischemia|96|119|cisplatin|178|187
2292051|Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/infarction shortly after cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy.|infarction|120|130|cis-diamine-dichloroplatinum II|145|176
2292051|Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/infarction shortly after cis-diamine-dichloroplatinum II (cisplatin) -based chemotherapy.|infarction|120|130|cisplatin|178|187
2295443|Bowel perforation associated with intraperitoneal chromic phosphate instillation.|Bowel perforation|0|17|chromic phosphate|50|67
2295443|Delayed bowel injury is an infrequently observed complication of chromic phosphate administration.|bowel injury|8|20|chromic phosphate|65|82
2295443|This report presents a case of colon perforation which occurred 4 months after treatment with intraperitoneal chromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma.|colon perforation|31|48|chromic phosphate|110|127
2297635|Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.|death|211|216|Ara-C|184|189
2297635|Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.|death|211|216|MTX|85|88
2297635|Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.|loss of consciousness|129|150|Ara-C|184|189
2297635|Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.|loss of consciousness|129|150|MTX|85|88
2297635|Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.|progressive visual loss|101|124|Ara-C|184|189
2297635|Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.|progressive visual loss|101|124|MTX|85|88
2299784|A 59-year-old woman with myasthenia gravis who received a large dose of pyridostigmine bromide developed postoperative psychosis and was diagnosed as having bromide intoxication.|bromide intoxication|157|177|pyridostigmine bromide|72|94
2299784|A 59-year-old woman with myasthenia gravis who received a large dose of pyridostigmine bromide developed postoperative psychosis and was diagnosed as having bromide intoxication.|postoperative psychosis|105|128|pyridostigmine bromide|72|94
2299784|Bromide intoxication secondary to pyridostigmine bromide therapy.|Bromide intoxication|0|20|pyridostigmine bromide|34|56
2299784|To our knowledge , this is the first reported case of bromide intoxication due to pyridostigmine bromide administration.|bromide intoxication|54|74|pyridostigmine bromide|82|104
2302898|Diazepam use by pregnant women can be associated with a later presentation of withdrawal symptoms in the neonate than that induced by the use of other drugs.|withdrawal symptoms|78|97|Diazepam|0|8
2305654|We conclude that neurosurgeons and neurologists should be aware of calcium antagonist--related ileus in patients treated with nimodipine.|ileus|95|100|nimodipine|126|136
2305654|We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon, a variant of adynamic ileus, while being treated with intravenous nimodipine.|adynamic ileus|139|153|nimodipine|192|202
2305654|We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon, a variant of adynamic ileus, while being treated with intravenous nimodipine.|pseudo-obstruction of the colon|93|124|nimodipine|192|202
2309833|After discontinuation of danazol the diabetes completely resolved.|diabetes|37|45|danazol|25|32
2309833|Insulin-dependent diabetes mellitus associated with danazol.|Insulin-dependent diabetes mellitus|0|35|danazol|52|59
2309833|Insulin-dependent diabetes mellitus developed in a young woman 8 weeks after the initiation of danazol for treatment of pelvic endometriosis.|Insulin-dependent diabetes mellitus|0|35|danazol|95|102
2316232|An 83-year-old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen.|symptomatic hypoglycemia|59|83|glipizide|29|38
2316232|An 83-year-old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen.|symptomatic hypoglycemia|59|83|SMX|147|150
2316232|An 83-year-old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen.|symptomatic hypoglycemia|59|83|sulfamethoxazole|125|141
2316232|An 83-year-old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen.|symptomatic hypoglycemia|59|83|TMP|143|146
2316232|An 83-year-old man receiving glipizide 10 mg bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen.|symptomatic hypoglycemia|59|83|trimethoprim|112|124
2316232|Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.|Symptomatic hypoglycemia|0|24|glipizide|40|49
2316232|Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.|Symptomatic hypoglycemia|0|24|sulfamethoxazole|63|79
2316232|Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.|Symptomatic hypoglycemia|0|24|trimethoprim|50|62
2320800|A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.|anuria|139|145|ifosfamide|174|184
2320800|A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.|irreversible lethal renal failure|100|133|ifosfamide|174|184
2320800|Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.|tubulopathies|57|70|Ifosfamide|0|10
2320800|Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.|Lethal anuria|0|13|ifosfamide|37|47
2320800|We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.|lethal anuria|30|43|ifosfamide|62|72
2327115|Ciprofloxacin is one drug that has been reported to cause interstitial nephritis.|interstitial nephritis|58|80|Ciprofloxacin|0|13
2327115|Renal toxicities have been reported in less than one percent of the patients receiving ciprofloxacin therapy.|Renal toxicities|0|16|ciprofloxacin|87|100
2327115|Suspected ciprofloxacin-induced interstitial nephritis.|interstitial nephritis|32|54|ciprofloxacin|10|23
2327115|This article describes a patient with suspected ciprofloxacin-induced interstitial nephritis.|interstitial nephritis|70|92|ciprofloxacin|48|61
2329972|In a female with acute lymphoblastic leukemia, inadvertent doxorubicin administration intrathecally caused severe, life-threatening, acute encephalopathy with high-pressure hydrocephalus.|acute encephalopathy|133|153|doxorubicin|59|70
2329972|In a female with acute lymphoblastic leukemia, inadvertent doxorubicin administration intrathecally caused severe, life-threatening, acute encephalopathy with high-pressure hydrocephalus.|high-pressure hydrocephalus|159|186|doxorubicin|59|70
2329972|Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration.|Severe acute encephalopathy|0|27|doxorubicin|62|73
2332596|Phenobarbital hepatotoxicity in an 8-month-old infant.|hepatotoxicity|14|28|Phenobarbital|0|13
2332596|Severe hepatotoxicity from phenobarbital occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis.|Severe hepatotoxicity|0|21|phenobarbital|27|40
2332596|Skin rash began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after phenobarbital had been started.|hepatocellular failure|57|79|phenobarbital|104|117
2332596|Skin rash began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after phenobarbital had been started.|Skin rash|0|9|phenobarbital|104|117
2347102|Atenolol-induced pseudolymphoma.|pseudolymphoma|17|31|Atenolol|0|8
2357706|Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist.|tardive dyskinesia|9|27|sulpiride|164|173
2357706|Tardive dyskinesia induced by sulpiride.|Tardive dyskinesia|0|18|sulpiride|30|39
2357706|These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.|tardive dyskinesia|46|64|sulpiride|26|35
2357706|We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms.|tardive dyskinesia|39|57|sulpiride|79|88
2369419|A patient with seropositive rheumatoid arthritis developed ascites while taking weekly doses of methotrexate (MTX).|ascites|59|66|methotrexate|96|108
2369419|A patient with seropositive rheumatoid arthritis developed ascites while taking weekly doses of methotrexate (MTX).|ascites|59|66|MTX|110|113
2369419|Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate.|bridging fibrosis|15|32|methotrexate|114|126
2369419|Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate.|Hepatitis|0|9|methotrexate|114|126
2369419|Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate.|reversible hepatic insufficiency|37|69|methotrexate|114|126
2369419|This is the third report of reversible hepatic decompensation associated with prolonged MTX therapy in patients with rheumatoid arthritis.|hepatic decompensation|39|61|MTX|88|91
2369419|Upon discontinuation of MTX, her ascites resolved, and her arthritis became more active.|ascites|33|40|MTX|24|27
2378415|Although high-dose methotrexate has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a fatal rise in intracranial pressure.|fatal rise in intracranial pressure|167|202|methotrexate|19|31
2378415|A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and brainstem herniation after she received a single dose of intravenous methotrexate.|brainstem herniation|150|170|methotrexate|219|231
2378415|A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and brainstem herniation after she received a single dose of intravenous methotrexate.|fatal cerebral edema|125|145|methotrexate|219|231
2378415|Transtentorial herniation caused by an intracranial mass lesion following high-dose methotrexate.|intracranial mass lesion|39|63|methotrexate|84|96
2378415|Transtentorial herniation caused by an intracranial mass lesion following high-dose methotrexate.|Transtentorial herniation|0|25|methotrexate|84|96
2394154|Fever, pulmonary infiltrates, and pleural effusion following acyclovir therapy for herpes zoster ophthalmicus.|Fever|0|5|acyclovir|61|70
2394154|Fever, pulmonary infiltrates, and pleural effusion following acyclovir therapy for herpes zoster ophthalmicus.|pleural effusion|34|50|acyclovir|61|70
2394154|Fever, pulmonary infiltrates, and pleural effusion following acyclovir therapy for herpes zoster ophthalmicus.|pulmonary infiltrates|7|28|acyclovir|61|70
2394154|Following the institution of intravenous therapy with acyclovir, the patient developed fever, hemoptysis, and a pleural friction rub.|fever|87|92|acyclovir|54|63
2394154|Following the institution of intravenous therapy with acyclovir, the patient developed fever, hemoptysis, and a pleural friction rub.|hemoptysis|94|104|acyclovir|54|63
2394154|Following the institution of intravenous therapy with acyclovir, the patient developed fever, hemoptysis, and a pleural friction rub.|pleural friction rub|112|132|acyclovir|54|63
2394154|The fever abated promptly following discontinuation of acyclovir, and radiographic abnormalities resolved over ten days.|fever|4|9|acyclovir|55|64
2394154|To our knowledge, the syndrome of fever, pulmonary infiltrates, and pleural effusion following use of acyclovir has not been previously reported.|fever|34|39|acyclovir|102|111
2394154|To our knowledge, the syndrome of fever, pulmonary infiltrates, and pleural effusion following use of acyclovir has not been previously reported.|pleural effusion|68|84|acyclovir|102|111
2394154|To our knowledge, the syndrome of fever, pulmonary infiltrates, and pleural effusion following use of acyclovir has not been previously reported.|pulmonary infiltrates|41|62|acyclovir|102|111
2406680|Quinine-induced hearing loss.|hearing loss|16|28|Quinine|0|7
2406680|Sensorineural hearing loss due to quinine therapy for malaria has frequently been mentioned in the literature but has not been a subject of research during the last decades.|Sensorineural hearing loss|0|26|quinine|34|41
2406680|The case of a 29-year-old man suffering from falciparum malaria disease who got a reversible hearing loss from quinine therapy is presented.|reversible hearing loss|82|105|quinine|111|118
2406680|The ototoxicity of quinine can accurately be studied with ultrahigh frequency audiometry (up to 20 kHz).|ototoxicity|4|15|quinine|19|26
2413037|Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.|Hemolytic uremic syndrome|0|25|bleomycin|72|81
2413037|Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.|Hemolytic uremic syndrome|0|25|cis-platinum|42|54
2413037|Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.|Hemolytic uremic syndrome|0|25|vinblastine|56|67
2417800|A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.|acute pneumonitis|42|59|bleomycin|66|75
2417800|A case of a 53-year-old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented.|acute pneumonitis|42|59|oxygen|89|95
2417800|Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.|pulmonary damage|67|83|bleomycin|38|47
2417800|Autopsy findings were consistent with bleomycin and oxygen-induced pulmonary damage.|pulmonary damage|67|83|oxygen|52|58
2417800|Bleomycin pneumonitis potentiated by oxygen administration.|pneumonitis|10|21|Bleomycin|0|9
2417800|Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.|pulmonary toxicity|41|59|bleomycin|23|32
2417800|Oxygen potentiation of bleomycin-induced pulmonary toxicity is discussed.|pulmonary toxicity|41|59|Oxygen|0|6
2429270|A patient with the Wolff-Parkinson-White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy.|incessant orthodromic atrioventricular tachycardia|65|115|procainamide|140|152
2429270|Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after procainamide.|tachycardia|138|149|procainamide|211|223
2429270|In addition, the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide.|tachycardia|17|28|procainamide|112|124
2429270|Procainamide-induced incessant supraventricular tachycardia in the Wolff-Parkinson-White syndrome.|incessant supraventricular tachycardia|21|59|Procainamide|0|12
2429270|The pro-arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.|pro-arrhythmic effects|4|26|procainamide|30|42
2442958|Multicentric hepatocellular carcinoma following phosphate diethylstilbestrol therapy for prostatic cancer.|Multicentric hepatocellular carcinoma|0|37|phosphate diethylstilbestrol|48|76
2442958|This is a unique autopsy case of hepatocellular carcinoma closely related to diethylstilbestrol (DES) therapy for prostatic cancer.|hepatocellular carcinoma|33|57|DES|97|100
2442958|This is a unique autopsy case of hepatocellular carcinoma closely related to diethylstilbestrol (DES) therapy for prostatic cancer.|hepatocellular carcinoma|33|57|diethylstilbestrol|77|95
2442958|This paper reports an autopsy case of a 78-year-old male with multiple nodules in the liver developed after long-termed administration of phosphate diethylstilbestrol (PDES) for prostatic cancer.|multiple nodules in the liver|62|91|PDES|168|172
2442958|This paper reports an autopsy case of a 78-year-old male with multiple nodules in the liver developed after long-termed administration of phosphate diethylstilbestrol (PDES) for prostatic cancer.|multiple nodules in the liver|62|91|phosphate diethylstilbestrol|138|166
2445709|A 52-year-old woman developed symmetric sensorimotor polyneuropathy and cerebellar syndrome after 24 months of amiodarone treatment.|cerebellar syndrome|72|91|amiodarone|111|121
2445709|A 52-year-old woman developed symmetric sensorimotor polyneuropathy and cerebellar syndrome after 24 months of amiodarone treatment.|symmetric sensorimotor polyneuropathy|30|67|amiodarone|111|121
2445709|Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy.|cerebellar syndrome|26|45|amiodarone|62|72
2445709|Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy.|Peripheral neuropathy|0|21|amiodarone|62|72
2452936|Life-threatening hyponatremia caused by vinblastine.|hyponatremia|17|29|vinblastine|40|51
2452936|The most likely cause of such hyponatremic episode is vinblastine.|hyponatremic episode|30|50|vinblastine|54|65
2461837|Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.|hyperpigmentation|22|39|bleomycin|107|116
2461837|Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.|hyperpigmentation|190|207|bleomycin|172|181
2461837|We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome (AIDS).|hyperpigmentation|20|37|bleomycin|45|54
2483959|A typical case of dextran-40 associated acute renal failure is presented.|acute renal failure|40|59|dextran-40|18|28
2483959|Renal failure associated with the use of dextran-40.|Renal failure|0|13|dextran-40|41|51
2483959|Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.|renal failure|50|63|dextran-40|91|101
2483959|While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.|renal failure|42|55|dextran|23|30
2505541|MR findings in methotrexate-induced CNS abnormalities.|CNS abnormalities|36|53|methotrexate|15|27
2523364|A 57-year-old man developed morphea while taking bromocriptine.|morphea|28|35|bromocriptine|49|62
2523364|Morphea after bromocriptine therapy.|Morphea|0|7|bromocriptine|14|27
2532694|A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.|erythroderma|96|108|dapsone|80|87
2532694|Dapsone-induced erythroderma with Beau's lines.|erythroderma|16|28|Dapsone|0|7
2549018|Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.|Akathisia|0|9|fluoxetine|49|59
2549018|Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.|akathisia|116|125|fluoxetine|24|34
2549018|Fluoxetine-induced akathisia: clinical and theoretical implications.|akathisia|19|28|Fluoxetine|0|10
2549018|The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced "jitteriness" may be identical.|akathisia|44|53|fluoxetine|25|35
2549018|The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced "jitteriness" may be identical.|akathisia|193|202|fluoxetine|174|184
2549018|The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.|constant pacing|57|72|fluoxetine|12|22
2549018|The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.|marked anxiety|122|136|fluoxetine|12|22
2549018|The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.|purposeless movements of the feet and legs|74|116|fluoxetine|12|22
2549018|The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.|restlessness|43|55|fluoxetine|12|22
2549018|Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.|akathisia|126|135|fluoxetine|107|117
2554727|Horner's syndrome and demyelinating peripheral neuropathy caused by high-dose cytosine arabinoside.|demyelinating peripheral neuropathy|22|57|cytosine arabinoside|78|98
2554727|Horner's syndrome and demyelinating peripheral neuropathy caused by high-dose cytosine arabinoside.|Horner's syndrome|0|17|cytosine arabinoside|78|98
2554727|Peripheral nerve dysfunction is a potentially serious complication of high-dose cytosine arabinoside.|Peripheral nerve dysfunction|0|28|cytosine arabinoside|80|100
2554727|Peripheral nervous system disturbances caused by cytosine arabinoside have rarely been reported.|Peripheral nervous system disturbances|0|38|cytosine arabinoside|49|69
2554727|We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose cytosine arabinoside.|death|134|139|cytosine arabinoside|166|186
2554727|We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose cytosine arabinoside.|Horner's syndrome|56|73|cytosine arabinoside|166|186
2554727|We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose cytosine arabinoside.|severe demyelinating peripheral neuropathy|80|122|cytosine arabinoside|166|186
2568058|Nail-changes induced by penicillamine.|Nail-changes|0|12|penicillamine|24|37
2568058|Peculiar nail-changes in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described.|nail-changes|9|21|penicillamine|111|124
2568058|Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described nail-changes.|nail-changes|136|148|penicillamine|104|117
2586773|Ibuprofen-induced meningitis: detection of intrathecal IgG synthesis and immune complexes.|meningitis|18|28|Ibuprofen|0|9
2586773|We report a case of ibuprofen-induced meningitis in an otherwise healthy individual.|meningitis|38|48|ibuprofen|20|29
2595431|Metoclopramide-induced parkinsonism is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity.|parkinsonism|23|35|Metoclopramide|0|14
2595431|Metoclopramide-induced parkinsonism.|parkinsonism|23|35|Metoclopramide|0|14
2595431|Their parkinsonism improved on discontinuation of metoclopramide therapy.|parkinsonism|6|18|metoclopramide|50|64
2595431|We have reported six cases of metoclopramide-induced parkinsonism seen in consultation over a two-year period.|parkinsonism|53|65|metoclopramide|30|44
2611886|It is suggested that the fatal stroke may have resulted from arterial spasm caused by ergotamine overdosage and possibly complicated by thrombosis.|arterial spasm|61|75|ergotamine|86|96
2611886|It is suggested that the fatal stroke may have resulted from arterial spasm caused by ergotamine overdosage and possibly complicated by thrombosis.|fatal stroke|25|37|ergotamine|86|96
2616440|Life-threatening acute hyponatraemia induced by low dose cyclophosphamide and indomethacin.|acute hyponatraemia|17|36|cyclophosphamide|57|73
2616440|Life-threatening acute hyponatraemia induced by low dose cyclophosphamide and indomethacin.|acute hyponatraemia|17|36|indomethacin|78|90
2616440|We report the case of a patient with multiple myeloma who developed acute life-threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide.|life-threatening water intoxication|74|109|cyclophosphamide|178|194
2616440|We report the case of a patient with multiple myeloma who developed acute life-threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide.|life-threatening water intoxication|74|109|indomethacin|140|152
2621382|Clofazimine induced nail changes.|nail changes|20|32|Clofazimine|0|11
2621382|These nail changes gradually disappeared when the dose of clofazimine was reduced.|nail changes|6|18|clofazimine|58|69
2621382|Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine, showed discoloration of nail plate, subungual hyperkeratosis and onycholysis.|discoloration of nail plate|110|137|clofazimine|90|101
2621382|Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine, showed discoloration of nail plate, subungual hyperkeratosis and onycholysis.|onycholysis|168|179|clofazimine|90|101
2621382|Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine, showed discoloration of nail plate, subungual hyperkeratosis and onycholysis.|subungual hyperkeratosis|139|163|clofazimine|90|101
2643458|Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation.|hyperglycemia|36|49|asparaginase|15|27
2663536|Development of persistent late onset asthma following treatment with captopril.|persistent late onset asthma|15|43|captopril|69|78
2663536|We describe the first case of de novo asthma following treatment with the angiotensin converting enzyme (ACE) inhibitor captopril.|asthma|38|44|captopril|120|129
2669373|A case report of a patient with probable cisplatin and bleomycin-induced TMA is presented.|TMA|73|76|bleomycin|55|64
2669373|A case report of a patient with probable cisplatin and bleomycin-induced TMA is presented.|TMA|73|76|cisplatin|41|50
267281|A patient with chronic myeloid leukaemia treated with busulphan for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice.|ascites|146|153|busulphan|54|63
267281|A patient with chronic myeloid leukaemia treated with busulphan for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice.|jaundice|179|187|busulphan|54|63
267281|A patient with chronic myeloid leukaemia treated with busulphan for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice.|oesophageal varices|155|174|busulphan|54|63
267281|A patient with chronic myeloid leukaemia treated with busulphan for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice.|portal hypertension|121|140|busulphan|54|63
2690546|Although a lot of amiodarone-induced torsades de pointe have been published, a review of all these cases and the underlying risk-factors has never been made.|torsades de pointe|37|55|amiodarone|18|28
2690546|Amiodarone induced torsades de pointe.|torsades de pointe|19|37|Amiodarone|0|10
2690546|We report three cases of amiodarone-induced torsades de pointe.|torsades de pointe|44|62|amiodarone|25|35
2717661|The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).|neurotoxicity|49|62|lithium|29|36
2719905|Long lasting respiratory depression induced by morphine-6-glucuronide?|respiratory depression|13|35|morphine-6-glucuronide|47|69
2719905|We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.|respiratory depression|33|55|morphine|92|100
2728526|Rifampin-associated thrombocytopenia secondary to poor compliance.|thrombocytopenia|20|36|Rifampin|0|8
2728526|Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia.|acute renal failure|74|93|Rifampin|0|8
2728526|Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia.|hemolytic anemia|95|111|Rifampin|0|8
2728526|Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia.|hepatitis|63|72|Rifampin|0|8
2728526|Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia.|thrombocytopenia|117|133|Rifampin|0|8
2728526|This article reports the occurrence of rifampin-associated thrombocytopenia in an indigent patient after a four-month lapse in therapy for pulmonary tuberculosis.|thrombocytopenia|59|75|rifampin|39|47
2738729|We present the first case of WES in an infant born to a mother taking haloperidol during her pregnancy.|WES|29|32|haloperidol|70|81
2738729|Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy.|Withdrawal emergent syndrome|0|28|haloperidol|67|78
2743258|This report describes two patients who developed acute myelocytic leukemia only after exposure to cyclophosphamide, methotrexate, and 5-fluorouracil adjuvant therapy.|acute myelocytic leukemia|49|74|5-fluorouracil|134|148
2743258|This report describes two patients who developed acute myelocytic leukemia only after exposure to cyclophosphamide, methotrexate, and 5-fluorouracil adjuvant therapy.|acute myelocytic leukemia|49|74|cyclophosphamide|98|114
2743258|This report describes two patients who developed acute myelocytic leukemia only after exposure to cyclophosphamide, methotrexate, and 5-fluorouracil adjuvant therapy.|acute myelocytic leukemia|49|74|methotrexate|116|128
2746565|Ibuprofen rarely causes lower gastrointestinal adverse reactions but has been implicated in systemic and local side effects in patients with lupus.|gastrointestinal adverse reactions|30|64|Ibuprofen|0|9
2746565|Ulcerative proctitis in juvenile systemic lupus erythematosus after ibuprofen treatment.|Ulcerative proctitis|0|20|ibuprofen|68|77
2746565|We describe a case of ulcerative proctitis after ibuprofen treatment in a girl with juvenile systemic lupus erythematosus.|ulcerative proctitis|22|42|ibuprofen|49|58
2768785|Intravenous cytarabine and methotrexate appear to act synergistically to enhance the potential for central nervous system toxicity.|central nervous system toxicity|99|130|cytarabine|12|22
2768785|Intravenous cytarabine and methotrexate appear to act synergistically to enhance the potential for central nervous system toxicity.|central nervous system toxicity|99|130|methotrexate|27|39
2768785|We present two children with acute lymphocytic leukemia who developed leukoencephalopathy following administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy.|leukoencephalopathy|70|89|ara = C|147|154
2768785|We present two children with acute lymphocytic leukemia who developed leukoencephalopathy following administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy.|leukoencephalopathy|70|89|methotrexate|159|171
2781955|Dexamethasone treatment of amiodarone-induced thyrotoxicosis (AIT) with or without persistent administration of the drug.|thyrotoxicosis|46|60|amiodarone|27|37
2781955|Treatment of amiodarone-induced thyrotoxicosis (AIT) with thionamide, lithium or radioactive iodine is ineffective.|thyrotoxicosis|32|46|amiodarone|13|23
278642|Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.|Acute myelogenous leukemia|0|26|chlorambucil|49|61
278642|After the chlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical AML.|AML|111|114|chlorambucil|10|22
2796025|Panic anxiety after abrupt discontinuation of mianserin.|Panic anxiety|0|13|mianserin|46|55
2796025|This panic anxiety was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re-administration of mianserin 30 mg/day, and because of that the depressive symptom also disappeared.|panic anxiety|5|18|mianserin|129|138
2803154|Prior neurologic illness and the syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).|neurotoxicity|78|91|lithium|58|65
2803154|Prior neurologic illness or CNS insult of any kind is known to increase the vulnerability to neurotoxicity of lithium.|neurotoxicity|93|106|lithium|110|117
2803154|The authors describe a patient with hemiparesis who developed the syndrome of irreversible lithium-effectuated neurotoxicity (SILENT) while being treated with lithium for a manic episode.|neurotoxicity|111|124|lithium|91|98
2811895|Abrupt, accidental withdrawal of trihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission.|acute respiratory difficulties|143|173|trihexyphenidyl|33|48
2811895|Abrupt, accidental withdrawal of trihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission.|cranial dystonia|86|102|trihexyphenidyl|33|48
2811895|Abrupt, accidental withdrawal of trihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission.|inspiratory stridor|119|138|trihexyphenidyl|33|48
2811895|Life-threatening cranial dystonia following trihexyphenidyl withdrawal.|cranial dystonia|17|33|trihexyphenidyl|44|59
2816647|MR findings in methotrexate-induced CNS abnormalities.|CNS abnormalities|36|53|methotrexate|15|27
282937|Administration of intrathecal Ara-C in the same dose over longer intervals within 3-5 days between consecutive doses resulted in mild, transient neurological symptoms (paresthesias) in only one of 30 patients so treated.|paresthesias|168|180|Ara-C|30|35
282937|Paraplegia following intrathecal cytosine arabinoside.|Paraplegia|0|10|cytosine arabinoside|33|53
282937|Paraplegia following prophylactic intrathecal cytosine arabinoside (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days.|Paraplegia|0|10|Ara-C|68|73
282937|Paraplegia following prophylactic intrathecal cytosine arabinoside (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days.|Paraplegia|0|10|cytosine arabinoside|46|66
2830062|Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.|hypoadrenalism|24|38|o,p'-DDD|48|56
2857534|Alprazolam-induced mania: two clinical cases.|mania|19|24|Alprazolam|0|10
2857534|The authors caution that treatment with alprazolam may be complicated by the induction of mania.|mania|90|95|alprazolam|40|50
2857534|Two patients treated with alprazolam had histories suggestive of a bipolar disorder and developed lithium-responsive manic episodes.|manic episodes|117|131|alprazolam|26|36
2862137|A case is presented in which a 68-year-old man became delirious after being withdrawn from a low dosage of alprazolam.|delirious|54|63|alprazolam|107|117
2862137|Alprazolam withdrawal delirium unresponsive to diazepam: case report.|delirium|22|30|Alprazolam|0|10
2863342|Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.|bronchopulmonary complications of inflammatory bowel disease|39|99|Sulfasalazine|0|13
2863342|Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease (IBD) in adults.|IBD|101|104|Sulfasalazine|0|13
2863342|We discuss a variety of bronchopulmonary complications of IBD and their association with sulfasalazine.|IBD|58|61|sulfasalazine|89|102
2875665|Administration of amantadine was associated with psychotic decompensations in two schizophrenic patients being maintained on concomitant neuroleptic medication.|psychotic decompensations|49|74|amantadine|18|28
2875665|Despite a postulated dopaminergic mechanism, there seems to have been only one previous report of amantadine's precipitating psychosis in a schizophrenic patient.|precipitating psychosis|111|134|amantadine|98|108
2875665|Exacerbation of schizophrenia associated with amantadine.|schizophrenia|16|29|amantadine|46|56
2887555|Soon after its introduction in 1952, chlorpromazine was noted to induce symptoms resembling Parkinson's disease.|symptoms resembling Parkinson's disease|72|111|chlorpromazine|37|51
2894766|It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.|lupus|59|64|sulfasalazine|37|50
2894766|It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.|pulmonary parenchymal involvement|102|135|sulfasalazine|37|50
2894766|It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.|serositis|88|97|sulfasalazine|37|50
2894766|Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.|lupus syndrome|137|151|sulfasalazine|115|128
2894766|Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.|bilateral pleural effusions|13|40|sulfasalazine|179|192
2894766|Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.|cardiac tamponade|72|89|sulfasalazine|179|192
2894766|Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.|Pneumonitis|0|11|sulfasalazine|179|192
2894766|Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.|positive autoantibodies|95|118|sulfasalazine|179|192
2894766|Sulfasalazine-induced lupus erythematosus.|lupus erythematosus|22|41|Sulfasalazine|0|13
2924444|Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.|Acute myocardial infarction|0|27|L-thyroxine|66|77
2924444|Acute myocardial infarction due to coronary spasm associated with L-thyroxine therapy.|coronary spasm|35|49|L-thyroxine|66|77
2924444|Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L-thyroxine therapy.|acute myocardial infarction|75|102|L-thyroxine|114|125
2924444|We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.|coronary spasm|68|82|L-thyroxine|128|139
2924444|We believe this is the first report of myocardial infarction due to coronary spasm, demonstrated by angiography associated with L-thyroxine therapy.|myocardial infarction|39|60|L-thyroxine|128|139
2931445|A study of in vitro reactivity to L-T4, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed leukopenia during treatment with L-T4.|leukopenia|167|177|L-T4|200|204
2931445|L-Thyroxine-induced leukopenia in a patient with Hashimoto's disease: involvement of suppressor-cytotoxic T cells.|leukopenia|20|30|L-Thyroxine|0|11
2935070|Ampicillin-induced interstitial nephritis with generalised exfoliative dermatitis.|generalised exfoliative dermatitis|47|81|Ampicillin|0|10
2935070|Ampicillin-induced interstitial nephritis with generalised exfoliative dermatitis.|interstitial nephritis|19|41|Ampicillin|0|10
2935070|However, there are few reports in the literature of ampicillin as a cause of acute interstitial nephritis.|acute interstitial nephritis|77|105|ampicillin|52|62
2935070|In the following case report, a patient developed acute interstitial nephritis with renal failure and exfoliative dermatitis following ampicillin therapy.|acute interstitial nephritis|50|78|ampicillin|135|145
2935070|In the following case report, a patient developed acute interstitial nephritis with renal failure and exfoliative dermatitis following ampicillin therapy.|exfoliative dermatitis|102|124|ampicillin|135|145
2935070|In the following case report, a patient developed acute interstitial nephritis with renal failure and exfoliative dermatitis following ampicillin therapy.|renal failure|84|97|ampicillin|135|145
2935070|The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of ampicillin.|eosinophilia|73|85|ampicillin|171|181
2935070|The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of ampicillin.|renal failure|46|59|ampicillin|171|181
2935070|The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of ampicillin.|skin rash|87|96|ampicillin|171|181
2937155|A patient receiving vancomycin for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips.|erythema of the cartilage of both ears|136|174|vancomycin|20|30
2937155|A patient receiving vancomycin for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips.|hemorrhagic lesions of the finger tips|204|242|vancomycin|20|30
2937155|A patient receiving vancomycin for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips.|lupus-like syndrome|76|95|vancomycin|20|30
2937155|A patient receiving vancomycin for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips.|malar rash|115|125|vancomycin|20|30
2937155|A patient receiving vancomycin for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips.|pain|127|131|vancomycin|20|30
2937155|A patient receiving vancomycin for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips.|tender erythematous|180|199|vancomycin|20|30
2937155|The possible development of a drug-induced vasculitis or lupus-like syndrome should be added to the list of rare toxic effects of vancomycin.|lupus-like syndrome|57|76|vancomycin|130|140
2937155|The possible development of a drug-induced vasculitis or lupus-like syndrome should be added to the list of rare toxic effects of vancomycin.|vasculitis|43|53|vancomycin|130|140
2937155|Vancomycin-induced vasculitis.|vasculitis|19|29|Vancomycin|0|10
2940999|Abnormal retinal function associated with isotretinoin therapy for acne.|Abnormal retinal function|0|25|isotretinoin|42|54
2940999|Three of 50 patients treated with isotretinoin (1 mg/kg/day) for cystic acne complained of poor night vision and/or excessive glare sensitivity.|excessive glare sensitivity|116|143|isotretinoin|34|46
2940999|Three of 50 patients treated with isotretinoin (1 mg/kg/day) for cystic acne complained of poor night vision and/or excessive glare sensitivity.|poor night vision|91|108|isotretinoin|34|46
2943526|Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.|Neurologic toxicity|0|19|FUdR|67|71
2956288|Ethambutol is frequently used in the treatment of tuberculosis, and, although optic neuropathies have been reported with the use of ethambutol, this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication.|optic neuropathies|78|96|Ethambutol|0|10
2956288|However, we recently saw two patients with renal tuberculosis treated with ethambutol in whom visual loss from toxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function.|toxic optic neuropathies|111|135|ethambutol|75|85
2956288|However, we recently saw two patients with renal tuberculosis treated with ethambutol in whom visual loss from toxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function.|visual loss|94|105|ethambutol|75|85
2956288|Optic neuropathy in ethambutol-treated renal tuberculosis.|Optic neuropathy|0|16|ethambutol|20|30
2956288|Since ethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce optic neuropathy.|optic neuropathy|202|218|ethambutol|6|16
2979256|A 57-year-old woman presented with a 3-week history of dysphagia for solids, 6 months after starting treatment with nifedipine.|dysphagia for solids|55|75|nifedipine|116|126
2979256|Gastro-oesophageal reflux associated with nifedipine.|Gastro-oesophageal reflux|0|25|nifedipine|42|52
2979256|Nifedipine may induce, or aggravate, pre-existing, gastro-oesophageal reflux.|gastro-oesophageal reflux|51|76|Nifedipine|0|10
3003260|A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.|bilateral posterior subcapsular cataracts|65|106|Decadron|151|159
3003260|A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.|nausea|232|238|cisplatin|211|220
3003260|A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.|visual impairment|33|50|Decadron|151|159
3003260|Cataracts induced by intermittent Decadron used as an antiemetic.|Cataracts|0|9|Decadron|34|42
3003260|Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.|vomiting|150|158|cisplatin|132|141
3030084|Transient phenytoin induced IgA deficiency and permanent IgE increase.|IgA deficiency|28|42|phenytoin|10|19
3030084|Transient phenytoin induced IgA deficiency and permanent IgE increase.|IgE increase|57|69|phenytoin|10|19
3059159|The pharmacology and toxicology of chloral hydrate are discussed with particular reference to the cardiac arrhythmias that are seen with overdosage.|cardiac arrhythmias|98|117|chloral hydrate|35|50
3067748|Adrenaline dacryolith: detection by ultrasound examination of the nasolacrimal duct.|dacryolith|11|21|Adrenaline|0|10
3067748|Histological examination of the dacryolith suggested its derivation from breakdown products of adrenaline.|dacryolith|32|42|adrenaline|95|105
3084231|Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.|hyperammonemia|290|304|valproic acid|268|281
3084231|Reversible valproic acid-induced dementia: a case report.|dementia|33|41|valproic acid|11|24
3084231|Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.|dementia|33|41|valproic acid|11|24
3101617|Co-trimoxazole red cell aplasia in leukaemia.|red cell aplasia|15|31|Co-trimoxazole|0|14
3101617|When co-trimoxazole was stopped the red cell aplasia resolved.|red cell aplasia|36|52|co-trimoxazole|5|19
3115809|A patient developed optic neuropathy while being treated with isoniazid and ethambutol.|optic neuropathy|20|36|ethambutol|76|86
3115809|A patient developed optic neuropathy while being treated with isoniazid and ethambutol.|optic neuropathy|20|36|isoniazid|62|71
3115809|A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.|ocular toxicity|88|103|isoniazid|107|116
3115809|A well-recognized complication of ethambutol use is optic neuropathy, but the potential ocular toxicity of isoniazid is often overlooked.|optic neuropathy|52|68|ethambutol|34|44
3115809|Isoniazid and ethambutol as a cause of optic neuropathy.|optic neuropathy|39|55|ethambutol|14|24
3115809|Isoniazid and ethambutol as a cause of optic neuropathy.|optic neuropathy|39|55|Isoniazid|0|9
3124393|A woman 38-year-old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal Depo-Medrol, developed a spastic paraparesis at the lower limbs.|spastic paraparesis at the lower limbs|156|194|Depo-Medrol|131|142
3124393|Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo-Medrol.|Calcification|0|13|Depo-Medrol|91|102
3124393|Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo-Medrol.|ossification of the spinal arachnoid|18|54|Depo-Medrol|91|102
3128415|A young woman with epilepsy had tonic-clonic seizures during antineoplastic therapy with adriamycin and cisplatin.|tonic-clonic seizures|32|53|adriamycin|89|99
3128415|A young woman with epilepsy had tonic-clonic seizures during antineoplastic therapy with adriamycin and cisplatin.|tonic-clonic seizures|32|53|cisplatin|104|113
3136101|Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.|Hyperkalemia|0|12|adrenocorticotropic hormone|48|75
3136101|Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.|hyperkalemia|22|34|ACTH|72|76
3136101|We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.|hyperkalemia|177|189|ACTH|72|76
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|acute renal impairment|281|303|folinic acid|102|114
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|acute renal impairment|281|303|methotrexate|84|96
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|hyperkalaemia|185|198|folinic acid|102|114
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|hyperkalaemia|185|198|methotrexate|84|96
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|hyperphosphataemia|203|221|folinic acid|102|114
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|hyperphosphataemia|203|221|methotrexate|84|96
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|hyper-uricaemia|168|183|folinic acid|102|114
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|hyper-uricaemia|168|183|methotrexate|84|96
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|hypocalcaemia|227|240|folinic acid|102|114
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|hypocalcaemia|227|240|methotrexate|84|96
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|metabolic acidosis|258|276|folinic acid|102|114
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|metabolic acidosis|258|276|methotrexate|84|96
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|phosphate shower syndrome|140|165|folinic acid|102|114
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|phosphate shower syndrome|140|165|methotrexate|84|96
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|tetany|245|251|folinic acid|102|114
400971|Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.|tetany|245|251|methotrexate|84|96
3143551|Accordingly, camptocormia is a dose-dependent side effect of valproate.|camptocormia|13|25|valproate|61|70
3143551|A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called camptocormia, during valproate monotherapy.|abnormal posture of extreme forward flexion|83|126|valproate|156|165
3143551|A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called camptocormia, during valproate monotherapy.|camptocormia|135|147|valproate|156|165
3143551|Camptocormia, a new side effect of sodium valproate.|Camptocormia|0|12|sodium valproate|35|51
3143551|Four weeks earlier she had developed hepatopathy during a regimen of carbamazepine, lynestrenol and sodium valproate.|hepatopathy|37|48|carbamazepine|69|82
3143551|Four weeks earlier she had developed hepatopathy during a regimen of carbamazepine, lynestrenol and sodium valproate.|hepatopathy|37|48|lynestrenol|84|95
3143551|Four weeks earlier she had developed hepatopathy during a regimen of carbamazepine, lynestrenol and sodium valproate.|hepatopathy|37|48|sodium valproate|100|116
3143551|Hepatopathy subsided after the cessation of carbamazepine and lynestrenol.|Hepatopathy|0|11|carbamazepine|44|57
3143551|Hepatopathy subsided after the cessation of carbamazepine and lynestrenol.|Hepatopathy|0|11|lynestrenol|62|73
3149484|A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported.|seizures|111|119|lorazepam|73|82
3149484|Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures.|Paradoxical precipitation of tonic seizures|0|43|lorazepam|47|56
3152997|Atrial fibrillation following methylprednisolone pulse therapy.|Atrial fibrillation|0|19|methylprednisolone|30|48
3156465|Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.|teratogenic effects|76|95|Isotretinoin|0|12
3156465|Isotretinoin teratogenicity.|teratogenicity|13|27|Isotretinoin|0|12
3156465|We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.|abnormalities of the corticospinal tracts|188|229|isotretinoin|32|44
3156465|We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.|agenesis of the cerebellar vermis|85|118|isotretinoin|32|44
3156465|We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.|hydrocephalus|169|182|isotretinoin|32|44
3156465|We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.|multiple leptomeningeal neuroglial heterotopias|120|167|isotretinoin|32|44
3156465|We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.|teratogenicity|45|59|isotretinoin|32|44
3159106|A case of allopurinol hypersensitivity, possibly the first in a black African, is reported.|hypersensitivity|22|38|allopurinol|10|21
3159106|Allopurinol hypersensitivity.|hypersensitivity|12|28|Allopurinol|0|11
3159106|The allopurinol hypersensitivity syndrome is a rare adverse drug reaction.|hypersensitivity syndrome|16|41|allopurinol|4|15
3166573|Bone formation induced in an infant by systemic prostaglandin-E2 administration.|Bone formation|0|14|prostaglandin-E2|48|64
3171334|A case of severe visual loss following a single dose of vincristine is described.|severe visual loss|10|28|vincristine|56|67
3171334|Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.|severe visual loss|133|151|vincristine|110|121
3171334|Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.|Severe visual loss|0|18|vincristine|42|53
3171334|The literature of vincristine optic nerve toxicity is reviewed.|optic nerve toxicity|30|50|vincristine|18|29
3171334|Visual loss after a single small dose of vincristine has never been reported.|Visual loss|0|11|vincristine|41|52
3174043|Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.|reversible toxic cystoid maculopathy|16|52|Niacin|0|6
3174043|Niacin maculopathy.|maculopathy|7|18|Niacin|0|6
3174043|The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.|visual symptoms|100|115|niacin|67|73
3174043|Three patients with niacin-induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin.|cystoid maculopathy|55|74|niacin|20|26
3174043|Three patients with niacin-induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin.|visual symptoms|192|207|niacin|232|238
3174043|Three patients with niacin-induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin.|visual symptoms|35|50|niacin|20|26
3195622|A case report of the hypersensitivity syndrome occurring in a patient being treated with dapsone for a brown recluse spider bite is presented.|hypersensitivity syndrome|21|46|dapsone|89|96
3195622|A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.|fever|51|56|dapsone|2|9
3195622|A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.|headache|58|66|dapsone|2|9
3195622|A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.|hemolysis|114|123|dapsone|2|9
3195622|A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.|hepatitis|103|112|dapsone|2|9
3195622|A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.|hypersensitivity syndrome|10|35|dapsone|2|9
3195622|A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.|leukopenia|125|135|dapsone|2|9
3195622|A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.|lymphadenopathy|86|101|dapsone|2|9
3195622|A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.|mononucleosis|141|154|dapsone|2|9
3195622|A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.|nausea|68|74|dapsone|2|9
3195622|A dapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.|vomiting|76|84|dapsone|2|9
3195622|Case report: dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider.|hypersensitivity syndrome|21|46|dapsone|13|20
3200786|Rifampicin-induced adrenal insufficiency in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment.|adrenal insufficiency|19|40|Rifampicin|0|10
3200786|We report the case of a patient with the acquired immunodeficiency syndrome treated with rifampicin who had a 'normal' screening test for adrenal insufficiency, yet had clinical evidence of adrenal failure.|adrenal failure|190|205|rifampicin|89|99
3211830|Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.|cutaneous vasculitis|24|44|diltiazem|79|88
3211830|Widespread cutaneous vasculitis associated with diltiazem.|cutaneous vasculitis|11|31|diltiazem|48|57
3242521|Intraventricular nafcillin-induced seizures in a neonate.|seizures|35|43|nafcillin|17|26
3242521|We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.|seizures|43|51|nafcillin|103|112
3259776|A 58-year old patient is reported who developed an ischaemic cerebrovascular accident 22 hours after successful thrombolysis with streptokinase for life-threatening pulmonary emboli.|ischaemic cerebrovascular accident|51|85|streptokinase|130|143
3259776|Thrombo-embolic complication after streptokinase therapy of pulmonary emboli.|Thrombo-embolic complication|0|28|streptokinase|35|48
3277077|Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.|Renal hypophosphatemia|0|22|doxycycline|81|92
3290702|A clinically atypical, neuropathologically verified case of Creutzfeldt-Jakob disease is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with human growth hormone processed from pooled cadaveric pituitary glands.|Creutzfeldt-Jakob disease|60|85|human growth hormone|227|247
3290702|A new case of Creutzfeldt-Jakob disease associated with human growth hormone therapy in New Zealand.|Creutzfeldt-Jakob disease|14|39|human growth hormone|56|76
3301251|A case of a 21-year-old woman who had developed mild hepatotoxicity while receiving choline magnesium trisalicylate therapy is described.|hepatotoxicity|53|67|choline magnesium trisalicylate|84|115
3301251|Hepatotoxicity associated with choline magnesium trisalicylate: case report and review of salicylate-induced hepatotoxicity.|hepatotoxicity|109|123|salicylate|90|100
3301251|Hepatotoxicity associated with choline magnesium trisalicylate: case report and review of salicylate-induced hepatotoxicity.|Hepatotoxicity|0|14|choline magnesium trisalicylate|31|62
3301251|Salicylate-induced hepatotoxicity is reviewed.|hepatotoxicity|19|33|Salicylate|0|10
3301251|They continued to rise for five more days before salicylate hepatotoxicity was suspected.|hepatotoxicity|60|74|salicylate|49|59
3310776|A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure.|attacks of asthma|121|138|captopril|144|153
3310776|A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure.|attacks of asthma|121|138|dyazide|183|190
3310776|A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure.|attacks of asthma|121|138|nadolol|171|178
3310776|Captopril-related (and -induced?) asthma.|asthma|34|40|Captopril|0|9
3310776|This confirmed the history of captopril-related asthma.|asthma|48|54|captopril|30|39
3318771|We also describe a case of timolol-induced ocular pemphigoid.|ocular pemphigoid|43|60|timolol|27|34
331881|Deposits of plasma proteins in the skin during treatment with carbamazepine and diphenylhydantoin.|Deposits of plasma proteins in the skin|0|39|carbamazepine|62|75
331881|Deposits of plasma proteins in the skin during treatment with carbamazepine and diphenylhydantoin.|Deposits of plasma proteins in the skin|0|39|diphenylhydantoin|80|97
3335488|The observations suggest that testicular swelling and pain are side effects of desipramine.|pain|54|58|desipramine|79|90
3335488|The observations suggest that testicular swelling and pain are side effects of desipramine.|testicular swelling|30|49|desipramine|79|90
3335488|Two patients are described who developed testicular swelling and pain during treatment with desipramine.|pain|65|69|desipramine|92|103
3335488|Two patients are described who developed testicular swelling and pain during treatment with desipramine.|testicular swelling|41|60|desipramine|92|103
3343188|Benzocaine, an ester-type local anesthetic, was believed responsible for apparent methemoglobinemia in a cat.|methemoglobinemia|82|99|Benzocaine|0|10
3343188|Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.|methemoglobinemia|19|36|Benzocaine|0|10
3343188|Methemoglobinemia associated with dermal application of benzocaine cream in a cat.|Methemoglobinemia|0|17|benzocaine|56|66
3346128|A 43-year-old white man developed a shallow erosion of a psoriatic plaque after chronic administration of methotrexate.|erosion of a psoriatic plaque|44|73|methotrexate|106|118
3346128|Erosion of psoriatic plaques after chronic methotrexate administration.|Erosion of psoriatic plaques|0|28|methotrexate|43|55
3359700|After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.|effective renal plasma flow|129|156|cyclosporine A|36|50
3359700|After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.|loss of glomerular filtration rate|90|124|cyclosporine A|36|50
3359700|Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.|fall of the filtration fraction|24|55|cyclosporine A|243|257
3359700|Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.|increase in proteinuria|132|155|cyclosporine A|243|257
3359700|Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.|nephrotoxicity|258|272|cyclosporine A|243|257
3359700|Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.|rise in the relative clearance of 99Tc-dimercaptosuccinic acid|61|123|cyclosporine A|243|257
3359700|Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.|nephrotoxicity|52|66|cyclosporine A|29|43
3365032|A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil (100 mg orally, three times a day).|hyperthyroidism|36|51|propylthiouracil|178|194
3365032|A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil (100 mg orally, three times a day).|raised creatine phosphokinase|107|136|propylthiouracil|178|194
3365032|A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil (100 mg orally, three times a day).|severe proximal muscle weakness|69|100|propylthiouracil|178|194
3365032|Polymyositis after propylthiouracil treatment for hyperthyroidism.|Polymyositis|0|12|propylthiouracil|19|35
3370103|Cardiopulmonary arrest following intravenous phenytoin loading.|Cardiopulmonary arrest|0|22|phenytoin|45|54
3379435|Evidence obtained indicated that the Reye-like syndrome might be caused by calcium hopantenate possibly due to the induction of pantothenic acid deficiency.|pantothenic acid deficiency|128|155|calcium hopantenate|75|94
3379435|Evidence obtained indicated that the Reye-like syndrome might be caused by calcium hopantenate possibly due to the induction of pantothenic acid deficiency.|Reye-like syndrome|37|55|calcium hopantenate|75|94
3379435|Reye-like syndrome following treatment with the pantothenic acid antagonist, calcium hopantenate.|Reye-like syndrome|0|18|calcium hopantenate|77|96
3379435|Three senile patients developed fatal acute encephalopathy while receiving calcium hopantenate.|fatal acute encephalopathy|32|58|calcium hopantenate|75|94
3391110|Dyspnea possibly associated with controlled-release morphine sulfate tablets.|Dyspnea|0|7|morphine sulfate|52|68
3397227|Anhedonic ejaculation with desipramine.|Anhedonic ejaculation|0|21|desipramine|27|38
3397227|We report two patients with anhedonic ejaculation (ejaculation without orgasm) associated with initiation of treatment with desipramine.|anhedonic ejaculation|28|49|desipramine|124|135
3397227|We report two patients with anhedonic ejaculation (ejaculation without orgasm) associated with initiation of treatment with desipramine.|ejaculation without orgasm|51|77|desipramine|124|135
3400849|Myoclonic spasms following intrathecal morphine.|Myoclonic spasms|0|16|morphine|39|47
3405528|A case of halothane induced hepatitis is reported in a middle aged woman who underwent gastric surgery for morbid obesity.|hepatitis|28|37|halothane|10|19
3405528|Halothane hepatitis and prompt resolution with methionine therapy: case report.|hepatitis|10|19|Halothane|0|9
3410226|Development of porphyria cutanea tarda after treatment with cyclophosphamide.|porphyria cutanea tarda|15|38|cyclophosphamide|60|76
3410226|We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.|porphyria cutanea tarda|65|88|cisplatin|121|130
3410226|We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.|porphyria cutanea tarda|65|88|cyclophosphamide|135|151
3417739|Acute renal failure in a patient treated by continuous povidone-iodine mediastinal irrigation.|Acute renal failure|0|19|iodine|64|70
3417739|Acute renal failure in a patient treated by continuous povidone-iodine mediastinal irrigation.|Acute renal failure|0|19|povidone|55|63
3417739|We describe a 63 year old woman with a suppurative mediastinitis, treated with continuous PI irrigation who developed an acute oliguric renal failure.|acute oliguric renal failure|121|149|PI|90|92
3430507|A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of D-penicillamine therapy and a cumulative dose of 1,200 g.|epithelial crescents|91|111|D-penicillamine|158|173
3430507|A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of D-penicillamine therapy and a cumulative dose of 1,200 g.|hemoptysis|128|138|D-penicillamine|158|173
3430507|A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of D-penicillamine therapy and a cumulative dose of 1,200 g.|rapidly progressive glomerulonephritis|47|85|D-penicillamine|158|173
3430507|D-penicillamine induced crescentic glomerulonephritis: report and review of the literature.|crescentic glomerulonephritis|24|53|D-penicillamine|0|15
3430507|The 9 other reported cases of D-penicillamine induced rapidly progressive glomerulonephritis have been reviewed.|rapidly progressive glomerulonephritis|54|92|D-penicillamine|30|45
3438585|Gold-induced pneumonitis is a rare complication of gold salt therapy.|pneumonitis|13|24|Gold|0|4
3438585|Gold-induced pneumonitis.|pneumonitis|13|24|Gold|0|4
3438585|This case supports the view that in gold-induced pneumonitis a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve.|pneumonitis|49|60|gold|36|40
3438585|We describe a patient with rheumatoid arthritis treated with gold salts, who developed bilateral interstitial pulmonary abnormalities and showed a dramatic response on corticosteroid therapy.|bilateral interstitial pulmonary abnormalities|87|133|gold|61|65
3449312|Gold-induced aplastic anemia.|aplastic anemia|13|28|Gold|0|4
3449312|Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia.|aplastic anemia|87|102|gold|25|29
3465489|Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia.|myelotoxicity|49|62|6-mercaptopurine|32|48
3470173|Because the cerebellar toxicity may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of HDARAC is recommended.|cerebellar toxicity|12|31|HDARAC|130|136
3470173|Cytarabine-induced cerebellar syndrome: case report and literature review.|cerebellar syndrome|19|38|Cytarabine|0|10
3470173|During the first treatment, dysarthria and ataxia were seen after completion of the patient's eighth and final dose of HDARAC.|ataxia|43|49|HDARAC|119|125
3470173|During the first treatment, dysarthria and ataxia were seen after completion of the patient's eighth and final dose of HDARAC.|dysarthria|28|38|HDARAC|119|125
3470173|The neurotoxicity seen with HDARAC is dose-related and has occurred in up to 60 percent of treated patients.|neurotoxicity|4|17|HDARAC|28|34
3470173|This case report illustrates the neurotoxicity unique to HDARAC.|neurotoxicity|33|46|HDARAC|57|63
3485422|Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin.|Macular infarction|0|18|gentamicin|82|92
3485422|We are concerned that the macular lesion was a retinal toxic effect of gentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug.|macular lesion|26|40|gentamicin|71|81
3493797|A woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a B-cell lymphoma of the lip following 4 1/2 years of treatment with razoxane.|B-cell lymphoma|147|162|razoxane|214|222
3501467|Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed hypogammaglobulinemia in the course of gold therapy.|hypogammaglobulinemia|129|150|gold|168|172
3501467|Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells.|Hypogammaglobulinemia|0|21|gold|38|42
3508194|Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.|leucopenia|10|20|sodium nitroprusside|58|78
3508194|Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion.|thrombocytopenia|25|41|sodium nitroprusside|58|78
3513544|Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A: a case report.|Herpes simplex esophagitis|0|26|cyclosporine A|70|84
3513544|We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy.|herpes esophagitis|28|46|Cyclosporine A|90|104
3513544|With the increasing use of Cyclosporine A in transplant patients, the incidence of herpes esophagitis may increase.|herpes esophagitis|83|101|Cyclosporine A|27|41
3528096|Administration of excessive insulin induced hypoglycemia within 4 to 8 hours, followed by rebound hyperglycemia.|hypoglycemia|44|56|insulin|28|35
3528096|Administration of excessive insulin induced hypoglycemia within 4 to 8 hours, followed by rebound hyperglycemia.|rebound hyperglycemia|90|111|insulin|28|35
3528096|Posthypoglycemic hyperglycemia (rebound hyperglycemia) after overdosing of insulin was diagnosed in 6 cats with diabetes mellitus.|Posthypoglycemic hyperglycemia|0|30|insulin|75|82
3528096|Posthypoglycemic hyperglycemia (rebound hyperglycemia) after overdosing of insulin was diagnosed in 6 cats with diabetes mellitus.|rebound hyperglycemia|32|53|insulin|75|82
3528096|Rebound hyperglycemia following overdosing of insulin in cats with diabetes mellitus.|hyperglycemia|8|21|insulin|46|53
3528096|Rebound hyperglycemia was observed with both intermediate (neutral protamine hagedorn) and long-acting (protamine zinc iletin) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat.|Rebound hyperglycemia|0|21|protamine hagedorn|67|85
3528096|Rebound hyperglycemia was observed with both intermediate (neutral protamine hagedorn) and long-acting (protamine zinc iletin) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat.|Rebound hyperglycemia|0|21|protamine zinc iletin|104|125
3542612|Captopril-induced lichen planus pemphigoides with pemphigus-like features.|lichen planus pemphigoides|18|44|Captopril|0|9
3542612|We report a case of a bullous lichenoid eruption due to the intake of captopril.|bullous lichenoid eruption|22|48|captopril|70|79
354311|An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.|osteomyelitis in the left calcaneus|102|137|BCG|49|52
354311|Metastatic osteomyelitis following BCG vaccination.|Metastatic osteomyelitis|0|24|BCG|35|38
3549808|One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.|arteriosclerotic disease|88|112|minoxidil|57|66
3549808|One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.|hypertension|71|83|minoxidil|57|66
3549808|One of the subjects who was using extemporaneous topical minoxidil had hypertension and arteriosclerotic disease and the other died of a myocardial infarction.|myocardial infarction|137|158|minoxidil|57|66
3558331|Amoxapine-induced cognitive impairment in two patients.|cognitive impairment|18|38|Amoxapine|0|9
3558331|Two patients are described in whom subtle cognitive impairments are associated with therapeutic doses of amoxapine.|cognitive impairments|42|63|amoxapine|105|114
3565435|A 23-year-old woman with systemic lupus erythematosus had a severe hypersensitivity reaction to the drug ibuprofen.|severe hypersensitivity reaction|60|92|ibuprofen|105|114
3565435|Severe systemic hypersensitivity reaction to ibuprofen occurring after prolonged therapy.|Severe systemic hypersensitivity reaction|0|41|ibuprofen|45|54
3569037|A brief review of reported cases of chloramphenicol hypersensitivity in the English-language literature, as well as possible alternative explanations in this case, are provided.|hypersensitivity|52|68|chloramphenicol|36|51
3569037|Hypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever.|Hypersensitivity reaction|0|25|chloramphenicol|36|51
3569037|Hypersensitivity reactions due to chloramphenicol are rarely reported in the literature.|Hypersensitivity reactions|0|26|chloramphenicol|34|49
3569037|We present a case report of a patient with typhoid fever who experienced a hypersensitivity reaction subsequent to the infusion of chloramphenicol sodium succinate.|hypersensitivity reaction|75|100|chloramphenicol sodium succinate|131|163
3579660|Replicate brain magnetic resonance imaging examinations after six weeks and 11 months of penicillamine therapy documented the development of new brain lesions during this period, while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred.|brain lesions|145|158|penicillamine|89|102
3579660|To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine.|neurologic disease|253|271|penicillamine|301|314
3579660|To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine.|neurologic worsening|62|82|penicillamine|106|119
3579660|We describe a patient with Wilson's disease who presented with neurologic disease, was treated with D-penicillamine, and suffered sudden neurologic deterioration coincident with therapy.|neurologic deterioration|137|161|D-penicillamine|100|115
3579660|Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.|Worsening of neurologic syndrome|0|32|penicillamine|80|93
3586163|Other upper tract neoplasms after cyclophosphamide are reviewed.|upper tract neoplasms|6|27|cyclophosphamide|34|50
3586163|Upper tract urothelial malignancy after cyclophosphamide therapy: a case report and literature review.|Upper tract urothelial malignancy|0|33|cyclophosphamide|40|56
3586163|We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.|distal ureter without transitional cell carcinoma of the bladder|94|158|cyclophosphamide|183|199
3586163|We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin's lymphoma.|transitional cell carcinoma of the renal pelvis|42|89|cyclophosphamide|183|199
3604756|Progressive pulmonary fibrosis complicating cyclophosphamide therapy.|Progressive pulmonary fibrosis|0|30|cyclophosphamide|44|60
3604756|The changes were progressive regardless of discontinuation of cyclophosphamide and led to severe restrictive ventilatory defect.|severe restrictive ventilatory defect|90|127|cyclophosphamide|62|78
3609047|Torsade de pointes during loading with amiodarone.|Torsade de pointes|0|18|amiodarone|39|49
3609047|Torsade de pointes represents a potential complication of chronic amiodarone therapy.|Torsade de pointes|0|18|amiodarone|66|76
3609047|We report a case of torsade de pointes following a single oral dose of amiodarone (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.|torsade de pointes|20|38|amiodarone|71|81
3612639|Pulmonary edema as a delayed complication of ritodrine therapy.|Pulmonary edema|0|15|ritodrine|45|54
3612639|Pulmonary edema occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy.|Pulmonary edema|0|15|ritodrine|52|61
3612639|Pulmonary edema occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy.|Pulmonary edema|0|15|terbutaline|102|113
3620420|Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.|abnormalities in liver function tests|110|147|Cyclosporin|0|11
3620420|Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.|hirsutism|34|43|Cyclosporin|0|11
3620420|Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.|hypertension|45|57|Cyclosporin|0|11
3620420|Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.|increased blood levels of urea and creatinine|59|104|Cyclosporin|0|11
3628148|Rupture of a cerebral aneurysm associated with nifedipine treatment.|Rupture of a cerebral aneurysm|0|30|nifedipine|47|57
3628148|We describe rupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of nifedipine treatment.|rupture of a cerebral arterial aneurysm|12|51|nifedipine|118|128
3652934|A small initial dose of prazosin ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and severe drop in blood pressure after the administration of the first dose of prazosin.|severe drop in blood pressure|144|173|prazosin|24|32
3652934|A small initial dose of prazosin ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and severe drop in blood pressure after the administration of the first dose of prazosin.|severe drop in blood pressure|144|173|prazosin|220|228
3652934|Prazosin-induced first-dose phenomenon possibly associated with hemorrhagic stroke: a report of three cases.|hemorrhagic stroke|64|82|Prazosin|0|8
3659584|A fatal massive pulmonary embolus developed in a patient treated with streptokinase for acute deep vein thrombosis.|fatal massive pulmonary embolus|2|33|streptokinase|70|83
3659584|Massive pulmonary embolism complicating streptokinase treatment for deep vein thrombosis.|Massive pulmonary embolism|0|26|streptokinase|40|53
3663292|Fatal digoxin poisoning: an unsuccessful resuscitation with use of digoxin-immune Fab.|Fatal digoxin poisoning|0|23|digoxin|6|13
3677571|A case of phenytoin-induced hepatitis with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed.|hepatitis|28|37|phenytoin|10|19
3677571|A case of phenytoin-induced hepatitis with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed.|hypersensitivity reactions|110|136|phenytoin|100|109
3677571|A case of phenytoin-induced hepatitis with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed.|mononucleosis|43|56|phenytoin|10|19
3677571|Phenytoin-induced hypersensitivity reactions.|hypersensitivity reactions|18|44|Phenytoin|0|9
3677571|Phenytoin was discontinued after admission; however, phenytoin 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and pruritus developed.|pruritus|181|189|phenytoin|53|62
3677571|Phenytoin was discontinued after admission; however, phenytoin 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and pruritus developed.|swelling of the face and legs|147|176|phenytoin|53|62
3677571|Serious phenytoin hypersensitivity reactions may appear as dermatologic, lymphoid, or hepatic syndromes.|dermatologic, lymphoid, or hepatic syndromes|59|103|phenytoin|8|17
3677571|Serious phenytoin hypersensitivity reactions may appear as dermatologic, lymphoid, or hepatic syndromes.|hypersensitivity reactions|18|44|phenytoin|8|17
3677571|She was receiving phenytoin sodium 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia.|leukopenia|145|155|carbamazepine|47|60
3677571|She was receiving phenytoin sodium 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia.|leukopenia|145|155|phenytoin sodium|18|34
3677571|The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.|fever|147|152|phenytoin|19|28
3677571|The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.|fever|147|152|phenytoin|101|110
3677571|The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.|hypersensitivity reactions|29|55|phenytoin|19|28
3677571|The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.|hypersensitivity reactions|29|55|phenytoin|101|110
3677571|The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.|lymphadenopathy|164|179|phenytoin|19|28
3677571|The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.|lymphadenopathy|164|179|phenytoin|101|110
3677571|The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.|rash|154|158|phenytoin|19|28
3677571|The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.|rash|154|158|phenytoin|101|110
3680913|It was restarted 6 weeks later, and 10 weeks after that, the patient presented with fulminant hepatic failure, which resolved rapidly after cessation of nicotinic acid therapy.|fulminant hepatic failure|84|109|nicotinic acid|153|167
3680913|Nicotinic acid-induced fulminant hepatic failure.|fulminant hepatic failure|23|48|Nicotinic acid|0|14
3680913|We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity.|hepatotoxicity|400|414|nicotinic acid|263|277
3680913|We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity.|liver disease|52|65|nicotinic acid|16|30
3680913|We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity.|liver disease|52|65|nicotinic acid|263|277
3688031|An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol.|athelia|37|44|methimazole|177|188
3688031|An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol.|athelia|37|44|propranolol|193|204
3688031|An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol.|choanal atresia|20|35|methimazole|177|188
3688031|An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol.|choanal atresia|20|35|propranolol|193|204
3688031|An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol.|mental retardation|84|102|methimazole|177|188
3688031|An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol.|mental retardation|84|102|propranolol|193|204
3688031|Choanal atresia and athelia: methimazole teratogenicity or a new syndrome?|athelia|20|27|methimazole|29|40
3688031|Choanal atresia and athelia: methimazole teratogenicity or a new syndrome?|Choanal atresia|0|15|methimazole|29|40
3688031|Choanal atresia and athelia: methimazole teratogenicity or a new syndrome?|teratogenicity|41|55|methimazole|29|40
3688031|The patient's defects may be due to methimazole teratogenicity or could represent a previously undescribed syndrome affecting ectodermal structures.|teratogenicity|48|62|methimazole|36|47
3693034|Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.|Toxic epidermal necrolysis|0|26|5-fluorocytosine|68|84
3693034|Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.|Toxic epidermal necrolysis|0|26|amphotericin B|89|103
369675|Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.|abdominal right lower quadrant pain|135|170|cyclophosphamide|78|94
369675|Five and one-half years after the diagnosis of myeloma, while in remission on cyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large cecal lymphoma.|cecal lymphoma|186|200|cyclophosphamide|78|94
3708949|After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.|fall in prothrombin time|222|246|amiodarone|30|40
3708949|After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.|jaundice|163|171|amiodarone|30|40
3708949|After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.|marked increase in serum transaminase levels|173|217|amiodarone|30|40
3708949|After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.|severe centrilobular necrosis|274|303|amiodarone|30|40
3708949|A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.|acute hepatitis|40|55|amiodarone|73|83
3708949|Probable early acute hepatitis with parenteral amiodarone.|acute hepatitis|15|30|amiodarone|47|57
3708949|Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.|acute hepatitis|64|79|amiodarone|22|32
3718111|He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal.|hyperkalemic|10|22|timolol|43|50
3718111|Severe hyperkalemia as a complication of timolol, a topically applied beta-adrenergic antagonist.|Severe hyperkalemia|0|19|timolol|41|48
3718111|Severe hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning prednisone therapy.|Severe hyperkalemia|0|19|prednisone|106|116
3720318|Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.|Noncardiogenic pulmonary edema|0|30|mono-octanoin|63|76
3720318|We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.|noncardiogenic pulmonary edema|30|60|monooctanoin|103|115
3725284|Paroxysmal supraventricular tachycardia during treatment with cisplatin and etoposide combination.|Paroxysmal supraventricular tachycardia|0|39|cisplatin|62|71
3725284|Paroxysmal supraventricular tachycardia during treatment with cisplatin and etoposide combination.|Paroxysmal supraventricular tachycardia|0|39|etoposide|76|85
3725284|We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed paroxysmal supraventricular tachycardia during cisplatin and etoposide combination chemotherapy.|paroxysmal supraventricular tachycardia|91|130|cisplatin|138|147
3725284|We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed paroxysmal supraventricular tachycardia during cisplatin and etoposide combination chemotherapy.|paroxysmal supraventricular tachycardia|91|130|etoposide|152|161
3732375|A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.|decrease in theophylline clearance|66|100|viloxazine|141|151
3732375|A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.|theophylline intoxication|22|47|theophylline|22|34
3732375|A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.|theophylline intoxication|22|47|viloxazine|141|151
3732375|Theophylline intoxication following viloxazine induced decrease in clearance.|decrease in clearance|55|76|viloxazine|36|46
3732375|Theophylline intoxication following viloxazine induced decrease in clearance.|Theophylline intoxication|0|25|Theophylline|0|12
3732375|Theophylline intoxication following viloxazine induced decrease in clearance.|Theophylline intoxication|0|25|viloxazine|36|46
3744305|Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.|eosinophilic pneumonia|89|111|nitrofurantoin|37|51
3744305|Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual, often presenting as eosinophilic pneumonia.|Idiosyncratic pulmonary reactions|0|33|nitrofurantoin|37|51
3753891|Acute myocardial necrosis during administration of amsacrine.|Acute myocardial necrosis|0|25|amsacrine|51|60
3753891|In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of amsacrine-related cardiotoxicity.|cardiotoxicity|155|169|amsacrine|137|146
3753891|In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of amsacrine-related cardiotoxicity.|myocardial necrosis|78|97|amsacrine|137|146
3753891|The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease.|acute myocardial infarction|84|111|amsacrine|166|175
3753891|The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease.|focal myocardial necrosis|29|54|amsacrine|166|175
3763264|A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.|alopecia|143|151|phenobarbital|18|31
3763264|A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.|a pruritic desquamating erythrodermic rash|99|141|phenobarbital|18|31
3763264|A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.|fever|92|97|phenobarbital|18|31
3763264|A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.|hypersensitivity|32|48|phenobarbital|18|31
3763264|A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.|icterus|153|160|phenobarbital|18|31
3763264|A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.|myositis|190|198|phenobarbital|18|31
3763264|A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.|nephritis|204|213|phenobarbital|18|31
3763264|A child in whom a phenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.|protein-losing enteropathy|162|188|phenobarbital|18|31
3763264|Graft versus host-like illness in a child with phenobarbital hypersensitivity.|Graft versus host-like illness|0|30|phenobarbital|47|60
3763264|Graft versus host-like illness in a child with phenobarbital hypersensitivity.|hypersensitivity|61|77|phenobarbital|47|60
3763264|The clinical findings and laboratory studies suggested an autoimmune cell-mediated hypersensitivity reaction triggered by phenobarbital.|autoimmune cell-mediated hypersensitivity|58|99|phenobarbital|122|135
3767790|Duodenal ulceration: a complication of tolazoline therapy.|Duodenal ulceration|0|19|tolazoline|39|49
3767790|Two patients who were receiving Tolazoline by infusion developed duodenal ulceration and subsequent intestinal perforation.|duodenal ulceration|65|84|Tolazoline|32|42
3767790|Two patients who were receiving Tolazoline by infusion developed duodenal ulceration and subsequent intestinal perforation.|intestinal perforation|100|122|Tolazoline|32|42
3773837|The latter form (Macrodantin) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here.|acute and chronic pulmonary reactions|172|209|Macrodantin|17|28
3773837|The latter form (Macrodantin) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here.|allergic reactions|255|273|Macrodantin|17|28
3773837|The latter form (Macrodantin) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here.|blood dyscrasias|234|250|Macrodantin|17|28
3773837|The latter form (Macrodantin) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here.|liver damage|158|170|Macrodantin|17|28
3773837|The latter form (Macrodantin) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here.|peripheral neuropathy|211|232|Macrodantin|17|28
3790438|Generalized pustular psoriasis precipitated by trazodone in the treatment of depression.|Generalized pustular psoriasis|0|30|trazodone|47|56
3790438|We report a patient in whom the anti-depressant trazodone hydrochloride (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (GPP).|generalized pustular psoriasis|127|157|Molipaxin|73|82
3790438|We report a patient in whom the anti-depressant trazodone hydrochloride (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (GPP).|generalized pustular psoriasis|127|157|trazodone hydrochloride|48|71
3790438|We report a patient in whom the anti-depressant trazodone hydrochloride (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (GPP).|GPP|159|162|Molipaxin|73|82
3790438|We report a patient in whom the anti-depressant trazodone hydrochloride (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (GPP).|GPP|159|162|trazodone hydrochloride|48|71
3797173|Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome.|apnea|50|55|quinidine|159|168
3797173|Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome.|apnea|50|55|verapamil|12|21
3797173|Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome.|atrial flutter|109|123|verapamil|12|21
3797173|Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome.|bradycardia|74|85|verapamil|12|21
3797173|Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome.|death|191|196|quinidine|159|168
3797173|Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome.|hypotension|57|68|verapamil|12|21
3797173|Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome.|long QT interval syndrome|262|287|quinidine|159|168
3797173|Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome.|sudden death|145|157|verapamil|12|21
3804181|Methimazole-associated cholestatic liver injury: case report and brief literature review.|cholestatic liver injury|23|47|Methimazole|0|11
3804181|The authors report a further case of methimazole-associated liver damage and present a brief review of eleven previous cases found in the literature.|liver damage|60|72|methimazole|37|48
3804181|The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily.|bile stasis|219|230|methimazole|308|319
3804181|The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily.|cholestasis|105|116|methimazole|308|319
3804181|The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily.|fatty liver parenchyma degeneration|141|176|methimazole|308|319
3804181|The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily.|granulocytic portal infiltration|182|214|methimazole|308|319
3804181|The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily.|leucopenia|90|100|methimazole|308|319
3806824|Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.|Fibrosis of corpus cavernosum|0|29|papaverine|77|87
3806824|Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.|Fibrosis of corpus cavernosum|0|29|phentolamine|64|76
3806824|We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.|penile fibrosis|20|35|papaverine|109|119
3806824|We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.|penile fibrosis|20|35|phentolamine|92|104
3815268|A 57-year-old woman developed pulmonary sarcoidosis during therapy with interferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes.|pulmonary sarcoidosis|30|51|interferon beta|72|87
3815268|The possible role of interferon beta in the pathogenesis of sarcoidosis in this patient is discussed.|sarcoidosis|60|71|interferon beta|21|36
3824704|Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.|Fatal outcome|0|13|formalin|30|38
3868420|We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.|alopecia|135|143|mebendazole|90|101
3868420|We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.|granulocytopenia|148|164|mebendazole|90|101
3873709|Antibiotic-associated colitis (pseudomembranous colitis) developed in four patients with spinal cord injury and taking oral trimethoprim-sulfamethoxazole.|colitis|22|29|sulfamethoxazole|137|153
3873709|Antibiotic-associated colitis (pseudomembranous colitis) developed in four patients with spinal cord injury and taking oral trimethoprim-sulfamethoxazole.|colitis|22|29|trimethoprim|124|136
3873709|Antibiotic-associated colitis (pseudomembranous colitis) developed in four patients with spinal cord injury and taking oral trimethoprim-sulfamethoxazole.|pseudomembranous colitis|31|55|sulfamethoxazole|137|153
3873709|Antibiotic-associated colitis (pseudomembranous colitis) developed in four patients with spinal cord injury and taking oral trimethoprim-sulfamethoxazole.|pseudomembranous colitis|31|55|trimethoprim|124|136
3873709|Pseudomembranous colitis readily occurs in at least certain population groups receiving trimethoprim-sulfamethoxazole.|Pseudomembranous colitis|0|24|sulfamethoxazole|101|117
3873709|Pseudomembranous colitis readily occurs in at least certain population groups receiving trimethoprim-sulfamethoxazole.|Pseudomembranous colitis|0|24|trimethoprim|88|100
3878320|A lethal complication of peripheral vein vasopressin infusion.|lethal complication|2|21|vasopressin|41|52
3878320|The condition should be suspected in patients who develop unexplained abdominal pain or collapse following vasopressin treatment.|abdominal pain|70|84|vasopressin|107|118
3878320|The condition should be suspected in patients who develop unexplained abdominal pain or collapse following vasopressin treatment.|collapse|88|96|vasopressin|107|118
3892171|Although adverse reactions to protamine are reported infrequently and are usually mild, we recently observed the first fatal case of type I anaphylaxis resulting from protamine.|type I anaphylaxis|133|151|protamine|167|176
3892171|Protamine-induced fatal anaphylaxis.|fatal anaphylaxis|18|35|Protamine|0|9
3899068|Ototoxicity as a result of cis-platinum administration is well documented.|Ototoxicity|0|11|cis-platinum|27|39
3917429|Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.|nephrotoxicity|27|41|lithium|45|52
3917429|Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.|renal failure|109|122|lithium|45|52
3917429|Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.|renal failure|109|122|lithium|130|137
3926849|Administration of intravenous nitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance.|decrease in blood flow|167|189|nitroglycerin|30|43
3926849|Administration of intravenous nitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance.|increase in pulmonary artery pressure|111|148|nitroglycerin|30|43
3926849|Administration of intravenous nitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance.|increase in pulmonary vascular resistance|219|260|nitroglycerin|30|43
3926849|Paradoxical pulmonary vasoconstriction induced by nitroglycerin in idiopathic pulmonary hypertension.|Paradoxical pulmonary vasoconstriction|0|38|nitroglycerin|50|63
3941210|Atrioventricular block complicating amiodarone-induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block.|Atrioventricular block|0|22|amiodarone|36|46
3941210|Atrioventricular block complicating amiodarone-induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block.|hypothyroidism|55|69|amiodarone|36|46
3941210|Such a case induced by hypothyroidism complicating long-term therapy with amiodarone in a 45 year old woman with pre-excitation is presented.|hypothyroidism|23|37|amiodarone|74|84
3947272|Ampicillin increased the preexisting electrical decrement in three rabbits with experimental autoimmune myasthenia gravis while the drug had no deleterious effects in less affected or normal animals.|electrical decrement|37|57|Ampicillin|0|10
3947272|Ampicillin may aggravate clinical and experimental myasthenia gravis.|myasthenia gravis|51|68|Ampicillin|0|10
3947272|Myasthenic patients receiving ampicillin should be closely monitored for possible acute exacerbations.|acute exacerbations|82|101|ampicillin|30|40
3947272|One patient had severe temporary weakness after an ampicillin sodium challenge.|severe temporary weakness|16|41|ampicillin sodium|51|68
3954165|A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.|ulcer|128|133|theophylline|42|54
3954165|A study following large patient groups on theophylline and a combination of theophylline and steroids might clarify the risk of ulcer formation in patients being treated with these medications for asthma.|ulcer|128|133|theophylline|76|88
3954165|We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.|perforated gastric ulcer|121|145|prednisone|94|104
3954165|We presented a patient with status asthmaticus treated with a combination of theophylline and prednisone who developed a perforated gastric ulcer.|perforated gastric ulcer|121|145|theophylline|77|89
3964363|A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.|esophageal spasm|46|62|propranolol|10|21
3964363|Esophageal spasm following propranolol overdose relieved by glucagon.|Esophageal spasm|0|16|propranolol|27|38
3967536|Hypotension and sinus arrest with nifedipine in pulmonary hypertension.|Hypotension|0|11|nifedipine|34|44
3967536|Hypotension and sinus arrest with nifedipine in pulmonary hypertension.|sinus arrest|16|28|nifedipine|34|44
3970339|A patient presented with a painful, oedematous, cyanosed hand having injected a solution of diamorphine and methylphenidate into his radial artery.|painful, oedematous, cyanosed hand|27|61|diamorphine|92|103
3970339|A patient presented with a painful, oedematous, cyanosed hand having injected a solution of diamorphine and methylphenidate into his radial artery.|painful, oedematous, cyanosed hand|27|61|methylphenidate|108|123
3970339|Ischaemia following selfadministered intra-arterial injection of methylphenidate and diamorphine.|Ischaemia|0|9|diamorphine|85|96
3970339|Ischaemia following selfadministered intra-arterial injection of methylphenidate and diamorphine.|Ischaemia|0|9|methylphenidate|65|80
3977377|Chronic photosensitivity associated with hydrochlorothiazide ingestion occurred in four patients.|Chronic photosensitivity|0|24|hydrochlorothiazide|41|60
3982906|Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia.|Cardiac decompensation|0|22|verapamil|33|42
3982906|However, each infant demonstrated hemodynamic decompensation shortly after verapamil administration and required cardiopulmonary resuscitation.|hemodynamic decompensation|34|60|verapamil|75|84
3982906|The risk of cardiac decompensation in infants with supraventricular tachycardia and congestive cardiac failure should be kept in mind prior to administration of verapamil.|cardiac decompensation|12|34|verapamil|161|170
3997294|Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.|neuropathy|54|64|amiodarone|72|82
3997294|Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.|pleural and pericardial effusion|17|49|amiodarone|72|82
3997294|Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.|Pneumonitis|0|11|amiodarone|72|82
3997294|Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.|pneumonitis|98|109|amiodarone|87|97
4004433|Heparin-induced hyperkalemia.|hyperkalemia|16|28|Heparin|0|7
4004433|Our findings suggest that hyperkalemia can develop with the use of low-dose heparin, within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication.|hyperkalemia|26|38|heparin|76|83
4004433|Our findings suggest that hyperkalemia can develop with the use of low-dose heparin, within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication.|hyperkalemia|26|38|heparin|117|124
4004433|We present four cases in which the use of heparin was associated with hyperkalemia and discuss the pathophysiology.|hyperkalemia|70|82|heparin|42|49
4004433|While most physicians are aware of heparin-induced thrombocytopenia and skin necrosis, the association of heparin and hyperkalemia is less well recognized.|hyperkalemia|118|130|heparin|106|113
4004433|While most physicians are aware of heparin-induced thrombocytopenia and skin necrosis, the association of heparin and hyperkalemia is less well recognized.|skin necrosis|72|85|heparin|35|42
4004433|While most physicians are aware of heparin-induced thrombocytopenia and skin necrosis, the association of heparin and hyperkalemia is less well recognized.|thrombocytopenia|51|67|heparin|35|42
4014301|Careful follow-up of so-called "self-limited" insulin edema is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure.|edema|54|59|insulin|46|53
4014301|Insulin-induced cardiac failure.|cardiac failure|16|31|Insulin|0|7
4014301|Self-limited edema is a well-recognized complication of insulin therapy.|Self-limited edema|0|18|insulin|56|63
4014301|This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.|cardiac failure|56|71|insulin|40|47
4018433|A case of pyridoxine-dependent seizures is reported.|seizures|31|39|pyridoxine|10|20
4018433|Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia.|acute hypotonia|93|108|pyridoxine|18|28
4025011|Prolonged severe cholestasis induced by oxacillin derivatives.|severe cholestasis|10|28|oxacillin|40|49
4025011|Two patients with osteomyelitis who developed reversible cholestatic jaundice during treatment with oxacillin derivatives are described.|reversible cholestatic jaundice|46|77|oxacillin|100|109
4031907|In all the patients, pellagra symptoms appeared during isoniazid therapy.|pellagra|21|29|isoniazid|55|64
4031907|Isoniazid inhibits the conversion of tryptophan to niacin and may induce pellagra, particularly in poorly nourished patients.|pellagra|73|81|Isoniazid|0|9
4031907|Pellagra encephalopathy among tuberculous patients: its relation to isoniazid therapy.|Pellagra encephalopathy|0|23|isoniazid|68|77
4031907|Pellagra should be suspected whenever tuberculous patients under treatment with isoniazid develop mental, neurological or gastrointestinal symptoms, even in the absence of typical pellagra dermatitis.|mental, neurological or gastrointestinal symptoms|98|147|isoniazid|80|89
4036917|Physicians should be aware of the potential for the development of RS among children who are receiving long-term aspirin therapy for the treatment of systemic inflammatory illnesses.|RS|67|69|aspirin|113|120
4036917|Reye syndrome (RS) is believed to occur infrequently among children receiving long-term aspirin therapy.|Reye syndrome|0|13|aspirin|88|95
4036917|Reye syndrome (RS) is believed to occur infrequently among children receiving long-term aspirin therapy.|RS|15|17|aspirin|88|95
4036917|These findings support previous studies that showed that the use of aspirin during the antecedent illness may be a risk factor for the development of RS.|RS|150|152|aspirin|68|75
4038927|Atrial fibrillation was induced by diltiazem in two patients and verapamil induced syncope in one patient.|Atrial fibrillation|0|19|diltiazem|35|44
4038927|Atrial fibrillation was induced by diltiazem in two patients and verapamil induced syncope in one patient.|syncope|83|90|verapamil|65|74
4044222|A 54-year-old man, treated with amiodarone, developed thyrotoxicosis.|thyrotoxicosis|54|68|amiodarone|32|42
4044222|Amiodarone-induced dysthyroidism.|dysthyroidism|19|32|Amiodarone|0|10
4051280|IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.|decrease in heart rate|95|117|propranolol|3|14
4051280|IV propranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a paroxsymal increase in blood pressure.|paroxsymal increase in blood pressure|124|161|propranolol|3|14
4051280|Propranolol-induced hypertension in treatment of cocaine intoxication.|hypertension|20|32|Propranolol|0|11
4054170|According to the literature, chlorambucil central nervous toxicity is found almost exclusively in childhood nephrotic syndrome.|central nervous toxicity|42|66|chlorambucil|29|41
4054170|Chlorambucil central nervous toxicity: a significant side effect of chlorambucil therapy in childhood nephrotic syndrome.|central nervous toxicity|13|37|Chlorambucil|0|12
4054170|EEG abnormalities were observed in two of the nine children during chlorambucil therapy.|EEG abnormalities|0|17|chlorambucil|67|79
4063627|A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.|IgA deficiency|77|91|fenclofenac|114|125
4063627|Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.|IgA deficiency|30|44|Fenclofenac|0|11
4063627|This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.|IgA deficiency|52|66|aurothiomalate|140|154
4063627|This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.|IgA deficiency|52|66|fenclofenac|117|128
4063627|This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.|IgA deficiency|52|66|sulphasalazine|159|173
4066620|A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.|movement disorder|132|149|lithium|104|111
4066620|A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.|movement disorder|132|149|trazodone|174|183
4066620|Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.|movement disorder|13|30|trazodone|73|82
4066620|The elicitation of a movement disorder by trazodone: case report.|movement disorder|21|38|trazodone|42|51
4066620|When the trazodone was reduced, the involuntary movements promptly ceased.|involuntary movements|36|57|trazodone|9|18
4075534|A review of the literature showed no previous description of this pattern in benzodiazepine coma.|coma|92|96|benzodiazepine|77|91
4075534|Spindle coma in benzodiazepine toxicity: case report.|Spindle coma|0|12|benzodiazepine|16|30
4075534|Two reports of spindle coma are noted with alcohol and imipramine.|spindle coma|15|27|imipramine|55|65
4082283|A literature review revealed 83 other reported cases of rifampicin-induced renal insufficiency.|renal insufficiency|75|94|rifampicin|56|66
4082283|Renal failure is a rare complication associated with the use of rifampicin for the treatment of tuberculosis, usually occurring well into the course of therapy.|Renal failure|0|13|rifampicin|64|74
4082283|Rifampicin-induced renal failure.|renal failure|19|32|Rifampicin|0|10
4082283|The following is a report of 2 cases of rifampicin-induced renal insufficiency.|renal insufficiency|59|78|rifampicin|40|50
4095247|Cerebral and ocular toxicity induced by desferrioxamine.|Cerebral and ocular toxicity|0|28|desferrioxamine|40|55
4095247|Subsequent in vivo/vitro studies clearly demonstrated that the neurological effects were due to a synergistic action of desferrioxamine and prochlorperazine, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems.|neurological effects|63|83|desferrioxamine|120|135
4095247|Subsequent in vivo/vitro studies clearly demonstrated that the neurological effects were due to a synergistic action of desferrioxamine and prochlorperazine, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems.|neurological effects|63|83|prochlorperazine|140|156
4095247|Two of these patients, who also received the anti-emetic prochlorperazine, lost consciousness for 48-72 h and then fully recovered.|lost consciousness|75|93|prochlorperazine|57|73
4095247|Two other patients who did not receive prochlorperazine, developed retinal problems which later improved, one after only 15 g of desferrioxamine.|retinal problems|67|83|desferrioxamine|129|144
412488|Gold nephropathy: tissue analysis by X-ray fluorescent spectroscopy.|nephropathy|5|16|Gold|0|4
412488|These findings are consistent with an immune-complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the renal disease associated with gold therapy in rheumatoid arthritis.|renal disease|290|303|gold|244|248
412488|These findings are consistent with an immune-complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the renal disease associated with gold therapy in rheumatoid arthritis.|renal disease|290|303|gold|320|324
412488|Three patients developed proteinuria following gold therapy for rheumatoid arthritis.|proteinuria|25|36|gold|47|51
417679|Four cases of fat embolism are described in infants receiving prolonged intravenous infusion of fat (Intralipid 20%).|fat embolism|14|26|Intralipid|101|111
424824|Conversely, diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving methotrexate who develop bilateral pulmonary infiltrates seen on chest roentgenograms.|bilateral pulmonary infiltrates|150|181|methotrexate|125|137
424824|Conversely, diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving methotrexate who develop bilateral pulmonary infiltrates seen on chest roentgenograms.|diffuse interstitial pulmonary fibrosis|12|51|methotrexate|125|137
424824|In all three cases, autopsy revealed gross and microscopic features indistinguishable from those seen in the Hamman-Rich syndrome, and methotrexate hepatotoxicity was present in one.|hepatotoxicity|148|162|methotrexate|135|147
424824|It is suggested therefore that methotrexate be added to the list of agents capable of inducing diffuse interstitial pulmonary fibrosis.|diffuse interstitial pulmonary fibrosis|95|134|methotrexate|31|43
424824|Methotrexate-induced diffuse interstitial pulmonary fibrosis.|diffuse interstitial pulmonary fibrosis|21|60|Methotrexate|0|12
424824|Pulmonary eosinophilia or granulomas, classically seen in previously reported cases of methotrexate pneumonitis, were not observed.|granulomas|26|36|methotrexate|87|99
424824|Pulmonary eosinophilia or granulomas, classically seen in previously reported cases of methotrexate pneumonitis, were not observed.|pneumonitis|100|111|methotrexate|87|99
424824|Pulmonary eosinophilia or granulomas, classically seen in previously reported cases of methotrexate pneumonitis, were not observed.|Pulmonary eosinophilia|0|22|methotrexate|87|99
424824|Three patients received respectively 190 mg, 175 mg, and 196 mg of methotrexate and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia.|bilateral pulmonary infiltrates|94|125|methotrexate|67|79
426502|A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of adenine arabinoside.|hyponatremia|114|126|adenine arabinoside|162|181
426502|A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of adenine arabinoside.|syndrome of inappropriate antidiuretic hormone|54|100|adenine arabinoside|162|181
426502|Inappropriate antidiuretic hormone following adenine arabinoside administration.|Inappropriate antidiuretic hormone|0|34|adenine arabinoside|45|64
433855|The toxic effects of methotrexate included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4).|abdominal pain|93|107|methotrexate|21|33
433855|The toxic effects of methotrexate included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4).|bone pain|115|124|methotrexate|21|33
433855|The toxic effects of methotrexate included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4).|elevated liver transaminases|43|71|methotrexate|21|33
433855|The toxic effects of methotrexate included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4).|mild neutropenia|132|148|methotrexate|21|33
433855|The toxic effects of methotrexate included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4).|mild pruritus|160|173|methotrexate|21|33
433855|The toxic effects of methotrexate included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4).|nausea|79|85|methotrexate|21|33
440873|Dystonia associated with carbamazepine administration: experience in brain-damaged children.|Dystonia|0|8|carbamazepine|25|38
440873|In one child, a second course of carbamazepine resulted in a return of the dystonia.|dystonia|75|83|carbamazepine|33|46
440873|The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.|dystonia|181|189|carbamazepine|74|87
440873|We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.|dystonia|58|66|carbamazepine|123|136
440873|We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.|opisthotonus|81|93|carbamazepine|123|136
448845|Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma.|agranulocytosis|20|35|methazolamide|54|67
448845|Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma.|Aplastic anemia|0|15|methazolamide|54|67
448845|Several case reports of aplastic anemia with use of acetazolamide, and two cases with use of methazolamide, have appeared in the literature.|aplastic anemia|24|39|acetazolamide|52|65
448845|Several case reports of aplastic anemia with use of acetazolamide, and two cases with use of methazolamide, have appeared in the literature.|aplastic anemia|24|39|methazolamide|93|106
448845|This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of methazolamide, and one case of agranulocytosis related to the use of methazolamide.|agranulocytosis|149|164|methazolamide|187|200
448845|This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of methazolamide, and one case of agranulocytosis related to the use of methazolamide.|aplastic anemia|36|51|methazolamide|118|131
458006|Squamous-cell carcinoma arising in a basal-cell epithelioma treated with 5-fluorouracil.|Squamous-cell carcinoma|0|23|5-fluorouracil|73|87
458006|We report the development of squamous-cell carcinoma within a basal-cell epithelioma that was treated with intralesional injections of 5-FU.|squamous-cell carcinoma|29|52|5-FU|135|139
464813|Lower extremity arterial insufficiency after long-term methysergide maleate therapy.|arterial insufficiency|16|38|methysergide maleate|55|75
464813|The patient whose case is reviewed had migraine headaches and received methysergide maleate for 13 years.|migraine headaches|39|57|methysergide|71|83
480917|A case of Erythema Multiforme Bullosum in patient of lepromatous leprosy with pulmonary tuberculosis due to Rifampicin is described.|Erythema Multiforme Bullosum|10|38|Rifampicin|108|118
480917|Erythema multiforme bullosum due to rifampicin.|Erythema multiforme bullosum|0|28|rifampicin|36|46
489527|Renal damage associated with long term use of lithium carbonate.|Renal damage|0|12|lithium carbonate|46|63
489527|The authors report 2 cases of renal damage associated with lithium carbonate treatment.|renal damage|30|42|lithium carbonate|59|76
507889|In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).|squamous cell carcinoma|42|65|psoralens|96|105
515777|Hyperglycemia and diabetic coma: possible relationship to diuretic-propranolol therapy.|diabetic coma|18|31|propranolol|67|78
515777|Hyperglycemia and diabetic coma: possible relationship to diuretic-propranolol therapy.|Hyperglycemia|0|13|propranolol|67|78
515777|Two patients developed diabetic coma when taking a combination of a thiazide diuretic and propranolol.|diabetic coma|23|36|propranolol|90|101
515777|Two patients developed diabetic coma when taking a combination of a thiazide diuretic and propranolol.|diabetic coma|23|36|thiazide|68|76
527355|An insulin-dependent diabetic patient with nephropathy developed severe acidosis after treatment with acetazolamide for glaucoma.|severe acidosis|65|80|acetazolamide|102|115
527355|Severe acidosis from acetazolamide in a diabetic patient.|Severe acidosis|0|15|acetazolamide|21|34
53128|This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.|tracheal compression|19|39|aspirin|77|84
536461|Five cases of clindamycin-associated pseudomembranous colitis in leukaemic patients are reported.|pseudomembranous colitis|37|61|clindamycin|14|25
556126|An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.|lost vision|59|70|Bromocryptine|106|119
566977|Fatal acute tubular necrosis occurred in 1 patient in whom intravesical formalin was used to control massive persistent hemorrhage from radiation cystitis.|Fatal acute tubular necrosis|0|28|formalin|72|80
566977|Fatal complication of intravesical formalin during control of intractable hemorrhage from radiation cystitis.|Fatal complication|0|18|formalin|35|43
566977|Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated metabolic acidosis due to absorbed formic acid.|metabolic acidosis|100|118|formic acid|135|146
573779|A young woman developed galactorrhea during treatment with a new dibenzoxazepine antidepressant, amoxapine.|galactorrhea|24|36|amoxapine|97|106
573779|A young woman developed galactorrhea during treatment with a new dibenzoxazepine antidepressant, amoxapine.|galactorrhea|24|36|dibenzoxazepine|65|80
576675|A 15-kg weight gain developed in a patient during the third week of ibuprofen therapy.|15-kg weight gain|2|19|ibuprofen|68|77
576675|Edema associated with ibuprofen therapy.|Edema|0|5|ibuprofen|22|31
576675|It should be recognized that ibuprofen may be associated with salt and water retention in the same fashion as previously described with phenylbutazone and indomethacin.|salt and water retention|62|86|ibuprofen|29|38
576675|It should be recognized that ibuprofen may be associated with salt and water retention in the same fashion as previously described with phenylbutazone and indomethacin.|salt and water retention|62|86|indomethacin|155|167
576675|It should be recognized that ibuprofen may be associated with salt and water retention in the same fashion as previously described with phenylbutazone and indomethacin.|salt and water retention|62|86|phenylbutazone|136|150
578255|Allopurinol-associated hand and foot deformities in chronic tophaceous gout.|hand and foot deformities|23|48|Allopurinol|0|11
578255|Telescoped digits of the hands and feet developed in a 69-year-old male with severe chronic tophaceous gout during allopurinol treatment.|Telescoped digits of the hands and feet|0|39|allopurinol|115|126
582099|A patient with coccidioidal meningitis was treated with intrathecally administered amphotericin B, and an acute toxic delirium with EEG abnormalities developed.|acute toxic delirium|106|126|amphotericin B|83|97
582099|A patient with coccidioidal meningitis was treated with intrathecally administered amphotericin B, and an acute toxic delirium with EEG abnormalities developed.|EEG abnormalities|132|149|amphotericin B|83|97
582099|Neurotoxicity of intrathecal administration of amphotericin B.|Neurotoxicity|0|13|amphotericin B|47|61
58443|In keeping with findings in the literature, the aortic wall in this case was damaged by secondary changes following irradiation and Bleomycin treatment.|aortic wall in this case was damaged|48|84|Bleomycin|132|141
589261|Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.|cardiomyopathy|54|68|doxorubicin|42|53
589261|Doxorubicin cardiotoxicity: possible role of digoxin in its prevention.|cardiotoxicity|12|26|Doxorubicin|0|11
589261|Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.|Minor electrocardiographical changes|0|36|ouabain|158|165
589261|One other patient on digoxin stopped taking it and developed cardiomyopathy.|cardiomyopathy|61|75|digoxin|21|28
589261|One patient on ouabain also developed cardiomyopathy.|cardiomyopathy|38|52|ouabain|15|22
6093724|A healthy, 30-year-old man, exposed to sulindac on two separate occasions, had an incapacitating isolated idential sensory neuropathy.|isolated idential sensory neuropathy|97|133|sulindac|39|47
6093724|Sulindac (Clinoril), a nonsteroidal anti-inflammatory agent, has few reported neurologic toxic effects, all of which have been associated with systemic disease.|neurologic toxic effects|78|102|Clinoril|10|18
6093724|Sulindac (Clinoril), a nonsteroidal anti-inflammatory agent, has few reported neurologic toxic effects, all of which have been associated with systemic disease.|neurologic toxic effects|78|102|Sulindac|0|8
6093724|To our knowledge, we describe the first reported case of isolated paresthesia and peripheral neuropathy, without systemic involvement, secondary to sulindac administration.|isolated paresthesia|57|77|sulindac|148|156
6093724|To our knowledge, we describe the first reported case of isolated paresthesia and peripheral neuropathy, without systemic involvement, secondary to sulindac administration.|peripheral neuropathy|82|103|sulindac|148|156
6102186|In addition, loading with one low oral dose of serine produced psychotic symptoms 5 h later which lasted 3-6 h.|psychotic symptoms|63|81|serine|47|53
6108450|Reversal of ergotamine-induced arteriospasm by mechanical intra-arterial dilatation.|arteriospasm|31|43|ergotamine|12|22
6108450|Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.|arteriospasm|79|91|ergot|65|70
6108450|Two patients with imminent gangrene of the extremities caused by ergot-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.|gangrene of the extremities|27|54|ergot|65|70
6113770|The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.|hyperpyrexia|90|102|haloperidol|52|63
6113770|The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.|hyperpyrexia|90|102|lithium|40|47
6113770|The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.|irreversible tardive dyskinesia|148|179|haloperidol|52|63
6113770|The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.|irreversible tardive dyskinesia|148|179|lithium|40|47
6113770|The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.|mutism|121|127|haloperidol|52|63
6113770|The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.|mutism|121|127|lithium|40|47
6113770|The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.|severe rigidity|104|119|haloperidol|52|63
6113770|The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.|severe rigidity|104|119|lithium|40|47
6113770|The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.|lithium toxicity|139|155|lithium|139|146
6113770|The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.|lithium toxicity|139|155|thioridazine|214|226
6113770|The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.|neuroleptic malignant extrapyramidal syndrome|87|132|lithium|139|146
6113770|The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.|neuroleptic malignant extrapyramidal syndrome|87|132|thioridazine|214|226
6142995|Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative.|chromosome damage|21|38|Chlorambucil|0|12
6159523|Anaphylactoid reaction to 50% solution of dextrose.|Anaphylactoid reaction|0|22|dextrose|42|50
6159523|Preliminary results suggest that the higher concentrations of dextrose induce increased histamine release from blood cells, and that this phenomenon is more marked in diabetic, and particularly diabetic-allergic, individuals.|increased histamine release|78|105|dextrose|62|70
6159523|Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus sustained an anaphylactoid reaction after the intravenous administration of 50% solution of dextrose.|anaphylactoid reaction|99|121|dextrose|178|186
6197014|Salicylate hepato toxicity in rheumatic fever.|hepato toxicity|11|26|Salicylate|0|10
6197014|Two children with rheumatic fever developed anicteric hepatitis while on high-dose aspirin therapy.|anicteric hepatitis|44|63|aspirin|83|90
6199475|A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.|encephalopathy|149|163|bleomycin|67|76
6199475|A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.|encephalopathy|149|163|cisplatinum|37|48
6199475|A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.|encephalopathy|149|163|vinblastine|50|61
6199475|A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.|left homonymous hemianopsia|120|147|bleomycin|67|76
6199475|A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.|left homonymous hemianopsia|120|147|cisplatinum|37|48
6199475|A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.|left homonymous hemianopsia|120|147|vinblastine|50|61
6199475|A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.|partial nondominant parietal lobe syndrome|171|213|bleomycin|67|76
6199475|A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.|partial nondominant parietal lobe syndrome|171|213|cisplatinum|37|48
6199475|A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.|partial nondominant parietal lobe syndrome|171|213|vinblastine|50|61
6199475|Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.|encephalopathy|42|56|bleomycin|136|145
6199475|Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.|encephalopathy|42|56|cisplatinum|106|117
6199475|Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.|encephalopathy|42|56|vinblastine|119|130
6199475|Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.|Transient left homonymous hemianopsia|0|37|bleomycin|136|145
6199475|Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.|Transient left homonymous hemianopsia|0|37|cisplatinum|106|117
6199475|Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.|Transient left homonymous hemianopsia|0|37|vinblastine|119|130
6221046|An association of granulocytopenia, eosinophilia, skin reaction and hepatitis during propylthiouracil (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.|eosinophilia|36|48|propylthiouracil|85|101
6221046|An association of granulocytopenia, eosinophilia, skin reaction and hepatitis during propylthiouracil (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.|eosinophilia|36|48|PTU|103|106
6221046|An association of granulocytopenia, eosinophilia, skin reaction and hepatitis during propylthiouracil (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.|granulocytopenia|18|34|propylthiouracil|85|101
6221046|An association of granulocytopenia, eosinophilia, skin reaction and hepatitis during propylthiouracil (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.|granulocytopenia|18|34|PTU|103|106
6221046|An association of granulocytopenia, eosinophilia, skin reaction and hepatitis during propylthiouracil (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.|hepatitis|68|77|propylthiouracil|85|101
6221046|An association of granulocytopenia, eosinophilia, skin reaction and hepatitis during propylthiouracil (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.|hepatitis|68|77|PTU|103|106
6221046|An association of granulocytopenia, eosinophilia, skin reaction and hepatitis during propylthiouracil (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.|skin reaction|50|63|propylthiouracil|85|101
6221046|An association of granulocytopenia, eosinophilia, skin reaction and hepatitis during propylthiouracil (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.|skin reaction|50|63|PTU|103|106
6221046|Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.|eosinophilia|72|84|propylthiouracil|26|42
6221046|Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.|granulocytopenia|54|70|propylthiouracil|26|42
6221046|Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.|hepatitis|104|113|propylthiouracil|26|42
6221046|Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.|lymphocyte sensitization|119|143|propylthiouracil|26|42
6221046|Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.|skin reaction|86|99|propylthiouracil|26|42
623061|A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.|ataxia|99|105|pentobarbital|220|233
623061|A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.|ataxia|99|105|pyrilamine maleate|238|256
623061|A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.|depressed level of consciousness|40|72|pentobarbital|220|233
623061|A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.|depressed level of consciousness|40|72|pyrilamine maleate|238|256
623061|A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.|marked irritability|74|93|pentobarbital|220|233
623061|A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.|marked irritability|74|93|pyrilamine maleate|238|256
623061|A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.|toxic encephalopathy|2|22|pentobarbital|220|233
623061|A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.|toxic encephalopathy|2|22|pyrilamine maleate|238|256
6233326|Optic neuropathy associated with penicillamine therapy in a patient with rheumatoid arthritis.|Optic neuropathy|0|16|penicillamine|33|46
6233326|Optic neuropathy developed in a patient with rheumatoid arthritis who had been receiving D-penicillamine for about 1 year.|Optic neuropathy|0|16|D-penicillamine|89|104
6233326|The case resembles two previously reported cases of optic neuropathy which occurred in patients with Wilson's disease who were receiving penicillamine.|optic neuropathy|52|68|penicillamine|137|150
6236730|A patient developed transient, acute myopia while on isotretinoin (Accutane) therapy for acne.|acute myopia|31|43|Accutane|67|75
6236730|A patient developed transient, acute myopia while on isotretinoin (Accutane) therapy for acne.|acute myopia|31|43|isotretinoin|53|65
6236730|There was a clear relationship between restarting the Accutane and recurrence of the transient myopia.|transient myopia|85|101|Accutane|54|62
6236730|Transient acute myopia resulting from isotretinoin (accutane) therapy.|Transient acute myopia|0|22|accutane|52|60
6236730|Transient acute myopia resulting from isotretinoin (accutane) therapy.|Transient acute myopia|0|22|isotretinoin|38|50
6239881|Allergic contact dermatitis to compound tincture of benzoin.|Allergic contact dermatitis|0|27|benzoin|52|59
6239881|Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.|allergic contact dermatitis|18|45|benzoin|70|77
6245286|Autopsy evidence of herpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine (cytosine arabinoside; Ara-C) shortly before their death.|herpesvirus infection|20|41|Ara-C|163|168
6245286|Autopsy evidence of herpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine (cytosine arabinoside; Ara-C) shortly before their death.|herpesvirus infection|20|41|cytarabine|129|139
6245286|Autopsy evidence of herpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine (cytosine arabinoside; Ara-C) shortly before their death.|herpesvirus infection|20|41|cytosine arabinoside|141|161
6245286|In three of these patients the infection was clinically unsuspected; in the fourth, cutaneous herpes zoster developed after administration of 300 mg of cytarabine daily for the preceding five days.|cutaneous herpes zoster|84|107|cytarabine|152|162
6245286|Visceral herpesvirus infections in leukemic patients receiving cytarabine.|Visceral herpesvirus infections|0|31|cytarabine|63|73
6251941|Clinical and morphological features of gold neuropathy.|neuropathy|44|54|gold|39|43
6251941|Three cases of gold-related neuropathy are reported.|neuropathy|28|38|gold|15|19
6260900|Intra-neural ceroid-like pigment following the treatment of lepromatous leprosy with clofazimine (B663; Lamprene).|Intra-neural ceroid-like pigment|0|32|B663|98|102
6260900|Intra-neural ceroid-like pigment following the treatment of lepromatous leprosy with clofazimine (B663; Lamprene).|Intra-neural ceroid-like pigment|0|32|clofazimine|85|96
6260900|Intra-neural ceroid-like pigment following the treatment of lepromatous leprosy with clofazimine (B663; Lamprene).|Intra-neural ceroid-like pigment|0|32|Lamprene|104|112
6260900|One of these was clofazimine, an aniline aposafranine derivative known to produce a ceroid-like pigment in the tissues of patients treated with this drug or lepromatous leprosy.|ceroid-like pigment|84|103|clofazimine|17|28
6292681|Severe neurotoxicity with methyl G: CALGB experience.|Severe neurotoxicity|0|20|methyl G: CALGB|26|41
6303138|A young patient experienced marked sinus tachycardia while smoking marijuana and receiving therapeutic doses of nortriptyline.|sinus tachycardia|35|52|nortriptyline|112|125
6303138|Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.|sinus tachycardia|7|24|nortriptyline|81|94
6311654|It is concluded that 'cerebral atrophy' on CT scans may represent an accumulative effect of ACTH and that ACTH should be given with the utmost discretion, and in as low a dose as possible.|cerebral atrophy|22|38|ACTH|92|96
6324592|Disulfiram-like reactions with newer cephalosporins: cefmenoxime.|Disulfiram-like reactions|0|25|cefmenoxime|53|64
6324592|This is the first report of a disulfiram-like reaction with cefmenoxime.|disulfiram-like reaction|30|54|cefmenoxime|60|71
6329575|k bipolar manic-depressive patient, developed while on lithium prophylaxis, akathisia at therapeutic serum lithium levels and subsequently bucco-linguo-masticatory dyskinesia.|akathisia|76|85|lithium|55|62
6329575|k bipolar manic-depressive patient, developed while on lithium prophylaxis, akathisia at therapeutic serum lithium levels and subsequently bucco-linguo-masticatory dyskinesia.|bucco-linguo-masticatory dyskinesia|139|174|lithium|55|62
633424|Acute leukopenia associated with silver sulfadiazine therapy.|Acute leukopenia|0|16|silver sulfadiazine|33|52
6340463|Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.|disseminated histoplasmosis|83|110|prednisone|139|149
6344831|Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys.|Acute renal failure|0|19|captopril|75|84
6344831|In a patient with severe renovascular hypertension, nonoliguric acute renal failure developed after she received captopril treatment.|nonoliguric acute renal failure|52|83|captopril|113|122
6344831|Nonoliguric acute renal failure after captopril therapy.|Nonoliguric acute renal failure|0|31|captopril|38|47
6353252|Captopril-induced acute reversible renal failure.|acute reversible renal failure|18|48|Captopril|0|9
6353252|The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure.|acute renal failure|140|159|captopril|122|131
6353252|We report 5 cases of acute reversible renal failure coinciding with the onset of treatment with captopril in patients with severe drug-resistant hypertension.|acute reversible renal failure|21|51|captopril|96|105
6362443|A case of mania associated with fluoxetine.|mania|10|15|fluoxetine|32|42
6362443|A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.|manic episode|65|78|fluoxetine|101|111
6385260|Alopecia, nausea, and vomiting were attributed to the cyclophosphamide component of the therapy.|Alopecia|0|8|cyclophosphamide|54|70
6385260|Alopecia, nausea, and vomiting were attributed to the cyclophosphamide component of the therapy.|nausea|10|16|cyclophosphamide|54|70
6385260|Alopecia, nausea, and vomiting were attributed to the cyclophosphamide component of the therapy.|vomiting|22|30|cyclophosphamide|54|70
6401771|Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.|Haemolytic-uraemic syndrome|0|27|5-fluorouracil|67|81
6401771|Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.|Haemolytic-uraemic syndrome|0|27|mitomycin C|51|62
6401771|Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.|acute renal toxicity|15|35|5-fluorouracil|97|111
6401771|Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.|acute renal toxicity|15|35|mitomycin C|81|92
640344|Oral 25-hydroxyvitain D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy.|ileal resection|70|85|25-hydroxyvitain D3|5|24
640344|Severe histological osteomalacia developed in a woman with Crohn's disease 2 years after ileal resection and the start of cholestyramine therapy.|osteomalacia|20|32|cholestyramine|122|136
6405633|Treatment of lithium tremor with metoprolol.|tremor|21|27|lithium|13|20
6405633|Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy.|tremor|99|105|lithium carbonate|113|130
6408978|Intravenous diazepam exacerbated the seizures.|seizures|37|45|diazepam|12|20
6414095|A 52-year-old Black woman on phenytoin therapy for post-traumatic epilepsy developed transient hemiparesis contralateral to the injury.|transient hemiparesis|85|106|phenytoin|29|38
6414095|A possible mechanism for focal neurological deficit in brain-damaged patients on phenytoin therapy is discussed.|focal neurological deficit|25|51|phenytoin|81|90
6414095|Transient hemiparesis caused by phenytoin toxicity.|Transient hemiparesis|0|21|phenytoin|32|41
6416845|A 7-year-old boy developed a severe unilateral grand mal seizure at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy.|severe unilateral grand mal seizure|29|64|2-propylpentanoic acid|140|162
6416845|A 7-year-old boy developed a severe unilateral grand mal seizure at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy.|severe unilateral grand mal seizure|29|64|phenobarbitone|88|102
6416845|A 7-year-old boy developed a severe unilateral grand mal seizure at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy.|severe unilateral grand mal seizure|29|64|valproate|129|138
6416845|A 7-year-old boy developed a severe unilateral grand mal seizure at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy.|severe unilateral grand mal seizure|29|64|VPA|164|167
6422563|Cefoxitin therapy for Mycobacterium fortuitum bacteremia with associated granulomatous hepatitis.|granulomatous hepatitis|73|96|Cefoxitin|0|9
6427463|Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.|Stroke-like syndrome|0|20|gold sodium thiomalate|27|49
6427463|Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.|vasomotor reaction|58|76|gold sodium thiomalate|27|49
6427463|Vasomotor reactions after gold sodium thiomalate are well recognized.|Vasomotor reactions|0|19|gold sodium thiomalate|26|48
6430252|Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.|Gold nephropathy|0|16|auranofin|24|33
6430252|Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.|Gold nephropathy|0|16|Gold|0|4
6430252|Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.|Gold nephropathy|0|16|tolmetin|46|54
6430252|Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.|pseudoproteinuria|55|72|tolmetin|46|54
6440806|A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.|cough|55|60|sodium aurothiomalate|103|124
6440806|A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.|dyspnea|66|73|sodium aurothiomalate|103|124
6440806|A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.|low-grade fever|38|53|sodium aurothiomalate|103|124
6440806|Pulmonary gold toxicity.|Pulmonary gold toxicity|0|23|gold|10|14
644545|Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.|fibrosis|63|71|Cyclophosphamide|0|16
644545|Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis.|interstitial pneumonitis|34|58|Cyclophosphamide|0|16
644545|Cyclophosphamide pneumonitis.|pneumonitis|17|28|Cyclophosphamide|0|16
644545|The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.|lung disease|206|218|cyclophosphamide|150|166
644545|The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that cyclophosphamide was aetiologically responsible for the lung disease.|respiratory insufficiency|29|54|cyclophosphamide|150|166
6453500|A reversible toxic liver damage was observed in a non-alcoholic woman treated with disulfiram.|reversible toxic liver damage|2|31|disulfiram|83|93
6453500|Toxic hepatitis induced by disulfiram in a non-alcoholic.|Toxic hepatitis|0|15|disulfiram|27|37
6460590|One type of SMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of clioquinol.|acrodermatitis enteropathica|36|64|clioquinol|149|159
6460590|One type of SMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of clioquinol.|SMON|12|16|clioquinol|149|159
647693|Four patients receiving high-dose tamoxifen for greater than 1 year have demonstrated similar retinal changes.|retinal changes|94|109|tamoxifen|34|43
647693|Tamoxifen retinopathy.|retinopathy|10|21|Tamoxifen|0|9
647693|These findings suggest that the corneal and retinal changes are the result of a toxic effect of tamoxifen when used in the doses and duration described.|corneal and retinal changes|32|59|tamoxifen|96|105
6478628|Mammary gigantism is a rare complication of D-penicillamine treatment.|Mammary gigantism|0|17|D-penicillamine|44|59
6484655|Although they had complex medical problems, the high serum concentrations of ampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy.|seizures|189|197|ampicillin|77|87
6484655|Although they had complex medical problems, the high serum concentrations of ampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy.|seizures|189|197|ampicillin|218|228
6484655|Ampicillin-associated seizures.|seizures|22|30|Ampicillin|0|10
6484655|Two patients had ampicillin-associated seizures.|seizures|39|47|ampicillin|17|27
6498095|After the patient discontinued rifampicin, the skin lesions cleared completely within 5 weeks without any systemic medication.|skin lesions|47|59|rifampicin|31|41
6498095|Pemphigus foliaceus induced by rifampicin.|Pemphigus foliaceus|0|19|rifampicin|31|41
6498095|Pemphigus foliaceus was seen in a patient with pulmonary tuberculosis during rifampicin therapy.|Pemphigus foliaceus|0|19|rifampicin|77|87
6507240|Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.|Hyponatremia|0|12|lorcainide|38|48
6507240|In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of lorcainide.|decrease in serum Na+|26|47|lorcainide|125|135
6507240|It is concluded that SIADH is an important side effect of lorcainide therapy.|SIADH|21|26|lorcainide|58|68
6507240|One patient developed severe hyponatremia with serum Na+ of 108 mEq/L when hydrochlorothiazide was given to control hypertension.|severe hyponatremia|22|41|hydrochlorothiazide|75|94
6507240|Sixteen of 33 patients developed significant hyponatremia and hypoosmolality during oral treatment with lorcainide.|hyponatremia|45|57|lorcainide|104|114
6507240|Sixteen of 33 patients developed significant hyponatremia and hypoosmolality during oral treatment with lorcainide.|hypoosmolality|62|76|lorcainide|104|114
6510223|Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.|Acute intravascular hemolysis|0|29|chlorpropamide|147|161
6510223|Acute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, chlorpropamide.|Acute intravascular hemolysis|0|29|glyburide|89|98
6510223|Chlorpropamide-induced hemolytic anemia.|hemolytic anemia|23|39|Chlorpropamide|0|14
6519218|In a 61-year-old man receiving chronic low-dosage amiodarone an interstitial pneumopathy was observed.|interstitial pneumopathy|64|88|amiodarone|50|60
6519218|Interstitial pneumopathy and low-dosage amiodarone.|Interstitial pneumopathy|0|24|amiodarone|40|50
6529939|Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol.|Alternating sinus rhythm|0|24|propranolol|70|81
6529939|Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol.|intermittent sinoatrial block|29|58|propranolol|70|81
6529939|Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily.|Alternating sinus rhythm|0|24|propranolol|140|151
6529939|Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily.|intermittent sinoatrial (S-A) block|29|64|propranolol|140|151
6529939|The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S-A block was seen.|abnormal rhythm|4|19|propranolol|55|66
6529939|This was accepted as evidence for propranolol being the cause of this conduction disorder.|conduction disorder|70|89|propranolol|34|45
6540393|A further case of anaphylactoid reaction to methylprednisolone is reported.|anaphylactoid reaction|18|40|methylprednisolone|44|62
6540393|Anaphylactoid reaction to methylprednisolone pulsed therapy for multiple sclerosis.|Anaphylactoid reaction|0|22|methylprednisolone|26|44
6572542|Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.|pulmonary toxicity|89|107|CCNU|111|115
6572542|Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.|Pulmonary fibrosis|0|18|CCNU|47|51
6572542|The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.|pulmonary fibrosis|50|68|CCNU|22|26
6572542|Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.|fatal pulmonary fibrosis|128|152|CCNU|69|73
6578007|Additive pulmonary toxicity with melphalan and busulfan therapy.|Additive pulmonary toxicity|0|27|busulfan|47|55
6578007|Additive pulmonary toxicity with melphalan and busulfan therapy.|Additive pulmonary toxicity|0|27|melphalan|33|42
6578007|We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.|severe interstitial lung fibrosis|77|110|busulfan|172|180
6578007|We report a 59-year-old patient with chronic myeloid leukemia, who developed severe interstitial lung fibrosis after short term and sequential treatment with melphalan and busulfan.|severe interstitial lung fibrosis|77|110|melphalan|158|167
6597713|After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.|confusion|95|104|cholestyramine II|13|30
6597713|After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.|drowsiness|109|119|cholestyramine II|13|30
6597713|After taking cholestyramine II sachets twice daily for two months she presented with lethargy, confusion and drowsiness.|lethargy|85|93|cholestyramine II|13|30
6597713|Cholestyramine induced hyperchloremic metabolic acidosis.|hyperchloremic metabolic acidosis|23|56|Cholestyramine|0|14
6597713|It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.|hyperchloremic metabolic acidosis|24|57|cholestyramine|75|89
6597713|The first reported case, in an adult, of cholestyramine induced hyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.|hyperchloremic metabolic acidosis|64|97|cholestyramine|41|55
6608139|Although myelosuppression is mild, immunosuppression and superinfection are potential hazards of treatment with DCF.|immunosuppression|35|52|DCF|112|115
6608139|Although myelosuppression is mild, immunosuppression and superinfection are potential hazards of treatment with DCF.|superinfection|57|71|DCF|112|115
6608139|The ocular toxicity of DCF, previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study.|conjunctivitis|52|66|DCF|23|26
6608139|The ocular toxicity of DCF, previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study.|keratitis|84|93|DCF|23|26
6608139|The ocular toxicity of DCF, previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study.|ocular toxicity|4|19|DCF|23|26
6610943|Because there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during vasopressin infusion, followed by release of myoglobin and renal damage.|renal damage|196|208|vasopressin|137|148
6610943|Because there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during vasopressin infusion, followed by release of myoglobin and renal damage.|skeletal muscle ischemia|95|119|vasopressin|137|148
6610943|Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.|acute renal failure|18|37|vasopressin|66|77
6610943|Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.|Myoglobinuria|0|13|vasopressin|66|77
6610943|Myoglobinuria and acute renal failure were observed in two patients with vasopressin-treated gastrointestinal hemorrhage.|acute renal failure|18|37|vasopressin|73|84
6610943|Myoglobinuria and acute renal failure were observed in two patients with vasopressin-treated gastrointestinal hemorrhage.|Myoglobinuria|0|13|vasopressin|73|84
6614033|A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity.|nephrotoxicity|74|88|amphotericin B|33|47
6614033|Amphotericin B nephrotoxicity in humans decreased by salt repletion.|nephrotoxicity|15|29|Amphotericin B|0|14
6614033|Experience with five patients in whom impaired renal function developed early during amphotericin B therapy is reported.|impaired renal function|38|61|amphotericin B|85|99
6618859|Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.|Gynecomastia|0|12|fluoresone|88|98
6618859|Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.|Gynecomastia|0|12|phenobarbital|119|132
6618859|Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.|Gynecomastia|0|12|phenytoin|137|146
6618859|Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.|Gynecomastia|0|12|fluoresone|69|79
6618859|Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.|Gynecomastia|0|12|phenobarbital|40|53
6618859|Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.|Gynecomastia|0|12|phenytoin|55|64
6625005|Case report of withdrawal dyskinesia associated with amoxapine.|dyskinesia|26|36|amoxapine|53|62
6625005|Occurrence of withdrawal dyskinesia indicates that the neuroleptic effects of amoxapine may be clinically significant.|dyskinesia|25|35|amoxapine|78|87
6625005|The authors describe a case of oral-facial dyskinesia that occurred after discontinuation of amoxapine, and antidepressant which may also have neuroleptic effects.|oral-facial dyskinesia|31|53|amoxapine|93|102
6628806|A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.|toxic hepatitis|10|25|etretinate|78|88
6628806|A case of toxic hepatitis caused by combination therapy with methotrexate and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.|toxic hepatitis|10|25|methotrexate|61|73
6628806|Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.|Toxic hepatitis|0|15|etretinate|65|75
6628806|Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis.|Toxic hepatitis|0|15|methotrexate|48|60
6635723|Metabolic balance studies and rechallenge with hydrochlorothiazide were undertaken to investigate the mechanism of the thiazide-induced hyponatremia.|hyponatremia|136|148|hydrochlorothiazide|47|66
6651138|A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).|unilateral acute angle-closure glaucoma|30|69|scopolamine|128|139
665845|A case history of a 15-year-old boy who developed incapacitating tardive dyskinesia that resolved during treatment with deanol is presented.|tardive dyskinesia|65|83|deanol|120|126
6671350|Cephalosporins are most likely associated with Vitamin K deficiency.|Vitamin K deficiency|47|67|Cephalosporins|0|14
6671350|Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.|Coagulopathy|0|12|cephalosporin|40|53
6671350|Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.|Coagulopathy|0|12|moxalactam|57|67
6671350|Moxalactam is more likely to be associated with platelet dysfunction.|platelet dysfunction|48|68|Moxalactam|0|10
6671350|Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.|coagulopathy|18|30|cephalosporin|99|112
6671350|Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.|coagulopathy|39|51|cephalosporin|86|99
6671350|Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.|coagulopathy|39|51|moxalactam|103|113
667809|A case is reported of a child with fatal pulmonary fibrosis following BCNU therapy.|fatal pulmonary fibrosis|35|59|BCNU|70|74
667809|Fatal pulmonary fibrosis following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.|Fatal pulmonary fibrosis|0|24|1,3-bis(2-chloroethyl)-1-nitrosourea|35|71
667809|Fatal pulmonary fibrosis following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy.|Fatal pulmonary fibrosis|0|24|BCNU|73|77
6683487|Thrombotic thrombocytopenic purpura during penicillamine therapy in rheumatoid arthritis.|Thrombotic thrombocytopenic purpura|0|35|penicillamine|43|56
6683487|Thrombotic thrombocytopenic purpura (TTP) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with penicillamine.|Thrombotic thrombocytopenic purpura|0|35|penicillamine|146|159
6683487|Thrombotic thrombocytopenic purpura (TTP) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with penicillamine.|TTP|37|40|penicillamine|146|159
6683487|To our knowledge, no prior cases of penicillamine-induced TTP in RA have been reported.|TTP|58|61|penicillamine|36|49
6692713|Amiodarone hydrochloride, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates.|cough|115|120|Amiodarone hydrochloride|0|24
6692713|Amiodarone hydrochloride, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates.|diffuse pulmonary infiltrates|134|163|Amiodarone hydrochloride|0|24
6692713|Amiodarone hydrochloride, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates.|dyspnea|122|129|Amiodarone hydrochloride|0|24
6692713|Amiodarone hydrochloride, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates.|pulmonary toxicity|79|97|Amiodarone hydrochloride|0|24
6692713|Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy.|pulmonary toxicity|34|52|amiodarone|23|33
6692713|To our knowledge, this recurrence of amiodarone pulmonary toxicity has not been reported previously.|pulmonary toxicity|48|66|amiodarone|37|47
6692713|We describe a case of fibrosing alveolitis, diagnosed by lung biopsy, in a patient receiving amiodarone which responded to corticosteroid therapy.|fibrosing alveolitis|22|42|amiodarone|93|103
6693840|A 61 year-old male patient developed gynecomastia after starting theophylline.|gynecomastia|37|49|theophylline|65|77
6693840|Gynecomastia associated with theophylline.|Gynecomastia|0|12|theophylline|29|41
6693840|No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.|gynecomastia|47|59|theophylline|90|102
6693840|The gynecomastia regressed when the theophylline was discontinued.|gynecomastia|4|16|theophylline|36|48
6697887|Parenteral-verapamil-induced sustained hypotension.|sustained hypotension|29|50|verapamil|11|20
6697887|The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.|hypotension|40|51|verapamil|22|31
6697887|We report a case of sustained hypotension after administration of parenteral verapamil.|sustained hypotension|20|41|verapamil|77|86
6702890|A 69-year-old man developed pure red cell aplasia after taking fenoprofen for ten months.|pure red cell aplasia|28|49|fenoprofen|63|73
6702890|Pure red cell aplasia associated with fenoprofen.|Pure red cell aplasia|0|21|fenoprofen|38|48
6702890|This case represents the third example of erythroid aplasia associated with an anti-inflammatory agent and the first instance due to fenoprofen.|erythroid aplasia|42|59|fenoprofen|133|143
6721543|Drug-induced psychosis resulted from the administration of quinacrine hydrochloride at a dosage of 100 mg twice daily for the treatment of discoid lupus.|psychosis|13|22|quinacrine hydrochloride|59|83
6725214|A case of priapism associated with trazodone is described.|priapism|10|18|trazodone|35|44
6725214|Priapism associated with trazodone therapy: case report.|Priapism|0|8|trazodone|25|34
672731|Charcoal haemoperfusion and cysteamine therapy led to the rapid removal of the paracetamol from the body and consequently prevented the development of severe hepatic necrosis.|severe hepatic necrosis|151|174|paracetamol|79|90
6731466|Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.|Anaphylactoid shock|0|19|zomepirac|137|146
6731466|Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.|anuric renal failure|65|85|zomepirac|137|146
6731466|Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.|disseminated intravascular coagulation|21|59|zomepirac|137|146
6731466|Focal renal cortical necrosis associated with zomepirac.|Focal renal cortical necrosis|0|29|zomepirac|46|55
6731466|The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.|anaphylactoid reaction|17|39|zomepirac|43|52
6733633|Cimetidine-induced fever.|fever|19|24|Cimetidine|0|10
6733633|Cimetidine is a rare cause of drug-induced fever.|fever|43|48|Cimetidine|0|10
6738830|A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.|behavioral change|59|76|cinepazide|114|124
6738830|Unique behavioral change with cinepazide in parkinsonism.|behavioral change|7|24|cinepazide|30|40
6744146|A 65-year-old woman, in the intensive care unit because of septic shock and acute renal failure, had a small-bowel obstruction due to Amphojel concretions.|small-bowel obstruction|103|126|Amphojel|134|142
6766717|A patient with alcoholic cerebellar degeneration had periodic alternating nystagmus during a period of phenytoin intoxication.|periodic alternating nystagmus|53|83|phenytoin|103|112
6788011|Although the data indicate an immune-complex cause for gold-salt nephropathy, the incident antigen (or antigens) and mechanism of action remain unidentified.|nephropathy|65|76|gold-salt|55|64
6788011|Gold nephropathy.|nephropathy|5|16|Gold|0|4
6788011|Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.|damage to proximal tubules|32|58|Gold-salt|0|9
6788011|The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.|nephrotic syndrome|4|22|gold|69|73
6794018|Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.|cutaneous bullae|29|45|glibenclamide|62|75
6794018|Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.|Intrahepatic cholestasis|0|24|glibenclamide|62|75
6794018|Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.|cutaneous bullae|29|45|glibenclamide|62|75
6794018|Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.|Intrahepatic cholestasis|0|24|glibenclamide|62|75
6794018|These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.|intrahepatic cholestasis|95|119|chlorpropamide|135|149
6797753|In four patients, spasm occurred spontaneous and in one patient after 0.05 mg of ergonovine.|spasm|18|23|ergonovine|81|91
6810714|The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.|delirium|72|80|propranolol|144|155
6810714|The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.|grand mal seizure|82|99|propranolol|144|155
6810714|The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.|photosensitivity|105|121|propranolol|144|155
681921|Catatonia associated with disulfiram therapy.|Catatonia|0|9|disulfiram|26|36
681921|Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.|catatonia|97|106|disulfiram|67|77
681921|This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.|catatonic syndrome|30|48|disulfiram|82|92
6826112|Hepatic reactions to cyclofenil.|Hepatic reactions|0|17|cyclofenil|21|31
6826112|Thirty patients with hepatic reactions to cyclofenil, a non-steroidal drug with a stimulating effect on ovulation, are reviewed.|hepatic reactions|21|38|cyclofenil|42|52
6830388|Since early symptoms of the toxic effects of theophylline can mimic peptic ulcer disease, cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning.|peptic ulcer disease|68|88|theophylline|45|57
6833205|A case of SIADH associated with desipramine treatment in an elderly depressed woman is described.|SIADH|10|15|desipramine|32|43
6833205|Desipramine-associated SIADH in an elderly woman: case report.|SIADH|23|28|Desipramine|0|11
6837655|Prior reports have emphasized the tubular and interstitial lesions associated with intermittent or discontinuous rifampin therapy for tuberculosis.|tubular and interstitial lesions|34|66|rifampin|113|121
6837655|The spectrum of renal lesions occurring during antituberculous therapy, particularly in association with rifampin, may be wider than previously suspected.|renal lesions|16|29|rifampin|105|113
6837655|Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed acute renal failure.|acute renal failure|124|143|isoniazid|45|54
6837655|Within 3 weeks of beginning continuous daily isoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed acute renal failure.|acute renal failure|124|143|rifampin|59|67
6851259|Nephrotic range pseudoproteinuria in a tolmetin-treated patient.|Nephrotic range pseudoproteinuria|0|33|tolmetin|39|47
6854698|When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.|histamine reaction|89|107|isoniazid|30|39
6860059|Fulminant hepatitis associated with disulfiram.|Fulminant hepatitis|0|19|disulfiram|36|46
6860059|We report a case of fatal fulminant hepatitis caused by the use of disulfiram in a man with previously normal hepatocellular function.|fatal fulminant hepatitis|20|45|disulfiram|67|77
6865827|A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.|agranulocytosis|50|65|propylthiouracil|87|103
6865827|The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.|agranulocytosis|83|98|methimazole|22|33
6865827|This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.|agranulocytosis|75|90|methimazole|141|152
6865827|This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.|agranulocytosis|75|90|propylthiouracil|120|136
6873616|A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.|prolonged jaundice|26|44|thiabendazole|81|94
6873616|A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.|sicca complex|49|62|thiabendazole|81|94
6873616|Intrahepatic cholestasis and sicca complex after thiabendazole.|Intrahepatic cholestasis|0|24|thiabendazole|49|62
6873616|Intrahepatic cholestasis and sicca complex after thiabendazole.|sicca complex|29|42|thiabendazole|49|62
6873616|The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.|cholestasis|40|51|thiabendazole|18|31
6873616|The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.|sicca complex|77|90|thiabendazole|18|31
6928097|She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.|Adriamycin toxicity|93|112|Adriamycin|27|37
6928097|She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.|Adriamycin toxicity|93|112|Adriamycin|93|103
6928097|She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.|Adriamycin toxicity|93|112|doxorubicin|39|50
6928097|She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.|died|85|89|Adriamycin|27|37
6928097|She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.|died|85|89|Adriamycin|93|103
6928097|She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.|died|85|89|doxorubicin|39|50
6933231|Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia.|focal seizures|28|42|L-asparaginase|63|77
6933231|Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia.|Intracranial hemorrhage|0|23|L-asparaginase|63|77
6947095|Dural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and asparaginase.|Dural sinus thrombosis|0|22|asparaginase|152|164
6947095|Dural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and asparaginase.|Dural sinus thrombosis|0|22|prednisone|136|146
6947095|Dural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and asparaginase.|Dural sinus thrombosis|0|22|vincristine sulfate|115|134
6947095|The cause is presumed to be secondary to hypercoagulability due to asparaginase-induced antithrombin III deficiency.|antithrombin III deficiency|88|115|asparaginase|67|79
6958210|Six patients with rheumatoid arthritis developed a syndrome resembling lupus erythematosus while being treated with penicillamine.|lupus erythematosus|71|90|penicillamine|116|129
6958210|Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis.|Systemic lupus erythematosus|0|28|penicillamine|36|49
6987607|However, the amount of prednisone required to maintain normotension resulted in Cushingoid features and has been discontinued.|Cushingoid features|80|99|prednisone|23|33
6998294|Clinicians should be aware of fasting hypoglycemia as an unusual but potentially serious complication of disopyramide therapy.|fasting hypoglycemia|30|50|disopyramide|105|117
6998294|Disopyramide (Norpace)-induced hypoglycemia.|hypoglycemia|31|43|Disopyramide|0|12
6998294|Disopyramide (Norpace)-induced hypoglycemia.|hypoglycemia|31|43|Norpace|14|21
7019786|Cefoxitin-associated renal failure.|renal failure|21|34|Cefoxitin|0|9
7019786|The other woman had rheumatoid arthritis and developed acute tubular necrosis after treatment with gentamicin and cefoxitin.|acute tubular necrosis|55|77|cefoxitin|114|123
7019786|The other woman had rheumatoid arthritis and developed acute tubular necrosis after treatment with gentamicin and cefoxitin.|acute tubular necrosis|55|77|gentamicin|99|109
7019786|Two elderly women suffered an acute deterioration of renal function after treatment with cefoxitin sodium.|acute deterioration of renal function|30|67|cefoxitin sodium|89|105
7035691|Transient anuria following administration of angiotensin I-converting enzyme inhibitor (SQ 14225) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.|Transient anuria|0|16|SQ 14225|88|96
7035691|We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.|acute renal impairment|84|106|captopril|167|176
7035691|We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril.|transient anuria|122|138|captopril|167|176
7056119|A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).|atypical ventricular tachycardia|121|153|amiodarone|41|51
7056119|A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).|atypical ventricular tachycardia|121|153|disopyramide|53|65
7056119|A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).|atypical ventricular tachycardia|121|153|quinidine|71|80
7056119|A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).|AVT|155|158|amiodarone|41|51
7056119|A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).|AVT|155|158|disopyramide|53|65
7056119|A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).|AVT|155|158|quinidine|71|80
7056119|A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).|torsade de pointes|160|178|amiodarone|41|51
7056119|A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).|torsade de pointes|160|178|disopyramide|53|65
7056119|A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).|torsade de pointes|160|178|quinidine|71|80
7056119|Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.|AVT|40|43|Amiodarone|0|10
7056119|Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.|arrhythmia|77|87|disopyramide|124|136
7056119|Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.|arrhythmia|77|87|quinidine|110|119
7056119|Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.|Atypical ventricular tachycardia|0|32|amiodarone|65|75
7056119|Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.|torsade de pointes|34|52|amiodarone|65|75
7056119|Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.|AVT|100|103|disopyramide|63|75
7056119|Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.|syncope|109|116|disopyramide|63|75
7067510|Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation cannot be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient coronary vasoconstriction induced by the dopamine infusion.|coronary vasoconstriction|304|329|dopamine|345|353
7071645|Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.|nephrosis|26|35|hydroxychloroquine|70|88
7081289|Hepatitis following cimetidine administration.|Hepatitis|0|9|cimetidine|20|30
7081289|The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.|hepatic dysfunction|40|59|cimetidine|115|125
7081289|The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.|impaired macrophage migration|67|96|cimetidine|115|125
7081289|There have been only two reports of cimetidine-induced hepatitis.|hepatitis|55|64|cimetidine|36|46
7098384|A 66-year-old mand suffering from severe coronary heart disease took digoxin with suicidal intent an was treated for the ensuing complete atrioventricular block with digoxin-specific antibody fragments.|complete atrioventricular block|129|160|digoxin|69|76
7105508|Verapamil in effort-induced angina pectoris in patients with normal coronary arteries.|angina pectoris|28|43|Verapamil|0|9
7117795|Flucytosine-associated diarrhea has been previously described in 6%-10% of patients receiving the drug.|diarrhea|23|31|Flucytosine|0|11
7117795|This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.|marked separation of loops of bowel|162|197|flucytosine|32|43
7117795|This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.|severe luminal narrowing|120|144|flucytosine|32|43
7117795|This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.|ulcerating enteritis|55|75|flucytosine|32|43
7117795|This report describes a case of flucytosine-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.|ulceration|146|156|flucytosine|32|43
7117795|Ulcerating enteritis associated with flucytosine therapy.|Ulcerating enteritis|0|20|flucytosine|37|48
7127202|Papilledema without peripheral neuropathy in a patient taking perhexiline maleate.|Papilledema|0|11|perhexiline maleate|62|81
7139589|An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.|acute pancreatitis|29|47|L-asparaginase|121|135
7139589|An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.|pseudocyst of the pancreas|52|78|L-asparaginase|121|135
7139589|Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.|Delayed pseudocyst of the pancreas|0|34|L-asparaginase|74|88
7139589|L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.|pancreatitis|23|35|L-asparaginase|0|14
7139589|Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.|pseudocyst of the pancreas|15|41|L-asparaginase|125|139
7151655|In one patient, treatment with DCA was associated with a decrease in blood lactate levels from 11.2 mM before treatment to 0.8 mM 16 h later.|decrease in blood lactate levels|57|89|DCA|31|34
7174620|Nine delirious patients suffering from lithium intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.|delirious|5|14|lithium|39|46
7174620|The course of delirium due to lithium intoxication.|delirium|14|22|lithium|30|37
717931|Life-threatening hyperkalemia induced by arginine.|hyperkalemia|17|29|arginine|41|49
717931|Marked hyperkalemia was observed during and immediately after an infusion of arginine monohydrochloride in two patients with severe hepatic disease and moderate renal insufficiency.|Marked hyperkalemia|0|19|arginine monohydrochloride|77|103
71813|A 58-year-old man with rheumatoid arthritis developed lichen planus during treatment with gold.|lichen planus|54|67|gold|90|94
71813|Acne provoked by gold seems not to have been described elsewhere.|Acne|0|4|gold|17|21
71813|Lichen planus and acne provoked by gold.|acne|18|22|gold|35|39
71813|Lichen planus and acne provoked by gold.|Lichen planus|0|13|gold|35|39
71813|The case history confirms that gold treatment, even in the same patient, can give rise to a wide range of skin disturbances, which in many cases do not break out until long after the drug has been withdrawn.|skin disturbances|106|123|gold|31|35
7212107|Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.|nephrotoxicity|63|77|lithium|55|62
7212107|Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.|Secondary hyperparathyroidism|0|29|lithium|55|62
7212107|These results indicate that lithium may cause biochemical hyperparathyroidism.|biochemical hyperparathyroidism|46|77|lithium|28|35
7226916|A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (CHB) following administration of disopyramide phosphate (Norpace).|CHB|127|130|disopyramide phosphate|160|182
7226916|A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (CHB) following administration of disopyramide phosphate (Norpace).|CHB|127|130|Norpace|184|191
7226916|A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (CHB) following administration of disopyramide phosphate (Norpace).|complete heart block|105|125|disopyramide phosphate|160|182
7226916|A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (CHB) following administration of disopyramide phosphate (Norpace).|complete heart block|105|125|Norpace|184|191
7226916|Disopyramide-induced heart block.|heart block|21|32|Disopyramide|0|12
7235792|Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.|cardiac arrest|194|208|bretylium|45|54
7235792|Although transient increases in ectopy after bretylium therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized.|ventricular arrhythmia|160|182|bretylium|45|54
7235792|In the first patient, two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium.|ventricular tachycardia|38|61|bretylium|141|150
7235792|In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.|cardiac arrests|25|40|bretylium|146|155
7235792|In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.|fibrillation|76|88|bretylium|146|155
7235792|In the second case, five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy.|ventricular tachycardia|48|71|bretylium|146|155
7235792|Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.|fibrillation|40|52|bretylium|71|80
7235792|Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy.|Paradoxical ventricular tachycardia|0|35|bretylium|71|80
7249424|Lithium is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized.|acute renal failure|26|45|Lithium|0|7
7249424|Lithium is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized.|nephrotic syndrome|138|156|Lithium|0|7
7249424|Lithium is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized.|proteinuria|123|134|Lithium|0|7
7249424|Lithium is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized.|tubulo-interstitial disease|50|77|Lithium|0|7
7249424|Nephrotic syndrome associated with lithium therapy.|Nephrotic syndrome|0|18|lithium|35|42
7249424|Two patients on long-term lithium therapy developed the nephrotic syndrome.|nephrotic syndrome|56|74|lithium|26|33
7258204|A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.|diarrhea|28|36|ampicillin|75|85
7272895|A 73-year-old woman with non-Hodgkin's lymphoma had two episodes of severe, bilateral, sensori-neural hearing loss after vincristine therapy.|sensori-neural hearing loss|87|114|vincristine|121|132
7272895|Acute acoustic nerve palsy associated with vincristine therapy.|Acute acoustic nerve palsy|0|26|vincristine|43|54
7272895|Bilateral acoustic (VIII) nerve palsy in this patient was most likely a manifestation of vincristine neurotoxicity.|Bilateral acoustic (VIII) nerve palsy|0|37|vincristine|89|100
7272895|Bilateral acoustic (VIII) nerve palsy in this patient was most likely a manifestation of vincristine neurotoxicity.|neurotoxicity|101|114|vincristine|89|100
7282702|A case of timolol-associated heart failure in a 73-year old white man is reported.|heart failure|29|42|timolol|10|17
7282702|Bradycardia and congestive heart failure associated with ocular timolol maleate.|Bradycardia|0|11|timolol maleate|64|79
7282702|Bradycardia and congestive heart failure associated with ocular timolol maleate.|congestive heart failure|16|40|timolol maleate|64|79
7282702|On the second day of hospitalization, it was noted that the patient's dyspnea and sinus bradycardia could be related to a recent increase in his timolol dosage.|dyspnea|70|77|timolol|145|152
7282702|On the second day of hospitalization, it was noted that the patient's dyspnea and sinus bradycardia could be related to a recent increase in his timolol dosage.|sinus bradycardia|82|99|timolol|145|152
7295427|Fatal ventricular fibrillation after treatment with digoxin in a 27-year-old man with mitral leaflet prolapse syndrome.|Fatal ventricular fibrillation|0|30|digoxin|52|59
7295427|He was started on digoxin, 0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment; he died of ventricular fibrillation 15 days later.|functional impairment|120|141|digoxin|18|25
7295427|He was started on digoxin, 0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment; he died of ventricular fibrillation 15 days later.|left ventricular dilatation|88|115|digoxin|18|25
7295427|He was started on digoxin, 0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment; he died of ventricular fibrillation 15 days later.|ventricular fibrillation|154|178|digoxin|18|25
7304798|Induction of rapid mood cycling during L-dopa treatment in a bipolar patient.|rapid mood cycling|13|31|L-dopa|39|45
7304798|The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which L-dopa shortened the manic-depressive cycle length when administered in a double-blind trial.|shortened the manic-depressive cycle|117|153|L-dopa|110|116
7321956|Liver disease induced by perhexiline maleate.|Liver disease|0|13|perhexiline maleate|25|44
7321956|This paper reports a case of fatal perhexiline maleate liver injury.|fatal perhexiline maleate liver injury|29|67|perhexiline maleate|35|54
7351000|Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan).|Acute non-lymphocytic leukemia|0|30|dihydroxybusulfan|115|132
7351000|Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan).|Acute non-lymphocytic leukemia|0|30|Treosulfan|101|111
7351000|Acute non-lymphocytic leukemia occurred in eight women following long-term treatment with Treosulfan (= dihydroxybusulfan) for ovarian carcinoma.|Acute non-lymphocytic leukemia|0|30|dihydroxybusulfan|104|121
7351000|Acute non-lymphocytic leukemia occurred in eight women following long-term treatment with Treosulfan (= dihydroxybusulfan) for ovarian carcinoma.|Acute non-lymphocytic leukemia|0|30|Treosulfan|90|100
7351000|Seven of the eight cases of acute leukemia occurred in a series of 553 patients treated with Treosulfan for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient-years up to February 1978.|acute leukemia|28|42|Treosulfan|93|103
7351000|The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan.|acute leukemia|30|44|Treosulfan|126|136
7355327|Propranolol-related bronchospasm in patients without history of asthma.|bronchospasm|20|32|Propranolol|0|11
7355327|Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.|bronchospasm|72|84|propranolol|131|142
7355327|Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.|bronchospasm|10|22|propranolol|60|71
7355327|Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.|bronchospasm|115|127|propranolol|157|168
7355327|Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.|bronchospasm|62|74|propranolol|88|99
7362333|Propranolol: an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass.|central nervous system dysfunction|38|72|Propranolol|0|11
7362333|The potential role of propranolol in inducing central nervous system disturbances is emphasized, and the literature on the subject is reviewed.|central nervous system disturbances|46|81|propranolol|22|33
736591|Interstitial fibrosis of the lung is a potential complication of methotrexate therapy for psoriasis.|Interstitial fibrosis of the lung|0|33|methotrexate|65|77
736591|Progressive interstitial fibrosis with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of methotrexate for 18 years.|Progressive interstitial fibrosis|0|33|methotrexate|143|155
736591|Progressive interstitial lung disease from prolonged methotrexate therapy.|Progressive interstitial lung disease|0|37|methotrexate|53|65
7369302|Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.|Abnormalities of the pupil|0|26|quinine|58|65
7369302|Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.|amblyopia|66|75|quinine|58|65
7369302|A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.|abnormal visual-evoked potentials|72|105|quinine|109|116
7369302|A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.|denervation supersensitivity|38|66|quinine|109|116
7369302|A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.|transient tonic pupillary response|2|36|quinine|109|116
7369302|Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.|abnormal visual-evoked potentials|93|126|quinine sulfate|175|190
7369302|Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.|denervation supersensitivity|59|87|quinine sulfate|175|190
7369302|Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.|Total blindness with a transient tonic pupillary response|0|57|quinine sulfate|175|190
7375145|Diagnosis: practolol induced sclerosing peritonitis.|sclerosing peritonitis|29|51|practolol|11|20
7379406|A case of skeletal fluorosis induced by prolonged treatment with niflumic acid, a fast-acting non-steroid antiinflammatory agent, is reported in a 35-year-old woman suffering from rheumatoid arthritis and treated, in addition, with corticosteroids.|skeletal fluorosis|10|28|niflumic acid|65|78
7379406|After ruling out a hydrotelluric source of fluorine, the patient's fluorosis was linked to chronic use of niflumic acid, following the publication in 1978 of the 2 previously reported cases affected by this drug.|fluorosis|67|76|niflumic acid|106|119
7379406|Niflumic acid-induced skeletal fluorosis: iatrogenic disease or therapeutic perspective for osteoporosis?|skeletal fluorosis|22|40|Niflumic acid|0|13
7379406|The fluorine contained in niflumic acid induced a marked densification of trabecular bone in all 3 cases.|densification of trabecular bone|57|89|niflumic acid|26|39
7387219|Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis.|Hepatotoxicity|0|14|D-penicillamine|38|53
7387219|These cases and a review of the literature suggested that hepatotoxicity, though rare, should be added to the list of adverse reactions to D-penicillamine.|hepatotoxicity|58|72|D-penicillamine|139|154
7387219|Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D-penicillamine.|hepatotoxicity|61|75|D-penicillamine|92|107
7393795|A 62-year-old Indian with diabetic nephropathy controlled with metformin, developed miliary tuberculosis for which he was treated with rifampicin, isoniazid and ethambutol.|miliary tuberculosis|84|104|metformin|63|72
7393795|Para-aminosalicylic acid-induced hypoglycaemia in a patient with diabetic nephropathy.|hypoglycaemia|33|46|Para-aminosalicylic acid|0|24
7393795|The induction of hypoglycaemia with PAS in this patient suggests a potential role for PAS in the treatment of diabetes mellitus.|hypoglycaemia|17|30|PAS|36|39
7393795|The introduction of para-aminosalicylic acid (PAS) led to hypoglycaemic coma.|hypoglycaemic coma|58|76|para-aminosalicylic acid|20|44
7393795|The introduction of para-aminosalicylic acid (PAS) led to hypoglycaemic coma.|hypoglycaemic coma|58|76|PAS|46|49
7397053|A patient developed papilloedema and hepatic dysfunction while being treated with perhexiline maleate.|hepatic dysfunction|37|56|perhexiline maleate|82|101
7397053|A patient developed papilloedema and hepatic dysfunction while being treated with perhexiline maleate.|papilloedema|20|32|perhexiline maleate|82|101
7397053|Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid).|hepatic dysfunction|17|36|perhexiline maleate|59|78
7397053|Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid).|hepatic dysfunction|17|36|Pexid|80|85
7397053|Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid).|Papilloedema|0|12|perhexiline maleate|59|78
7397053|Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid).|Papilloedema|0|12|Pexid|80|85
7408538|Markedly increased pigmementation of skin immediately overlying veins used for multiple 5-fluorouracil infusions was noted.|increased pigmementation of skin|9|41|5-fluorouracil|88|102
7408538|Unusual pigmentary changes associated with 5-fluorouracil therapy.|pigmentary changes|8|26|5-fluorouracil|43|57
7416268|Although useful in the management of chronic alcoholism, disulfiram is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include catatonia.|catatonia|187|196|disulfiram|57|67
7416268|Disulfiram encephalopathy as a cause of the catatonia syndrome.|catatonia syndrome|44|62|Disulfiram|0|10
7416268|Disulfiram encephalopathy as a cause of the catatonia syndrome.|encephalopathy|11|25|Disulfiram|0|10
7416268|The authors describe a case of the catatonia syndrome associated with disulfiram therapy.|catatonia syndrome|35|53|disulfiram|70|80
7420580|Inappropriate antidiuretic hormone secretion after high dose vinblastine.|Inappropriate antidiuretic hormone secretion|0|44|vinblastine|61|72
7420580|We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine.|inappropriate secretion of antidiuretic hormone|97|144|vinblastine|176|187
7428724|Four cases of oesophageal damage associated with ingestion of the urinary anti-spasmodic agent emepronium bromide are described.|oesophageal damage|14|32|emepronium bromide|95|113
7428724|Oesophageal ulceration due to emepronium bromide.|Oesophageal ulceration|0|22|emepronium bromide|30|48
7436161|Cardiorespiratory toxicity due to miconazole.|Cardiorespiratory toxicity|0|26|miconazole|34|44
7436161|None of them had a history of cardiac disease, and with the possible exception of one case of cardiac arrest, where the patient received doxorubicin, no predisposing factors could be found.|cardiac arrest|94|108|doxorubicin|137|148
7436161|Seven patients with hematologic malignancies who were treated with miconazole for either suspected or proven fungal infections developed eight episodes of major adverse cardiorespiratory and anaphylactic reactions.|cardiorespiratory and anaphylactic reactions|169|213|miconazole|67|77
7439122|Clofibrate-induced myopathy in patients with diabetes insipidus.|myopathy|19|27|Clofibrate|0|10
7439122|However, we have recently had four cases of clofibrate-induced myopathy in patients with diabetes insipidus due to hypothalamic lesions.|myopathy|63|71|clofibrate|44|54
7439122|Physicians should therefore be aware of its occurrence and carefully monitor serum levels of CPK, GOT and GPT during the treatment of diabetes insipidus with clofibrate, especially in patients with associated hypothyroidism, latent or overt, which possibly favors the development of myopathy.|myopathy|283|291|clofibrate|158|168
7448830|Hepatotoxicity of hycanthone in patients with metastatic breast cancer.|Hepatotoxicity|0|14|hycanthone|18|28
7448830|In a phase II study of hycanthone in patients with breast cancer we have recently observed severe hepatotoxicity, even at lower doses, which resulted in two drug-related deaths.|severe hepatotoxicity|91|112|hycanthone|23|33
7459812|Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.|Fatal interstitial pneumonitis|0|30|chlorambucil|64|76
7459812|Following several of these courses of therapy, respiratory distress occurred 9 to 12 days after the chlorambucil was given.|respiratory distress|47|67|chlorambucil|100|112
7468565|A case of barbiturate-induced submassive hepatic necrosis is presented and the literature is reviewed.|submassive hepatic necrosis|30|57|barbiturate|10|21
7468565|Barbiturate-induced submassive hepatic necrosis.|submassive hepatic necrosis|20|47|Barbiturate|0|11
7468565|The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis.|submassive hepatic necrosis|195|222|barbiturates|131|143
7474364|A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day).|granulocytopenia|114|130|procainamide|193|205
7474364|Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.|reversible granulocytopenia|39|66|procainamide|18|30
7474364|The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.|granulocytopenia|34|50|procainamide|79|91
748238|Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.|Monoclonal gammopathy|0|21|diphenylhydantoin|78|95
748238|Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.|multiple myeloma|37|53|diphenylhydantoin|78|95
748238|The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.|IgG lambda-type monoclonal gammopathy|22|59|DILANTIN|137|145
748238|The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.|IgG lambda-type monoclonal gammopathy|22|59|diphenylhydantoin|118|135
748238|The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.|multiple myeloma|75|91|DILANTIN|137|145
748238|The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.|multiple myeloma|75|91|diphenylhydantoin|118|135
748238|We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.|monoclonal gammopathy|132|153|diphenylhydantoin|80|97
7485371|CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.|vortex keratopathy|69|87|Atovaquone|12|22
7485371|PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.|vortex keratopathy|30|48|atovaquone|85|95
7485371|RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.|vortex keratopathy|54|72|atovaquone|74|84
7485371|RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.|vortex keratopathy|85|103|atovaquone|74|84
7485371|Vortex keratopathy associated with atovaquone.|Vortex keratopathy|0|18|atovaquone|35|45
7495990|Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.|severe pain|72|83|naloxone|20|28
7495990|Used injudiciously, naloxone can lead to withdrawal syndrome, return of severe pain, and other adverse effects.|withdrawal syndrome|41|60|naloxone|20|28
7519913|However, there remain questions concerning whether these drugs, especially methimazole (MMI), may be associated with aplasia cutis congenita (ACC) and how best to avoid impairment of fetal thyroid function during their use.|ACC|142|145|methimazole|75|86
7519913|However, there remain questions concerning whether these drugs, especially methimazole (MMI), may be associated with aplasia cutis congenita (ACC) and how best to avoid impairment of fetal thyroid function during their use.|ACC|142|145|MMI|88|91
7519913|However, there remain questions concerning whether these drugs, especially methimazole (MMI), may be associated with aplasia cutis congenita (ACC) and how best to avoid impairment of fetal thyroid function during their use.|aplasia cutis congenita|117|140|methimazole|75|86
7519913|However, there remain questions concerning whether these drugs, especially methimazole (MMI), may be associated with aplasia cutis congenita (ACC) and how best to avoid impairment of fetal thyroid function during their use.|aplasia cutis congenita|117|140|MMI|88|91
7526455|A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.|acute reversible encephalopathy|115|146|flecainide|179|189
7526455|Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy.|Acute reversible ataxo-myoclonic encephalopathy|0|47|flecainide|53|63
7538828|A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (MTX).|bone marrow aplasia|120|139|methotrexate|204|216
7538828|A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (MTX).|bone marrow aplasia|120|139|MTX|218|221
7538828|A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (MTX).|severe skin rash|99|115|methotrexate|204|216
7538828|A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (MTX).|severe skin rash|99|115|MTX|218|221
7538828|Bone marrow aplasia and severe skin rash after a single low dose of methotrexate.|Bone marrow aplasia|0|19|methotrexate|68|80
7538828|Bone marrow aplasia and severe skin rash after a single low dose of methotrexate.|severe skin rash|24|40|methotrexate|68|80
7538828|Development of an extensive skin rash following a single dose of MTX may be an early warning sign for life-threatening bone marrow aplasia.|extensive skin rash|18|37|MTX|65|68
7538828|In the absence of mucositis or diarrhea, severe dermatologic toxicity following a single low dose of the drug suggests an 'allergic' or acute hypersensitivity reaction to MTX in this patient.|acute hypersensitivity reaction|136|167|MTX|171|174
7538828|In the absence of mucositis or diarrhea, severe dermatologic toxicity following a single low dose of the drug suggests an 'allergic' or acute hypersensitivity reaction to MTX in this patient.|severe dermatologic toxicity|41|69|MTX|171|174
7545251|Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.|withdrawal syndrome|22|41|Chlormadinone acetate|0|21
7549443|The second had acute cystitis and was treated by sulphonamide and the third developed myopia coincident with metronidazole treatment for trichomonas vaginalis.|myopia|86|92|metronidazole|109|122
7549443|The second had acute cystitis and was treated by sulphonamide and the third developed myopia coincident with metronidazole treatment for trichomonas vaginalis.|myopia|86|92|sulphonamide|49|61
7577414|Nephrotic syndrome related to systemic lupus erythematosus after griseofulvin therapy.|Nephrotic syndrome|0|18|griseofulvin|65|77
7577414|Nephrotic syndrome related to systemic lupus erythematosus after griseofulvin therapy.|systemic lupus erythematosus|30|58|griseofulvin|65|77
7577414|To our knowledge, this is the first case of griseofulvin-exacerbated lupus in which nephrotic syndrome has been observed.|lupus|69|74|griseofulvin|44|56
7577414|To our knowledge, this is the first case of griseofulvin-exacerbated lupus in which nephrotic syndrome has been observed.|nephrotic syndrome|84|102|griseofulvin|44|56
7577414|We report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with griseofulvin.|nephrotic syndrome|43|61|griseofulvin|191|203
7577414|We report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with griseofulvin.|systemic lupus erythematosus|141|169|griseofulvin|191|203
7582710|Neurological side effects in two patients receiving gold injections for rheumatoid arthritis.|Neurological side effects|0|25|gold|52|56
7582710|The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (GSTM) injection.|mild nitritoid symptoms|28|51|gold sodium thiomalate|141|163
7582710|The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (GSTM) injection.|mild nitritoid symptoms|28|51|GSTM|165|169
7582710|The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (GSTM) injection.|pain|56|60|gold sodium thiomalate|141|163
7582710|The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (GSTM) injection.|pain|56|60|GSTM|165|169
7582710|The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (GSTM) injection.|T10-T12 dermatomes|107|125|gold sodium thiomalate|141|163
7582710|The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (GSTM) injection.|T10-T12 dermatomes|107|125|GSTM|165|169
7582710|The second patient experienced mild nitritoid symptoms following several GSTM injections prior experiencing a cerebrovascular accident within several hours of her next injection.|mild nitritoid symptoms|31|54|GSTM|73|77
7594371|Acute sensorineural hearing loss following intravenous ketoralac administration.|Acute sensorineural hearing loss|0|32|ketoralac|55|64
7594371|Both PAN and methotrexate have been independently demonstrated to cause sensorineural hearing loss.|sensorineural hearing loss|72|98|methotrexate|13|25
7594371|Both PAN and methotrexate have been independently demonstrated to cause sensorineural hearing loss.|sensorineural hearing loss|72|98|PAN|5|8
7594371|We recommend the cautious use of ketorolac in patients with underlying illnesses where NSAID-induced ototoxicity could result in adverse otologic consequences.|ototoxicity|101|112|ketorolac|33|42
7594371|We report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed bilateral sensorineural hearing loss 25 minutes after receiving 30 mg of intravenous ketoralac.|bilateral sensorineural hearing loss|89|125|ketoralac|174|183
7606071|Anaphylactoid reactions with intraperitoneal cisplatin.|Anaphylactoid reactions|0|23|cisplatin|45|54
7606071|CASE SUMMARIES: While conducting a protocol evaluating the efficacy of intraperitoneal cisplatin and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit anaphylactoid reactions.|anaphylactoid reactions|193|216|cisplatin|87|96
7606071|CONCLUSIONS: We conclude that a high dose combined with a short infusion time increases the risk of anaphylactoid reactions with the administration of intraperitoneal cisplatin.|anaphylactoid reactions|100|123|cisplatin|167|176
7606071|DISCUSSION: Anaphylactoid reactions have been described previously with cisplatin administration.|Anaphylactoid reactions|12|35|cisplatin|72|81
7606071|During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema.|100 mg/m2|53|62|cisplatin|43|52
7606071|During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema.|edema|125|130|cisplatin|43|52
7606071|During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema.|palmar pruritus|93|108|cisplatin|43|52
7606071|During her third cycle, she again received cisplatin 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and edema.|urticaria|110|119|cisplatin|43|52
7606071|OBJECTIVE: To report the occurrence of anaphylactoid reactions to intraperitoneal cisplatin in 3 patients.|anaphylactoid reactions|39|62|cisplatin|82|91
7606071|We observed 5 reactions in 3 patients that appear to be related to a high dose-infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating anaphylactoid reactions with cisplatin.|anaphylactoid reactions|184|207|cisplatin|213|222
7619765|Etoposide-related myocardial infarction.|myocardial infarction|18|39|Etoposide|0|9
7619765|The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.|myocardial infarction|20|41|etoposide|84|93
7632529|A 9-year-old boy developed acute renal failure following intravenous acyclovir (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.|acute renal failure|27|46|acyclovir|69|78
7632529|Acute renal failure in a child associated with acyclovir.|Acute renal failure|0|19|acyclovir|47|56
7639655|Anterior ischemic optic neuropathy secondary to interferon alfa.|Anterior ischemic optic neuropathy|0|34|interferon alfa|48|63
7639655|CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.|Anterior ischemic optic neuropathy|12|46|interferon alfa|77|92
7639655|OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.|anterior ischemic optic neuropathy|39|73|interferon alfa|110|125
7639655|PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.|sudden bilateral, sequential visual loss|124|164|interferon alfa|72|87
7639655|The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon-associated vascular retinopathy.|anterior ischemic optic neuropathy|76|110|interferon alfa|47|62
7639655|The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon-associated vascular retinopathy.|vascular retinopathy|156|176|interferon|134|144
7647084|The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate.|neuroleptic malignant syndrome|31|61|amitriptyline|92|105
7647084|The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate.|neuroleptic malignant syndrome|31|61|lithium carbonate|110|127
7655130|CASE SUMMARIES: Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid-stimulating hormone (TSH) concentrations after switching from 1 levothyroxine product to another.|increased serum thyroid-stimulating hormone|100|143|levothyroxine|188|201
7661076|Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter.|arrhythmia|91|101|adenosine|38|47
7661076|Life-threatening alterations in heart rate after the use of adenosine in atrial flutter.|alterations in heart rate|17|42|adenosine|60|69
7663030|Comparable adverse effects, such as disorientation and temporary amnesia, have been reported in patients in the analogous agent, propranolol.|disorientation|36|50|propranolol|129|140
7663030|Comparable adverse effects, such as disorientation and temporary amnesia, have been reported in patients in the analogous agent, propranolol.|temporary amnesia|55|72|propranolol|129|140
7663030|OBJECTIVE: To describe a probable case of transient global amnesia caused by propafenone.|transient global amnesia|42|66|propafenone|77|88
7663030|Probable propafenone-induced transient global amnesia.|transient global amnesia|29|53|propafenone|9|20
7668127|A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented.|acute subdural haematoma|10|34|aspirin|128|135
7668127|Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis: a case report.|Intracranial haemorrhage|0|24|aspirin|66|73
7673653|Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient.|akathisia|63|72|fluvoxamine|43|54
7673653|Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and sertraline, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD).|Extrapyramidal side effects|0|27|fluoxetine|98|108
7673653|Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and sertraline, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD).|Extrapyramidal side effects|0|27|sertraline|113|123
7673653|However, the occurrence and management of akathisia induced by fluvoxamine have not been described.|akathisia|42|51|fluvoxamine|63|74
7673653|In the presented case fluvoxamine-induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin.|akathisia|42|51|fluvoxamine|22|33
7679525|A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included bleomycin, developed life threatening interstitial pneumonitis.|interstitial pneumonitis|134|158|bleomycin|96|105
7679525|Severe bleomycin lung toxicity: reversal with high dose corticosteroids.|lung toxicity|17|30|bleomycin|7|16
7679525|This report suggests that bleomycin lung toxicity may be reversible if treated aggressively.|lung toxicity|36|49|bleomycin|26|35
7685228|Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF).|neutropenia|25|36|gold|12|16
7685228|We have successfully overcome severe neutropenia in an RA patient treated with gold salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.|severe neutropenia|30|48|gold|79|83
7696938|Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them.|Arrhythmias|0|11|amphotericin B|57|71
7696938|Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them.|cardiac arrest|16|30|amphotericin B|57|71
7696938|Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration.|cardiac arrhythmia|51|69|amphotericin B|77|91
7696938|I saw two patients with kala-azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion (in spite of tolerating a test dose).|cardiac arrest|83|97|amphotericin|104|116
7712052|We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.|angry outbursts|152|167|lithium|49|56
7712052|We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.|irritability|136|148|lithium|49|56
7718983|Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.|Graves' hyperthyroidism|0|23|interferon|66|76
7718983|Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.|transient thyrotoxicosis|34|58|interferon|66|76
7718983|This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH-receptor autoantibodies, and then the occurrence of Graves' hyperthyroidism during IFN therapy.|Graves' hyperthyroidism|149|172|IFN|180|183
7718983|We report a case of Graves' hyperthyroidism induced by long-term interferon (IFN) therapy.|Graves' hyperthyroidism|20|43|IFN|77|80
7718983|We report a case of Graves' hyperthyroidism induced by long-term interferon (IFN) therapy.|Graves' hyperthyroidism|20|43|interferon|65|75
7724306|Acute INH neurotoxicity was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH neurotoxicity was made.|neurotoxicity|10|23|INH|6|9
7724306|Acute INH neurotoxicity was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH neurotoxicity was made.|neurotoxicity|154|167|INH|150|153
7724306|Acute isoniazid neurotoxicity in an urban hospital.|neurotoxicity|16|29|isoniazid|6|15
7724306|CONCLUSIONS: We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City.|neurotoxicity|62|75|INH|58|61
7724306|In patients with a known access to INH, seizures should be considered to be caused by INH toxicity unless proved otherwise.|seizures|40|48|INH|86|89
7724306|OBJECTIVES: To describe the presentation and treatment of acute isoniazid (INH) neurotoxicity appearing at an inner-city municipal hospital.|neurotoxicity|80|93|INH|75|78
7724306|OBJECTIVES: To describe the presentation and treatment of acute isoniazid (INH) neurotoxicity appearing at an inner-city municipal hospital.|neurotoxicity|80|93|isoniazid|64|73
7724306|Parenteral pyridoxine, the specific antidote for INH-induced refractory seizures, should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB.|refractory seizures|61|80|INH|49|52
7724306|RESULTS: At our institution, no children appeared with acute INH neurotoxicity in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993.|neurotoxicity|65|78|INH|61|64
7730124|Arterial hypertension associated with topical ocular use of phenylephrine in dogs.|Arterial hypertension|0|21|phenylephrine|60|73
7748076|CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.|Squamous metaplasia|12|31|progestin|78|87
7748076|OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.|squamous metaplasia within endometrial glands|36|81|progestin|107|116
7748076|RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.|squamous metaplasia|19|38|progestin|81|90
7752014|Fever caused by the use of furosemide was proved; the fever resolved after discontinuation of this medication and recurred after its reintroduction.|Fever|0|5|furosemide|27|37
7752014|Furosemide-associated fever.|fever|22|27|Furosemide|0|10
7756684|The dose-limiting toxicity of KW-2149 is pulmonary toxicity.|pulmonary toxicity|41|59|KW-2149|30|37
7761316|Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.|Musculoskeletal complaints|0|26|cyclophosphamide|152|168
7761316|Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.|Musculoskeletal complaints|0|26|ifosfamide|124|134
7761316|Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.|Fanconi syndrome|40|56|ifosfamide|136|146
7776854|Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone.|cirrhosis|149|158|benzarone|46|55
7776854|Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone.|cirrhosis|149|158|benzarone|170|179
7776854|Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone.|hepatotoxicity|56|70|benzarone|46|55
7776854|Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone.|(sub)fulminant hepatitis|120|144|benzarone|46|55
7776854|Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone.|(sub)fulminant hepatitis|120|144|benzarone|170|179
7776854|Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities.|Severe hepatotoxicity|0|21|benzarone|33|42
7776854|We report three cases of severe hepatotoxicity related to benzarone, a benzofuran derivative.|severe hepatotoxicity|25|46|benzarone|58|67
7776854|We stress the potential of benzarone to cause hepatotoxicity, which usually resembles severe chronic active hepatitis.|hepatotoxicity|46|60|benzarone|27|36
7776854|We stress the potential of benzarone to cause hepatotoxicity, which usually resembles severe chronic active hepatitis.|severe chronic active hepatitis|86|117|benzarone|27|36
7779233|Case study: a modified topical treatment regimen for sodium warfarin-induced necrotizing fasciitis.|necrotizing fasciitis|77|98|warfarin|60|68
7779233|This case study describes an atypical case of refractory, sodium warfarin-induced necrotizing fasciitis and myonecrosis.|myonecrosis|108|119|sodium warfarin|58|73
7779233|This case study describes an atypical case of refractory, sodium warfarin-induced necrotizing fasciitis and myonecrosis.|necrotizing fasciitis|82|103|sodium warfarin|58|73
7781845|Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and/or receiving anti-malarial drugs including mefloquine, should be aware of the risk of severe hypoglycaemia.|severe hypoglycaemia|177|197|mefloquine|134|144
7781845|Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti-malarial quinine analogues are discussed.|hypoglycaemia|37|50|mefloquine|62|72
7781845|Mefloquine-associated hypoglycaemia in a cachectic AIDS patient.|hypoglycaemia|22|35|Mefloquine|0|10
7781845|Quinine and its isomer quinidine are well-known causes of iatrogenic hypoglycaemia, due to excessive insulin secretion.|iatrogenic hypoglycaemia|58|82|quinidine|23|32
7781845|Quinine and its isomer quinidine are well-known causes of iatrogenic hypoglycaemia, due to excessive insulin secretion.|iatrogenic hypoglycaemia|58|82|Quinine|0|7
7781845|We report a case of hypoglycaemia after mefloquine therapy (1,500 mg over two days) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea.|hypoglycaemia|20|33|mefloquine|40|50
7783891|Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.|coronary artery vasospasm|30|55|sumatriptan|8|19
7783891|Cardiac arrest following use of sumatriptan.|Cardiac arrest|0|14|sumatriptan|32|43
7783891|I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.|cardiac arrest|81|95|sumatriptan|161|172
7787496|Sotalol-induced bradycardia reversed by glucagon.|bradycardia|16|27|Sotalol|0|7
7787496|We present a case of sotalol-induced bradycardia reversed by glucagon.|bradycardia|37|48|sotalol|21|28
7789881|Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer: a report of a case.|Secretory endometrial adenocarcinoma|0|36|tamoxifen|53|62
7789881|This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.|low-grade endometrial carcinoma|24|55|tamoxifen|114|123
7789881|This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy.|uterine neoplasia|80|97|tamoxifen|114|123
7789881|We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use.|secretory carcinoma of the endometrium|44|82|tamoxifen|99|108
7789881|Well-differentiated endometrial adenocarcinoma of the secretory type (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma.|endometrial adenocarcinoma of the secretory type|20|68|tamoxifen|157|166
7797283|Esophageal candidiasis following omeprazole therapy: a report of two cases.|Esophageal candidiasis|0|22|omeprazole|33|43
7797283|Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy.|Esophageal candidiasis|0|22|omeprazole|76|86
7814182|High-grade atrioventricular block during dipyridamole stress testing.|High-grade atrioventricular block|0|33|dipyridamole|41|53
7814182|We present a case in which dipyridamole induced high-grade atrioventricular (AV) block that responded promptly to intravenous aminophylline but not to atropine.|high-grade atrioventricular (AV) block|48|86|dipyridamole|27|39
7831179|Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin.|cardiomyopathy|45|59|doxorubicin|91|102
7831179|Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin.|cardiomyopathy|45|59|doxorubicin|25|36
7831179|There is a dose-effect relationship between doxorubicin and the incidence of symptomatic cardiac failure.|symptomatic cardiac failure|77|104|doxorubicin|44|55
7835785|Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature.|endometriosis|35|48|tamoxifen|109|118
7835785|Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature.|Ovarian endometrioid carcinoma|0|30|tamoxifen|109|118
7835785|The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed.|ovarian endometrioid carcinoma|125|155|tamoxifen|72|81
7835785|We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer.|endometriosis|64|77|tamoxifen|127|136
7835785|We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer.|ovarian endometrioid carcinoma|29|59|tamoxifen|127|136
7854541|Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma.|Cerebral demyelinating disease|0|30|levamisole|83|93
7854541|Multifocal inflammatory leukoencephalopathy associated with levamisole therapy.|Multifocal inflammatory leukoencephalopathy|0|43|levamisole|60|70
7854541|Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole.|leukoencephalopathy|45|64|5-fluorouracil|125|139
7854541|Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole.|leukoencephalopathy|45|64|levamisole|144|154
7854541|Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole.|leukoencephalopathy|45|64|levamisole|195|205
7865488|A case of noncardiogenic pulmonary edema by ethanolamine oleate.|noncardiogenic pulmonary edema|10|40|ethanolamine oleate|44|63
7865488|However, EO-induced noncardiogenic pulmonary edema has not been reported in human.|noncardiogenic pulmonary edema|20|50|EO|9|11
7865488|We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix.|noncardiogenic pulmonary edema|20|50|EO|88|90
788666|Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure.|acute renal failure|85|104|gentamicin sulfate|41|59
788666|Gentamicin-associated acute renal failure.|acute renal failure|22|41|Gentamicin|0|10
788666|Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml/min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq/liter, proteinuria, and cylindruria.|Renal failure|0|13|gentamicin|52|62
7887138|A 15-year follow-up of phenytoin-induced unilateral gingival hyperplasia: a case report.|unilateral gingival hyperplasia|41|72|phenytoin|23|32
7887138|INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).|unilateral gingival hyperplasia|127|158|phenytoin|93|102
7887138|INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (PHT) intoxication with unilateral gingival hyperplasia (GH).|unilateral gingival hyperplasia|127|158|PHT|104|107
7889679|We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.|generalized cutaneous sclerosis|20|51|aminotriazole|170|183
7889679|We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.|generalized cutaneous sclerosis|20|51|bromocil|149|157
7889679|We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and aminotriazole.|generalized cutaneous sclerosis|20|51|diuron|159|165
7893301|Albuterol-induced hypokalemia and its potential cardiac toxicity are discussed briefly.|cardiac toxicity|48|64|Albuterol|0|9
7893301|Albuterol-induced hypokalemia and its potential cardiac toxicity are discussed briefly.|hypokalemia|18|29|Albuterol|0|9
7893301|Hypokalemia after normal doses of neubulized albuterol (salbutamol).|Hypokalemia|0|11|albuterol|45|54
7893301|Hypokalemia after normal doses of neubulized albuterol (salbutamol).|Hypokalemia|0|11|salbutamol|56|66
7893301|The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented.|hypokalemic|47|58|albuterol|95|104
7897759|Propoxyphene-induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature.|wide complex dysrhythmia|21|45|Propoxyphene|0|12
7897759|Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate--a case report.|wide QRS complex dysrhythmia|21|49|Propoxyphene|0|12
7900744|Case report: mannitol nephrotoxicity syndrome: role of hemodialysis and postulate of mechanisms.|nephrotoxicity syndrome|22|45|mannitol|13|21
7900744|Hemodialysis should be performed for rapid reversal of mannitol-induced ARF.|ARF|72|75|mannitol|55|63
7900744|High-dose intravenous mannitol infusion in various clinical settings may result in acute renal failure (ARF).|acute renal failure|83|102|mannitol|22|30
7900744|High-dose intravenous mannitol infusion in various clinical settings may result in acute renal failure (ARF).|ARF|104|107|mannitol|22|30
7900744|Mannitol-induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure.|ARF|17|20|Mannitol|0|8
7900744|The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of mannitol nephrotoxicity are discussed.|ARF|36|39|mannitol|56|64
7900744|The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of mannitol nephrotoxicity are discussed.|nephrotoxicity|190|204|mannitol|181|189
7900744|This is a report of a case of anuric ARF after high-dose mannitol infusion for treatment of narrow-angle glaucoma that readily responded to acute hemodialysis.|anuric ARF|30|40|mannitol|57|65
7907218|Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM-SPECT.|extrapyramidal side effects|18|45|fluphenazine decanoate|63|85
7914463|Flumazenil reversal of benzodiazepine-induced sedation for a patient with severe pre-ECT anxiety.|sedation|46|54|benzodiazepine|23|37
7919557|CASE SUMMARY: A 68-year-old woman developed a dry, irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension.|irritating cough|51|67|quinapril|97|106
7919557|Cough induced by quinapril with resolution after changing to fosinopril.|Cough|0|5|quinapril|17|26
7919557|OBJECTIVE: To report a case of chronic, nonproductive cough secondary to the angiotensin-converting enzyme (ACE) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, fosinopril.|cough|54|59|quinapril|123|132
7919557|The cough continued for the duration of therapy with quinapril.|cough|4|9|quinapril|53|62
7919557|We report a case of cough following the administration of quinapril, with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension.|cough|20|25|quinapril|58|67
7933665|Fracture of the femoral neck occurred in one patient during PSL therapy, although the relationship between the fracture and PSL therapy was uncertain.|Fracture of the femoral neck|0|28|PSL|60|63
7937287|Cefuroxime-induced acute renal failure.|acute renal failure|19|38|Cefuroxime|0|10
7937287|In our patient, DIAN possibly was related to cefuroxime, but the patient did not experience associated allergic symptoms.|DIAN|16|20|cefuroxime|45|55
7937287|The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation; the pattern repeated with rechallenge.|renal deterioration|54|73|cefuroxime|93|103
7937287|This is the first reported case of suspected DIAN due to cefuroxime.|DIAN|45|49|cefuroxime|57|67
7946029|A case of basilar invagination which is thought to have arisen from the patient's intrauterine exposure to phenytoin is presented.|basilar invagination|10|30|phenytoin|107|116
7946029|Basilar invagination and mid-line skeletal abnormalities due to in utero exposure to phenytoin.|Basilar invagination|0|20|phenytoin|85|94
7946029|Basilar invagination and mid-line skeletal abnormalities due to in utero exposure to phenytoin.|mid-line skeletal abnormalities|25|56|phenytoin|85|94
7946029|His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed.|craniocervical abnormality|106|132|phenytoin|71|80
7949255|Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.|Temporary neurologic abnormalities|0|34|methotrexate|114|126
7949255|This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.|altered consciousness|93|114|HD-MTX|149|155
7949255|This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.|dysarthria|78|88|HD-MTX|149|155
7949255|This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.|hemiparesis|65|76|HD-MTX|149|155
7949255|Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.|Transient neurological disturbances|0|35|methotrexate|77|89
7953234|We report a 5-year-old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to high-lipase pancreatin therapy.|stricture of the hepatic flexure region with associated narrowing|45|110|high-lipase pancreatin|176|198
7953234|We report a 5-year-old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to high-lipase pancreatin therapy.|submucosal fibrosis of the transverse colon|118|161|high-lipase pancreatin|176|198
7962394|Acute pancreatitis associated with danazol treatment for endometriosis.|Acute pancreatitis|0|18|danazol|35|42
7962394|Additionally, danazol produces hepatocellular damage in approximately 10% of women.|hepatocellular damage|31|52|danazol|14|21
7962394|Hypo-oestrogenic and anabolic/androgenic side-effects of danazol are well known by the gynaecologist and some of them are present in > 50% of patients being treated for endometriosis.|Hypo-oestrogenic and anabolic/androgenic side-effects|0|53|danazol|57|64
7962394|The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis.|acute pancreatitis|47|65|danazol|82|89
7973922|Acyclovir neurotoxicity: clinical experience and review of the literature.|neurotoxicity|10|23|Acyclovir|0|9
7973922|Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system.|neurologic symptoms|19|38|Acyclovir|0|9
7973922|Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of acyclovir neurotoxicity.|neurotoxicity|95|108|acyclovir|85|94
7973922|We discuss our observations in the cases of two patients with acyclovir neurotoxicity and review the findings of all previous reports in the English language literature.|neurotoxicity|72|85|acyclovir|62|71
7978578|Response of a promethazine-induced coma to flumazenil.|coma|35|39|promethazine|14|26
7978578|We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.|coma|64|68|promethazine|43|55
7986915|Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.|Amebic abscess of the spleen|0|28|metronidazole|44|57
7986915|Amebic abscess of the spleen complicated by metronidazole-induced neurotoxicity: case report.|neurotoxicity|66|79|metronidazole|44|57
7986915|We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.|ataxia|189|195|metronidazole|81|94
7986915|We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.|liver abscess|29|42|metronidazole|81|94
7986915|We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.|reversible deafness|154|173|metronidazole|81|94
7986915|We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.|splenic abscess|235|250|metronidazole|81|94
7986915|We describe a patient with a liver abscess due to Entamoeba histolytica, in whom metronidazole therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.|tinnitus|175|183|metronidazole|81|94
7991279|Actinomycin D associated hepatic veno-occlusive disease--a report of 2 cases.|hepatic veno-occlusive disease|25|55|Actinomycin D|0|13
7991279|There are now reports of liver failure following treatment of childhood cancers with AMD.|liver failure|25|38|AMD|85|88
7995508|Phenylpropanolamine-induced psychosis.|psychosis|28|37|Phenylpropanolamine|0|19
7995508|We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines.|paranoid psychosis|19|37|PPA|81|84
7995508|We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines.|psychiatric adverse effects|129|156|PPA|160|163
8002140|CONCLUSIONS: Although budesonide may be beneficial because of its anti-inflammatory effects, clinicians should be alert to its potential for causing contact dermatitis.|contact dermatitis|149|167|budesonide|22|32
8002140|Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature.|Contact dermatitis|0|18|budesonide|26|36
8002140|METHODS: Five cases of contact dermatitis due to budesonide, a nonhalogenated steroid, are described.|contact dermatitis|23|41|budesonide|49|59
8002140|RESULTS: Budesonide use can cause contact dermatitis.|contact dermatitis|34|52|Budesonide|9|19
8007037|Although other nitrites induce methemoglobinemia, exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia.|methemoglobinemia|31|48|methyl nitrite|62|76
8007037|Although other nitrites induce methemoglobinemia, exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia.|methemoglobinemia|157|174|methyl nitrite|62|76
8007037|Methemoglobinemia: an occupational hazard of phenylpropanolamine production.|Methemoglobinemia|0|17|phenylpropanolamine|45|64
8013261|During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully.|IDDM|81|85|IFN|17|20
8013261|Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started.|moderate hyperglycemia|68|90|IFN|34|37
8013261|Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started.|severe ketonuria|95|111|IFN|34|37
8013261|Occurrence of IDDM during interferon therapy for chronic viral hepatitis.|IDDM|14|18|interferon|26|36
8013261|We report a case of IDDM which occurred during interferon therapy for chronic hepatitis.|IDDM|20|24|interferon|47|57
8024670|Four patients who manifested symptoms of the antiepileptic drug (AED) hypersensitivity syndrome during therapy with carbamazepine are reported.|hypersensitivity syndrome|70|95|carbamazepine|116|129
8031432|Recurrent hypotension immediately after seizures in nortriptyline overdose.|Recurrent hypotension|0|21|nortriptyline|52|65
8031432|Recurrent hypotension immediately after seizures in nortriptyline overdose.|seizures|40|48|nortriptyline|52|65
8034807|The use of methotrexate (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease.|accelerate HIV disease|217|239|methotrexate|11|23
8034807|The use of methotrexate (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease.|accelerate HIV disease|217|239|MTX|25|28
8034807|The use of methotrexate (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease.|accelerate HIV disease|217|239|MTX|161|164
8038468|CONCLUSIONS: This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone.|increase of INR|60|75|5-FU|152|156
8038468|CONCLUSIONS: This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone.|increase of INR|60|75|levamisole|137|147
8038468|CONCLUSIONS: This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone.|increase of INR|60|75|warfarin|182|190
8038468|However, prolongation of 5-FU half-life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin.|increase in INR|47|62|5-FU|109|113
8038468|However, prolongation of 5-FU half-life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin.|increase in INR|47|62|warfarin|118|126
8053440|Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole.|Cholestatic liver disease|0|25|clindamycin|97|108
8053440|Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole.|Cholestatic liver disease|0|25|trimethoprim-sulfamethoxazole|113|142
8053440|Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole.|ductopenia|31|41|clindamycin|97|108
8053440|Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole.|ductopenia|31|41|trimethoprim-sulfamethoxazole|113|142
8053440|Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole.|vanishing bile duct syndrome|43|71|clindamycin|97|108
8053440|Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole.|vanishing bile duct syndrome|43|71|trimethoprim-sulfamethoxazole|113|142
8053440|One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia).|bile duct injury|107|123|clindamycin|25|36
8053440|One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia).|bile duct paucity|128|145|clindamycin|25|36
8053440|One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia).|ductopenia|147|157|clindamycin|25|36
8053440|One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia).|marked cholestasis|66|84|clindamycin|25|36
8053440|One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia).|portal inflammation|86|105|clindamycin|25|36
8053440|The second patient, who developed cholestasis after receiving trimethoprim-sulfamethoxazole, had marked duct paucity in the liver biopsy.|cholestasis|34|45|trimethoprim-sulfamethoxazole|62|91
8053440|The second patient, who developed cholestasis after receiving trimethoprim-sulfamethoxazole, had marked duct paucity in the liver biopsy.|duct paucity|104|116|trimethoprim-sulfamethoxazole|62|91
8053440|This is the first description, to our knowledge, of ductopenia apparently caused by clindamycin.|ductopenia|52|62|clindamycin|84|95
8053440|Three years later, treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy.|cholestasis|98|109|ampicillin|34|44
8053440|Three years later, treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy.|cholestatic hepatitis|71|92|ampicillin|34|44
8053440|Three years later, treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy.|duct paucity|114|126|ampicillin|34|44
8071504|METHODS: A patient who developed dramatic, permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented.|vision loss|53|64|ethambutol|106|116
8071504|METHODS: A patient who developed dramatic, permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented.|vision loss|53|64|isoniazid|121|130
8071504|RESULTS: Ethambutol, and to a lesser extent isoniazid, are both implicated in the development of visually related side effects.|development of visually related side effects|82|126|Ethambutol|9|19
8071504|RESULTS: Ethambutol, and to a lesser extent isoniazid, are both implicated in the development of visually related side effects.|development of visually related side effects|82|126|isoniazid|44|53
8071504|There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe.|ocular toxicity|26|41|ethambutol|47|57
8071504|Toxic optic neuropathy associated with ethambutol: implications for current therapy.|Toxic optic neuropathy|0|22|ethambutol|39|49
8083821|Currently the use of zidovudine is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage.|fetal damage|199|211|zidovudine|21|31
8083821|Currently the use of zidovudine is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage.|fetotoxic|116|125|zidovudine|21|31
8083821|Currently the use of zidovudine is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage.|teratogenic|100|111|zidovudine|21|31
8083821|In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy, there were eight spontaneous first trimester abortions, eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed.|fetal abnormality|218|235|zidovudine|62|72
8083821|In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy, there were eight spontaneous first trimester abortions, eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed.|first trimester abortions|140|165|zidovudine|62|72
8083821|Zidovudine use in pregnancy: a report on 104 cases and the occurrence of birth defects.|birth defects|73|86|Zidovudine|0|10
8098286|Celiprolol pneumonitis.|pneumonitis|11|22|Celiprolol|0|10
8098286|Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis, 10 weeks after drug readministration.|pneumonitis|76|87|celiprolol|40|50
8098286|We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta-blocker, celiprolol.|hypersensitivity pneumonitis|37|65|celiprolol|106|116
8104147|Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.|leukopenia|29|39|Ibopamine|0|9
8104147|Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive ibopamine 100 mg t.i.d. for chronic congestive heart failure.|Reversible leukopenia|0|21|ibopamine|85|94
812008|Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria.|acute intermittent porphyria|100|128|Diphenylhydantoin|0|17
812008|Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin.|porphyria|40|49|diphenylhydantoin|77|94
8120934|A 53-year-old male, without any prior history of psychosis, developed schizophrenia 4 days after starting low-dose bromocriptine therapy for a macroprolactinoma.|schizophrenia|70|83|bromocriptine|115|128
8120934|Bromocriptine-induced schizophrenia.|schizophrenia|22|35|Bromocriptine|0|13
8124920|Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.|Concurrent acute megaloblastic anaemia|0|38|methotrexate|89|101
8124920|Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.|pneumonitis|43|54|methotrexate|89|101
8124920|In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.|acute megaloblastic anaemia|143|170|methotrexate|126|138
8124920|In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.|pneumonitis|177|188|methotrexate|126|138
8145359|An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.|respiratory distress syndrome|211|240|Levemepromazine|93|108
8145359|An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.|respiratory distress syndrome|211|240|methotrimeprazine meleate|66|91
8145359|The association of phenothiazine overdose and respiratory distress syndrome merits consideration.|respiratory distress syndrome|46|75|phenothiazine|19|32
8149366|In two patients, apomorphine remained effective in the morning, but increased the intensity of the dyskinesias in the afternoon.|dyskinesias|99|110|apomorphine|17|28
8149366|We report on three observations of parkinsonian patients with levo-dopa-induced diphasic dyskinesias, who received subcutaneous apomorphine to reduce the duration of abnormal movements.|diphasic dyskinesias|80|100|levo-dopa|62|71
8151270|Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.|Fulminant hepatitis|0|19|didanosine|77|87
8151270|Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.|severe lactate acidosis|25|48|didanosine|77|87
8151270|This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.|fulminant hepatitis|62|81|ddI|33|36
8151270|We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).|fulminant hepatic failure|23|48|ddI|101|104
8151270|We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).|fulminant hepatic failure|23|48|didanosine|89|99
8157823|Generalized argyria after habitual use of AgNO3.|Generalized argyria|0|19|AgNO3|42|47
8162401|A case of fluoxetine induced seizures, in a person with Down syndrome, is described.|seizures|29|37|fluoxetine|10|20
8162401|Seizures associated with fluoxetine therapy are uncommon.|Seizures|0|8|fluoxetine|25|35
8162401|Seizures associated with fluoxetine therapy.|Seizures|0|8|fluoxetine|25|35
8164831|Although fluoxetine-induced headache occurred in one patient, the other five reported no side effects at the doses used.|headache|28|36|fluoxetine|9|19
8175330|Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.|psoriasiform eruptions|193|215|carbamazepine|21|34
8175330|Sodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce psoriasiform eruptions.|psoriasiform eruptions|193|215|Sodium valproate|0|16
8175330|We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.|psoriasiform eruption|58|79|carbamazepine|144|157
8175330|We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine.|psoriasiform eruption|58|79|sodium valproate|123|139
8181372|Severe diffuse interstitial pneumonitis induced by carmustine (BCNU).|Severe diffuse interstitial pneumonitis|0|39|BCNU|63|67
8181372|Severe diffuse interstitial pneumonitis induced by carmustine (BCNU).|Severe diffuse interstitial pneumonitis|0|39|carmustine|51|61
8181372|We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine (BCNU) for a brain tumor.|fatal case of acute interstitial pneumonitis|12|56|BCNU|95|99
8181372|We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine (BCNU) for a brain tumor.|fatal case of acute interstitial pneumonitis|12|56|carmustine|83|93
8186884|A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy.|shocks|90|96|procainamide|109|121
8186884|Electrical proarrhythmia with procainamide: a new ICD-drug interaction.|Electrical proarrhythmia|0|24|procainamide|30|42
8186884|The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of, or idiosyncratic response to, procainamide.|electrophysiologic effect|126|151|procainamide|186|198
8192712|Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status.|altered mental status|163|184|valproic acid|124|137
8192712|Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department.|Hyperammonemia|0|14|valproic acid|55|68
8192712|Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department.|lethargy|119|127|valproic acid|55|68
8192712|Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient.|Hyperammonemia|0|14|valproic acid|28|41
8192712|Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient.|lethargy|56|64|valproic acid|28|41
8192712|We present the case of a postictal patient with lethargy, hyperammonemia, otherwise normal liver function tests, and a therapeutic valproic acid level.|hyperammonemia|58|72|valproic acid|131|144
8192712|We present the case of a postictal patient with lethargy, hyperammonemia, otherwise normal liver function tests, and a therapeutic valproic acid level.|lethargy|48|56|valproic acid|131|144
8197046|Central nervous system toxicity associated with meperidine use in hepatic disease.|Central nervous system toxicity|0|31|meperidine|48|58
8197046|In patients with cirrhosis, the metabolism of meperidine is decreased, leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy.|accumulation of the parent drug|82|113|meperidine|46|56
8197046|In patients with cirrhosis, the metabolism of meperidine is decreased, leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy.|CNS depressive effects|127|149|meperidine|46|56
8197046|Meperidine-associated central nervous system (CNS) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine.|accumulation of the active metabolite normeperidine|102|153|Meperidine|0|10
8197046|Meperidine-associated central nervous system (CNS) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine.|central nervous system (CNS) excitatory toxicities|22|72|Meperidine|0|10
8207519|She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.|hypertension|90|102|morphine|53|61
8207519|She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.|intracerebral hemorrhage|124|148|morphine|53|61
8207519|She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.|respiratory failure|154|173|morphine|53|61
8207519|She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.|status epilepticus|104|122|morphine|53|61
8222875|Mitomycin C (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (HUS).|hemolytic-uremic syndrome|84|109|Mitomycin C|0|11
8222875|Mitomycin C (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (HUS).|hemolytic-uremic syndrome|84|109|MMC|13|16
8222875|Mitomycin C (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (HUS).|HUS|111|114|Mitomycin C|0|11
8222875|Mitomycin C (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (HUS).|HUS|111|114|MMC|13|16
8222875|Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy.|hemolytic-uremic syndrome|52|77|mitomycin C|94|105
8222875|Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy.|Pulmonary hemorrhage|0|20|mitomycin C|94|105
8222875|Pulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with MMC therapy.|HUS|51|54|MMC|114|117
8222875|Pulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with MMC therapy.|HUS|94|97|MMC|114|117
8222875|Pulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with MMC therapy.|Pulmonary hemorrhage|0|20|MMC|114|117
8222875|We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding.|HUS|36|39|MMC|46|49
8222875|We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding.|massive pulmonary bleeding|72|98|MMC|46|49
8239963|Clonidine-induced bradycardia in patients with spinal cord injury.|bradycardia|18|29|Clonidine|0|9
8239963|Possible mechanisms by which clonidine decreases spasticity are described, probable mechanisms of induced bradycardia are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented.|bradycardia|106|117|clonidine|29|38
8239963|Possible mechanisms by which clonidine decreases spasticity are described, probable mechanisms of induced bradycardia are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented.|bradycardia|106|117|clonidine|186|195
8239963|Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of clonidine-induced bradycardia is less well recognized and is rare.|bradycardia|131|142|clonidine|113|122
8239963|Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of clonidine-induced bradycardia is less well recognized and is rare.|constipation|35|47|clonidine|113|122
8239963|Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of clonidine-induced bradycardia is less well recognized and is rare.|dry mouth|20|29|clonidine|113|122
8239963|Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of clonidine-induced bradycardia is less well recognized and is rare.|hypotension|7|18|clonidine|113|122
8244201|A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.|elevation of serum creatinine and blood urea|60|104|cotrimoxazole|15|28
8244201|A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.|hyperkalaemia|37|50|cotrimoxazole|15|28
8244201|A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.|increased urinary N-acetyl glucosaminase|110|150|cotrimoxazole|15|28
8244201|A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.|one patient became unconscious|216|246|cotrimoxazole|15|28
8244201|Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.|Hyperkalaemia|0|13|co-trimoxazole|95|109
8244201|Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.|Hyperkalaemia|0|13|sulfamethoxazole-trimethoprim|64|93
8244201|Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.|renal tubular dysfunction|19|44|co-trimoxazole|95|109
8244201|Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.|renal tubular dysfunction|19|44|sulfamethoxazole-trimethoprim|64|93
8244201|Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy.|Hyperkalaemia|0|13|sulfamethoxazole-trimethoprim|48|77
8244201|Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy.|renal tubular dysfunction|19|44|sulfamethoxazole-trimethoprim|48|77
8250714|Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.|subacute combined degeneration of the spinal cord|142|191|nitrous oxide|202|215
8250714|Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.|Neurologic degeneration|0|23|nitrous oxide|40|53
8250714|Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.|neurologic deterioration|66|90|nitrous oxide|101|114
8253700|BACKGROUND: Fluoxetine, a highly specific serotonin reuptake inhibitor, has been reported to cause sexual dysfunction in a minority of patients.|sexual dysfunction|99|117|Fluoxetine|12|22
8255797|Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21.|bone marrow suppression|18|41|Captopril|0|9
8255797|Neutropenia is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, captopril.|Neutropenia|0|11|captopril|121|130
8255797|We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21.|neutropenia|23|34|captopril|45|54
8260059|Can magnesium sulfate therapy impact lactogenesis?|lactogenesis|37|49|magnesium sulfate|4|21
8260059|No explanation for this delay was found, other than the possibility that magnesium sulfate treatment impeded lactogenesis.|impeded lactogenesis|101|121|magnesium sulfate|73|90
8266863|Four days after the initial injection of 3.6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up.|flare-up|163|171|goserelin acetate|51|68
8266863|Four days after the initial injection of 3.6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up.|severe dyspnea|70|84|goserelin acetate|51|68
8266863|Four days after the initial injection of 3.6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up.|worsening pleuritis carcinomatosa|102|135|goserelin acetate|51|68
8276031|Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children.|Imidazoline intoxication|0|24|Imidazoline|0|11
8276031|Imidazoline intoxication in children.|Imidazoline intoxication|0|24|Imidazoline|0|11
8292513|Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits.|aphasia|83|90|L-asparaginase|33|47
8292513|Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits.|Cerebrovascular complications|0|29|L-asparaginase|33|47
8292513|Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits.|neuropsychological deficits|101|128|L-asparaginase|33|47
8292513|Children with acute lymphoblastic leukemia (ALL), treated with L-asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies.|cerebral thrombosis|94|113|L-asparaginase|63|77
8292513|Children with acute lymphoblastic leukemia (ALL), treated with L-asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies.|coagulation protein deficiencies|139|171|L-asparaginase|63|77
8292513|Children with acute lymphoblastic leukemia (ALL), treated with L-asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies.|hemorrhage|117|127|L-asparaginase|63|77
8301877|Myoclonus and seizures disappeared after discontinuation of L-dopa and the introduction of valproate sodium (VPA).|Myoclonus|0|9|L-dopa|60|66
8301877|Myoclonus and seizures disappeared after discontinuation of L-dopa and the introduction of valproate sodium (VPA).|seizures|14|22|L-dopa|60|66
8301877|Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPs.|Myoclonus|0|9|levodopa|68|76
8301877|Myoclonus and seizures in a patient with parkinsonism: induction by levodopa and its confirmation on SEPs.|seizures|14|22|levodopa|68|76
8301877|Myoclonus was induced and enhanced by L-dopa, developing into generalized seizures.|generalized seizures|62|82|L-dopa|38|44
8301877|Myoclonus was induced and enhanced by L-dopa, developing into generalized seizures.|Myoclonus|0|9|L-dopa|38|44
8301877|We described the occurrence of L-dopa-induced myoclonus and seizures in a case of parkinsonism with its SEPs findings.|myoclonus|46|55|L-dopa|31|37
8301877|We described the occurrence of L-dopa-induced myoclonus and seizures in a case of parkinsonism with its SEPs findings.|seizures|60|68|L-dopa|31|37
8308511|Unintended exposure to acyclovir early in pregnancy, which is not uncommon, may cause excessive maternal and physician anxiety.|excessive maternal and physician anxiety|86|126|acyclovir|23|32
8313300|A severe form of exophthalmos resulting from lithium therapy has not been described in the literature.|exophthalmos|17|29|lithium|45|52
8313300|Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria.|polyuria|94|102|Lithium|0|7
8313300|Regression of thyrotoxic ophthalmopathy following lithium withdrawal.|thyrotoxic ophthalmopathy|14|39|lithium|50|57
8313300|The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described.|severe exophthalmos|64|83|lithium|93|100
8313300|The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described.|thyrotoxicosis|44|58|lithium|93|100
8313300|The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium.|exophthalmos|4|16|lithium|76|83
8316494|Severe abdominal pain in low dosage clofazimine.|abdominal pain|7|21|clofazimine|36|47
8316494|We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.|abdominal pain|112|126|clofazimine|64|75
8329789|Amphotericin B overdose in pediatric patients with associated cardiac arrest.|cardiac arrest|62|76|Amphotericin B|0|14
8329789|CONCLUSIONS: Amphotericin B overdose can be fatal in children and infants.|fatal|44|49|Amphotericin B|13|27
8329789|Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.|cardiac arrhythmias|71|90|amphotericin B|113|127
8329789|Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses.|mortality|45|54|amphotericin B|113|127
8329789|INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B.|Cardiac complications|27|48|amphotericin B|135|149
8329789|OBJECTIVE: To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population.|cardiac complications|84|105|amphotericin B|45|59
8340162|Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone.|Hypertension|0|12|cyclosporine|96|108
8340162|Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone.|Hypertension|0|12|prednisone|113|123
834512|Sudden death in an infant from methemoglobinemia after administration of "sweet spirits of nitre".|Sudden death|0|12|sweet spirits of nitre|74|96
834512|The administration of "sweet spirits of nitre" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.|acute methemoglobinemia|113|136|4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol|48|95
834512|The administration of "sweet spirits of nitre" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.|acute methemoglobinemia|113|136|sweet spirits of nitre|23|45
834512|The administration of "sweet spirits of nitre" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.|died|270|274|4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol|48|95
834512|The administration of "sweet spirits of nitre" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.|died|270|274|sweet spirits of nitre|23|45
834512|The administration of "sweet spirits of nitre" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.|hypoxemia|300|309|4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol|48|95
834512|The administration of "sweet spirits of nitre" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.|hypoxemia|300|309|sweet spirits of nitre|23|45
834512|The administration of "sweet spirits of nitre" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.|severe anoxic metabolic acidosis|141|173|4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol|48|95
834512|The administration of "sweet spirits of nitre" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.|severe anoxic metabolic acidosis|141|173|sweet spirits of nitre|23|45
8345435|Hepatotoxic effects in a child receiving valproate and carnitine.|Hepatotoxic effects|0|19|carnitine|55|64
8345435|Hepatotoxic effects in a child receiving valproate and carnitine.|Hepatotoxic effects|0|19|valproate|41|50
8345435|L-Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid.|fatal hepatotoxic effects|64|89|valproic acid|106|119
8345435|We report on a child with fatal valproate-related hepatotoxic effects despite this supplementation.|fatal|26|31|valproate|32|41
8345435|We report on a child with fatal valproate-related hepatotoxic effects despite this supplementation.|hepatotoxic effects|50|69|valproate|32|41
8360712|A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction.|cognitive dysfunction|130|151|IL-2|72|76
8360712|Delayed neurotoxicity of intraventricular interleukin-2: a case report.|neurotoxicity|8|21|interleukin-2|42|55
8360712|The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed.|brain injury|30|42|IL-2|97|101
8360712|The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed.|disability|58|68|IL-2|97|101
8363533|Albeit rare among Western patients, such lithium-associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese.|thyroid dysfunctions|60|80|lithium|41|48
8363533|Four Chinese female patients who suffered from manic-depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy.|thyrotoxicosis|143|157|lithium|177|184
8363533|Lithium-associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis.|transient thyrotoxicosis|19|43|Lithium|0|7
8363533|They seemed to involve multiple aetiological factors, such as autoimmune thyroid disease, the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors.|toxic and immunomodulatory roles|94|126|lithium|130|137
8375752|Although retinoic acid is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported: "the retinoic acid syndrome".|fatal complication|102|120|retinoic acid|9|22
8375752|Although retinoic acid is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported: "the retinoic acid syndrome".|retinoic acid syndrome|171|193|retinoic acid|9|22
8384030|CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient.|electrolyte disorders|62|83|foscarnet|33|42
8384030|DISCUSSION: Electrolyte disorders associated with foscarnet are reviewed.|Electrolyte disorders|12|33|foscarnet|50|59
8384030|Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.|electrolyte disorders|50|71|Foscarnet|0|9
8384030|Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.|severe hypomagnesemia|18|39|Foscarnet|0|9
8384030|OBJECTIVE: To report a case of possible foscarnet-induced severe hypomagnesemia and other electrolyte disorders.|electrolyte disorders|90|111|foscarnet|40|49
8384030|OBJECTIVE: To report a case of possible foscarnet-induced severe hypomagnesemia and other electrolyte disorders.|severe hypomagnesemia|58|79|foscarnet|40|49
8384030|The patient experienced muscle twitches, tremulousness, and anxiety on day 17 of foscarnet therapy.|anxiety|60|67|foscarnet|81|90
8384030|The patient experienced muscle twitches, tremulousness, and anxiety on day 17 of foscarnet therapy.|muscle twitches|24|39|foscarnet|81|90
8384030|The patient experienced muscle twitches, tremulousness, and anxiety on day 17 of foscarnet therapy.|tremulousness|41|54|foscarnet|81|90
8396491|Interference with the cortisol axis by the microtubule antagonist, CPH82.|Interference with the cortisol axis|0|35|CPH82|67|72
8396491|The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism.|hypercortisolism|177|193|CPH82|37|42
8396491|The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism.|suppression of the endogeneous production of ACTH and cortisol|63|125|CPH82|37|42
8404753|A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.|movement disorders|13|31|carbamazepine|71|84
8404753|A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.|movement disorders|13|31|CBZ|86|89
8404753|A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.|tics|142|146|carbamazepine|71|84
8404753|A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.|tics|142|146|CBZ|86|89
8404753|Carbamazepine-induced tics.|tics|22|26|Carbamazepine|0|13
8404753|In the third child, the tics ceased after CBZ discontinuation.|tics|24|28|CBZ|42|45
8404753|These cases demonstrate that CBZ can induce simple motor tics in children.|motor tics|51|61|CBZ|29|32
8404753|We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.|facial motor tics|49|66|CBZ|87|90
8430717|Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.|neurotoxicity|18|31|Acyclovir|0|9
8430717|CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.|neurotoxicity|34|47|acyclovir|95|104
8430717|CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.|neurotoxicity|34|47|acyclovir|163|172
8430717|METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.|coma|101|105|acyclovir|68|77
8430717|METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.|nonoliguric renal failure|110|135|acyclovir|68|77
8430717|PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.|central nervous system side effects|191|226|acyclovir|234|243
8430717|PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.|neurotoxicity|110|123|acyclovir|92|101
8435665|A 16-year-old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan, which were given during his initial induction chemotherapy and also after autologous marrow transplantation.|eosinophilia myalgia syndrome|84|113|tryptophan|193|203
8435665|Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan.|Fatal eosinophilia myalgia syndrome|0|35|tryptophan|135|145
8435665|Thus, the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration.|eosinophilia myalgia syndrome|10|39|tryptophan|74|84
8438851|A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin.|fatal rhabdomyolysis|60|80|vasopressin|140|151
8438851|Idiosyncratic factors involving vasopressin receptor affinity and distribution, vasopressin-associated vasodilation in some vascular beds, and the effect of vasopressin on the renin-angiotensin system may further contribute to impaired tissue perfusion.|impaired tissue perfusion|227|252|vasopressin|157|168
8438851|Idiosyncratic factors involving vasopressin receptor affinity and distribution, vasopressin-associated vasodilation in some vascular beds, and the effect of vasopressin on the renin-angiotensin system may further contribute to impaired tissue perfusion.|vasodilation|103|115|vasopressin|80|91
8438851|Rhabdomyolysis associated with the use of intravenous vasopressin.|Rhabdomyolysis|0|14|vasopressin|54|65
8438851|These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion.|rhabdomyolysis|52|66|vasopressin|103|114
8442800|In one case, disulfiram was the only potential teratogen exposed to the fetus.|teratogen|47|56|disulfiram|13|23
8442800|Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.|significant abnormalities|16|41|disulfiram|99|109
8445549|Although the essential cause of PV is unclear, its onset has occasionally been associated with drug therapy, in particular penicillamine.|PV|32|34|penicillamine|123|136
8445549|Pemphigus vulgaris precipitated by glibenclamide therapy.|Pemphigus vulgaris|0|18|glibenclamide|35|48
8445549|The patient described in this paper was a 78-year-old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy.|oral lesions of PV|81|99|glibenclamide|125|138
8452107|Piritrexim-induced pulmonary toxicity.|pulmonary toxicity|19|37|Piritrexim|0|10
8452107|The pulmonary toxicity is probably induced by piritrexim.|pulmonary toxicity|4|22|piritrexim|46|56
8452107|We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.|abnormal chest x-ray with diffuse interstitial opacities|120|176|piritrexim|204|214
8452107|We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a methotrexate analog.|respiratory dysfunction|89|112|piritrexim|204|214
8461228|A 12 year old patient with atrial flutter is presented, in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia.|acceleration of the heart rate|102|132|adenosine|76|85
8461228|A 12 year old patient with atrial flutter is presented, in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia.|arrhythmia|160|170|adenosine|76|85
8461228|Acceleration of ventricular response to atrial flutter after intravenous adenosine.|Acceleration of ventricular response|0|36|adenosine|73|82
8467620|Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.|Lymphoma|0|8|methotrexate|66|78
8467620|The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.|lymphoproliferative diseases|144|172|methotrexate|44|56
8467620|We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.|non-Hodgkin lymphoma|22|42|methotrexate|121|133
847572|Hepatotoxicity of paracetamol enhanced by ingestion of alcohol: report of two cases.|Hepatotoxicity|0|14|paracetamol|18|29
847572|The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon.|hepatotoxic effects|121|140|paracetamol|144|155
847572|The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon.|hepatotoxicity|32|46|paracetamol|20|31
847572|Two fatal cases of poisoning by paracetamol are described.|fatal|4|9|paracetamol|32|43
8485005|We report a case of drug-induced Kaposi's sarcoma (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy (prednisolone 25 mg/day) for pericardial effusion.|Kaposi's sarcoma|33|49|prednisolone|157|169
8496127|Acute dystonic reaction with low-dose pimozide.|Acute dystonic reaction|0|23|pimozide|38|46
8496127|This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.|acute dystonic reactions|86|110|pimozide|127|135
8496127|This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.|acute dystonic reactions|86|110|pimozide|226|234
8496127|This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.|acute dystonic reactions|86|110|thioridazine|276|288
8503421|Although there is one case report of cholesterol crystal embolization following t-PA therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following t-PA therapy.|atheroembolic acute renal failure|195|228|t-PA|239|243
8503421|Although there is one case report of cholesterol crystal embolization following t-PA therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following t-PA therapy.|cholesterol crystal embolization|37|69|t-PA|80|84
8503421|Although there is one case report of cholesterol crystal embolization following t-PA therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following t-PA therapy.|extrarenal manifestations|103|128|t-PA|80|84
8503421|Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator.|Cholesterol crystal embolization|0|32|tissue-type plasminogen activator|89|122
8503421|Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator.|renal failure|44|57|tissue-type plasminogen activator|89|122
8503421|We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA).|cholesterol crystal embolization|49|81|recombinant tissue-type plasminogen activator|130|175
8503421|We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA).|cholesterol crystal embolization|49|81|t-PA|177|181
8503421|We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA).|renal failure|28|41|recombinant tissue-type plasminogen activator|130|175
8503421|We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (t-PA).|renal failure|28|41|t-PA|177|181
8520081|Intravenous haloperidol is generally well tolerated, but multiform ventricular tachycardia has been reported.|multiform ventricular tachycardia|57|90|haloperidol|12|23
8523340|All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.|mucocutaneous side effects|14|40|gold|73|77
8523340|How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.|mucocutaneous reactions|68|91|gold|46|50
85289|Anterior spinal artery syndrome--a complication of cervical intrathecal phenol injection.|Anterior spinal artery syndrome|0|31|phenol|72|78
85289|We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of anterior spinal artery syndrome, developed following the injection of 0.3 ml of 10% phenol-glycerine into the cervical subarachnoid space at the C4--C5 level for the control of severe right arm pain.|anterior spinal artery syndrome|99|130|phenol-glycerine|183|199
8530331|One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.|feeding gastrostomy|50|69|risperidone|119|130
8530331|One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.|feeding gastrostomy|50|69|risperidone|224|235
8530331|One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.|worsening parkinsonism|89|111|risperidone|119|130
8530331|One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.|worsening parkinsonism|89|111|risperidone|224|235
8530331|Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment; the encephalopathy resolved when the patients were switched to clozapine treatment.|encephalopathy|65|79|risperidone|87|98
8530331|Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment; the encephalopathy resolved when the patients were switched to clozapine treatment.|worsened motorically|29|49|risperidone|87|98
8551001|Azathioprine can cause severe myelosuppression.|myelosuppression|30|46|Azathioprine|0|12
8551001|Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.|myelosuppression|21|37|Azathioprine|0|12
8551001|The azathioprine dose was low (1 mg/kg) and pancytopenia occurred after 56 days therapy.|pancytopenia|44|56|azathioprine|4|16
8551001|Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine.|myelosuppression|108|124|azathioprine|149|161
8551001|We describe the first documented case of azathioprine-induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease.|myelosuppression|69|85|azathioprine|41|53
8570441|Nabumetone-associated interstitial nephritis.|interstitial nephritis|22|44|Nabumetone|0|10
8570441|She had been taking nabumetone for 6 months, but had discontinued the agent 2 weeks before admission due to progressive edema.|edema|120|125|nabumetone|20|30
8579054|Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.|Acute myeloid leukemia|0|22|hydroxyurea|92|103
8579054|In this report, two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents, and which were treated with long-term hydroxyurea therapy, are described.|AL|51|53|hydroxyurea|150|161
8579054|Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.|acute leukemia|81|95|hydroxyurea|18|29
8586895|However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with halofantrine, including one sudden death after the treatment.|cardiac effects|94|109|halofantrine|141|153
8586895|However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with halofantrine, including one sudden death after the treatment.|sudden death|169|181|halofantrine|141|153
8586895|In the present paper, we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine.|QT interval was prolonged|80|105|halofantrine|127|139
8586895|Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine.|Prolongation of the QT interval|0|31|halofantrine|107|119
8586895|The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.|cardiac arrests|59|74|Halfan|37|43
8586895|The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.|cardiac arrests|59|74|mefloquine|190|200
8586895|The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.|deaths|89|95|Halfan|37|43
8586895|The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.|deaths|89|95|mefloquine|190|200
8589490|Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.|Supravenous hyperpigmentation|0|29|CHOP|50|54
8589490|We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.|supravenous hyperpigmentation|32|61|CHOP|78|82
8597009|Phenytoin toxicity due to concomitant antituberculosis therapy.|Phenytoin toxicity|0|18|Phenytoin|0|9
8597009|Seventy-four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6% of these had blood levels in the toxic range.|blood levels in the toxic range|157|188|phenytoin|124|133
8597009|Slow acetylators, who comprise roughly 50% of the South African population, are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy.|phenytoin toxicity|135|153|phenytoin|135|144
8597009|The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity.|phenytoin toxicity|185|203|phenytoin|16|25
8597009|The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity.|phenytoin toxicity|185|203|phenytoin|185|194
8604715|Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy.|Nephrogenic diabetes insipidus|0|30|foscarnet|71|80
8604715|Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy.|renal tubular acidosis|35|57|foscarnet|71|80
8604715|No cases of renal acidosis, and only one case of nephrogenic diabetes insipidus, has been previously reported as a complication of foscarnet treatment.|nephrogenic diabetes insipidus|49|79|foscarnet|131|140
8604715|Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities.|nephrogenic diabetes insipidus|27|57|foscarnet|142|151
8604715|Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities.|renal tubular acidosis|62|84|foscarnet|142|151
8604715|We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria.|polyuria|143|151|foscarnet|86|95
8604715|We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria.|thirst|132|138|foscarnet|86|95
8610807|Choroidal hemorrhage associated with systemic tissue plasminogen activator.|Choroidal hemorrhage|0|20|tissue plasminogen activator|46|74
8610807|CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.|hemorrhage|103|113|tissue plasminogen activator|34|62
8610807|CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.|hemorrhagic choroidal detachment|172|204|tissue plasminogen activator|34|62
8610807|PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.|spontaneous choroidal hemorrhage|35|67|tissue plasminogen activator|141|169
8627446|Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.|Accelerated nodulosis|0|21|methotrexate|29|41
8627446|Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.|nodules|29|36|methotrexate|125|137
8627446|Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients.|nodules|55|62|methotrexate|125|137
8627446|Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect.|extraarticular side effect|103|129|methotrexate|34|46
8627446|The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.|nodules|4|11|methotrexate|42|54
8627446|We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy.|accelerated nodulosis|116|137|methotrexate|155|167
8636829|A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.|macrophage activation syndrome|2|32|methotrexate|54|66
8636829|A macrophage activation syndrome, possibly related to methotrexate toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.|methotrexate toxicity|54|75|methotrexate|54|66
8638872|Jaundice induced by streptokinase.|Jaundice|0|8|streptokinase|20|33
8638872|Only a few reports of overt jaundice are associated with streptokinase.|jaundice|28|36|streptokinase|57|70
8641617|Although both patients recovered from the colitis after the administration of vancomycin, the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin.|colitis|135|142|cisplatin|209|218
8641617|Based on our findings, it is thus concluded that cisplatin may cause C. difficile colitis.|C. difficile colitis|69|89|cisplatin|49|58
8641617|Both patients were then treated with a carboplatin alternative to cisplatin in the following courses, which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time.|colitis|145|152|cisplatin|66|75
8641617|Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients.|Clostridium difficile colitis|0|29|cisplatin|46|55
8641617|Severe C. difficile colitis occurred in 2 patients (6.1%) after receiving cisplatin-based combination chemotherapy for ovarian malignancies.|C. difficile colitis|7|27|cisplatin|74|83
8641617|The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin-based combination chemotherapy in ovarian cancer patients.|Clostridium difficile colitis|68|97|cisplatin|114|123
8645078|A patient with severe cholestatic jaundice induced by captopril is presented.|severe cholestatic jaundice|15|42|captopril|54|63
8645078|Captopril-associated "pseudocholangitis'.|pseudocholangitis|22|39|Captopril|0|9
8645078|Captopril is known to be associated with dermatologic, hematologic, and pulmonary adverse effects.|dermatologic, hematologic, and pulmonary adverse effects|41|97|Captopril|0|9
8645078|Patients treated with captopril who develop "atypical cholangitis" should be suspected of having captopril-associated liver damage.|atypical cholangitis|45|65|captopril|22|31
8645078|Patients treated with captopril who develop "atypical cholangitis" should be suspected of having captopril-associated liver damage.|liver damage|118|130|captopril|97|106
8651254|Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage-colony-stimulating factor.|nephrotic syndrome|15|33|macrophage-colony-stimulating factor|101|137
8651254|It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy, including M-CSF, whereas the bone marrow still remained completely remitted.|nephrotic syndrome|47|65|M-CSF|123|128
8651254|The possibility can be raised that M-CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome.|nephrotic syndrome|188|206|M-CSF|35|40
8651254|The possibility can be raised that M-CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome.|renal disease|68|81|M-CSF|35|40
8651254|These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M-CSF treatment and macrophage-related glomerular injury.|macrophage-related glomerular injury|127|163|M-CSF|107|112
8651254|We describe a patient with acute myeloblastic leukemia (AML) who developed nephrotic syndrome after receiving several courses of chemotherapy, including macrophage-colony-stimulating factor (M-CSF).|nephrotic syndrome|75|93|macrophage-colony-stimulating factor|153|189
8651254|We describe a patient with acute myeloblastic leukemia (AML) who developed nephrotic syndrome after receiving several courses of chemotherapy, including macrophage-colony-stimulating factor (M-CSF).|nephrotic syndrome|75|93|M-CSF|191|196
8656412|On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and betamethasone, edema developed in both labia.|edema|97|102|betamethasone|82|95
8656412|On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and betamethasone, edema developed in both labia.|edema|97|102|magnesium sulfate|35|52
8656412|On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and betamethasone, edema developed in both labia.|edema|97|102|nifedipine|54|64
8656412|On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and betamethasone, edema developed in both labia.|edema|97|102|terbutaline|66|77
8667442|Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism.|Milk-alkali syndrome|0|20|1,25(OH)2D|32|42
8667442|This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.|milk-alkali syndrome|158|178|calcitriol|99|109
8667442|This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.|milk-alkali syndrome|158|178|calcium carbonate|77|94
8672829|After receiving 3 doses of ifosfamide/mesna, she was found to be unresponsive.|unresponsive|65|77|ifosfamide|27|37
8672829|After receiving 3 doses of ifosfamide/mesna, she was found to be unresponsive.|unresponsive|65|77|mesna|38|43
8672829|CONCLUSIONS: There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion.|nonconvulsive status epilepticus|68|100|ifosfamide|119|129
8672829|DISCUSSION: Central nervous system (CNS) toxicity has been described with ifosfamide, with most cases reported in the pediatric population.|Central nervous system (CNS) toxicity|12|49|ifosfamide|74|84
8672829|Ifosfamide-induced nonconvulsive status epilepticus.|nonconvulsive status epilepticus|19|51|Ifosfamide|0|10
8672829|OBJECTIVE: To describe a patient with ifosfamide-induced nonconvulsive status epilepticus.|nonconvulsive status epilepticus|57|89|ifosfamide|38|48
8672829|This represents the first report of nonconvulsive status epilepticus induced by ifosfamide.|nonconvulsive status epilepticus|36|68|ifosfamide|80|90
8678015|Albendazole-induced pseudomembranous colitis.|pseudomembranous colitis|20|44|Albendazole|0|11
8678015|Although a few case reports link metronidazole with the development of pseudomembranous colitis, albendazole has not been associated with the development of this condition.|pseudomembranous colitis|71|95|metronidazole|33|46
8678015|While undergoing treatment with albendazole, he developed worsening diarrhea with abdominal pain and fever.|abdominal pain|82|96|albendazole|32|43
8678015|While undergoing treatment with albendazole, he developed worsening diarrhea with abdominal pain and fever.|fever|101|106|albendazole|32|43
8678015|While undergoing treatment with albendazole, he developed worsening diarrhea with abdominal pain and fever.|worsening diarrhea|58|76|albendazole|32|43
8684546|Aluminum intoxication, along with other factors, was considered to be the cause of TC development.|Aluminum intoxication|0|21|Aluminum|0|8
8684546|Aluminum intoxication, along with other factors, was considered to be the cause of TC development.|TC|83|85|Aluminum|0|8
868978|Oculomotor disturbances associated with 5-fluorouracil chemotherapy.|Oculomotor disturbances|0|23|5-fluorouracil|40|54
868978|The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.|neurotoxicity|74|87|5-FU|69|73
868978|The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.|ocular motor disturbances|4|29|5-FU|69|73
868978|Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.|cerebellar dysfunction|103|125|5-fluorouracil|26|40
868978|Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.|cerebellar dysfunction|103|125|5-FU|42|46
868978|Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.|cerebellar dysfunction|103|125|5-FU|137|141
868978|Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.|neurotoxicity|142|155|5-fluorouracil|26|40
868978|Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.|neurotoxicity|142|155|5-FU|42|46
868978|Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.|neurotoxicity|142|155|5-FU|137|141
8691927|Assessment of cortisol response was by insulin-induced hypoglycaemia in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one.|hypoglycaemia|55|68|insulin|39|46
8691927|FINDINGS: Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression.|adrenal suppression|126|145|fluticasone propionate|84|106
8691927|FINDINGS: Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression.|growth retardation|28|46|fluticasone propionate|84|106
8691927|Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate.|Growth and adrenal suppression|0|30|fluticasone propionate|76|98
8691927|INTERPRETATION: When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur.|adrenal suppression|95|114|fluticasone propionate|35|57
8691927|INTERPRETATION: When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur.|growth may be retarded|68|90|fluticasone propionate|35|57
8691927|METHODS: Growth retardation was observed in six severely asthmatic children after introduction of high-dose fluticasone propionate treatment (dry powder).|Growth retardation|9|27|fluticasone propionate|108|130
8696525|Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.|granulomatous anterior uveitis|24|54|Metipranolol|0|12
8696525|Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.|bilateral granulomatous anterior uveitis|20|60|metripranolol|125|138
8700794|A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.|altered mental status|160|181|desmopressin|77|89
8700794|A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.|hyponatremia|110|122|desmopressin|77|89
8700794|A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia, all of whom experienced seizures or altered mental status.|seizures|148|156|desmopressin|77|89
8700794|Intranasal desmopressin-induced hyponatremia.|hyponatremia|32|44|desmopressin|11|23
8700794|When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.|hyponatremia|57|69|desmopressin|35|47
8700794|When vague symptoms develop during desmopressin therapy, hyponatremia must be considered as part of the differential diagnosis.|vague symptoms|5|19|desmopressin|35|47
8700794|Within 24 hours of fluid restriction and cessation of desmopressin, her symptoms and hyponatremia resolved.|hyponatremia|85|97|desmopressin|54|66
8700794|Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.|hyponatremia|29|41|desmopressin|139|151
8700794|Without other causes for the hyponatremia, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by desmopressin.|syndrome of inappropriate antidiuretic hormone|70|116|desmopressin|139|151
8710040|Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol.|Uveitis|0|7|clarithromycin|129|143
8710040|Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol.|Uveitis|0|7|ethambutol|148|158
8710040|Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol.|Uveitis|0|7|rifabutin|118|127
8726608|Does acyclovir increase serum lithium levels?|increase serum lithium levels|15|44|acyclovir|5|14
8726608|Six days after starting acyclovir she exhibited signs of lithium toxicity.|lithium toxicity|57|73|acyclovir|24|33
8726608|Six days after starting acyclovir she exhibited signs of lithium toxicity.|lithium toxicity|57|73|lithium|57|64
8726608|This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.|increased serum lithium|94|117|acyclovir|24|33
8726608|This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.|increased serum lithium|94|117|lithium|110|117
8726608|Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.|lithium toxicity|159|175|acyclovir|52|61
8726608|Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.|lithium toxicity|159|175|lithium|159|166
8726608|When measured, the serum lithium level had increased 4-fold during acyclovir therapy.|serum lithium level had increased|19|52|acyclovir|67|76
8726608|When measured, the serum lithium level had increased 4-fold during acyclovir therapy.|serum lithium level had increased|19|52|lithium|25|32
8730143|Dapsone syndrome in cutaneous lupus erythematosus.|Dapsone syndrome|0|16|Dapsone|0|7
8730143|Physicians should be aware of the potentially lethal side effects of dapsone.|lethal|46|52|dapsone|69|76
8730143|We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy, with a fatal outcome in one.|dapsone reaction|79|95|dapsone|79|86
8730143|We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy, with a fatal outcome in one.|fatal|127|132|dapsone|79|86
8733532|A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder.|fatal interaction|49|66|minoxidil|75|84
8739289|Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.|NDI|32|35|lithium|74|81
8739289|Nephrogenic diabetes insipidus (NDI) is a well-documented complication of lithium use.|Nephrogenic diabetes insipidus|0|30|lithium|74|81
8739289|Potential mechanisms regarding the pathophysiology of lithium-associated CDI are discussed.|CDI|73|76|lithium|54|61
8739289|The association of central diabetes insipidus (CDI) with lithium use is rare.|CDI|47|50|lithium|57|64
8739289|The association of central diabetes insipidus (CDI) with lithium use is rare.|central diabetes insipidus|19|45|lithium|57|64
8739289|This case emphasizes the importance of the evaluation of lithium-associated polyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.|polyuria|76|84|lithium|57|64
8739289|To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.|CDI|75|78|lithium|56|63
8739289|To the best of our knowledge, this is the first case of lithium-associated CDI and NDI presenting concurrently.|NDI|83|86|lithium|56|63
8739289|Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.|Transient central diabetes insipidus|0|36|lithium|121|128
8739289|We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI.|CDI|85|88|lithium|38|45
8742573|CASE: We report a case of a woman with severe human insulin-induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM.|lipoatrophy|68|79|human insulin|46|59
8742573|CASE: We report a case of a woman with severe human insulin-induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM.|lipoatrophy|68|79|recombinant DNA human insulin|118|147
8742573|CONCLUSIONS: Jet-injection devices might constitute a helpful method to treat those patients affected by severe human insulin-induced lipoatrophy.|lipoatrophy|134|145|human insulin|112|125
8742573|Human insulin-induced lipoatrophy.|lipoatrophy|22|33|Human insulin|0|13
8742573|OBJECTIVE: To evaluate the efficacy of the administration of insulin by a jet-injector device in stopping and reversing severe human insulin-induced lipoatrophy.|lipoatrophy|149|160|human insulin|127|140
8749646|Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use.|neurotoxic effects|57|75|ofloxacin|79|88
8749646|Seizures associated with ofloxacin therapy.|Seizures|0|8|ofloxacin|25|34
8749646|The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor.|renal insufficiency|4|23|ofloxacin|99|108
8749646|The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor.|seizures|64|72|ofloxacin|99|108
8749646|We describe four patients who had seizures while receiving ofloxacin; no other causes were evident.|seizures|34|42|ofloxacin|59|68
8763435|A patient is described with the characteristic features of phenytoin hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.|abnormal liver function tests|192|221|phenytoin|59|68
8763435|A patient is described with the characteristic features of phenytoin hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.|erythroderma|118|130|phenytoin|59|68
8763435|A patient is described with the characteristic features of phenytoin hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.|fever|111|116|phenytoin|59|68
8763435|A patient is described with the characteristic features of phenytoin hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.|phenytoin hypersensitivity syndrome|59|94|phenytoin|59|68
8763435|A patient is described with the characteristic features of phenytoin hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.|pinhead-sized facial pustules|158|187|phenytoin|59|68
8763435|A patient is described with the characteristic features of phenytoin hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.|tibial and facial oedema|132|156|phenytoin|59|68
8763435|Systemic corticosteroids in the phenytoin hypersensitivity syndrome.|phenytoin hypersensitivity syndrome|32|67|phenytoin|32|41
876914|A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis.|sarcoma|61|68|cyclophosphamide|75|91
876914|Sarcoma complicating therapy with cyclophosphamide.|Sarcoma|0|7|cyclophosphamide|34|50
8771575|A chronic reaction associated with long-term treatment with nitrofurantoin has also been reported and causes irreversible pulmonary fibrosis.|pulmonary fibrosis|122|140|nitrofurantoin|60|74
8771575|Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction.|Acute pulmonary reactions|0|25|nitrofurantoin|29|43
8771575|Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction.|pulmonary dysfunction|123|144|nitrofurantoin|29|43
8771575|Despite the known pulmonary side effects of nitrofurantoin, there is no report of this toxicity occurring in pregnant patients.|pulmonary side effects|18|40|nitrofurantoin|44|58
8771575|Nitrofurantoin-induced pulmonary toxicity during pregnancy: a report of a case and review of the literature.|pulmonary toxicity|23|41|Nitrofurantoin|0|14
8771575|We present a case of respiratory failure occurring in a woman at 16 weeks' gestation who was being treated with nitrofurantoin for a urinary tract infection.|respiratory failure|21|40|nitrofurantoin|112|126
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|agranulocytosis|92|107|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|an infectious mononucleosis-like syndrome|293|334|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|cholestatic jaundice|181|201|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|cutaneous eruptions|109|128|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|leukopenia|77|87|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|minor neurological and gastrointestinal complaints|340|390|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|nephrotic syndrome|203|221|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|peripheral neuropathy|130|151|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|psychosis|153|162|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|renal papillary necrosis|223|247|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|severe hypoalbuminemia without proteinuria|249|291|dapsone|30|37
8792511|Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.|toxic hepatitis|164|179|dapsone|30|37
8792511|Methemoglobinemia is another common finding among patients receiving dapsone therapy, but rarely does it result in prominent symptoms other than transient pallor.|Methemoglobinemia|0|17|dapsone|69|76
879939|Acetazolamide-accelerated anticonvulsant osteomalacia.|osteomalacia|41|53|Acetazolamide|0|13
879939|Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.|osteomalacia|54|66|Acetazolamide|0|13
879939|Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.|Severe osteomalacia|0|19|acetazolamide|141|154
879939|Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.|Severe osteomalacia|0|19|phenobarbital|122|135
879939|Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.|Severe osteomalacia|0|19|phenytoin|111|120
8816294|The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate.|encephalopathy|12|26|methotrexate|102|114
8816294|We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation.|hydrocephalus|180|193|methotrexate|289|301
8816294|We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation.|hydrocephalus|180|193|methotrexate|351|363
8816294|We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation.|leukoencephalopathy|156|175|methotrexate|289|301
8816294|We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation.|leukoencephalopathy|156|175|methotrexate|351|363
8825747|A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires.|loperamide poisoning|42|62|loperamide|42|52
8825747|Loperamide poisoning in the dog.|Loperamide poisoning|0|20|Loperamide|0|10
8828999|a 67-year-old man with bipolar disorder developed a Creutzfeldt-Jakob like syndrome during lithium carbonate treatment.|Creutzfeldt-Jakob like syndrome|52|83|lithium carbonate|91|108
8828999|Lithium-induced Creutzfeldt-Jakob syndrome.|Creutzfeldt-Jakob syndrome|16|42|Lithium|0|7
8828999|Lithium neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable.|Creutzfeldt-Jakob disease|46|71|Lithium|0|7
8828999|Lithium neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable.|Lithium neurotoxicity|0|21|Lithium|0|7
8828999|Several cases of lithium-induced Creutzfeldt-Jakob syndrome have been reported to date; all of them were elderly patients and a half had "therapeutic" lithium serum levels.|Creutzfeldt-Jakob syndrome|33|59|lithium|17|24
8828999|Several cases of lithium-induced Creutzfeldt-Jakob syndrome have been reported to date; all of them were elderly patients and a half had "therapeutic" lithium serum levels.|Creutzfeldt-Jakob syndrome|33|59|lithium|151|158
8832451|A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient.|protracted neuromuscular block|95|125|magnesium|77|86
8832451|A noninvasive method in the differential diagnosis of vecuronium-induced and magnesium-induced protracted neuromuscular block in a severely preeclamptic patient.|protracted neuromuscular block|95|125|vecuronium|54|64
8832451|The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate (MgSO4) administration is well known.|neuromuscular blockade|18|40|magnesium sulfate|99|116
8832451|The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate (MgSO4) administration is well known.|neuromuscular blockade|18|40|MgSO4|118|123
8832451|The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate (MgSO4) administration is well known.|potentiation of muscle relaxants|59|91|magnesium sulfate|99|116
8832451|The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate (MgSO4) administration is well known.|potentiation of muscle relaxants|59|91|MgSO4|118|123
8832451|We also describe a new, noninvasive method to assess magnesium-induced neuromuscular block when curariform muscle relaxant was given simultaneously.|neuromuscular block|71|90|magnesium|53|62
8835752|Hepatobiliary disorders associated with orally administered terbinafine have rarely been reported.|Hepatobiliary disorders|0|23|terbinafine|60|71
8835752|Terbinafine-induced cholestatic liver disease.|cholestatic liver disease|20|45|Terbinafine|0|11
8835752|We describe a case of prolonged terbinafine-induced cholestatic liver disease.|cholestatic liver disease|52|77|terbinafine|32|43
8840640|A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.|metabolic acidosis|76|94|cetrimide|127|136
8840640|A patient with a large hydatid cyst of the left lobe of the liver developed metabolic acidosis following rather liberal use of cetrimide-chlorhexidine solution as a scolicidal agent.|metabolic acidosis|76|94|chlorhexidine|137|150
8840640|Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.|Metabolic acidosis|0|18|cetrimide|30|39
8840640|Metabolic acidosis induced by cetrimide-chlorhexidine solution in hydatid cyst surgery.|Metabolic acidosis|0|18|chlorhexidine|40|53
8844232|An unusual case of Ecstasy poisoning.|Ecstasy poisoning|19|36|Ecstasy|19|26
8844232|We describe a case of poisoning with 3,4-methylenedioxymet-amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.|poisoning|22|31|3,4-methylenedioxymet-amphetamine Ecstasy|37|78
8850251|However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.|photosensitivity|51|67|mequitazine|88|99
8850251|In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.|erythematous macule|26|45|mequitazine|90|101
8850251|In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.|immediate erythema|154|172|mequitazine|90|101
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|cross-reaction to promethazine|245|275|mequitazine|130|141
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|cross-reaction to promethazine|245|275|mequitazine|412|423
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|cross-reaction to promethazine|245|275|promethazine|263|275
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|decreased MED to both UVA and UVB|277|310|mequitazine|130|141
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|decreased MED to both UVA and UVB|277|310|mequitazine|412|423
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|decreased MED to both UVA and UVB|277|310|promethazine|263|275
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|erythema|226|234|mequitazine|130|141
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|erythema|226|234|mequitazine|412|423
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|erythema|226|234|promethazine|263|275
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|persistence of the photosensitivity|316|351|mequitazine|130|141
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|persistence of the photosensitivity|316|351|mequitazine|412|423
8850251|In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.|persistence of the photosensitivity|316|351|promethazine|263|275
8850251|Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.|photosensitivity|96|112|mequitazine|76|87
8850251|Two cases of mequitazine-induced photosensitivity reactions.|photosensitivity reactions|33|59|mequitazine|13|24
8850251|We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.|photosensitivity reaction|46|71|mequitazine|26|37
8850251|We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.|photosensitivity reaction|46|71|mequitazine|93|104
8862924|Keratitis in methamphetamine abusers.|Keratitis|0|9|methamphetamine|13|28
8862924|Methamphetamine's extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for injury to the cornea.|injury to the cornea|144|164|Methamphetamine|0|15
8862924|Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product.|keratitis|44|53|lidocaine|233|242
8862924|Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product.|keratitis|44|53|methamphetamine|20|35
8862924|Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product.|keratitis|44|53|quinine|247|254
8862924|Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product.|toxic effects|179|192|lidocaine|233|242
8862924|Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product.|toxic effects|179|192|methamphetamine|20|35
8862924|Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product.|toxic effects|179|192|quinine|247|254
8862924|The increasing prevalence of methamphetamine abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of methamphetamine-related keratitis.|keratitis|165|174|methamphetamine|141|156
8862924|The increasing prevalence of methamphetamine abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of methamphetamine-related keratitis.|ulcers|86|92|methamphetamine|29|44
8862924|We report four cases of severe corneal ulceration in methamphetamine abusers.|severe corneal ulceration|24|49|methamphetamine|53|68
8864370|BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.|cirrhosis|106|115|Methotrexate|12|24
8864370|BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.|cirrhosis|106|115|MTX|26|29
8864370|BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.|fibrosis|94|102|Methotrexate|12|24
8864370|BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.|fibrosis|94|102|MTX|26|29
8864370|BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.|liver damage|42|54|Methotrexate|12|24
8864370|BACKGROUND: Methotrexate (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or cirrhosis.|liver damage|42|54|MTX|26|29
8864370|CONCLUSIONS: This study confirmed that in most patients MTX-induced liver cirrhosis is not aggressive.|liver cirrhosis|68|83|MTX|56|59
8864370|However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.|death|120|125|MTX|28|31
8864370|However, continued low-dose MTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and death in 1 of our patients.|liver failure|102|115|MTX|28|31
8864370|Methotrexate-induced liver cirrhosis.|liver cirrhosis|21|36|Methotrexate|0|12
8864370|Studies performed 10 years ago on 25 patients with MTX-induced liver cirrhosis indicated that this type of cirrhosis was not of an aggressive nature.|cirrhosis|107|116|MTX|51|54
8864370|Studies performed 10 years ago on 25 patients with MTX-induced liver cirrhosis indicated that this type of cirrhosis was not of an aggressive nature.|liver cirrhosis|63|78|MTX|51|54
8880251|After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness.|high fever|179|189|cresol|74|80
8880251|After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness.|high fever|179|189|insulin|37|44
8880251|After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness.|increasing myalgia|147|165|cresol|74|80
8880251|After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness.|increasing myalgia|147|165|insulin|37|44
8880251|After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness.|lost consciousness|233|251|cresol|74|80
8880251|After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness.|lost consciousness|233|251|insulin|37|44
8880251|After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness.|respiratory and metabolic acidosis|194|228|cresol|74|80
8880251|After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness.|respiratory and metabolic acidosis|194|228|insulin|37|44
8880251|However, other factors or drugs (e.g. cresol) are thought to induce MH.|MH|68|70|cresol|38|44
8880251|This case supports the assessment that MH and diabetes are associated diseases and that cresol could possibly trigger MH.|MH|118|120|cresol|88|94
889156|The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction.|eosinophilic pneumonia reaction|85|116|beclomethasone diproprionate|11|39
8891729|Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia.|Fatal intravascular autoimmune hemolytic anemia|0|47|fludarabine|54|65
8891729|Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.|AIHA|49|53|fludarabine|136|147
8891729|Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.|AIHA|49|53|fludarabine|253|264
8891729|Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.|AIHA|88|92|fludarabine|136|147
8891729|Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.|AIHA|88|92|fludarabine|253|264
8891729|Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.|positivation of the DAT|96|119|fludarabine|136|147
8891729|Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.|positivation of the DAT|96|119|fludarabine|253|264
8891729|The occurrence of severe AIHA in CLL patients treated with fludarabine has been reported by several authors.|AIHA|25|29|fludarabine|59|70
8891729|We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia (AIHA) after fludarabine treatment.|AIHA|135|139|fludarabine|147|158
8891729|We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia (AIHA) after fludarabine treatment.|fatal intravascular autoimmune hemolytic anemia|86|133|fludarabine|147|158
8891729|When the patient was treated again with fludarabine nine months later, the DAT became positive with anti-IgG and anti-C3d antiglobulins after the second course of treatment.|DAT became positive with anti-IgG and anti-C3d antiglobulins|75|135|fludarabine|40|51
8903300|She had just finished a 3-week course of intravenous tobramycin for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of tetany.|tetany|160|166|tobramycin|53|63
8903300|Tetany in a child with AIDS receiving intravenous tobramycin.|Tetany|0|6|tobramycin|50|60
8903300|This pattern is suggestive of renal toxicity due to tobramycin.|renal toxicity|30|44|tobramycin|52|62
8908396|CONCLUSIONS: In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone.|dedifferentiation of the adipocytes|148|183|insulin|122|129
8908396|CONCLUSIONS: In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone.|hyperproduction of TNF-alpha|43|71|insulin|122|129
8908396|Insulin-induced lipoatrophy in type I diabetes.|lipoatrophy|16|27|Insulin|0|7
8908396|OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions.|lipoatrophies|170|183|insulin|154|161
8912599|Erosion of psoriatic plaques: an early sign of methotrexate toxicity.|Erosion of psoriatic plaques|0|28|methotrexate|47|59
8912599|Erosion of psoriatic plaques: an early sign of methotrexate toxicity.|methotrexate toxicity|47|68|methotrexate|47|59
8912599|Methotrexate is an effective but potentially toxic treatment for psoriasis.|potentially toxic|33|50|Methotrexate|0|12
8912599|Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.|bone marrow suppression|113|136|methotrexate|62|74
8912599|Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.|methotrexate toxicity|62|83|methotrexate|62|74
8912599|Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.|Painful erosion of psoriatic plaques|0|36|methotrexate|62|74
8912599|We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.|methotrexate toxicity|105|126|methotrexate|105|117
8912599|We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.|painful erosions of their psoriasis|33|68|methotrexate|105|117
8912599|Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.|bone marrow suppression|50|73|methotrexate|20|32
8912599|Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.|methotrexate toxicity|20|41|methotrexate|20|32
8912599|Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.|oral and gastrointestinal ulceration|78|114|methotrexate|20|32
8921647|After treatment with cimetidine, there was a rapid deterioration with decreased oxygen saturation and arterial PO2 values.|decreased oxygen saturation and arterial PO2|70|114|cimetidine|21|31
8921647|Caution with use of cimetidine in tolazoline induced upper gastrointestinal bleeding.|upper gastrointestinal bleeding|53|84|cimetidine|20|30
8921647|Caution with use of cimetidine in tolazoline induced upper gastrointestinal bleeding.|upper gastrointestinal bleeding|53|84|tolazoline|34|44
8921647|However, given the clinically significant result to the interaction between tolazoline and cimetidine we report, the use of cimetidine in tolazoline induced upper gastrointestinal hemorrhage should deserve more attention.|upper gastrointestinal hemorrhage|157|190|cimetidine|91|101
8921647|However, given the clinically significant result to the interaction between tolazoline and cimetidine we report, the use of cimetidine in tolazoline induced upper gastrointestinal hemorrhage should deserve more attention.|upper gastrointestinal hemorrhage|157|190|cimetidine|124|134
8921647|However, given the clinically significant result to the interaction between tolazoline and cimetidine we report, the use of cimetidine in tolazoline induced upper gastrointestinal hemorrhage should deserve more attention.|upper gastrointestinal hemorrhage|157|190|tolazoline|76|86
8921647|However, given the clinically significant result to the interaction between tolazoline and cimetidine we report, the use of cimetidine in tolazoline induced upper gastrointestinal hemorrhage should deserve more attention.|upper gastrointestinal hemorrhage|157|190|tolazoline|138|148
8921647|Hypoxemia improved during continuous tolazoline infusion, but gastrointestinal bleeding occurred.|gastrointestinal bleeding|62|87|tolazoline|37|47
8926752|Zolpidem (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the death of a 39-year-old obese male who was being treated for depression and insomnia.|death|93|98|Ambien|10|16
8926752|Zolpidem (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the death of a 39-year-old obese male who was being treated for depression and insomnia.|death|93|98|Zolpidem|0|8
8926752|Zolpidem tissue concentrations in a multiple drug related death involving Ambien.|death|58|63|Ambien|74|80
8926752|Zolpidem tissue concentrations in a multiple drug related death involving Ambien.|death|58|63|Zolpidem|0|8
8933322|Acute nitrite toxicity results from industrial exposure, accidental ingestion (e.g., abuse of organic nitrites as an aphrodisiac, especially in the male homosexual population), and suicidal ingestion.|nitrite toxicity|6|22|nitrite|6|13
8933322|Infants are particularly susceptible to chronic nitrate-induced methemoglobinemia because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.|methemoglobinemia|64|81|nitrate|48|55
8936932|Acute esmolol toxicity may be self-limiting because of its extremely short half-life.|esmolol toxicity|6|22|esmolol|6|13
8936932|After induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride, her cardiac rhythm progressed to asystole.|asystole|147|155|esmolol hydrochloride|91|112
8936932|Cardiac arrest after esmolol administration: a review of acute beta-blocker toxicity.|Cardiac arrest|0|14|esmolol|21|28
8942269|Atenolol induced memory impairment: a case report.|memory impairment|17|34|Atenolol|0|8
8942269|His impaired memory was found to be due to the atenolol he was on and he made a complete recovery on withdrawing the beta-blocker.|impaired memory|4|19|atenolol|47|55
8949576|A potential role for renal and hepatic impairment in the observed protracted course of amiodarone-induced thyrotoxicosis is suggested.|thyrotoxicosis|106|120|amiodarone|87|97
8949576|Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis.|thyroiditis|113|124|amiodarone|94|104
8949576|We report a case of amiodarone-induced thyrotoxicosis of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions.|thyrotoxicosis|39|53|amiodarone|20|30
8961730|Psychotic disorder associated with isoniazid.|Psychotic disorder|0|18|isoniazid|35|44
8961730|We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test.|psychotic disorder|39|57|isoniazid|76|85
8969033|A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and right ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement.|pulmonary vasoconstriction|91|117|protamine|174|183
8969033|A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and right ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement.|right ventricular failure|122|147|protamine|174|183
8969033|Ketanserin in the treatment of protamine-induced pulmonary hypertension.|pulmonary hypertension|49|71|protamine|31|40
8969033|The reversal of heparin by protamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction.|bronchoconstriction|148|167|protamine|27|36
8969033|The reversal of heparin by protamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction.|pulmonary hypertension|120|142|protamine|27|36
8969033|The reversal of heparin by protamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction.|severe hemodynamic deterioration|47|79|protamine|27|36
8969033|The reversal of heparin by protamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction.|systemic hypotension|98|118|protamine|27|36
897744|A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.|acute nephritic syndrome|111|135|methicillin|60|71
897744|A drug addict with staphylococcal endocarditis treated with methicillin, who developed massive proteinuria and acute nephritic syndrome is described.|massive proteinuria|87|106|methicillin|60|71
897744|Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.|Focal glomerulonephritis|0|24|methicillin|55|66
897744|Focal glomerulonephritis and interstitial nephritis in methicillin-treated, heroin-related infective endocarditis.|interstitial nephritis|29|51|methicillin|55|66
8979664|METHODS/RESULTS: This paper presents a new case of rifabutin uveitis and a review of the various published reports to date.|uveitis|61|68|rifabutin|51|60
8979664|over the past 3 years there have been several reports of uveitis associated with rifabutin therapy.|uveitis|57|64|rifabutin|81|90
8979664|Uveitis associated with rifabutin therapy: a clinical alert.|Uveitis|0|7|rifabutin|24|33
8996514|CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a large cerebral infarction during praziquantel therapy.|large cerebral infarction|78|103|praziquantel|111|123
8996514|Large cerebral infarction during praziquantel therapy in neurocysticercosis.|Large cerebral infarction|0|25|praziquantel|33|45
9007910|DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.|diarrhea|228|236|5-FU|86|90
9007910|DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.|diarrhea|228|236|5-FU|315|319
9007910|DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.|mucositis|250|259|5-FU|86|90
9007910|DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.|mucositis|250|259|5-FU|315|319
9007910|DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.|myelosuppression|261|277|5-FU|86|90
9007910|DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.|myelosuppression|261|277|5-FU|315|319
9007910|DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.|neurotoxicity|279|292|5-FU|86|90
9007910|DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.|neurotoxicity|279|292|5-FU|315|319
9007910|DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.|stomatitis|238|248|5-FU|86|90
9007910|DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.|stomatitis|238|248|5-FU|315|319
9007910|Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.|severe adverse reactions|77|101|5-fluorouracil|105|119
9007910|PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.|lethal adverse reactions|168|192|5-fluorouracil|203|217
9007910|PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.|lethal adverse reactions|168|192|5-FU|219|223
9007910|The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.|coma|236|240|5-FU|176|180
9007910|The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.|coma|236|240|5-FU|69|73
9007910|The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.|encephalopathy|217|231|5-FU|176|180
9007910|The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.|encephalopathy|217|231|5-FU|69|73
9007910|The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.|neurologic symptoms|189|208|5-FU|176|180
9007910|The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.|neurologic symptoms|189|208|5-FU|69|73
9007910|The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.|severe acute 5-FU reactions|56|83|5-FU|176|180
9007910|The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.|severe acute 5-FU reactions|56|83|5-FU|69|73
9013348|A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever.|fever|131|136|5-ASA|79|84
9013348|A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever.|fever|131|136|mesalamine|67|77
9013348|A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever.|fever|131|136|prednisone|52|62
9013348|A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever.|worsening respiratory distress|96|126|5-ASA|79|84
9013348|A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever.|worsening respiratory distress|96|126|mesalamine|67|77
9013348|A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (5-ASA) developed worsening respiratory distress and fever.|worsening respiratory distress|96|126|prednisone|52|62
9013348|Mesalamine-induced hypersensitivity pneumonitis.|hypersensitivity pneumonitis|19|47|Mesalamine|0|10
9013348|Mesalamine may cause hypersensitivity pneumonitis in patients with Crohn's disease.|hypersensitivity pneumonitis|21|49|Mesalamine|0|10
9017913|Immunosuppression elicited by the extensive administration of prednisolone was suspected for the initiation of the generalized mite infestation.|mite infestation|127|143|prednisolone|62|74
9022114|BACKGROUND: Colchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation.|adverse effect on wound healing|35|66|Colchicine|12|22
9022114|BACKGROUND: Colchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation.|collagenase activation|145|167|Colchicine|12|22
9022114|CONCLUSION: The findings in these two patients suggest that colchicine may delay corneal wound healing.|delay corneal wound healing|75|102|colchicine|60|70
9022114|Delay of corneal wound healing in patients treated with colchicine.|Delay of corneal wound healing|0|30|colchicine|56|66
9022114|The authors report on two patients with corneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy.|corneal ulcers refractory to conventional treatment|40|91|colchicine|132|142
9022114|The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving colchicine, cessation of colchicine therapy should be considered.|corneal ulcers refractory to conventional treatment|42|93|colchicine|112|122
9037299|Fulminant hepatic failure associated with bicalutamide.|Fulminant hepatic failure|0|25|bicalutamide|42|54
9039216|A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.|eruption|120|128|minocycline|54|65
9039216|A 17-year-old female patient who had been taking oral minocycline (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.|exfoliative dermatitis|151|173|minocycline|54|65
9039216|Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.|dermatitis|68|78|minocycline|109|120
9039216|Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.|eosinophilia|24|36|minocycline|109|120
9039216|Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.|Fever|0|5|minocycline|109|120
9039216|Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.|hepatitis|53|62|minocycline|109|120
9039216|Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.|lymphadenopathy|7|22|minocycline|109|120
9039216|Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to minocycline.|lymphocytosis|38|51|minocycline|109|120
9039216|This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.|lymphocyte over-activation|130|156|minocycline|76|87
9039216|This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.|massive cytokine release|161|185|minocycline|76|87
9039216|This severe illness was likely caused by minocycline, and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.|severe illness|5|19|minocycline|41|52
9042097|Delayed hypersensitivity to flurbiprofen.|Delayed hypersensitivity|0|24|flurbiprofen|28|40
9052919|Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir.|Eye movement disorders|0|22|cyclosporin|61|72
9052919|Eye movement disorders in bone marrow transplant patients on cyclosporin and ganciclovir.|Eye movement disorders|0|22|ganciclovir|77|88
9052919|One patient had MRI T2 abnormalities compatible with cyclosporin neurotoxicity.|MRI T2 abnormalities|16|36|cyclosporin|53|64
9052919|One patient had MRI T2 abnormalities compatible with cyclosporin neurotoxicity.|neurotoxicity|65|78|cyclosporin|53|64
9052919|We postulate that cyclosporin, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients.|eye movement abnormality|134|158|cyclosporin|18|29
9052919|We postulate that cyclosporin, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients.|eye movement abnormality|134|158|ganciclovir|54|65
9052919|We postulate that cyclosporin, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients.|transient brain stem or neuromuscular dysfunction|79|128|cyclosporin|18|29
9052919|We postulate that cyclosporin, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients.|transient brain stem or neuromuscular dysfunction|79|128|ganciclovir|54|65
9058350|CONCLUSION: While thrombosis has been reported with GnRH-a therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size.|thrombosis|18|28|GnRH-a|52|58
9094821|The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.|endometrial carcinoma|129|150|tamoxifen|103|112
9094821|The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis.|endometriosis|155|168|tamoxifen|103|112
9100429|Case study: adverse response to clonidine.|adverse response|12|28|clonidine|32|41
9100429|Four cases of adverse experiences with clonidine are described.|adverse experiences|14|33|clonidine|39|48
910864|In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.|confusion|78|87|acetohexamide|158|171
910864|In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.|head trauma|62|73|acetohexamide|158|171
910864|In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.|systemic hypoglycemic reaction|18|48|acetohexamide|158|171
9111724|Discontinuation of the itraconazole caused resolution of the drug eruption.|drug eruption|61|74|itraconazole|23|35
9111724|Primary cutaneous coccidioidomycosis and subsequent drug eruption to itraconazole in a dog.|drug eruption|52|65|itraconazole|69|81
9111724|Primary cutaneous coccidioidomycosis and subsequent drug eruption to itraconazole in a dog.|Primary cutaneous coccidioidomycosis|0|36|itraconazole|69|81
9128433|Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "retinoic acid syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis.|potentially fatal symptom|140|165|retinoic acid|190|203
9128433|Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "retinoic acid syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis.|retinoic acid syndrome|190|212|retinoic acid|190|203
9128433|Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "retinoic acid syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis.|toxicity|12|20|retinoic acid|190|203
9149614|Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.|polymorphous ventricular tachycardia|133|169|amiodarone|45|55
9149614|Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.|syncope|81|88|amiodarone|45|55
9149614|Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.|Nonsustained polymorphous ventricular tachycardia|0|49|amiodarone|57|67
9149614|The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.|proarrhythmic|13|26|amiodarone|37|47
9161656|Acute asthma associated with sustained-release verapamil.|Acute asthma|0|12|verapamil|47|56
9161656|Although dyspnea associated with verapamil administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release verapamil administration.|acute asthma|182|194|verapamil|230|239
9161656|Although dyspnea associated with verapamil administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release verapamil administration.|dyspnea|9|16|verapamil|33|42
9161656|CONCLUSIONS: Sustained-release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation.|asthma attack|75|88|verapamil|31|40
9161656|CONCLUSIONS: Sustained-release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation.|asthma attack|75|88|verapamil|222|231
9161656|OBJECTIVE: To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained-release verapamil.|acute asthma|102|114|verapamil|156|165
9161656|She continued taking verapamil for 6 months, then, on her own, stopped all medications including the sustained-release verapamil, and her asthma symptoms disappeared.|asthma|138|144|verapamil|119|128
9169264|Cephalexin rash in infectious mononucleosis.|Cephalexin rash|0|15|Cephalexin|0|10
9169264|The ampicillin rash occurring in cases of infectious mononucleosis is well documented.|ampicillin rash|4|19|ampicillin|4|14
9169264|The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed.|rash|95|99|cephalexin|65|75
9169264|The rash seen in this patient, who was treated with cephalexin, may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis.|rash|4|8|cephalexin|52|62
9169264|The rash seen in this patient, who was treated with cephalexin, may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis.|rash|86|90|ampicillin|101|111
9177620|A possible case of carbamazepine induced pancreatitis.|pancreatitis|41|53|carbamazepine|19|32
9177620|The authors report a case of acute pancreatitis (AP) occurring in a patient under treatment with carbamazepine (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP.|pancreatitis|35|47|carbamazepine|97|110
9177620|The authors report a case of acute pancreatitis (AP) occurring in a patient under treatment with carbamazepine (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP.|pancreatitis|35|47|CBZ|112|115
9177620|The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of acute pancreatitis.|acute pancreatitis|202|220|CBZ|41|44
9177620|The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of acute pancreatitis.|acute pancreatitis|202|220|CBZ|139|142
9184269|Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis.|pneumonitis|368|379|MTX|364|367
9184269|Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis.|pulmonary toxicity|38|56|MTX|26|29
9184269|Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature.|pneumonitis|21|32|Methotrexate|0|12
9184269|On the other hand, MTX-induced pneumonitis seems to be very rare in psoriatic arthritis (PsA).|pneumonitis|31|42|MTX|19|22
9184269|Our review of 194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient with MTX-induced pneumonitis, giving a prevalence of 2.1% and 0.03%, respectively.|pneumonitis|133|144|MTX|121|124
9184269|Pneumonitis is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with MTX.|Pneumonitis|0|11|MTX|116|119
9184269|The presence of a lymphocyte alveolitis with a predominance of CD4+ T cells in 3 RA patients and CD8+ T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in MTX-induced pneumonitis.|pneumonitis|261|272|MTX|249|252
91848|A retrospective epidemiological study of deaths from hepatic angiosarcoma (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, 'Thorotrast', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids.|hepatic angiosarcoma|53|73|inorganic arsenic|245|262
91848|A retrospective epidemiological study of deaths from hepatic angiosarcoma (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, 'Thorotrast', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids.|hepatic angiosarcoma|53|73|Thorotrast|228|238
91848|A retrospective epidemiological study of deaths from hepatic angiosarcoma (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, 'Thorotrast', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids.|hepatic angiosarcoma|53|73|vinyl chloride|211|225
9191742|Recent studies have shown that under experimental conditions ferrous sulfate may reduce the gastrointestinal absorption of orally administered levothyroxine sodium in patients with primary hypothyroidism.|reduce the gastrointestinal absorption of orally administered levothyroxine sodium|81|163|ferrous sulfate|61|76
9191742|We describe a patient who became hypothyroid while taking ferrous sulfate.|hypothyroid|33|44|ferrous sulfate|58|73
9195619|However, as the use of hepatitis B vaccination is growing, adverse side effects, including mental nerve neuropathy, should be observed with an increased frequency.|mental nerve neuropathy|91|114|hepatitis B vaccination|23|46
9195619|Mental nerve neuropathy as a result of hepatitis B vaccination.|Mental nerve neuropathy|0|23|hepatitis B vaccination|39|62
9205466|Although its side effects are few, tamoxifen increases the incidence of proliferative lesions of the endometrium, which theoretically should be preventable with progestational agents.|proliferative lesions of the endometrium|72|112|tamoxifen|35|44
9205466|CASES: Two postmenopausal women treated with tamoxifen and progestational agents for breast carcinoma developed uterine enlargement and intermittent spotting.|intermittent spotting|136|157|tamoxifen|45|54
9205466|CASES: Two postmenopausal women treated with tamoxifen and progestational agents for breast carcinoma developed uterine enlargement and intermittent spotting.|uterine enlargement|112|131|tamoxifen|45|54
9205466|CONCLUSIONS: The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to tamoxifen may not reduce of developing endometrial lesions, including carcinoma.|carcinoma|194|203|tamoxifen|124|133
9205466|CONCLUSIONS: The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to tamoxifen may not reduce of developing endometrial lesions, including carcinoma.|endometrial lesions|163|182|tamoxifen|124|133
9211543|Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer.|metastatic nodules|51|69|Bleomycin|0|9
9211543|Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer.|metastatic nodules|51|69|cyclophosphamide|14|30
9211543|Thoracoscopic biopsy to confirm metastasis revealed instead fibrotic lesions apparently attributable to bleomycin or cyclophosphamide.|fibrotic lesions|60|76|bleomycin|104|113
9211543|Thoracoscopic biopsy to confirm metastasis revealed instead fibrotic lesions apparently attributable to bleomycin or cyclophosphamide.|fibrotic lesions|60|76|cyclophosphamide|117|133
921427|An elderly man with procainamide hydrochloride-induced lupus syndrome had a circulating anticoagulant against factor XI and a biologic false-positive (BFP) test result for syphilis.|lupus syndrome|55|69|procainamide hydrochloride|20|46
921427|Circulating anticoagulant in the procainamide-induced lupus syndrome.|lupus syndrome|54|68|procainamide|33|45
9215418|Clinical signs of hypermagnesemia are an uncommon complication following oral administration of magnesium sulfate.|hypermagnesemia|18|33|magnesium sulfate|96|113
9215418|Establishment of diuresis with fluids and IV administration of calcium may provide successful treatment of magnesium toxicosis in horses.|magnesium toxicosis|107|126|magnesium|107|116
9215418|Magnesium toxicosis in two horses.|Magnesium toxicosis|0|19|Magnesium|0|9
9215418|Overdose of magnesium sulfate in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to magnesium toxicosis.|magnesium toxicosis|148|167|magnesium|148|157
9215418|Overdose of magnesium sulfate in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to magnesium toxicosis.|magnesium toxicosis|148|167|magnesium sulfate|12|29
9220046|CASE SUMMARIES: In each case, the patients were treated over 5 years with lovastatin and developed rhabdomyolysis that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic.|rhabdomyolysis|99|113|lovastatin|74|84
9220046|CONCLUSIONS: The risk of drug-induced rhabdomyolysis due to the potential interaction between lovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents.|rhabdomyolysis|38|52|azithromycin|109|121
9220046|CONCLUSIONS: The risk of drug-induced rhabdomyolysis due to the potential interaction between lovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents.|rhabdomyolysis|38|52|clarithromycin|125|139
9220046|CONCLUSIONS: The risk of drug-induced rhabdomyolysis due to the potential interaction between lovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents.|rhabdomyolysis|38|52|lovastatin|94|104
9220046|DISCUSSION: Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis, including lovastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor.|rhabdomyolysis|175|189|lovastatin|201|211
9220046|Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin-induced rhabdomyolysis.|rhabdomyolysis|88|102|Erythromycin|0|12
9220046|Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin-induced rhabdomyolysis.|rhabdomyolysis|88|102|lovastatin|69|79
9220046|Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.|rhabdomyolysis|19|33|azithromycin|78|90
9220046|Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.|rhabdomyolysis|19|33|clarithromycin|59|73
9220046|Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.|rhabdomyolysis|19|33|Lovastatin|0|10
9220046|OBJECTIVE: To describe two cases of rhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin.|rhabdomyolysis|36|50|azithromycin|169|181
9220046|OBJECTIVE: To describe two cases of rhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin.|rhabdomyolysis|36|50|clarithromycin|150|164
9220046|OBJECTIVE: To describe two cases of rhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin.|rhabdomyolysis|36|50|lovastatin|70|80
9220046|To our knowledge, these cases are the first published reports of lovastatin-induced rhabdomyolysis associated with azithromycin and clarithromycin.|rhabdomyolysis|84|98|azithromycin|115|127
9220046|To our knowledge, these cases are the first published reports of lovastatin-induced rhabdomyolysis associated with azithromycin and clarithromycin.|rhabdomyolysis|84|98|clarithromycin|132|146
9220046|To our knowledge, these cases are the first published reports of lovastatin-induced rhabdomyolysis associated with azithromycin and clarithromycin.|rhabdomyolysis|84|98|lovastatin|65|75
9224230|These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients died of PCP occurring during the first month of treatment with prednisone.|died|173|177|prednisone|236|246
9230324|We report the specifics of 12 cases of severe hypertension after the intraoperative use of topical phenylephrine, submucosal epinephrine, or both.|severe hypertension|39|58|epinephrine|125|136
9230324|We report the specifics of 12 cases of severe hypertension after the intraoperative use of topical phenylephrine, submucosal epinephrine, or both.|severe hypertension|39|58|phenylephrine|99|112
9232614|Acute leukaemia during tamoxifen therapy.|Acute leukaemia|0|15|tamoxifen|23|32
9232614|Tamoxifen is suggested to be carcinogenic both through direct genotoxic and epigenetic mechanisms.|carcinogenic|29|41|Tamoxifen|0|9
9232614|We report two cases that developed acute myeloid leukaemia (AML) during tamoxifen therapy for breast cancer.|acute myeloid leukaemia|35|58|tamoxifen|72|81
9232614|We report two cases that developed acute myeloid leukaemia (AML) during tamoxifen therapy for breast cancer.|AML|60|63|tamoxifen|72|81
9240497|Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.|Relapse in the external auditory canal of acute promyelocytic leukemia|0|70|all-trans retinoic acid|92|115
9240497|This case suggests the importance of careful observation for extramedullary relapse in patients who are treated with ATRA.|extramedullary relapse|61|83|ATRA|117|121
9247841|Cutaneous reactions to propylthiouracil and methimazole occur in 3%-5% of adults.|Cutaneous reactions|0|19|methimazole|44|55
9247841|Cutaneous reactions to propylthiouracil and methimazole occur in 3%-5% of adults.|Cutaneous reactions|0|19|propylthiouracil|23|39
9247841|Generalized maculopapular and papular purpuric eruptions are perhaps the most common thionamide-induced reactions.|Generalized maculopapular and papular purpuric eruptions|0|56|thionamide|85|95
9247841|Propylthiouracil-induced cutaneous vasculitis.|cutaneous vasculitis|25|45|Propylthiouracil|0|16
9247841|The observation of cutaneous vasculitis during administration of propylthiouracil suggested that clinical awareness of this complication should be of considerable importance.|cutaneous vasculitis|19|39|propylthiouracil|65|81
9253492|A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.|heat stroke|103|114|zonisamide|144|154
9253492|Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.|neurological symptoms|91|112|zonisamide|19|29
9253492|Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.|oligohidrosis|54|67|zonisamide|19|29
9253492|Heat stroke-like episode in a child caused by zonisamide.|Heat stroke-like episode|0|24|zonisamide|46|56
9253492|The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.|oligohidrosis|4|17|zonisamide|28|38
9256906|Acute renal failure in a patient receiving treatment with suramin.|Acute renal failure|0|19|suramin|58|65
9256906|Acute renal failure should be recognized as a potential complication of suramin treatment.|renal failure|6|19|suramin|72|79
9256906|Other potential causes of renal failure were not present in our patient and his renal function gradually recovered with the cessation of suramin treatment.|renal failure|26|39|suramin|137|144
9256906|We describe a patient with metastatic prostate cancer who developed nonoliguric renal failure during treatment with suramin.|nonoliguric renal failure|68|93|suramin|116|123
9260733|Clozapine induced polyserositis.|polyserositis|18|31|Clozapine|0|9
9260733|We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine.|pericardial effusion|61|81|clozapine|142|151
9260733|We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine.|pericardial effusion|61|81|clozapine|205|214
9260733|We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine.|pericarditis|105|117|clozapine|142|151
9260733|We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine.|pericarditis|105|117|clozapine|205|214
9260733|We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine.|pleural effusion|83|99|clozapine|142|151
9260733|We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine.|pleural effusion|83|99|clozapine|205|214
9260733|We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine.|polyserositis|46|59|clozapine|142|151
9260733|We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and pericarditis) after being started on clozapine, and whose symptoms remitted upon discontinuation of clozapine.|polyserositis|46|59|clozapine|205|214
9279731|When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.|severe side effects|103|122|amphotericin B|39|53
9291634|Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias.|fever|218|223|ARA-C|152|157
9291634|Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias.|fever|218|223|cytosine arabinoside|130|150
9291634|Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias.|gastrointestinal tract symptoms|251|282|ARA-C|152|157
9291634|Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias.|gastrointestinal tract symptoms|251|282|cytosine arabinoside|130|150
9291634|Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias.|infectious complications|225|249|ARA-C|152|157
9291634|Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias.|infectious complications|225|249|cytosine arabinoside|130|150
9291634|Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias.|severe myalgias|287|302|ARA-C|152|157
9291634|Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and severe myalgias.|severe myalgias|287|302|cytosine arabinoside|130|150
9302445|CONCLUSION: We believe this to be the first reported case of rhGH-induced hypercalcemia in an HIV-infected patient.|hypercalcemia|74|87|rhGH|61|65
9302445|Hypercalcemia in an AIDS patient treated with growth hormone.|Hypercalcemia|0|13|growth hormone|46|60
9302445|The hypercalcemia responded to discontinuation of rhGH and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow-up.|hypercalcemia|4|17|rhGH|50|54
9302445|We report a male patient with advanced AIDS who developed hypercalcemia 2 weeks after institution of rhGH therapy.|hypercalcemia|58|71|rhGH|101|105
9311175|Hypersensitivity reactions to cisplatin following multiple uncomplicated courses: a report on two cases.|Hypersensitivity reactions|0|26|cisplatin|30|39
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|abdominal pain|309|323|cisplatin|70|79
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|abdominal pain|309|323|cisplatin|144|153
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|dyspnea|229|236|cisplatin|70|79
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|dyspnea|229|236|cisplatin|144|153
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|fever|347|352|cisplatin|70|79
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|fever|347|352|cisplatin|144|153
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|general erythema|211|227|cisplatin|70|79
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|general erythema|211|227|cisplatin|144|153
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|general erythema|325|341|cisplatin|70|79
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|general erythema|325|341|cisplatin|144|153
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|hypersensitivity reactions|114|140|cisplatin|70|79
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|hypersensitivity reactions|114|140|cisplatin|144|153
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|hypotension|242|253|cisplatin|70|79
9311175|Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.|hypotension|242|253|cisplatin|144|153
9315405|We report an unusually short lived and asymptomatic episode of severe cisplatin-induced renal tubular salt wasting in a fit 41-year-old patient with malignant teratoma.|renal tubular salt wasting|88|114|cisplatin|70|79
9337441|Clinicians should include phenolphthalein in their list of possible causes of drug-induced TEN.|TEN|91|94|phenolphthalein|26|41
9337441|DISCUSSION: Phenolphthalein is the active ingredient in several over-the-counter laxative preparations and has only rarely been reported to cause TEN.|TEN|146|149|Phenolphthalein|12|27
9337441|OBJECTIVE: To report a case of phenolphthalein-induced toxic epidermal necrolysis (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN.|TEN|83|86|phenolphthalein|31|46
9337441|OBJECTIVE: To report a case of phenolphthalein-induced toxic epidermal necrolysis (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN.|TEN|183|186|phenolphthalein|31|46
9337441|OBJECTIVE: To report a case of phenolphthalein-induced toxic epidermal necrolysis (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN.|toxic epidermal necrolysis|55|81|phenolphthalein|31|46
9337441|Phenolphthalein-induced toxic epidermal necrolysis.|toxic epidermal necrolysis|24|50|Phenolphthalein|0|15
9337441|The patient's previous rash and the temporal relation of this event and the ingestion of phenolphthalein, as well as the similarity of this case to other reports, point to phenolphthalein as the cause of TEN in this patient.|rash|23|27|phenolphthalein|89|104
9337441|The patient's previous rash and the temporal relation of this event and the ingestion of phenolphthalein, as well as the similarity of this case to other reports, point to phenolphthalein as the cause of TEN in this patient.|TEN|204|207|phenolphthalein|172|187
9347384|Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients.|Carbamazepine toxicity|0|22|Carbamazepine|0|13
9347384|Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients.|Carbamazepine toxicity|0|22|clarithromycin|34|48
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|ataxia|168|174|carbamazepine|118|131
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|ataxia|168|174|clarithromycin|7|21
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|ataxia|168|174|clarithromycin|211|225
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|dizziness|153|162|carbamazepine|118|131
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|dizziness|153|162|clarithromycin|7|21
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|dizziness|153|162|clarithromycin|211|225
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|drowsiness|141|151|carbamazepine|118|131
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|drowsiness|141|151|clarithromycin|7|21
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|drowsiness|141|151|clarithromycin|211|225
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|toxic symptoms|100|114|carbamazepine|118|131
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|toxic symptoms|100|114|clarithromycin|7|21
9347384|During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.|toxic symptoms|100|114|clarithromycin|211|225
9347384|The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity.|carbamazepine toxicity|140|162|carbamazepine|90|103
9347384|The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity.|carbamazepine toxicity|140|162|carbamazepine|140|153
9347384|The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity.|carbamazepine toxicity|140|162|clarithromycin|33|47
9347384|The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity.|increased plasma carbamazepine|73|103|carbamazepine|90|103
9347384|The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity.|increased plasma carbamazepine|73|103|carbamazepine|140|153
9347384|The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in carbamazepine toxicity.|increased plasma carbamazepine|73|103|clarithromycin|33|47
9352164|Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.|acetazolamide intoxication|44|70|acetazolamide|44|57
9352164|Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.|Acute hemorrhagic gastritis|0|27|acetazolamide|44|57
9352164|As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.|acute hemorrhagic gastritis|52|79|AZ|96|98
9352164|As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.|AZ intoxication|96|111|AZ|96|98
9352164|She was thus diagnosed as having AZ intoxication.|AZ intoxication|33|48|AZ|33|35
9352164|We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.|acute hemorrhagic gastritis|75|102|AZ|119|121
9352164|We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.|AZ intoxication|119|134|AZ|119|121
9352164|We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.|destroyed the gastric mucosal barrier|60|97|AZ|44|46
9352164|We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.|hemorrhagic gastritis|192|213|AZ|44|46
9352164|We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.|thrombocytopenia due to bone marrow disorder|101|145|AZ|44|46
9360190|In association with this tocolysis, urinary calculus of magnesium ammonium phosphate occurred at 34 weeks gestation.|urinary calculus|36|52|magnesium ammonium phosphate|56|84
9360190|Magnesium tocolysis as the cause of urinary calculus during pregnancy.|urinary calculus|36|52|Magnesium|0|9
9362107|Danazol induced thrombocytopenia.|thrombocytopenia|16|32|Danazol|0|7
9362107|On the next day, after a total dose of only 600 mg of danazol, gingival bleeding and purpura occurred.|gingival bleeding|63|80|danazol|54|61
9362107|On the next day, after a total dose of only 600 mg of danazol, gingival bleeding and purpura occurred.|purpura|85|92|danazol|54|61
9362107|We diagnosed this case as danazol induced thrombocytopenia.|thrombocytopenia|42|58|danazol|26|33
9366852|It occasionally accompanies the heparin-associated thrombocytopenia and thrombosis syndrome.|thrombocytopenia|51|67|heparin|32|39
9366852|It occasionally accompanies the heparin-associated thrombocytopenia and thrombosis syndrome.|thrombosis syndrome|72|91|heparin|32|39
9366852|Skin necrosis is a rare complication of subcutaneous heparin therapy that usually occurs at injection sites.|Skin necrosis|0|13|heparin|53|60
9366852|Skin necrosis secondary to low-molecular weight heparin in a patient with antiphospholipid antibody syndrome.|Skin necrosis|0|13|low-molecular weight heparin|27|55
9366852|We describe a patient with the antiphospholipid syndrome who had skin necrosis develop from low-molecular weight heparin therapy at sites distant from injection sites.|skin necrosis|65|78|low-molecular weight heparin|92|120
937377|Finally, reserpine toxicity, in particular central nervous system (CNS) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects.|reserpine toxicity|9|27|reserpine|9|18
9375469|A case of contact dermatitis due to sodium bisulfite in an ophthalmic solution.|contact dermatitis|10|28|sodium bisulfite|36|52
9375469|Therefore, we diagnosed her eruption as contact dermatitis due to sodium bisulfite.|contact dermatitis|40|58|sodium bisulfite|66|82
9375469|Therefore, we diagnosed her eruption as contact dermatitis due to sodium bisulfite.|eruption|28|36|sodium bisulfite|66|82
9375469|We report a case of contact dermatitis due to sodium bisulfite in Tathion eye drops.|contact dermatitis|20|38|sodium bisulfite|46|62
9399776|Acute pancreatitis after long-term 5-aminosalicylic acid therapy.|Acute pancreatitis|0|18|5-aminosalicylic acid|35|56
9399776|Acute pancreatitis is a known, although rare, complication of mesalamine treatment.|Acute pancreatitis|0|18|mesalamine|62|72
9399776|A rechallenge, performed in both patients, confirmed the diagnosis of mesalamine-induced pancreatitis.|pancreatitis|89|101|mesalamine|70|80
9399776|These case reports provide evidence that 5-aminosalicylic acid may induce acute pancreatitis after long term treatment.|acute pancreatitis|74|92|5-aminosalicylic acid|41|62
9399776|We describe two cases of acute pancreatitis that occurred after long term mesalamine therapy for ulcerative colitis.|acute pancreatitis|25|43|mesalamine|74|84
9403220|A 35-year-old nephrotic man developed acute renal failure with serum creatinine to 1543 micromol/l after a month of therapy with enalapril.|acute renal failure|38|57|enalapril|129|138
9403220|Acute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with enalapril.|Acute renal failure|0|19|enalapril|124|133
9403220|Acute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with enalapril.|severe tubulointerstitial changes|25|58|enalapril|124|133
9407188|Early ritonavir-induced maculopapular eruption.|maculopapular eruption|24|46|ritonavir|6|15
9407188|Ritonavir should be added to the list of drugs that can induce adverse cutaneous reactions in HIV patients.|adverse cutaneous reactions|63|90|Ritonavir|0|9
9407188|We report 2 cases of maculopapular eruption and fever in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of ritonavir, a protease inhibitor.|fever|48|53|ritonavir|157|166
9407188|We report 2 cases of maculopapular eruption and fever in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of ritonavir, a protease inhibitor.|maculopapular eruption|21|43|ritonavir|157|166
941054|Nephropathy caused by methicillin therapy for staphylococcal septicemia.|Nephropathy|0|11|methicillin|22|33
941054|Review of the literature relating to methicillin-induced nephropathy suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis.|nephropathy|57|68|methicillin|37|48
9413296|A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.|retroperitoneal fibrosis|84|108|methysergide|130|142
9413296|Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.|retroperitoneal fibrosis|21|45|Methysergide|0|12
9426968|Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.|Vitiligo|0|8|alpha-interferon|25|41
9426968|We report a case of vitiligo that occurred during the second month of interferon alpha 2a therapy for chronic active hepatitis C.|vitiligo|20|28|interferon alpha 2a|70|89
9433539|A case is reported of an elderly woman who developed febrile agranulocytosis several weeks after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with filgastrim.|febrile agranulocytosis|53|76|ticlopidine|108|119
9433539|Agranulocytosis associated with ticlopidine: a possible benefit with filgastim.|Agranulocytosis|0|15|ticlopidine|32|43
9433539|Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically aplastic anemia.|aplastic anemia|178|193|Ticlopidine|0|11
9433539|Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically aplastic anemia.|severe bone marrow suppression|136|166|Ticlopidine|0|11
9443627|Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.|neurotoxicity|58|71|ifosfamide|39|49
9443627|Ifosfamide-associated neurotoxicity was noted within hours of drug administration and improved rapidly following hemodialysis.|neurotoxicity|22|35|Ifosfamide|0|10
9443627|PURPOSE: We evaluated the in vitro hemodialysis ratio and subsequent toxicity and pharmacokinetics of ifosfamide in an anephric patient with Wilms' tumor.|ifosfamide|102|112|toxicity|69|77
9443627|The toxicity and plasma concentrations of ifosfamide, chloroacetaldehyde, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.|toxicity|4|12|4-hydroxyifosfamide|78|97
9443627|The toxicity and plasma concentrations of ifosfamide, chloroacetaldehyde, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.|toxicity|4|12|chloroacetaldehyde|54|72
9443627|The toxicity and plasma concentrations of ifosfamide, chloroacetaldehyde, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.|toxicity|4|12|ifosfamide|42|52
9443627|The toxicity and plasma concentrations of ifosfamide, chloroacetaldehyde, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.|toxicity|4|12|ifosfamide|161|171
9443627|Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor.|Toxicity|0|8|ifosfamide|67|77
946400|A 55-year-old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension.|hepatitis|53|62|methyldopa|94|104
946400|Methyldopa-induced liver injury.|liver injury|19|31|Methyldopa|0|10
946400|Such a rapid and relentless progression of methyldopa-induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.|liver injury|62|74|methyldopa|43|53
9466030|Acute respiratory depression as a complication of nebulised morphine.|Acute respiratory depression|0|28|morphine|60|68
9466030|Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.|bradypneic|102|112|morphine|65|73
9466030|Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.|hypotensive|142|153|morphine|65|73
9466030|PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine.|respiratory depression|30|52|morphine|95|103
9476721|Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease.|Acute dystonia|0|14|penicillamine|65|78
9476721|Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease.|thalamic and brainstem lesions|20|50|penicillamine|65|78
9476721|From these data, acute generalized dystonia with brainstem and thalamic lesions may occur in WD patients after an initial d-penicillamine therapy.|acute generalized dystonia|17|43|d-penicillamine|122|137
9476721|From these data, acute generalized dystonia with brainstem and thalamic lesions may occur in WD patients after an initial d-penicillamine therapy.|brainstem and thalamic lesions|49|79|d-penicillamine|122|137
9476721|We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with d-penicillamine 125-500 mg daily.|acute generalized dystonia|37|63|d-penicillamine|126|141
9476721|We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with d-penicillamine 125-500 mg daily.|akinetic rigid syndrome|68|91|d-penicillamine|126|141
9491301|Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.|Ballistic movements|0|19|heroin|63|69
9491301|Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases.|ischemic infarcts|27|44|heroin|63|69
9491301|Patient 1 presented bilateral ballism 1 week after intravenous heroin injection.|bilateral ballism|20|37|heroin|63|69
9491301|Stroke is an infrequent but recognized complication of heroin addiction.|Stroke|0|6|heroin|55|61
9491301|Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose.|ballistic movements|52|71|heroin|90|96
9494448|A MEDLINE search identified all the reported cases of hypersensitivity reactions to cyclosporine.|hypersensitivity reactions|54|80|cyclosporine|84|96
9494448|Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review.|Anaphylaxis|0|11|cyclosporine|27|39
9494448|BACKGROUND: Hypersensitivity reactions to cyclosporine are rare.|Hypersensitivity reactions|12|38|cyclosporine|42|54
9494448|CONCLUSIONS: Hypersensitivity reactions to cyclosporine are due to Cremophor EL.|Hypersensitivity reactions|13|39|Cremophor EL|67|79
9494448|CONCLUSIONS: Hypersensitivity reactions to cyclosporine are due to Cremophor EL.|Hypersensitivity reactions|13|39|cyclosporine|43|55
9494448|Fortunately, a hypersensitivity reaction to one formulation of cyclosporine does not preclude use of a different formulation.|hypersensitivity reaction|15|40|cyclosporine|63|75
9494448|METHODS: We report a patient who had an anaphylactic reaction during the intravenous infusion of cyclosporine.|anaphylactic reaction|40|61|cyclosporine|97|109
9494448|OBJECTIVE: To investigate the mechanisms involved in hypersensitivity reactions to cyclosporine and determine the feasibility of future cyclosporine use.|hypersensitivity reactions|53|79|cyclosporine|83|95
9494448|OBJECTIVE: To investigate the mechanisms involved in hypersensitivity reactions to cyclosporine and determine the feasibility of future cyclosporine use.|hypersensitivity reactions|53|79|cyclosporine|136|148
9494448|The literature search revealed 22 cases of hypersensitivity reaction to cyclosporine.|hypersensitivity reaction|43|68|cyclosporine|72|84
9497597|Prothipendylhydrochloride-induced priapism: case report.|priapism|34|42|Prothipendylhydrochloride|0|25
9497597|We present the first case of a patient with priapism after oral intake of the phenothiazine prothipendylhydrochloride.|priapism|44|52|prothipendylhydrochloride|92|117
9509511|The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed.|hepatotoxicity|153|167|actinomycin D|46|59
9509511|The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed.|hepatotoxicity|153|167|actinomycin D|106|119
9509511|The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed.|hepatotoxicity|153|167|epirubicin|65|75
9509511|The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed.|hepatotoxicity|153|167|vincristine|33|44
9509511|The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed.|hepatotoxicity|153|167|vincristine|90|101
9509511|We conclude that vincristine and actinomycin D were the cause of this rare from of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery.|hepatotoxicity|83|97|actinomycin D|33|46
9509511|We conclude that vincristine and actinomycin D were the cause of this rare from of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery.|hepatotoxicity|83|97|vincristine|17|28
9512187|Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy.|acral necrosis|178|192|bleomycin|27|36
9512187|Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy.|Raynaud's phenomenon|217|237|bleomycin|27|36
9512187|In this report, one patient who developed gangrene after bleomycin and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.|gangrene|42|50|bleomycin|57|66
9512187|In this report, one patient who developed gangrene after bleomycin and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.|gangrene|42|50|vinblastine|83|94
9512187|In this report, one patient who developed gangrene after bleomycin and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.|gangrene|42|50|vincristine|71|82
9512187|In this report, one patient who developed gangrene after bleomycin and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.|severe Raynaud's phenomenon|201|228|bleomycin|57|66
9512187|In this report, one patient who developed gangrene after bleomycin and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.|severe Raynaud's phenomenon|201|228|vinblastine|83|94
9512187|In this report, one patient who developed gangrene after bleomycin and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.|severe Raynaud's phenomenon|201|228|vincristine|71|82
9517515|Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.|thrombocythemia|25|40|interferon alfa|67|82
9517515|Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.|thrombocythemia|25|40|pentostatin|87|98
9517515|Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.|hematological malignancy|42|66|interferon alfa|152|167
9517515|Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa.|Second cancers|0|14|interferon alfa|152|167
9527943|Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review.|hypertrophic obstructive cardiomyopathy|61|100|dexamethasone|39|52
9527943|One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.|lower average heart rate|18|42|propranolol|112|123
9527943|One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant.|lower average mean blood pressure|64|97|propranolol|112|123
9527943|STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.|left ventricular outflow tract obstruction|194|236|dexamethasone|254|267
9527943|STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and left ventricular outflow tract obstruction developed during dexamethasone treatment for bronchopulmonary dysplasia.|septal hypertrophy|171|189|dexamethasone|254|267
9533061|CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.|abdominal cramping|88|106|clindamycin|132|143
9533061|CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.|multiple watery stools|61|83|clindamycin|132|143
9533061|Clostridium difficile toxin-induced colitis after use of clindamycin phosphate vaginal cream.|Clostridium difficile toxin-induced colitis|0|43|clindamycin phosphate|57|78
9533061|CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.|CDIC|101|105|clindamycin|178|189
9533061|CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.|CDIC|101|105|clindamycin phosphate|35|56
9533061|CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.|C. difficile toxin|260|278|clindamycin|178|189
9533061|CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.|C. difficile toxin|260|278|clindamycin phosphate|35|56
9533061|CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.|diarrhea|165|173|clindamycin|178|189
9533061|CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.|diarrhea|165|173|clindamycin phosphate|35|56
9533061|DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.|C. difficile toxin in stool|130|157|clindamycin|64|75
9533061|DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.|diarrhea|183|191|clindamycin|64|75
9533061|OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.|toxin-positive Clostridium difficile-induced colitis|31|83|clindamycin phosphate|104|125
9545161|A 54-year-old man developed TEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor.|TEN|28|31|lamotrigine|56|67
9545161|Administration of lamotrigine, especially in combination with valproic acid, may lead to the development of TEN.|TEN|108|111|lamotrigine|18|29
9545161|Administration of lamotrigine, especially in combination with valproic acid, may lead to the development of TEN.|TEN|108|111|valproic acid|62|75
9545161|Fatal toxic epidermal necrolysis related to lamotrigine administration.|Fatal toxic epidermal necrolysis|0|32|lamotrigine|44|55
9545161|It was hypothesized that valproic acid may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite.|accumulation of a toxic intermediate metabolite|190|237|lamotrigine|77|88
9545161|It was hypothesized that valproic acid may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite.|accumulation of a toxic intermediate metabolite|190|237|valproic acid|25|38
9545161|It was hypothesized that valproic acid may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite.|increased serum lamotrigine levels|101|135|lamotrigine|77|88
9545161|It was hypothesized that valproic acid may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite.|increased serum lamotrigine levels|101|135|valproic acid|25|38
9545161|To date, eight cases of TEN and one of SJS related to lamotrigine administration have been reported in the literature.|SJS|39|42|lamotrigine|54|65
9545161|To date, eight cases of TEN and one of SJS related to lamotrigine administration have been reported in the literature.|TEN|24|27|lamotrigine|54|65
9550246|A syndrome of increased affect in response to risperidone among patients with schizophrenia.|syndrome of increased affect|2|30|risperidone|46|57
9550246|Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.|depression|228|238|risperidone|86|97
9550246|Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.|feelings of agitation|202|223|risperidone|86|97
9550246|Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.|insomnia|265|273|risperidone|86|97
9550246|Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.|intolerable affect|172|190|risperidone|86|97
9550246|Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.|periods of crying|243|260|risperidone|86|97
9550246|The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.|increase affect|41|56|risperidone|25|36
9554064|Methanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies.|bilateral putaminal injury|102|128|Methanol|0|8
9554064|Methanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies.|Methanol toxicity|0|17|Methanol|0|8
9554064|Methanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies.|severe central nervous system insult|28|64|Methanol|0|8
9554064|Putaminal infarct in methanol intoxication: case report and role of brain imaging studies.|methanol intoxication|21|42|methanol|21|29
9554064|Putaminal infarct in methanol intoxication: case report and role of brain imaging studies.|Putaminal infarct|0|17|methanol|21|29
9554064|Theoretical basal ganglia toxicologic mechanisms of methanol poisoning are reviewed, and the role of brain imaging studies will regard to diagnosis, prognosis and impact on management is discussed.|methanol poisoning|52|70|methanol|52|60
9554064|We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.|bilateral putaminal necrosis|107|135|methanol|36|44
9554064|We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.|cerebral edema|140|154|methanol|36|44
9554064|We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.|diffuse brain involvement|70|95|methanol|36|44
9554064|We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.|fatal|13|18|methanol|36|44
9554064|We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.|methanol toxicity|36|53|methanol|36|44
9554064|We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.|ventricular compression|160|183|methanol|36|44
9562211|A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.|dyskinetic movements|115|135|risperidone|54|65
9562211|Risperidone-induced tardive dyskinesia.|tardive dyskinesia|20|38|Risperidone|0|11
9562211|This report presents a potential case of risperidone-induced tardive dyskinesia.|tardive dyskinesia|61|79|risperidone|41|52
9579301|Increased ocular pressure in two patients with narrow angle glaucoma treated with venlafaxine.|Increased ocular pressure|0|25|venlafaxine|82|93
95811|A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.|clinical lupus syndrome|28|51|procainamide|208|220
95811|A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.|diffuse proliferative glomerulonephritis|144|184|procainamide|208|220
95811|A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.|lupus erythematosus|97|116|procainamide|208|220
95811|Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.|Glomerulonephritis|0|18|procainamide|22|34
95811|Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature.|lupus erythematosus|43|62|procainamide|22|34
9602881|We report a 76-year-old man who developed an acute blistering eruption following high-dose penicillin treatment for pneumococcal septicaemia.|acute blistering eruption|45|70|penicillin|91|101
961329|A case of prolonged suxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported.|apnoea|34|40|suxamethonium|20|33
961329|Suxamethonium apnoea terminated with commercial serumcholinesterase.|apnoea|14|20|Suxamethonium|0|13
9619226|Cardiac arrest associated with sulprostone use during caesarean section.|Cardiac arrest|0|14|sulprostone|31|42
9619226|We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.|cardiac arrest|96|110|sulprostone|31|42
9619226|We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest.|coronary spasm|64|78|sulprostone|31|42
9627209|In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.|doubling of the lamotrigine blood level|133|172|desmethylsertraline|85|104
9627209|In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.|doubling of the lamotrigine blood level|133|172|lamotrigine|149|160
9627209|In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.|doubling of the lamotrigine blood level|133|172|sertraline|39|49
9627209|In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.|doubling of the lamotrigine blood level|133|172|sertraline|70|80
9627209|In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.|symptoms of toxicity|178|198|desmethylsertraline|85|104
9627209|In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.|symptoms of toxicity|178|198|lamotrigine|149|160
9627209|In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.|symptoms of toxicity|178|198|sertraline|39|49
9627209|In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.|symptoms of toxicity|178|198|sertraline|70|80
9627209|Lamotrigine toxicity secondary to sertraline.|Lamotrigine toxicity|0|20|Lamotrigine|0|11
9627209|Lamotrigine toxicity secondary to sertraline.|Lamotrigine toxicity|0|20|sertraline|34|44
9634122|Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.|decrease in prostate-specific antigen|52|89|Flutamide|0|9
9634122|Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.|decrease in prostate-specific antigen|52|89|flutamide|102|111
9634122|Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.|Flutamide withdrawal syndrome|0|29|Flutamide|0|9
9634122|Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.|Flutamide withdrawal syndrome|0|29|flutamide|102|111
9634122|Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.|flutamide withdrawal syndrome|48|77|flutamide|48|57
9634122|Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.|Prolonged prostate-specific antigen response|0|44|flutamide|48|57
9634122|This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal.|decoupling of PSA response|36|62|flutamide|86|95
9634122|We describe a patient with androgen-independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal.|PSA continued to decrease|72|97|flutamide|130|139
9642842|Anaphylactic reaction to oral prednisone: a case report and review of the literature.|Anaphylactic reaction|0|21|prednisone|30|40
9642842|We describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral prednisone.|anaphylactic reaction|124|145|prednisone|154|164
9647315|Animals treated with HAL showed a highly significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons in the substantia nigra, and 20% contraction of the TH stained dendritic arbour.|significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons|41|117|HAL|21|24
9651465|METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.|vomiting|112|120|Pancrease MT 16|177|192
9651465|METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo.|vomiting|112|120|Viokase|165|172
9651465|She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes.|vomiting|57|65|Pancrease MT 16|21|36
9651465|The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.|vomiting|4|12|Creon 10|85|93
9651465|The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.|vomiting|4|12|Pancrease MT 16|108|123
9651465|The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16.|vomiting|4|12|Viokase|95|102
9655664|Acute valproate ingestion induces symptomatic methemoglobinemia.|symptomatic methemoglobinemia|34|63|valproate|6|15
9655664|We report for the first time the development of symptomatic methemoglobinemia after an acute ingestion of divalproex sodium (Depakote), resulting in serum concentrations 10 times greater than the therapeutic range.|symptomatic methemoglobinemia|48|77|Depakote|125|133
9655664|We report for the first time the development of symptomatic methemoglobinemia after an acute ingestion of divalproex sodium (Depakote), resulting in serum concentrations 10 times greater than the therapeutic range.|symptomatic methemoglobinemia|48|77|divalproex sodium|106|123
9660541|In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.|hemolytic anemia|114|130|mitomycin C|14|25
9660541|In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.|hemolytic anemia|114|130|MMC|27|30
9660541|In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.|hemolytic uremic syndrome|61|86|mitomycin C|14|25
9660541|In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.|hemolytic uremic syndrome|61|86|MMC|27|30
9660541|In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.|progressive renal failure|153|178|mitomycin C|14|25
9660541|In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.|progressive renal failure|153|178|MMC|27|30
9660541|In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.|thrombocytopenia|132|148|mitomycin C|14|25
9660541|In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.|thrombocytopenia|132|148|MMC|27|30
9660541|Mitomycin C-related hemolytic uremic syndrome in cancer patients.|hemolytic uremic syndrome|20|45|Mitomycin C|0|11
9660541|We report a case of MMC-related hemolytic uremic syndrome, and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome.|hemolytic uremic syndrome|32|57|MMC|20|23
9671138|CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.|CD4 T-lymphocyte depletion|0|26|fludarabine phosphate|109|130
9671138|CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.|myelosuppression|28|44|fludarabine phosphate|109|130
9671138|CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.|severe infections|61|78|fludarabine phosphate|109|130
9671138|Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.|Severe respiratory syncytial virus pulmonary infection|0|54|fludarabine|81|92
9671138|We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.|respiratory syncytial virus (RSV) infection|43|86|fludarabine phosphate|169|190
9674820|Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.|Serotonin syndrome|0|18|phenelzine|49|59
9674820|Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.|Serotonin syndrome|0|18|venlafaxine|63|74
9681211|Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis.|leucocytosis|27|39|G-CSF|14|19
9681211|Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF.|Leukaemoid monocytosis|0|22|G-CSF|60|65
9681211|We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.|monocytosis|108|119|G-CSF|81|86
9681211|We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy.|monocytosis|108|119|G-CSF|132|137
968449|Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells.|balanced translocation|70|92|chlorambucil|39|51
968449|Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.|Chromosome abnormalities|0|24|chlorambucil|31|43
9695308|Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared.|ANCA|99|103|PTU|53|56
9695308|Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy.|Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis|0|74|propylthiouracil|91|107
9695308|A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.|antineutrophil cytoplasmic antibody|54|89|propylthiouracil|129|145
9695308|A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis.|antineutrophil cytoplasmic antibody|54|89|PTU|147|150
9695308|It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.|ANCA|22|26|PTU|123|126
9695308|It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA.|ANCA|146|150|PTU|123|126
9701106|A drug interaction between zafirlukast and theophylline.|drug interaction|2|18|theophylline|43|55
9701106|A drug interaction between zafirlukast and theophylline.|drug interaction|2|18|zafirlukast|27|38
9701106|Attempts were made to stop and then restart the theophylline therapy at progressively lower doses; however, with each attempt, the patient's reaction to the drug became more toxic, with serum theophylline levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL).|reaction to the drug became more toxic|141|179|theophylline|48|60
9701106|Attempts were made to stop and then restart the theophylline therapy at progressively lower doses; however, with each attempt, the patient's reaction to the drug became more toxic, with serum theophylline levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL).|reaction to the drug became more toxic|141|179|theophylline|192|204
9701106|One explanation for the noted increase in the theophylline level is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of zafirlukast.|increase in the theophylline level|30|64|theophylline|46|58
9701106|One explanation for the noted increase in the theophylline level is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of zafirlukast.|increase in the theophylline level|30|64|zafirlukast|196|207
9701106|Recently, her serum theophylline levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.|theophylline levels had increased to the toxic range|20|72|Accolate|150|158
9701106|Recently, her serum theophylline levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.|theophylline levels had increased to the toxic range|20|72|theophylline|20|32
9701106|Recently, her serum theophylline levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.|theophylline levels had increased to the toxic range|20|72|zafirlukast|137|148
9701106|The noted increase in the theophylline level after zafirlukast administration is in contrast to the original reports by the manufacturer.|increase in the theophylline level|10|44|theophylline|26|38
9701106|The noted increase in the theophylline level after zafirlukast administration is in contrast to the original reports by the manufacturer.|increase in the theophylline level|10|44|zafirlukast|51|62
9701106|We present the first case (to our knowledge) of a potentially serious drug-drug interaction between zafirlukast and theophylline.|drug-drug interaction|70|91|theophylline|116|128
9701106|We present the first case (to our knowledge) of a potentially serious drug-drug interaction between zafirlukast and theophylline.|drug-drug interaction|70|91|zafirlukast|100|111
9704170|A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.|rhabdomyolysis|32|46|clozapine|92|101
9704170|Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.|rhabdomyolysis|33|47|Clozapine|0|9
9704170|Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.|Rhabdomyolysis|0|14|clozapine|31|40
9709726|We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.|anticholinergic symptoms|124|148|diphenhydramine|165|180
9709726|We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine.|drug-seeking behavior|99|120|diphenhydramine|165|180
9719245|Excluding other causes, Pentasa-associated pancytopenia was considered.|pancytopenia|43|55|Pentasa|24|31
9719245|He developed fever, nausea, diarrhea, and malaise and stopped taking on the third day after commencing Pentasa.|diarrhea|28|36|Pentasa|103|110
9719245|He developed fever, nausea, diarrhea, and malaise and stopped taking on the third day after commencing Pentasa.|fever|13|18|Pentasa|103|110
9719245|He developed fever, nausea, diarrhea, and malaise and stopped taking on the third day after commencing Pentasa.|malaise|42|49|Pentasa|103|110
9719245|He developed fever, nausea, diarrhea, and malaise and stopped taking on the third day after commencing Pentasa.|nausea|20|26|Pentasa|103|110
9719245|Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease.|Pancytopenia|0|12|5-aminosalicylic acid|29|50
9719245|We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day.|pancytopenia|20|32|5-aminosalicylic acid|96|117
9719245|We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day.|pancytopenia|20|32|Pentasa|119|126
9723127|1. Changes in the plasma cortisol level were reported in a male patient with panic disorder during the period of low-dose alprazolam treatment (mean 0.62 +/- 0.15 mg/day) compared with during the period of high-dose period (mean 1.08 +/- 0.28 mg/day).|Changes in the plasma cortisol level|3|39|alprazolam|122|132
9723127|3. Thus, the decreased plasma cortisol level during alprazolam treatment of panic disorder was suggested to be caused not by symptom alleviation due to alprazolam but by alprazolam administration itself.|decreased plasma cortisol level|13|44|alprazolam|52|62
9723127|Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report.|Decreased plasma cortisol level|0|31|alprazolam|39|49
9725786|We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.|Nocardia Asteroides brain abscess|94|127|cyclosporine|55|67
9725786|We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.|Nocardia Asteroides brain abscess|94|127|prednisone|72|82
9733234|Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss.|progressive sensorineural hearing loss|77|115|cisplatin|26|35
9737132|A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.|gradual stiffness|121|138|pentazocine|62|73
9737132|A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.|weakness of the lower extremities|143|176|pentazocine|62|73
9737132|Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.|fibrous myopathy|164|180|pentazocine|51|62
9737132|Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.|neuromuscular complication|77|103|pentazocine|51|62
9737132|Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.|neuropathy|195|205|pentazocine|51|62
9737132|Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.|pentazocine toxicity|51|71|pentazocine|51|62
9737132|Pentazocine-induced fibrous myopathy and localized neuropathy.|fibrous myopathy|20|36|Pentazocine|0|11
9737132|Pentazocine-induced fibrous myopathy and localized neuropathy.|neuropathy|51|61|Pentazocine|0|11
9754850|In two of these cases akathisia resolved after withdrawal of olanzapine and substitution by a classical or an atypical neuroleptic agent, respectively.|akathisia|22|31|olanzapine|61|71
9754850|Like other atypical neuroleptics olanzapine is considered to show a reduced prevalence of extrapyramidal side effects when compared to classical neuroleptic drugs.|extrapyramidal side effects|90|117|olanzapine|33|43
9754850|One should therefore be aware of possible extrapyramidal side effects with olanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated.|extrapyramidal side effects|42|69|olanzapine|75|85
9754850|Severe akathisia during olanzapine treatment of acute schizophrenia.|Severe akathisia|0|16|olanzapine|24|34
9754850|We report on three patients with acute schizophrenia, who developed severe akathisia during treatment with olanzapine (20-25 mg/d).|severe akathisia|68|84|olanzapine|107|117
9758325|Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor.|Seizures|0|8|metrifonate|112|123
9760614|However, 1 eye had vitreous hemorrhage after repeated injections of tPA.|vitreous hemorrhage|19|38|tPA|68|71
9760614|However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage.|vitreous hemorrhage|87|106|tPA|31|34
9770151|Although praziquantel administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked inflammation as a result of treatment.|inflammation|151|163|praziquantel|9|21
9776099|NMS is a drug-related response to various medications, such as Haloperidol, which the patient was receiving.|NMS|0|3|Haloperidol|63|74
9777751|Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.|aplastic anemia|20|35|Methimazole|0|11
9777751|We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).|AA|85|87|methimazole|113|124
9787325|FSGS induced by Adriamycin (Pharmacia & Upjohn, Columbus, OH) has been observed experimentally in rats.|FSGS|0|4|Adriamycin|16|26
9792602|The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.|ATIN|81|85|pranlukast|56|66
9792602|The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.|ATIN|81|85|pranlukast|153|163
9792602|The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.|hypersensitivity reaction|27|52|pranlukast|56|66
9792602|The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.|hypersensitivity reaction|27|52|pranlukast|153|163
9792602|Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast.|Tubulointerstitial nephritis|0|28|pranlukast|76|86
9792602|Within 6 months of pranlukast withdrawal, anemia resolved and urinary sediment and renal function normalized.|anemia|42|48|pranlukast|19|29
9796135|A 65-year-old woman with angina pectoris presented with syncope after sublingual ingestion of isosorbide dinitrate (5 mg).|syncope|56|63|isosorbide dinitrate|94|114
9796135|Elderly patients for whom nitrate has been prescribed should be warned of the occurrence of hypotension, leading to unconsciousness.|hypotension|92|103|nitrate|26|33
9796135|Elderly patients for whom nitrate has been prescribed should be warned of the occurrence of hypotension, leading to unconsciousness.|unconsciousness|116|131|nitrate|26|33
9796135|In a postural challenge test after administration of isosorbide dinitrate (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min.|blood pressure decreased|82|106|isosorbide dinitrate|53|73
9796135|In a postural challenge test after administration of isosorbide dinitrate (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min.|sudden decrease in pulse rate|161|190|isosorbide dinitrate|53|73
9796135|In a postural challenge test after administration of isosorbide dinitrate (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min.|syncope|146|153|isosorbide dinitrate|53|73
9796135|Syncope in a 65-year-old woman after nitrate ingestion.|Syncope|0|7|nitrate|37|44
9804082|Three diabetic cases of acute dizziness due to initial administration of voglibose.|acute dizziness|24|39|voglibose|73|82
9804082|We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.|intolerable dizziness|37|58|voglibose|171|180
9804082|We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.|nausea|71|77|voglibose|171|180
9804082|We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose.|vomiting|82|90|voglibose|171|180
9819544|Naproxen-associated sudden sensorineural hearing loss.|sudden sensorineural hearing loss|20|53|Naproxen|0|8
9819544|Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.|tinnitus|99|107|Naproxen|0|8
9819544|Naproxen is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and transient hearing loss.|transient hearing loss|112|134|Naproxen|0|8
9819544|This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of naproxen and reviews the literature on NSAID-related permanent sensorineural hearing loss.|sensorineural hearing loss|88|114|naproxen|139|147
9824032|Dental and gingival pain as side effects of niacin therapy.|Dental and gingival pain|0|24|niacin|44|50
9824032|The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth.|hyperalgesia of sensory nerve receptors|146|185|niacin|57|63
9824032|The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth.|pain to the teeth|252|269|niacin|57|63
9824032|The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth.|potentiation of inflammation in the gingiva|191|234|niacin|57|63
9824032|The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth.|prostaglandin-mediated vasodilatation|107|144|niacin|57|63
9824032|Two 65-year-old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment.|intense dental and gingival pain|117|149|niacin|61|67
9824032|Two 65-year-old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment.|intense dental and gingival pain|117|149|niacin|238|244
9831311|Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind.|potassium loss|161|175|calcitriol|88|98
9831311|Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind.|potassium loss|161|175|phosphate|74|83
9831311|Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind.|secondary hyperparathyroidism|103|132|calcitriol|88|98
9831311|Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind.|secondary hyperparathyroidism|103|132|phosphate|74|83
9831311|Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind.|vitamin D intoxication|137|159|calcitriol|88|98
9831311|Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind.|vitamin D intoxication|137|159|phosphate|74|83
9831311|High-dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia.|hypokalemia|39|50|phosphate|10|19
9831311|It was concluded that potassium loss occurred by a non-renal (intestinal) route in phosphate-induced hypokalemia.|hypokalemia|101|112|phosphate|83|92
9831311|It was concluded that potassium loss occurred by a non-renal (intestinal) route in phosphate-induced hypokalemia.|potassium loss|22|36|phosphate|83|92
9831311|Progressive hypokalemia developed during phosphate treatment.|Progressive hypokalemia|0|23|phosphate|41|50
9831311|The mechanism of the decrease in plasma potassium induced by phosphate treatment was investigated in a 24-year-old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations.|decrease in plasma potassium|21|49|phosphate|61|70
9831311|Transtubular potassium gradient (TTKG) also decreased and an inverse correlation was found between TTKG and doses of phosphate (r = -0.37; p < 0.02; N = 38).|Transtubular potassium gradient (TTKG) also decreased|0|53|phosphate|117|126
9840249|Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation.|Alveolar-interstitial pneumopathy|0|33|gold|40|44
9840249|The pulmonary toxicity of gold salts is an uncommon cause of life-threatening respiratory failure.|pulmonary toxicity|4|22|gold|26|30
9840249|The pulmonary toxicity of gold salts is an uncommon cause of life-threatening respiratory failure.|respiratory failure|78|97|gold|26|30
9840249|We report a case of severe respiratory failure due to gold salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation.|respiratory failure|27|46|gold|54|58
9847899|As this relapse coincided with development of a strong delayed-type hypersensitivity response to tuberculin and improved after treatment with the anti-inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen-specific cellular immunity.|hypersensitivity response|68|93|tuberculin|97|107
984862|A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and glycosuria during a period of topical administration of a corticosteroid cream, halcinonide cream 0.1%, under occlusion.|glycosuria|182|192|halcinonide|262|273
984862|A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and glycosuria during a period of topical administration of a corticosteroid cream, halcinonide cream 0.1%, under occlusion.|postprandial hyperglycemia|151|177|halcinonide|262|273
984862|A second patient with a similar glucose tolerance test result showed postprandial hyperglycemia when treated similarly with betamethasone valerate cream 0.1%.|postprandial hyperglycemia|69|95|betamethasone valerate|124|146
9855339|After 1 week of nefazodone therapy the patient experienced headache, confusion, and "gray areas" in her vision, without abnormal ophthalmologic findings.|confusion|69|78|nefazodone|16|26
9855339|After 1 week of nefazodone therapy the patient experienced headache, confusion, and "gray areas" in her vision, without abnormal ophthalmologic findings.|gray areas|85|95|nefazodone|16|26
9855339|After 1 week of nefazodone therapy the patient experienced headache, confusion, and "gray areas" in her vision, without abnormal ophthalmologic findings.|headache|59|67|nefazodone|16|26
9855339|Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to interfere with tacrolimus metabolism.|interfere with tacrolimus metabolism|151|187|nefazodone|50|60
9855339|Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to interfere with tacrolimus metabolism.|interfere with tacrolimus metabolism|151|187|tacrolimus|166|176
9855339|Interaction between tacrolimus and nefazodone in a stable renal transplant recipient.|Interaction|0|11|nefazodone|35|45
9855339|Interaction between tacrolimus and nefazodone in a stable renal transplant recipient.|Interaction|0|11|tacrolimus|20|30
9855339|We suspect that nefazodone inhibits metabolism of tacrolimus.|inhibits metabolism of tacrolimus|27|60|nefazodone|16|26
9855339|We suspect that nefazodone inhibits metabolism of tacrolimus.|inhibits metabolism of tacrolimus|27|60|tacrolimus|50|60
9861579|We report the case of intoxication of a 41-year-old female patient suffering from major depression with mirtazapine complicated by severe hypothermia.|intoxication|22|34|mirtazapine|104|115
9865241|CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.|acute vitamin D poisoning|98|123|vitamin D|104|113
9865241|CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.|hypercalcemia|71|84|vitamin D|104|113
9865241|Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.|acute vitamin D poisoning|85|110|vitamin D|91|100
9865241|Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.|hypercalcemia|58|71|vitamin D|91|100
9865241|The patient was initially treated with hydration and furosemide but developed congestive heart failure.|congestive heart failure|78|102|furosemide|53|63
9865241|The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.|vitamin D intoxication|60|82|vitamin D|60|69
9865241|We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.|severe hypercalcemia|44|64|vitamin D|89|98
9865241|We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.|vitamin D poisoning|89|108|vitamin D|89|98
9870779|A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.|overwhelming hepatic necrosis|131|160|MTX|88|91
9870779|Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.|hepatic necrosis|21|37|Methotrexate|0|12
9870779|MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.|hepatic injury|12|26|MTX|0|3
9870779|MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.|liver enzyme elevations|31|54|MTX|0|3
9876812|Clinicians should be aware of the possibility that vinorelbine may cause SIADH and possibly hypokalemia.|hypokalemia|92|103|vinorelbine|51|62
9876812|Clinicians should be aware of the possibility that vinorelbine may cause SIADH and possibly hypokalemia.|SIADH|73|78|vinorelbine|51|62
9876812|CONCLUSIONS: Because of its structural similarity to the other vinca alkaloids, vinorelbine is believed to be responsible for SIADH in our patient.|SIADH|126|131|vinorelbine|80|91
9876812|OBJECTIVE: To describe onset of syndrome of inappropriate antidiuretic hormone (SIADH) associated with vinorelbine therapy for advanced breast cancer.|SIADH|80|85|vinorelbine|103|114
9876812|OBJECTIVE: To describe onset of syndrome of inappropriate antidiuretic hormone (SIADH) associated with vinorelbine therapy for advanced breast cancer.|syndrome of inappropriate antidiuretic hormone|32|78|vinorelbine|103|114
9876812|Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy.|Syndrome of inappropriate antidiuretic hormone|0|46|vinorelbine|63|74
9883483|Pirmenol hydrochloride-induced QT prolongation and T wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation.|QT prolongation|31|46|Pirmenol hydrochloride|0|22
9883483|Pirmenol hydrochloride-induced QT prolongation and T wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation.|T wave inversion|51|67|Pirmenol hydrochloride|0|22
9883483|Thus, an immunological mechanism might be involved in the mechanism of pirmenol-induced QT prolongation and T wave inversion on the electrocardiogram.|QT prolongation|88|103|pirmenol|71|79
9883483|Thus, an immunological mechanism might be involved in the mechanism of pirmenol-induced QT prolongation and T wave inversion on the electrocardiogram.|T wave inversion|108|124|pirmenol|71|79
9883483|We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral pirmenol therapy.|prolongation of the QT interval|112|143|pirmenol|257|265
9883483|We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral pirmenol therapy.|T wave inversion|148|164|pirmenol|257|265
9886213|Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.|myositis|41|49|praziquantel|61|73
9886213|We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.|diffuse myalgia|87|102|praziquantel|195|207
9886213|We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.|fever|80|85|praziquantel|195|207
9886213|We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.|inflammatory reaction around dying cysticerci|137|182|praziquantel|195|207
9886213|We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.|myositis|70|78|praziquantel|195|207
9886213|We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.|weakness of the lower limbs|104|131|praziquantel|195|207
9892272|Massive subfascial hematoma after alteplase therapy for acute myocardial infarction.|Massive subfascial hematoma|0|27|alteplase|34|43
9892272|Physicians should be aware of the possible association between the use of alteplase and the development of subfascial hemorrhage.|subfascial hemorrhage|107|128|alteplase|74|83
9892272|The authors report a case of a patient who received alteplase for acute myocardial infarction and developed spontaneous subfascial hematoma without any evidence of direct trauma.|subfascial hematoma|120|139|alteplase|52|61
9892272|The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma.|cutaneous ecchymosis|19|39|alteplase|112|121
9892272|The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma.|diffuse subfascial hematoma|165|192|alteplase|112|121
9892272|The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma.|sudden fall in hemoglobin|58|83|alteplase|112|121
990658|A fatal case of pancytopenia due to levomepromazine.|fatal case of pancytopenia|2|28|levomepromazine|36|51
990658|A fatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and lithium carbonate.|fatal pancytopenia|2|20|diazepam|161|169
990658|A fatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and lithium carbonate.|fatal pancytopenia|2|20|levomepromazine|144|159
990658|A fatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and lithium carbonate.|fatal pancytopenia|2|20|lithium carbonate|174|191
9920368|Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody.|thyrotoxicosis|19|33|Amiodarone|0|10
9920368|Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody.|thyrotropin receptor antibody|50|79|Amiodarone|0|10
9920368|Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII).|thyrotoxicosis|143|157|amiodarone|109|119
9920368|Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII).|thyrotropin-binding inhibiting immunoglobulin|262|307|amiodarone|109|119
9920368|Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking amiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII).|transiently positive thyrotropin (TSH) receptor antibody|194|250|amiodarone|109|119
9920368|Since amiodarone was first marketed in 1992 in Japan, the incidence of amiodarone-induced thyrotoxicosis (AIT) has been increasing.|AIT|106|109|amiodarone|71|81
9920368|Since amiodarone was first marketed in 1992 in Japan, the incidence of amiodarone-induced thyrotoxicosis (AIT) has been increasing.|thyrotoxicosis|90|104|amiodarone|71|81
9920368|These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with amiodarone-induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.|destructive thyroiditis|152|175|amiodarone|133|143
9920368|These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with amiodarone-induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.|destructive thyroiditis|206|229|amiodarone|133|143
9920368|These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with amiodarone-induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.|thyroiditis|259|270|amiodarone|133|143
9920368|These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with amiodarone-induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.|TRAb/TBII without thyroid-stimulating activity|57|103|amiodarone|133|143
9925865|CONCLUSION: Lipoid pneumonia as a result of mineral oil aspiration still occurs in the pediatric population.|Lipoid pneumonia|12|28|mineral oil|44|55
9925865|In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.|ELP|122|125|mineral oil|68|79
9925865|In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.|ELP|122|125|mineral oil|180|191
9925865|In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.|pneumonia|44|53|mineral oil|68|79
9925865|In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.|pneumonia|44|53|mineral oil|180|191
9925865|In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.|swallowing dysfunction|17|39|mineral oil|68|79
9925865|In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.|swallowing dysfunction|17|39|mineral oil|180|191
9925865|Lipoid pneumonia: a silent complication of mineral oil aspiration.|Lipoid pneumonia|0|16|mineral oil|43|54
9925865|Mineral oil, a hydrocarbon, may not elicit a normal protective cough reflex and may impair mucociliary transport.|impair mucociliary transport|84|112|Mineral oil|0|11
9925865|Our case points to the need for increased awareness by the general pediatricians of the potential hazards of mineral oil use for chronic constipation.|potential hazards|88|105|mineral oil|109|120
9925865|Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.|ELP|13|16|mineral oil|157|168
9925865|Treatment of ELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of mineral oil.|roentgenographic abnormalities|76|106|mineral oil|157|168
9925865|We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic mineral oil ingestion presenting as asymptomatic exogenous lipoid pneumonia (ELP).|ELP|186|189|mineral oil|109|120
9925865|We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic mineral oil ingestion presenting as asymptomatic exogenous lipoid pneumonia (ELP).|exogenous lipoid pneumonia|158|184|mineral oil|109|120
9934637|An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.|psoralens|72|81|burn injury|20|31
9934637|Because psoralens sensitize skin to ultraviolet A light, phototoxic reactions are the most frequent adverse effect of this treatment.|phototoxic reactions|57|77|psoralens|8|17
9934637|In this article, we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8-methoxypsoralen solution as a suntanning agent.|intense burn|100|112|8-methoxypsoralen|138|155
9934637|Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.|skin extremely sensitive|125|149|psoralen|43|51
9934637|Sunburn may sometimes be a major injury in psoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive.|Sunburn|0|7|psoralen|43|51
9972383|CONCLUSIONS: Metoclopramide may cause reversible nonthrombocytopenic vascular-type palpable purpura.|nonthrombocytopenic vascular-type palpable purpura|49|99|Metoclopramide|13|27
9972383|OBJECTIVE: To report a case of reversible nonthrombocytopenic palpable purpura associated with metoclopramide.|nonthrombocytopenic palpable purpura|42|78|metoclopramide|95|109
9972383|Reversible nonthrombocytopenic palpable purpura associated with metoclopramide.|nonthrombocytopenic palpable purpura|11|47|metoclopramide|64|78
998323|Lithium treatment was terminated in 1975 because of lithium intoxication with a diabetes insipidus-like syndrome.|diabetes insipidus-like syndrome|80|112|Lithium|0|7
998323|Lithium treatment was terminated in 1975 because of lithium intoxication with a diabetes insipidus-like syndrome.|diabetes insipidus-like syndrome|80|112|lithium|52|59
998323|Lithium treatment was terminated in 1975 because of lithium intoxication with a diabetes insipidus-like syndrome.|lithium intoxication|52|72|Lithium|0|7
998323|Lithium treatment was terminated in 1975 because of lithium intoxication with a diabetes insipidus-like syndrome.|lithium intoxication|52|72|lithium|52|59
9988365|Eosinophilia caused by clozapine was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).|Eosinophilia|0|12|clozapine|23|32
9988365|Eosinophilia has been encountered from 0.2 to 61.7% in clozapine-treated patients, mostly with a transient course and spontaneous remission.|Eosinophilia|0|12|clozapine|55|64
9988365|Successful challenge with clozapine in a history of eosinophilia.|eosinophilia|52|64|clozapine|26|35
